[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCwbbjhFIuZW5rXGkotXzSNRdzuHUYtGJYdlp1i6z5CI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"University of Chicago",[4],903,false,235,27,473484,134,468,[14,17,20,22,25,28,31,33],{"name":15,"count":16},"Breast Cancer",22,{"name":18,"count":19},"Prostate Cancer",21,{"name":21,"count":19},"Head and Neck Cancer",{"name":23,"count":24},"Substance-Related Disorders",18,{"name":26,"count":27},"Opioid-Related Disorders",17,{"name":29,"count":30},"Sleep",16,{"name":32,"count":30},"Healthy",{"name":34,"count":35},"Obesity",12,[37,42,47,51,56,61,66,70,75,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT01342367","Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer","2020-05-01","Bicalutamide",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT02608385","Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors","2022-04-01","Pembrolizumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":46},"NCT02743819","Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma","2022-06-01",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT02788981","Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer","2022-12-21","Mifepristone",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT03879577","Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","2023-03-30","Docetaxel",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT03011671","Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma","2025-06-26","Acetazolamide",{"nctId":67,"briefTitle":68,"date":69,"intervention":46},"NCT03360890","Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors","2025-12-05",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT04295863","Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers","2026-04-12","Nivolumab Standard",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06291987","Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation","2026-05","Ivosidenib",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05624528","A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder","2026-06","Tolcapone",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,121,146,175,193,211,229,255,273,298,544,591,718,757,824,868,886,914,1141,1405,1541,1627,1665,1767,1814,1844,1870,1896,1944,1970,1996,2023,2053,2108,2160,2198,2235,2261,2296,2339,2369,2391,2413,2435,2457,2479,2501,2519,2543,2561,2579,2603,2621,2639,2657,2675,2693,2718,2736,2760,2778,2799,2817,2835,2853,2871,2889,2916,2934,2959,2977,2995,3013,3031,3049,3067,3085,3103,3129,3147,3171,3189,3210,3228,3253,3308,3403,3427,3565,3615,3661,3738,3760,3817,3850,3880,3902,3928,3952,3970,3988,4006,4024,4051,4073,4091,4115,4133,4157,4175,4193,4211,4229,4247,4265,4283,4301,4319,4345,4376,4413,4437,4455,4473,4491,4515,4540,4587,4622,4644,4678,4703,4727,4745,4763,4826,4860,4894,4940,4973,5010,5047,5073,5098,5116,5141,5159,5183,5207,5233,5251,5276,5299,5322,5348,5366,5384,5402,5425,5443,5468,5486,5508,5532,5556,5579,5602,5624,5648,5666,5684,5702,5720,5747,5770,5788,5806,5824,5846,5871,5894,5919,5942,5960,5983,6001,6023,6045,6072,6090,6152,6190,6224,6256,6294,6318,6340,6358,6381,6404,6422,6445,6463,6550,6582,6612,6642,6673,6699,6739,6765,6799,6825,6865,6891,6916,6950,6972,7003,7037,7067,7089,7121,7150,7172,7206,7228,7304,7326,7357,7386,7408,7426,7444,7462,7484,7509,7532,7550,7577,7605,7628,7646,7664,7682,7706,7730,7748,7772,7790,7822,7840,7862,7887,7910,7933,7955,7973,7991,8009,8027,8045,8063,8086,8104,8125,8143,8164,8187,8205,8229,8247,8265,8283,8307,8325,8346,8364,8382,8400,8424,8442,8467,8485,8503,8521,8539,8557,8579,8597,8615,8633,8651,8677,8695,8717,8768,8786,8808,8829,8853,8875,8893,8914,8936,8960,8978,9000,9024,9042,9060,9084,9102,9120,9138,9163,9188,9220,9238,9259,9282,9300,9318,9336,9358,9379,9404,9422,9443,9461,9482,9500,9518,9542,9560,9578,9596,9618,9640,9664,9682,9706,9724,9749,9770,9791,9814,9836,9859,9880,9938,9971,9993,10023,10045,10070,10088,10106,10128,10146,10164,10186,10208,10226,10251,10269,10287,10305,10323,10347,10365,10388,10406,10424,10449,10467,10490,10513,10531,10549,10571,10589,10613,10631,10654,10672,10696,10714,10738,10760,10778,10796,10822,10840,10863,10887,10905,10923,10941,10959,10977,10995,11013,11031,11049,11067,11091,11109,11127,11145,11163,11181,11207,11230,11257,11282,11305,11323,11348,11372,11390,11414,11471,11518,11575,11626,11656,11686,11725,11764,11790,11822,11844,11866,11888,11919,11941,11973,11999,12031,12064,12089,12120,12143,12161,12185,12203,12227,12249,12273,12291,12313,12331,12349,12367,12390,12408,12434,12452,12470,12493,12516,12540,12564,12582,12603,12621,12639,12663,12688,12706,12724,12749,12767,12791,12816,12834,12852,12870,12895,12913,12931,12949,12967,12985,13003,13024,13048,13070,13099,13117,13135,13153,13174,13196,13214,13236,13259,13277,13299,13323,13345,13363,13381],{"intervention":94,"totalTrials":95,"cells":96},"Experimental: Primary Cohort",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":119},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT06008860","A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection","RECRUITING",[90],"2026-12","2023-07-01",280,[117],"COVID-19",[94],{"trials":120,"activeCount":99},[],{"intervention":122,"totalTrials":95,"cells":123},"Ibuprofen 400 mg",{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":132,"NA":144},{"trials":125,"activeCount":99},[],{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":99},[],{"trials":131,"activeCount":99},[],{"trials":133,"activeCount":95,"soonestReadout":138},[134],{"nctId":135,"briefTitle":136,"status":111,"phases":137,"primaryCompletion":138,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT05512754","Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen",[90],"2027-12-31","2022-08-01",200,[142],"Elevated Serum PSA",[122],{"trials":145,"activeCount":99},[],{"intervention":147,"totalTrials":95,"cells":148},"Norepinephrine",{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":173},{"trials":150,"activeCount":99},[],{"trials":152,"activeCount":99},[],{"trials":154,"activeCount":99},[],{"trials":156,"activeCount":99},[],{"trials":158,"activeCount":95,"soonestReadout":163},[159],{"nctId":160,"briefTitle":161,"status":111,"phases":162,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT02118467","Vasoactive Drugs in Intensive Care Unit",[90],"2026-10-01","2026-12-01","2014-05-15",836,[168],"Shock",[147,170,171,172],"Epinephrine","Phenylephrine","Vasopressin",{"trials":174,"activeCount":99},[],{"intervention":170,"totalTrials":95,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":191},{"trials":178,"activeCount":99},[],{"trials":180,"activeCount":99},[],{"trials":182,"activeCount":99},[],{"trials":184,"activeCount":99},[],{"trials":186,"activeCount":95,"soonestReadout":163},[187],{"nctId":160,"briefTitle":161,"status":111,"phases":188,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":189,"interventions":190},[90],[168],[147,170,171,172],{"trials":192,"activeCount":99},[],{"intervention":171,"totalTrials":95,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":209},{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":99},[],{"trials":200,"activeCount":99},[],{"trials":202,"activeCount":99},[],{"trials":204,"activeCount":95,"soonestReadout":163},[205],{"nctId":160,"briefTitle":161,"status":111,"phases":206,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":207,"interventions":208},[90],[168],[147,170,171,172],{"trials":210,"activeCount":99},[],{"intervention":172,"totalTrials":95,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":227},{"trials":214,"activeCount":99},[],{"trials":216,"activeCount":99},[],{"trials":218,"activeCount":99},[],{"trials":220,"activeCount":99},[],{"trials":222,"activeCount":95,"soonestReadout":163},[223],{"nctId":160,"briefTitle":161,"status":111,"phases":224,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":225,"interventions":226},[90],[168],[147,170,171,172],{"trials":228,"activeCount":99},[],{"intervention":230,"totalTrials":95,"cells":231},"Darolutamide",{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":253},{"trials":233,"activeCount":99},[],{"trials":235,"activeCount":99},[],{"trials":237,"activeCount":99},[],{"trials":239,"activeCount":99},[],{"trials":241,"activeCount":95,"soonestReadout":247},[242],{"nctId":243,"briefTitle":244,"status":245,"phases":246,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":251},"NCT06660862","Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.","NOT_YET_RECRUITING",[90],"2029-11","2026-11",80,[18],[230,252],"Physician choice Androgen Deprivation (Hormone) Therapy",{"trials":254,"activeCount":99},[],{"intervention":252,"totalTrials":95,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":271},{"trials":258,"activeCount":99},[],{"trials":260,"activeCount":99},[],{"trials":262,"activeCount":99},[],{"trials":264,"activeCount":99},[],{"trials":266,"activeCount":95,"soonestReadout":247},[267],{"nctId":243,"briefTitle":244,"status":245,"phases":268,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":269,"interventions":270},[90],[18],[230,252],{"trials":272,"activeCount":99},[],{"intervention":274,"totalTrials":95,"cells":275},"Aspirin 81 mg",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":296},{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":99},[],{"trials":285,"activeCount":95,"soonestReadout":164},[286],{"nctId":287,"briefTitle":288,"status":111,"phases":289,"primaryCompletion":164,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT04479072","Aspirin and Preeclampsia",[90],"2026-12-31","2021-02-15",180,[294],"Preeclampsia Postpartum",[274],{"trials":297,"activeCount":99},[],{"intervention":299,"totalTrials":24,"cells":300},"Dexamethasone",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":344,"PHASE3":489,"PHASE4":509,"NA":531},{"trials":302,"activeCount":99},[],{"trials":304,"activeCount":95,"soonestReadout":309},[305,329],{"nctId":306,"briefTitle":307,"status":111,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":317},"NCT03571321","Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia",[87],"2026-09-01","2027-09-05","2019-05-28",15,[314,315,316],"Acute Lymphoblastic Leukemia","ALL, Childhood","ALL",[318,319,320,321,322,323,324,325,325,299,326,327,328],"Ruxolitinib","Cyclophosphamide","Cytarabine","Mercaptopurine","Vincristine","Pegaspargase","Rituximab","Methotrexate","Doxorubicin","Thioguanine","Methotrexate Oral Product",{"nctId":330,"briefTitle":331,"status":332,"phases":333,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":340},"NCT02199665","Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","COMPLETED",[87],"2025-10","2025-10-25","2014-06-12",52,[339],"Refractory Multiple Myeloma",[341,342,343],"selinexor","carfilzomib","dexamethasone",{"trials":345,"activeCount":488,"soonestReadout":83},[346,360,373,393,404,414,426,440,452,465,478],{"nctId":347,"briefTitle":348,"status":111,"phases":349,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":356},"NCT05789303","Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma",[88],"2028-07-01","2023-05-30",83,[354,355],"Multiple Myeloma","Relapse Multiple Myeloma",[357,358,359,299],"Belantamab mafodotin","Carfilzomib","Pomalidomide",{"nctId":361,"briefTitle":362,"status":363,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":370},"NCT02420210","Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma","TERMINATED",[88],"2016-08","2015-11",2,[369],"Diffuse Large B-Cell Lymphoma",[371,372,299],"Bendamustine Hydrochloride","Obinutuzumab",{"nctId":374,"briefTitle":375,"status":332,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":383},"NCT03107182","Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer",[88],"2024-09-06","2017-06-27",72,[381,382],"HPV-Related Squamous Cell Carcinoma","HNSCC",[384,385,386,387,388,389,299,390,391,392],"nab-paclitaxel","Carboplatin","Nivolumab","Cisplatin","Hydroxyurea","5-FU","Famotidine","Diphenhydramine","Paclitaxel",{"nctId":394,"briefTitle":395,"status":332,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":402},"NCT00006002","SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy",[88],"2002-09","2006-01","2000-06",36,[18],[343,403],"semaxanib",{"nctId":405,"briefTitle":406,"status":332,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":412},"NCT01665794","Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",[87,88],"2025-11-14","2012-08-13",25,[354],[359,358,343,413],"Daratumumab",{"nctId":415,"briefTitle":416,"status":332,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":423},"NCT02969837","Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma",[88],"2021-10-11","2025-12-01","2017-07-10",46,[354],[424,358,425,299],"Elotuzumab","Lenalidomide",{"nctId":427,"briefTitle":428,"status":332,"phases":429,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":438},"NCT01816971","Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma",[88],"2018-04-01","2026-03-30","2013-01",76,[435,436,437],"Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma",[343,342,439],"lenalidomide",{"nctId":441,"briefTitle":442,"status":111,"phases":443,"primaryCompletion":164,"completion":164,"start":444,"enrollment":312,"conditions":445,"interventions":449},"NCT06207123","A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed\u002FRefractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)",[87,88],"2024-09-13",[446,447,448],"Acute Leukemia","Lymphoblastic Leukemia","Lymphoblastic Lymphoma",[450,451,322,299,325],"LP-118","Ponatinib",{"nctId":453,"briefTitle":454,"status":332,"phases":455,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":463},"NCT02389517","Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant",[88],"2021-02","2024-01","2015-03-02",42,[461,462],"Plasma Cell Myeloma","Residual Disease",[464,425,299],"Ixazomib Citrate",{"nctId":466,"briefTitle":467,"status":468,"phases":469,"primaryCompletion":470,"completion":470,"start":471,"enrollment":410,"conditions":472,"interventions":474},"NCT04747912","Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","SUSPENDED",[88],"2027-03-01","2021-03-02",[447,314,473],"ph+ Acute Lymphoblastic Leukemia",[475,476,299,325,322,451,477],"Inotuzumab ozogamicin","Dasatinib","Methotrexate for",{"nctId":479,"briefTitle":480,"status":481,"phases":482,"primaryCompletion":83,"completion":83,"start":483,"enrollment":484,"conditions":485,"interventions":487},"NCT03500445","Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma","ACTIVE_NOT_RECRUITING",[88],"2019-02-13",75,[486,354],"Myeloma",[413,358,425,299],3,{"trials":490,"activeCount":367,"soonestReadout":495},[491,501],{"nctId":492,"briefTitle":493,"status":481,"phases":494,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":499},"NCT03729804","Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)",[89],"2026-12-28","2019-05-07",250,[354],[358,425,299,500],"Bortezomib",{"nctId":502,"briefTitle":503,"status":481,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":292,"conditions":507,"interventions":508},"NCT02659293","Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma",[89],"2027-11","2016-04-26",[354],[425,358,299,425],{"trials":510,"activeCount":99},[511,520],{"nctId":512,"briefTitle":513,"status":332,"phases":514,"primaryCompletion":432,"completion":432,"start":515,"enrollment":516,"conditions":517,"interventions":519},"NCT00817479","Tumor Gene Expression in Women With Ovarian Cancer",[90],"2003-01",20,[518],"Ovarian Cancer",[299],{"nctId":521,"briefTitle":522,"status":363,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":529},"NCT01756586","Dexamethasone and Lower Extremity Block Duration",[90],"2014-12","2013-02",4,[528],"Analgesia Duration",[299,530],"Bupivacaine",{"trials":532,"activeCount":99},[533],{"nctId":534,"briefTitle":535,"status":363,"phases":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":542},"NCT00152620","Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease",[91],"2007-05","2004-06",40,[541],"Inflammatory Bowel Disease (IBD)",[299,543],"Methylprednisolone",{"intervention":358,"totalTrials":545,"cells":546},8,{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":555,"PHASE3":577,"PHASE4":587,"NA":589},{"trials":548,"activeCount":99},[],{"trials":550,"activeCount":99},[551],{"nctId":330,"briefTitle":331,"status":332,"phases":552,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":553,"interventions":554},[87],[339],[341,342,343],{"trials":556,"activeCount":367,"soonestReadout":83},[557,561,565,569,573],{"nctId":347,"briefTitle":348,"status":111,"phases":558,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":559,"interventions":560},[88],[354,355],[357,358,359,299],{"nctId":405,"briefTitle":406,"status":332,"phases":562,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":563,"interventions":564},[87,88],[354],[359,358,343,413],{"nctId":415,"briefTitle":416,"status":332,"phases":566,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":567,"interventions":568},[88],[354],[424,358,425,299],{"nctId":427,"briefTitle":428,"status":332,"phases":570,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":571,"interventions":572},[88],[435,436,437],[343,342,439],{"nctId":479,"briefTitle":480,"status":481,"phases":574,"primaryCompletion":83,"completion":83,"start":483,"enrollment":484,"conditions":575,"interventions":576},[88],[486,354],[413,358,425,299],{"trials":578,"activeCount":367,"soonestReadout":495},[579,583],{"nctId":492,"briefTitle":493,"status":481,"phases":580,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":581,"interventions":582},[89],[354],[358,425,299,500],{"nctId":502,"briefTitle":503,"status":481,"phases":584,"primaryCompletion":505,"completion":505,"start":506,"enrollment":292,"conditions":585,"interventions":586},[89],[354],[425,358,299,425],{"trials":588,"activeCount":99},[],{"trials":590,"activeCount":99},[],{"intervention":425,"totalTrials":592,"cells":593},7,{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":704,"PHASE4":714,"NA":716},{"trials":595,"activeCount":99},[],{"trials":597,"activeCount":99},[],{"trials":599,"activeCount":95,"soonestReadout":83},[600,688,692,696,700],{"nctId":601,"briefTitle":602,"status":332,"phases":603,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":681},"NCT02213913","Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas",[87,88],"2024-10-01","2024-10-29","2014-07-29",55,[609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680],"Adult Grade III Lymphomatoid Granulomatosis","B-cell Chronic Lymphocytic Leukemia","Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Mantle Cell Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Progressive Hairy Cell Leukemia, Initial Treatment","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","Stage 0 Chronic Lymphocytic Leukemia","Stage I Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Adult Hodgkin Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Chronic Lymphocytic Leukemia","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Mantle Cell Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Small Lymphocytic Lymphoma","Stage II Adult Hodgkin Lymphoma","Stage II Chronic Lymphocytic Leukemia","Stage II Small Lymphocytic Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Hodgkin Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Small Lymphocytic Lymphoma","Testicular Lymphoma","Untreated Hairy Cell Leukemia","Waldenström Macroglobulinemia",[439,682,683,684,685,686,687],"etoposide","prednisone","vincristine sulfate","doxorubicin hydrochloride","cyclophosphamide","rituximab",{"nctId":415,"briefTitle":416,"status":332,"phases":689,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":690,"interventions":691},[88],[354],[424,358,425,299],{"nctId":427,"briefTitle":428,"status":332,"phases":693,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":694,"interventions":695},[88],[435,436,437],[343,342,439],{"nctId":453,"briefTitle":454,"status":332,"phases":697,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":698,"interventions":699},[88],[461,462],[464,425,299],{"nctId":479,"briefTitle":480,"status":481,"phases":701,"primaryCompletion":83,"completion":83,"start":483,"enrollment":484,"conditions":702,"interventions":703},[88],[486,354],[413,358,425,299],{"trials":705,"activeCount":367,"soonestReadout":495},[706,710],{"nctId":492,"briefTitle":493,"status":481,"phases":707,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":708,"interventions":709},[89],[354],[358,425,299,500],{"nctId":502,"briefTitle":503,"status":481,"phases":711,"primaryCompletion":505,"completion":505,"start":506,"enrollment":292,"conditions":712,"interventions":713},[89],[354],[425,358,299,425],{"trials":715,"activeCount":99},[],{"trials":717,"activeCount":99},[],{"intervention":719,"totalTrials":367,"cells":720},"Semaglutide",{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":740,"PHASE4":753,"NA":755},{"trials":722,"activeCount":99},[],{"trials":724,"activeCount":99},[],{"trials":726,"activeCount":95,"soonestReadout":731},[727],{"nctId":728,"briefTitle":729,"status":245,"phases":730,"primaryCompletion":731,"completion":731,"start":78,"enrollment":732,"conditions":733,"interventions":739},"NCT07282769","Semaglutide (Wegovy) Treatment for Trichotillomania",[88],"2027-02",10,[734,735,736,737,738],"Trichotillomania (Hair-Pulling Disorder)","Trichotillomania","Hair Pulling Disorder","Hair Pulling","Hair-Pulling Disorder",[719],{"trials":741,"activeCount":95,"soonestReadout":746},[742],{"nctId":743,"briefTitle":744,"status":111,"phases":745,"primaryCompletion":746,"completion":747,"start":748,"enrollment":140,"conditions":749,"interventions":752},"NCT06499857","Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation",[89],"2027-12","2028-06","2025-04-14",[750,751],"Overweight or Obesity","Atrial Fibrillation",[719],{"trials":754,"activeCount":99},[],{"trials":756,"activeCount":99},[],{"intervention":758,"totalTrials":526,"cells":759},"sirolimus",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":793,"PHASE3":795,"PHASE4":808,"NA":822},{"trials":761,"activeCount":99},[],{"trials":763,"activeCount":99},[764,775],{"nctId":765,"briefTitle":766,"status":332,"phases":767,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":774},"NCT01791088","Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",[87],"2018-08-17","2012-06-13",56,[772,773],"Unspecified Adult Solid Tumor, Protocol Specific","Unspecified Childhood Solid Tumor, Protocol Specific",[758],{"nctId":776,"briefTitle":777,"status":332,"phases":778,"primaryCompletion":779,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":789},"NCT02145559","A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors",[87],"2016-11-15","2018-07","2014-04",24,[784,785,786,787,788],"Breast Neoplasms","Lung Neoplasms","Cancer of Liver","Lymphoma","Cancer of Kidney",[790,791,792],"Metformin XR","Delayed Metformin","Sirolimus",{"trials":794,"activeCount":99},[],{"trials":796,"activeCount":95,"soonestReadout":113},[797],{"nctId":798,"briefTitle":799,"status":481,"phases":800,"primaryCompletion":113,"completion":113,"start":801,"enrollment":802,"conditions":803,"interventions":807},"NCT04948203","Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis",[88,89],"2021-07-09",60,[804,805,806],"Pulmonary Fibrosis","COVID-19 Pneumonia","Long COVID",[792],{"trials":809,"activeCount":99},[810],{"nctId":811,"briefTitle":812,"status":332,"phases":813,"primaryCompletion":814,"completion":814,"start":815,"enrollment":816,"conditions":817,"interventions":820},"NCT00321906","Comparison of Sirolimus and Azathioprine in Lung Transplantation",[90],"2011-08","2002-04",181,[818,819],"Delayed Graft Function","Acute Graft Rejection",[821,758],"azathioprine",{"trials":823,"activeCount":99},[],{"intervention":825,"totalTrials":488,"cells":826},"Memantine",{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":853,"PHASE4":864,"NA":866},{"trials":828,"activeCount":99},[],{"trials":830,"activeCount":99},[],{"trials":832,"activeCount":99},[833,843],{"nctId":834,"briefTitle":835,"status":332,"phases":836,"primaryCompletion":837,"completion":838,"start":839,"enrollment":35,"conditions":840,"interventions":842},"NCT00880685","Memantine in the Treatment of Kleptomania",[88],"2012-05","2012-06","2009-03",[841],"Kleptomania",[825],{"nctId":844,"briefTitle":845,"status":332,"phases":846,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":850,"interventions":852},"NCT04792645","Memantine in Body Focused Repetitive Behaviors",[88],"2022-07-08","2021-06-15",100,[734,851],"Dermatillomania",[825],{"trials":854,"activeCount":95,"soonestReadout":83},[855],{"nctId":856,"briefTitle":857,"status":481,"phases":858,"primaryCompletion":83,"completion":83,"start":859,"enrollment":860,"conditions":861,"interventions":863},"NCT05796752","Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors",[88,89],"2023-08-02",26,[862,734],"Skin-Picking",[825],{"trials":865,"activeCount":99},[],{"trials":867,"activeCount":99},[],{"intervention":500,"totalTrials":95,"cells":869},{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":876,"PHASE4":882,"NA":884},{"trials":871,"activeCount":99},[],{"trials":873,"activeCount":99},[],{"trials":875,"activeCount":99},[],{"trials":877,"activeCount":95,"soonestReadout":495},[878],{"nctId":492,"briefTitle":493,"status":481,"phases":879,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":880,"interventions":881},[89],[354],[358,425,299,500],{"trials":883,"activeCount":99},[],{"trials":885,"activeCount":99},[],{"intervention":887,"totalTrials":95,"cells":888},"Cystine",{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":910,"NA":912},{"trials":890,"activeCount":99},[],{"trials":892,"activeCount":99},[],{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":95,"soonestReadout":901},[897],{"nctId":898,"briefTitle":899,"status":245,"phases":900,"primaryCompletion":901,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":909},"NCT06790342","Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya",[89],"2029-08-01","2030-02-01","2026-06-01",300,[906,907,908],"HIV","Tobacco Use","Alcohol Use Disorder",[887],{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":99},[],{"intervention":46,"totalTrials":516,"cells":915},{"EARLY_PHASE1":916,"PHASE1":931,"PHASE2":976,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":917,"activeCount":99},[918],{"nctId":919,"briefTitle":920,"status":332,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":35,"conditions":925,"interventions":930},"NCT02981914","Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation",[86],"2020-10-09","2020-11-01","2017-03-07",[926,927,928,929],"Classical Hodgkin Lymphoma","B-cell Non-Hodgkin Lymphoma","Acute Myeloid Leukemia","Myelodysplastic Syndromes",[46],{"trials":932,"activeCount":488,"soonestReadout":45},[933,943,959,966],{"nctId":934,"briefTitle":935,"status":363,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":592,"conditions":939,"interventions":941},"NCT02707666","A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma",[87],"2023-04-24","2016-02-25",[940],"Pleural Mesothelioma",[46,942],"Cisplatin and Pemetrexed",{"nctId":944,"briefTitle":945,"status":111,"phases":946,"primaryCompletion":947,"completion":947,"start":948,"enrollment":400,"conditions":949,"interventions":956},"NCT06912087","Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC",[87],"2027-06-05","2025-09-29",[950,951,952,953,954,955],"Head and Neck Neoplasms","Carcinoma, Squamous Cell","Neoplasm Recurrence, Local","Neoplasm Metastasis","Recurrent Squamous Cell Carcinoma","Metastatic Squamous Cell Carcinoma",[957,958,46],"Zanzalintinib","Cetuximab",{"nctId":43,"briefTitle":44,"status":481,"phases":960,"primaryCompletion":45,"completion":248,"start":961,"enrollment":962,"conditions":963,"interventions":965},[87],"2015-12",117,[964],"Solid Tumor",[46],{"nctId":967,"briefTitle":968,"status":481,"phases":969,"primaryCompletion":746,"completion":746,"start":970,"enrollment":516,"conditions":971,"interventions":974},"NCT03283137","Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed\u002FRefractory CLL and B-cell NHL",[87],"2018-01-23",[972,973],"CLL","B-cell Non Hodgkin Lymphoma",[975,46],"TGR-1202",{"trials":977,"activeCount":994,"soonestReadout":50},[978,988,998,1009,1029,1040,1049,1057,1067,1080,1091,1100,1111,1118,1127],{"nctId":979,"briefTitle":980,"status":981,"phases":982,"primaryCompletion":983,"completion":983,"start":984,"enrollment":99,"conditions":985,"interventions":987},"NCT04231526","Pembrolizumab in Early Stage Colon Cancer","WITHDRAWN",[88],"2022-12-01","2020-05-20",[986],"Colon Cancer",[46],{"nctId":989,"briefTitle":990,"status":363,"phases":991,"primaryCompletion":992,"completion":992,"start":993,"enrollment":994,"conditions":995,"interventions":997},"NCT03990961","Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)",[88],"2024-04-01","2019-09-04",5,[996,787],"Diffuse Large B Cell Lymphoma",[46],{"nctId":999,"briefTitle":1000,"status":363,"phases":1001,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":545,"conditions":1004,"interventions":1007},"NCT03595683","Pembrolizumab and EDP1503 in Advanced Melanoma",[88],"2025-07-31","2018-10-02",[1005,1006],"Melanoma (Skin)","Melanoma",[46,1008],"EDP1503",{"nctId":1010,"briefTitle":1011,"status":332,"phases":1012,"primaryCompletion":1013,"completion":1014,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1028},"NCT02399371","Pembrolizumab in Treating Patients With Malignant Mesothelioma",[88],"2024-08-13","2026-03-20","2015-03-31",65,[1018,1019,1020,1021,1022,1023,1024,1025,1026,1027],"Biphasic Mesothelioma","Epithelioid Mesothelioma","Peritoneal Malignant Mesothelioma","Pleural Biphasic Mesothelioma","Pleural Epithelioid Mesothelioma","Pleural Malignant Mesothelioma","Pleural Sarcomatoid Mesothelioma","Recurrent Peritoneal Malignant Mesothelioma","Recurrent Pleural Malignant Mesothelioma","Sarcomatoid Mesothelioma",[46],{"nctId":1030,"briefTitle":1031,"status":363,"phases":1032,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":488,"conditions":1035,"interventions":1039},"NCT04089904","Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma",[88],"2023-03-11","2019-10-11",[1036,1037,1038],"Gastroesophageal Junction Adenocarcinoma","Gastric Adenocarcinoma","Esophageal Adenocarcinoma",[46],{"nctId":1041,"briefTitle":1042,"status":981,"phases":1043,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":99,"conditions":1046,"interventions":1047},"NCT03238638","A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1\u002FPD-L1 Therapy",[88],"2020-12","2018-09",[21],[46,1048],"epacadostat",{"nctId":67,"briefTitle":68,"status":481,"phases":1050,"primaryCompletion":69,"completion":1051,"start":1052,"enrollment":421,"conditions":1053,"interventions":1056},[88],"2032-09","2018-03-26",[1054,1055],"Thyroid Cancer","Salivary Gland Cancer",[46,60],{"nctId":1058,"briefTitle":1059,"status":981,"phases":1060,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":99,"conditions":1063,"interventions":1065},"NCT03325465","Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck",[88],"2018-11-07","2018-01-22",[1064],"Squamous Cell Carcinoma of the Head and Neck",[46,1066],"Epacadostat",{"nctId":1068,"briefTitle":1069,"status":481,"phases":1070,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1078},"NCT03995147","Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma",[88],"2027-02-20","2019-08-29",51,[1075,787,1076,996,1077],"B Cell Lymphoma","Lymphoma, B-Cell","High-grade B-cell Lymphoma",[46,1079],"R-CHOP Protocol",{"nctId":1081,"briefTitle":1082,"status":111,"phases":1083,"primaryCompletion":164,"completion":164,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1090},"NCT05420948","A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer",[88],"2022-10-17",30,[21,1087,950,1088,1089],"Head and Neck Squamous Cell Carcinoma","Head Cancer","Throat Carcinoma",[46,385,392],{"nctId":1092,"briefTitle":1093,"status":363,"phases":1094,"primaryCompletion":1095,"completion":1095,"start":1096,"enrollment":782,"conditions":1097,"interventions":1099},"NCT03225547","Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer",[88],"2025-09-30","2018-02-12",[1098,15],"Triple Negative Breast Neoplasms",[46,55],{"nctId":1101,"briefTitle":1102,"status":111,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1109},"NCT06669572","Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment",[88],"2029-03-26","2025-07-11",35,[951,1108],"Anorectal Cancer",[46,1110],"Lenvatinib",{"nctId":48,"briefTitle":49,"status":481,"phases":1112,"primaryCompletion":50,"completion":83,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1116},[88],"2016-06-28",70,[1006],[46,1117],"Ipilimumab",{"nctId":1119,"briefTitle":1120,"status":332,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":849,"conditions":1125,"interventions":1126},"NCT02841748","A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study",[88],"2025-02-11","2025-10-23","2017-05-10",[21,1064],[46],{"nctId":1128,"briefTitle":1129,"status":363,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":367,"conditions":1133,"interventions":1134},"NCT03463161","Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy",[88],"2018-12-04","2018-03-23",[1087,21],[46,1066],{"trials":1136,"activeCount":99},[],{"trials":1138,"activeCount":99},[],{"trials":1140,"activeCount":99},[],{"intervention":385,"totalTrials":19,"cells":1142},{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1219,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1144,"activeCount":99},[],{"trials":1146,"activeCount":95,"soonestReadout":83},[1147,1171,1190,1200,1209],{"nctId":1148,"briefTitle":1149,"status":332,"phases":1150,"primaryCompletion":1151,"completion":1151,"start":1152,"enrollment":1153,"conditions":1154,"interventions":1166},"NCT01847326","Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer",[87],"2024-01-22","2013-03-26",48,[1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165],"Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Tongue Cancer",[1167,1168,1169,1170],"carboplatin","paclitaxel albumin-stabilized nanoparticle formulation","fluorouracil","hydroxyurea",{"nctId":1172,"briefTitle":1173,"status":332,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1187},"NCT02046421","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",[87],"2018-05","2013-11",31,[1179,1180,1181,1182,1183,1184,1185,1186],"Male Breast Cancer","Recurrent Breast Cancer","Recurrent Fallopian Tube Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Primary Peritoneal Cavity Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer",[1188,1167,1189],"mifepristone","gemcitabine hydrochloride",{"nctId":1191,"briefTitle":1192,"status":363,"phases":1193,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":459,"conditions":1196,"interventions":1198},"NCT06110195","Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer",[87],"2025-05-12","2024-01-24",[21,950,1197],"Squamous Cell Carcinoma of Head and Neck",[1199,385,392],"Xevinapant",{"nctId":1201,"briefTitle":1202,"status":111,"phases":1203,"primaryCompletion":83,"completion":113,"start":1204,"enrollment":400,"conditions":1205,"interventions":1207},"NCT06005324","Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer",[87],"2023-12-18",[1206],"HPV-Negative Squamous Cell Carcinoma",[392,385,958,387,1208],"TFHX Regimen",{"nctId":1210,"briefTitle":1211,"status":332,"phases":1212,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":1216,"interventions":1218},"NCT04572100","Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer",[87],"2023-01-09","2020-10-01",50,[1217],"Oropharyngeal Squamous Cell Carcinoma",[392,385],{"trials":1220,"activeCount":592,"soonestReadout":164},[1221,1233,1246,1263,1275,1287,1298,1308,1312,1325,1329,1340,1352,1362,1375],{"nctId":1222,"briefTitle":1223,"status":363,"phases":1224,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1231},"NCT00517361","Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2\u002FNeu Neg Metastatic Breast Cancer",[88],"2011-04","2012-04","2007-08",11,[1230],"Metastatic Breast Cancer",[1167,1232],"bevacizumab",{"nctId":1234,"briefTitle":1235,"status":332,"phases":1236,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1106,"conditions":1239,"interventions":1242},"NCT03944915","De-Escalation Therapy for Human Papillomavirus Negative Disease",[88],"2023-11-01","2019-08-26",[1240,1241,1064,381,382],"Human Papilloma Virus","Squamous Cell Carcinoma",[385,392,386,1243,1244,1245,387],"Hydroxyurea Pill","5-fluorouracil","Filgrastim",{"nctId":1247,"briefTitle":1248,"status":981,"phases":1249,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":99,"conditions":1253,"interventions":1256},"NCT03058939","Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer",[88],"2019-04","2019-06","2018-11",[15,1254,1255],"Breast Cancer Stage II","Breast Cancer Stage III",[392,1257,1258,1259,1260,1261,1262,385],"Perjeta","Herceptin SC","Tamoxifen","Letrozole","LHRH agonist","FEC",{"nctId":1264,"briefTitle":1265,"status":332,"phases":1266,"primaryCompletion":1267,"completion":1268,"start":1269,"enrollment":1228,"conditions":1270,"interventions":1272},"NCT00003136","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer",[87,88],"2000-12","2001-10","1996-12",[518,1271],"Primary Peritoneal Cavity Cancer",[1273,1274,1167,686],"filgrastim","amifostine trihydrate",{"nctId":1276,"briefTitle":1277,"status":332,"phases":1278,"primaryCompletion":1279,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1284},"NCT01172470","Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients",[88],"2007-06","2010-07","2005-06",34,[21],[1285,1286,385],"Gemcitabine","Pemetrexed",{"nctId":1288,"briefTitle":1289,"status":111,"phases":1290,"primaryCompletion":1291,"completion":1292,"start":1293,"enrollment":1085,"conditions":1294,"interventions":1296},"NCT07290621","Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer",[88],"2030-02","2033-02","2026-02",[1295],"Oropharyngeal Cancer",[1297,385,392],"Toripalimab",{"nctId":1299,"briefTitle":1300,"status":332,"phases":1301,"primaryCompletion":1302,"completion":1227,"start":1303,"enrollment":545,"conditions":1304,"interventions":1306},"NCT00025389","Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer",[88],"2005-12","2001-11",[1305],"Lung Cancer",[1232,1167,1307],"paclitaxel",{"nctId":374,"briefTitle":375,"status":332,"phases":1309,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":1310,"interventions":1311},[88],[381,382],[384,385,386,387,388,389,299,390,391,392],{"nctId":1313,"briefTitle":1314,"status":332,"phases":1315,"primaryCompletion":377,"completion":377,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1323},"NCT02258659","Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer",[88],"2014-09-22",62,[1319,1320,1321,1322],"Human Papilloma Virus Infection","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Oropharynx",[1168,1167,1307,1169,1170,1324],"cisplatin",{"nctId":1081,"briefTitle":1082,"status":111,"phases":1326,"primaryCompletion":164,"completion":164,"start":1084,"enrollment":1085,"conditions":1327,"interventions":1328},[88],[21,1087,950,1088,1089],[46,385,392],{"nctId":1330,"briefTitle":1331,"status":245,"phases":1332,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1337},"NCT07346196","A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck",[88],"2031-08-22","2027-02-07",90,[1241],[1338,1339,385,392],"Cemiplimab","Fianlimab",{"nctId":1341,"briefTitle":1342,"status":481,"phases":1343,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1106,"conditions":1346,"interventions":1349},"NCT05108870","TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers",[87,88],"2027-01-01","2022-08-22",[1240,1347,1348,21],"HPV","HPV Positive Oropharyngeal Squamous Cell Carcinoma",[1350,1351,385,392],"HB-201","HB-202",{"nctId":1353,"briefTitle":1354,"status":111,"phases":1355,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1360},"NCT07065630","Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer",[88],"2029-08-13","2025-10-07",38,[21,1347],[1361,385,392],"Volrustomig",{"nctId":1363,"briefTitle":1364,"status":111,"phases":1365,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1372},"NCT05068232","Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)",[88],"2027-10-01","2022-08-19",49,[1370,1371,1305],"Small-cell Lung Cancer","Extensive-stage Small-cell Lung Cancer",[1373,1374,385],"Durvalumab","Etoposide",{"nctId":1376,"briefTitle":1377,"status":111,"phases":1378,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":1382,"conditions":1383,"interventions":1385},"NCT06291064","Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer",[88],"2029-06","2032-06","2025-03-18",85,[1384],"Triple Negative Breast Cancer",[319,1386,60,385,1387],"Epirubicin","Capecitabine",{"trials":1389,"activeCount":99},[],{"trials":1391,"activeCount":99},[],{"trials":1393,"activeCount":99},[1394],{"nctId":1395,"briefTitle":1396,"status":332,"phases":1397,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":516,"conditions":1400,"interventions":1402},"NCT01063283","Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC",[91],"2016-06","2010-03",[1401],"Advanced Non-squamous Non-Small Cell Lung Cancer",[1286,385,1403,1404],"Bevacizumab 7.5 mg\u002Fkg","Bevacizumab 15 mg\u002Fkg",{"intervention":392,"totalTrials":516,"cells":1406},{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1457,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1408,"activeCount":99},[],{"trials":1410,"activeCount":95,"soonestReadout":83},[1411,1421,1425,1440,1449,1453],{"nctId":1412,"briefTitle":1413,"status":332,"phases":1414,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":860,"conditions":1418,"interventions":1419},"NCT00724386","Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer",[87],"2005-10","2012-11","1999-06",[15],[392,1420,1245],"Vinorelbine",{"nctId":1191,"briefTitle":1192,"status":363,"phases":1422,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":459,"conditions":1423,"interventions":1424},[87],[21,950,1197],[1199,385,392],{"nctId":1426,"briefTitle":1427,"status":332,"phases":1428,"primaryCompletion":1429,"completion":1430,"start":1431,"enrollment":1432,"conditions":1433,"interventions":1438},"NCT00002949","Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis",[87],"2000-11","2001-05","1996-07",33,[1434,1435,1436,1437],"Bladder Cancer","Cervical Cancer","Endometrial Cancer","Vaginal Cancer",[1307,1439],"vinorelbine tartrate",{"nctId":1441,"briefTitle":1442,"status":332,"phases":1443,"primaryCompletion":1444,"completion":815,"start":1445,"enrollment":19,"conditions":1446,"interventions":1447},"NCT00002939","Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer",[87],"2001-02","1996-11",[772],[1448,1307],"irinotecan hydrochloride",{"nctId":1201,"briefTitle":1202,"status":111,"phases":1450,"primaryCompletion":83,"completion":113,"start":1204,"enrollment":400,"conditions":1451,"interventions":1452},[87],[1206],[392,385,958,387,1208],{"nctId":1210,"briefTitle":1211,"status":332,"phases":1454,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":1455,"interventions":1456},[87],[1217],[392,385],{"trials":1458,"activeCount":994,"soonestReadout":164},[1459,1463,1467,1471,1475,1479,1489,1493,1497,1506,1510,1514,1522],{"nctId":1234,"briefTitle":1235,"status":332,"phases":1460,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1106,"conditions":1461,"interventions":1462},[88],[1240,1241,1064,381,382],[385,392,386,1243,1244,1245,387],{"nctId":1247,"briefTitle":1248,"status":981,"phases":1464,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":99,"conditions":1465,"interventions":1466},[88],[15,1254,1255],[392,1257,1258,1259,1260,1261,1262,385],{"nctId":1288,"briefTitle":1289,"status":111,"phases":1468,"primaryCompletion":1291,"completion":1292,"start":1293,"enrollment":1085,"conditions":1469,"interventions":1470},[88],[1295],[1297,385,392],{"nctId":1299,"briefTitle":1300,"status":332,"phases":1472,"primaryCompletion":1302,"completion":1227,"start":1303,"enrollment":545,"conditions":1473,"interventions":1474},[88],[1305],[1232,1167,1307],{"nctId":374,"briefTitle":375,"status":332,"phases":1476,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":1477,"interventions":1478},[88],[381,382],[384,385,386,387,388,389,299,390,391,392],{"nctId":1480,"briefTitle":1481,"status":332,"phases":1482,"primaryCompletion":1483,"completion":1484,"start":1485,"enrollment":1358,"conditions":1486,"interventions":1487},"NCT00004126","Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer",[88],"2001-01","2003-08","1999-11",[1305],[1488,1307],"oxaliplatin",{"nctId":1313,"briefTitle":1314,"status":332,"phases":1490,"primaryCompletion":377,"completion":377,"start":1316,"enrollment":1317,"conditions":1491,"interventions":1492},[88],[1319,1320,1321,1322],[1168,1167,1307,1169,1170,1324],{"nctId":1081,"briefTitle":1082,"status":111,"phases":1494,"primaryCompletion":164,"completion":164,"start":1084,"enrollment":1085,"conditions":1495,"interventions":1496},[88],[21,1087,950,1088,1089],[46,385,392],{"nctId":1498,"briefTitle":1499,"status":332,"phases":1500,"primaryCompletion":397,"completion":1501,"start":1502,"enrollment":312,"conditions":1503,"interventions":1504},"NCT00005849","Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer",[88],"2003-11","2000-04",[1305],[1505,1307],"bryostatin 1",{"nctId":1330,"briefTitle":1331,"status":245,"phases":1507,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":1508,"interventions":1509},[88],[1241],[1338,1339,385,392],{"nctId":1341,"briefTitle":1342,"status":481,"phases":1511,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1106,"conditions":1512,"interventions":1513},[87,88],[1240,1347,1348,21],[1350,1351,385,392],{"nctId":1515,"briefTitle":1516,"status":332,"phases":1517,"primaryCompletion":1483,"completion":1518,"start":1502,"enrollment":35,"conditions":1519,"interventions":1520},"NCT00005032","Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer",[87,88],"2001-09",[1305],[1521,1307],"oblimersen sodium",{"nctId":1353,"briefTitle":1354,"status":111,"phases":1523,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":1358,"conditions":1524,"interventions":1525},[88],[21,1347],[1361,385,392],{"trials":1527,"activeCount":99},[],{"trials":1529,"activeCount":99},[],{"trials":1531,"activeCount":99},[1532],{"nctId":1533,"briefTitle":1534,"status":981,"phases":1535,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":99,"conditions":1538,"interventions":1539},"NCT02637375","A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer",[91],"2018-12","2016-05",[15],[1540,392,326,319],"Ganetespib",{"intervention":60,"totalTrials":592,"cells":1542},{"EARLY_PHASE1":1543,"PHASE1":1545,"PHASE2":1562,"PHASE3":1607,"PHASE4":1623,"NA":1625},{"trials":1544,"activeCount":99},[],{"trials":1546,"activeCount":95,"soonestReadout":83},[1547],{"nctId":1548,"briefTitle":1549,"status":111,"phases":1550,"primaryCompletion":83,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1557},"NCT04361708","Safety of Combining Irinotecan With 5-FU, Leucovorin\u002FFolinic Acid, Oxaliplatin, and Docetaxel Chemotherapies",[87],"2027-05","2020-05-08",54,[1555,1036,1556],"Pancreatic Adenocarcinoma","Adenocarcinoma",[1558,60,1559,1560,1561],"Oxaliplatin","Leucovorin","Irinotecan","5-Fluorouracil",{"trials":1563,"activeCount":526,"soonestReadout":59},[1564,1576,1586,1590,1603],{"nctId":1565,"briefTitle":1566,"status":332,"phases":1567,"primaryCompletion":1568,"completion":1569,"start":1570,"enrollment":1571,"conditions":1572,"interventions":1573},"NCT00005086","Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer",[88],"2002-08","2005-04","1999-08",6,[1434],[1324,1574,1189,1575],"docetaxel","methotrexate",{"nctId":57,"briefTitle":58,"status":481,"phases":1577,"primaryCompletion":59,"completion":1578,"start":1579,"enrollment":1580,"conditions":1581,"interventions":1584},[88],"2026-09-30","2019-11-25",53,[15,1582,1583,1254,1255],"Breast Cancer Female","HER2-positive Breast Cancer",[60,1585,1262,1259,1260,1261],"Herceptin",{"nctId":67,"briefTitle":68,"status":481,"phases":1587,"primaryCompletion":69,"completion":1051,"start":1052,"enrollment":421,"conditions":1588,"interventions":1589},[88],[1054,1055],[46,60],{"nctId":1591,"briefTitle":1592,"status":111,"phases":1593,"primaryCompletion":1594,"completion":1595,"start":1381,"enrollment":1596,"conditions":1597,"interventions":1599},"NCT06348134","Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery",[88],"2034-07-01","2036-07-01",74,[1598,1583,15],"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",[1600,1601,60,1259,1260,1602],"Trastuzumab emtansine","Pertuzumab","Goserelin",{"nctId":1376,"briefTitle":1377,"status":111,"phases":1604,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":1382,"conditions":1605,"interventions":1606},[88],[1384],[319,1386,60,385,1387],{"trials":1608,"activeCount":99},[1609],{"nctId":1610,"briefTitle":1611,"status":332,"phases":1612,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":1615,"conditions":1616,"interventions":1622},"NCT00117572","Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)",[89],"2016-12","2004-11",285,[1617,1618,1619,1620,1621],"Cancer of the Pharynx","Cancer of the Larynx","Cancer of the Nasal Cavity","Paranasal Sinus Neoplasms","Cancer of the Oral Cavity",[1574,1324,1170,1169],{"trials":1624,"activeCount":99},[],{"trials":1626,"activeCount":99},[],{"intervention":1628,"totalTrials":488,"cells":1629},"Allogenic islet cells",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1631,"activeCount":99},[],{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":367,"soonestReadout":113},[1636,1645],{"nctId":1637,"briefTitle":1638,"status":481,"phases":1639,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":1215,"conditions":1642,"interventions":1644},"NCT00160732","Allogenic Islet Cell Transplantation",[87,88],"2030-10","2003-10",[1643],"Diabetes Mellitus, Type 1",[1628],{"nctId":1646,"briefTitle":1647,"status":111,"phases":1648,"primaryCompletion":113,"completion":113,"start":1649,"enrollment":732,"conditions":1650,"interventions":1651},"NCT01241864","Islet Transplantation in Type 1 Diabetic Kidney Allograft",[88],"2010-12",[1643],[1628],{"trials":1653,"activeCount":99},[],{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":95,"soonestReadout":1662},[1658],{"nctId":1659,"briefTitle":1660,"status":111,"phases":1661,"primaryCompletion":1662,"completion":1662,"start":837,"enrollment":516,"conditions":1663,"interventions":1664},"NCT01630850","Islet Transplantation in Patients With \"Brittle\" Type I Diabetes",[91],"2030-06",[1643],[1628],{"intervention":387,"totalTrials":35,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1689,"PHASE3":1757,"PHASE4":1763,"NA":1765},{"trials":1668,"activeCount":99},[],{"trials":1670,"activeCount":95,"soonestReadout":83},[1671,1685],{"nctId":1672,"briefTitle":1673,"status":363,"phases":1674,"primaryCompletion":1675,"completion":1675,"start":1280,"enrollment":367,"conditions":1676,"interventions":1679},"NCT01258634","A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response",[87],"2011-11",[1677,1678],"Osteosarcoma","Lung Metastases",[1680,326,387,1681,1682,1374,1683,1684,1559],"Dexrazoxane","G-CSF","PEG-filgrastim","Ifosfamide","Mesna",{"nctId":1201,"briefTitle":1202,"status":111,"phases":1686,"primaryCompletion":83,"completion":113,"start":1204,"enrollment":400,"conditions":1687,"interventions":1688},[87],[1206],[392,385,958,387,1208],{"trials":1690,"activeCount":95,"soonestReadout":903},[1691,1695,1705,1714,1718,1722,1731,1743,1747],{"nctId":1234,"briefTitle":1235,"status":332,"phases":1692,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1106,"conditions":1693,"interventions":1694},[88],[1240,1241,1064,381,382],[385,392,386,1243,1244,1245,387],{"nctId":1696,"briefTitle":1697,"status":111,"phases":1698,"primaryCompletion":903,"completion":903,"start":1699,"enrollment":19,"conditions":1700,"interventions":1703},"NCT04107077","Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer",[88],"2025-09-09",[1701,1702],"Gastric Cancer","Peritoneal Carcinomatosis",[387,1704],"Mitomycin",{"nctId":1706,"briefTitle":1707,"status":332,"phases":1708,"primaryCompletion":1614,"completion":1709,"start":399,"enrollment":1710,"conditions":1711,"interventions":1713},"NCT00006105","Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer",[88],"2006-09",37,[1434,1712],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan",[1274,1324,1189],{"nctId":1565,"briefTitle":1566,"status":332,"phases":1715,"primaryCompletion":1568,"completion":1569,"start":1570,"enrollment":1571,"conditions":1716,"interventions":1717},[88],[1434],[1324,1574,1189,1575],{"nctId":374,"briefTitle":375,"status":332,"phases":1719,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":1720,"interventions":1721},[88],[381,382],[384,385,386,387,388,389,299,390,391,392],{"nctId":1723,"briefTitle":1724,"status":332,"phases":1725,"primaryCompletion":1726,"completion":1416,"start":1727,"enrollment":1728,"conditions":1729,"interventions":1730},"NCT00468169","Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer",[88],"2012-08","2006-07",110,[21],[958,389,388,387],{"nctId":1732,"briefTitle":1733,"status":332,"phases":1734,"primaryCompletion":1735,"completion":1736,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1741},"NCT01693718","A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer",[88],"2003-09","2004-09","2003-03",44,[1740],"Head and Neck",[388,1742,387],"5- Fluorouracil",{"nctId":1313,"briefTitle":1314,"status":332,"phases":1744,"primaryCompletion":377,"completion":377,"start":1316,"enrollment":1317,"conditions":1745,"interventions":1746},[88],[1319,1320,1321,1322],[1168,1167,1307,1169,1170,1324],{"nctId":1748,"briefTitle":1749,"status":332,"phases":1750,"primaryCompletion":515,"completion":1751,"start":1752,"enrollment":421,"conditions":1753,"interventions":1754},"NCT00004141","Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma",[88],"2006-04","1998-08",[1005],[387,1755,1756],"dacarbazine","Granulocyte-macrophage colony-stimulating factor",{"trials":1758,"activeCount":99},[1759],{"nctId":1610,"briefTitle":1611,"status":332,"phases":1760,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":1615,"conditions":1761,"interventions":1762},[89],[1617,1618,1619,1620,1621],[1574,1324,1170,1169],{"trials":1764,"activeCount":99},[],{"trials":1766,"activeCount":99},[],{"intervention":1117,"totalTrials":526,"cells":1768},{"EARLY_PHASE1":1769,"PHASE1":1771,"PHASE2":1792,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1770,"activeCount":99},[],{"trials":1772,"activeCount":95,"soonestReadout":113},[1773,1783],{"nctId":1774,"briefTitle":1775,"status":363,"phases":1776,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1779,"conditions":1780,"interventions":1782},"NCT03203304","Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer",[87],"2019-03-13","2017-08-25",14,[1781],"Hepatocellular Carcinoma",[386,1117],{"nctId":1784,"briefTitle":1785,"status":481,"phases":1786,"primaryCompletion":113,"completion":746,"start":1787,"enrollment":1788,"conditions":1789,"interventions":1791},"NCT03223155","Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer",[87],"2017-09-07",78,[1790],"Stage IV Small Cell Lung Cancer",[386,1117],{"trials":1793,"activeCount":95,"soonestReadout":50},[1794,1804],{"nctId":1795,"briefTitle":1796,"status":332,"phases":1797,"primaryCompletion":1798,"completion":1798,"start":1799,"enrollment":367,"conditions":1800,"interventions":1803},"NCT05041062","A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w\u002FResectable Malignant Peritoneal Mesothelioma",[88],"2023-04-13","2021-12-01",[1801,1802],"Mesothelioma","Peritoneal Mesothelioma",[386,1117],{"nctId":48,"briefTitle":49,"status":481,"phases":1805,"primaryCompletion":50,"completion":83,"start":1113,"enrollment":1114,"conditions":1806,"interventions":1807},[88],[1006],[46,1117],{"trials":1809,"activeCount":99},[],{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":99},[],{"intervention":325,"totalTrials":526,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1824,"PHASE3":1838,"PHASE4":1840,"NA":1842},{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":95,"soonestReadout":309},[1820],{"nctId":306,"briefTitle":307,"status":111,"phases":1821,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":1822,"interventions":1823},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"trials":1825,"activeCount":95,"soonestReadout":164},[1826,1830,1834],{"nctId":1565,"briefTitle":1566,"status":332,"phases":1827,"primaryCompletion":1568,"completion":1569,"start":1570,"enrollment":1571,"conditions":1828,"interventions":1829},[88],[1434],[1324,1574,1189,1575],{"nctId":441,"briefTitle":442,"status":111,"phases":1831,"primaryCompletion":164,"completion":164,"start":444,"enrollment":312,"conditions":1832,"interventions":1833},[87,88],[446,447,448],[450,451,322,299,325],{"nctId":466,"briefTitle":467,"status":468,"phases":1835,"primaryCompletion":470,"completion":470,"start":471,"enrollment":410,"conditions":1836,"interventions":1837},[88],[447,314,473],[475,476,299,325,322,451,477],{"trials":1839,"activeCount":99},[],{"trials":1841,"activeCount":99},[],{"trials":1843,"activeCount":99},[],{"intervention":1259,"totalTrials":488,"cells":1845},{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1864,"PHASE4":1866,"NA":1868},{"trials":1847,"activeCount":99},[],{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":367,"soonestReadout":59},[1852,1856,1860],{"nctId":1247,"briefTitle":1248,"status":981,"phases":1853,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":99,"conditions":1854,"interventions":1855},[88],[15,1254,1255],[392,1257,1258,1259,1260,1261,1262,385],{"nctId":57,"briefTitle":58,"status":481,"phases":1857,"primaryCompletion":59,"completion":1578,"start":1579,"enrollment":1580,"conditions":1858,"interventions":1859},[88],[15,1582,1583,1254,1255],[60,1585,1262,1259,1260,1261],{"nctId":1591,"briefTitle":1592,"status":111,"phases":1861,"primaryCompletion":1594,"completion":1595,"start":1381,"enrollment":1596,"conditions":1862,"interventions":1863},[88],[1598,1583,15],[1600,1601,60,1259,1260,1602],{"trials":1865,"activeCount":99},[],{"trials":1867,"activeCount":99},[],{"trials":1869,"activeCount":99},[],{"intervention":1260,"totalTrials":488,"cells":1871},{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1890,"PHASE4":1892,"NA":1894},{"trials":1873,"activeCount":99},[],{"trials":1875,"activeCount":99},[],{"trials":1877,"activeCount":367,"soonestReadout":59},[1878,1882,1886],{"nctId":1247,"briefTitle":1248,"status":981,"phases":1879,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":99,"conditions":1880,"interventions":1881},[88],[15,1254,1255],[392,1257,1258,1259,1260,1261,1262,385],{"nctId":57,"briefTitle":58,"status":481,"phases":1883,"primaryCompletion":59,"completion":1578,"start":1579,"enrollment":1580,"conditions":1884,"interventions":1885},[88],[15,1582,1583,1254,1255],[60,1585,1262,1259,1260,1261],{"nctId":1591,"briefTitle":1592,"status":111,"phases":1887,"primaryCompletion":1594,"completion":1595,"start":1381,"enrollment":1596,"conditions":1888,"interventions":1889},[88],[1598,1583,15],[1600,1601,60,1259,1260,1602],{"trials":1891,"activeCount":99},[],{"trials":1893,"activeCount":99},[],{"trials":1895,"activeCount":99},[],{"intervention":1897,"totalTrials":488,"cells":1898},"Venetoclax",{"EARLY_PHASE1":1899,"PHASE1":1901,"PHASE2":1912,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1900,"activeCount":99},[],{"trials":1902,"activeCount":95,"soonestReadout":1907},[1903],{"nctId":1904,"briefTitle":1905,"status":481,"phases":1906,"primaryCompletion":1907,"completion":1907,"start":1908,"enrollment":860,"conditions":1909,"interventions":1910},"NCT03844815","Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia",[87],"2027-12-10","2019-11-18",[928],[1911,1897],"Decitabine",{"trials":1913,"activeCount":95,"soonestReadout":1928},[1914,1924],{"nctId":1915,"briefTitle":1916,"status":363,"phases":1917,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":367,"conditions":1920,"interventions":1922},"NCT04722601","A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma",[87,88],"2023-03-31","2021-09-01",[1921],"Follicular Lymphoma",[1897,372,1923],"CC-486",{"nctId":1925,"briefTitle":1926,"status":111,"phases":1927,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":1930,"conditions":1931,"interventions":1933},"NCT07294677","CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL\u002FLBL",[87,88],"2032-03","2026-03-17",104,[1932,787],"Leukemia",[1934,1897,324,1935,1936,1937],"Capivasertib","Blinatumomab","Nelarabine","mini-hyperCVD",{"trials":1939,"activeCount":99},[],{"trials":1941,"activeCount":99},[],{"trials":1943,"activeCount":99},[],{"intervention":324,"totalTrials":488,"cells":1945},{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1954,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1947,"activeCount":99},[],{"trials":1949,"activeCount":95,"soonestReadout":309},[1950],{"nctId":306,"briefTitle":307,"status":111,"phases":1951,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":1952,"interventions":1953},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"trials":1955,"activeCount":95,"soonestReadout":1928},[1956,1960],{"nctId":1925,"briefTitle":1926,"status":111,"phases":1957,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":1930,"conditions":1958,"interventions":1959},[87,88],[1932,787],[1934,1897,324,1935,1936,1937],{"nctId":601,"briefTitle":602,"status":332,"phases":1961,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":1962,"interventions":1963},[87,88],[609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680],[439,682,683,684,685,686,687],{"trials":1965,"activeCount":99},[],{"trials":1967,"activeCount":99},[],{"trials":1969,"activeCount":99},[],{"intervention":322,"totalTrials":488,"cells":1971},{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1980,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":95,"soonestReadout":309},[1976],{"nctId":306,"briefTitle":307,"status":111,"phases":1977,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":1978,"interventions":1979},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"trials":1981,"activeCount":95,"soonestReadout":164},[1982,1986],{"nctId":441,"briefTitle":442,"status":111,"phases":1983,"primaryCompletion":164,"completion":164,"start":444,"enrollment":312,"conditions":1984,"interventions":1985},[87,88],[446,447,448],[450,451,322,299,325],{"nctId":466,"briefTitle":467,"status":468,"phases":1987,"primaryCompletion":470,"completion":470,"start":471,"enrollment":410,"conditions":1988,"interventions":1989},[88],[447,314,473],[475,476,299,325,322,451,477],{"trials":1991,"activeCount":99},[],{"trials":1993,"activeCount":99},[],{"trials":1995,"activeCount":99},[],{"intervention":1338,"totalTrials":367,"cells":1997},{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2017,"PHASE4":2019,"NA":2021},{"trials":1999,"activeCount":99},[],{"trials":2001,"activeCount":99},[],{"trials":2003,"activeCount":367,"soonestReadout":2012},[2004,2008],{"nctId":1330,"briefTitle":1331,"status":245,"phases":2005,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":2006,"interventions":2007},[88],[1241],[1338,1339,385,392],{"nctId":2009,"briefTitle":2010,"status":245,"phases":2011,"primaryCompletion":2012,"completion":2012,"start":164,"enrollment":2013,"conditions":2014,"interventions":2015},"NCT07179315","A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment",[88],"2029-11-30",68,[21],[2016,1338],"cemiplimab+fianlimab",{"trials":2018,"activeCount":99},[],{"trials":2020,"activeCount":99},[],{"trials":2022,"activeCount":99},[],{"intervention":1911,"totalTrials":367,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2033,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":95,"soonestReadout":1907},[2029],{"nctId":1904,"briefTitle":1905,"status":481,"phases":2030,"primaryCompletion":1907,"completion":1907,"start":1908,"enrollment":860,"conditions":2031,"interventions":2032},[87],[928],[1911,1897],{"trials":2034,"activeCount":95,"soonestReadout":2039},[2035],{"nctId":2036,"briefTitle":2037,"status":245,"phases":2038,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":782,"conditions":2041,"interventions":2043},"NCT07389239","A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.",[87,88],"2031-12-10","2026-06-23",[518,2042],"Advanced Malignant Solid Tumor",[1911,2044,2045,2046],"Cyclophosphamide Conditioning","NY-ESO-1 TCR\u002F dnTGFβRII","Aldesleukin",{"trials":2048,"activeCount":99},[],{"trials":2050,"activeCount":99},[],{"trials":2052,"activeCount":99},[],{"intervention":686,"totalTrials":592,"cells":2054},{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2063,"PHASE3":2098,"PHASE4":2100,"NA":2102},{"trials":2056,"activeCount":99},[],{"trials":2058,"activeCount":95,"soonestReadout":309},[2059],{"nctId":306,"briefTitle":307,"status":111,"phases":2060,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":2061,"interventions":2062},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"trials":2064,"activeCount":95,"soonestReadout":1379},[2065,2069,2081,2085,2094],{"nctId":1264,"briefTitle":1265,"status":332,"phases":2066,"primaryCompletion":1267,"completion":1268,"start":1269,"enrollment":1228,"conditions":2067,"interventions":2068},[87,88],[518,1271],[1273,1274,1167,686],{"nctId":2070,"briefTitle":2071,"status":332,"phases":2072,"primaryCompletion":2073,"completion":1227,"start":2074,"enrollment":2075,"conditions":2076,"interventions":2078},"NCT00004135","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer",[88],"2004-10","1999-02",19,[2077,1005],"Kidney Cancer",[1273,2079,686,2080],"therapeutic allogeneic lymphocytes","fludarabine phosphate",{"nctId":601,"briefTitle":602,"status":332,"phases":2082,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":2083,"interventions":2084},[87,88],[609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680],[439,682,683,684,685,686,687],{"nctId":2086,"briefTitle":2087,"status":332,"phases":2088,"primaryCompletion":1501,"completion":814,"start":2089,"enrollment":30,"conditions":2090,"interventions":2092},"NCT00004145","Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",[88],"1998-11",[1932,787,2091,929],"Multiple Myeloma and Plasma Cell Neoplasm",[2093,686,2080],"anti-thymocyte globulin",{"nctId":1376,"briefTitle":1377,"status":111,"phases":2095,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":1382,"conditions":2096,"interventions":2097},[88],[1384],[319,1386,60,385,1387],{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[2104],{"nctId":1533,"briefTitle":1534,"status":981,"phases":2105,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":99,"conditions":2106,"interventions":2107},[91],[15],[1540,392,326,319],{"intervention":1188,"totalTrials":994,"cells":2109},{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2126,"PHASE3":2154,"PHASE4":2156,"NA":2158},{"trials":2111,"activeCount":99},[],{"trials":2113,"activeCount":99},[2114,2122],{"nctId":2115,"briefTitle":2116,"status":332,"phases":2117,"primaryCompletion":1175,"completion":1175,"start":1675,"enrollment":2118,"conditions":2119,"interventions":2121},"NCT01493310","Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer",[87],9,[1179,1180,2120,1184,1185,1186],"Stage IIIA Breast Cancer",[1188,384],{"nctId":1172,"briefTitle":1173,"status":332,"phases":2123,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":2124,"interventions":2125},[87],[1179,1180,1181,1182,1183,1184,1185,1186],[1188,1167,1189],{"trials":2127,"activeCount":95,"soonestReadout":54},[2128,2142,2150],{"nctId":2129,"briefTitle":2130,"status":332,"phases":2131,"primaryCompletion":2132,"completion":2133,"start":2134,"enrollment":2135,"conditions":2136,"interventions":2140},"NCT02012296","Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer",[87,88],"2019-06-10","2020-08-01","2013-12-13",88,[2137,2138,2139],"Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer","Stage IV Prostate Cancer",[2141,1188],"enzalutamide",{"nctId":52,"briefTitle":53,"status":481,"phases":2143,"primaryCompletion":54,"completion":2144,"start":2145,"enrollment":2146,"conditions":2147,"interventions":2148},[88],"2026-08","2017-03-28",29,[15],[55,2149],"Nab-Paclitaxel",{"nctId":1092,"briefTitle":1093,"status":363,"phases":2151,"primaryCompletion":1095,"completion":1095,"start":1096,"enrollment":782,"conditions":2152,"interventions":2153},[88],[1098,15],[46,55],{"trials":2155,"activeCount":99},[],{"trials":2157,"activeCount":99},[],{"trials":2159,"activeCount":99},[],{"intervention":1374,"totalTrials":526,"cells":2161},{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2170,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2163,"activeCount":99},[],{"trials":2165,"activeCount":99},[2166],{"nctId":1672,"briefTitle":1673,"status":363,"phases":2167,"primaryCompletion":1675,"completion":1675,"start":1280,"enrollment":367,"conditions":2168,"interventions":2169},[87],[1677,1678],[1680,326,387,1681,1682,1374,1683,1684,1559],{"trials":2171,"activeCount":95,"soonestReadout":1366},[2172,2184,2188],{"nctId":2173,"briefTitle":2174,"status":332,"phases":2175,"primaryCompletion":2176,"completion":2176,"start":2177,"enrollment":2178,"conditions":2179,"interventions":2181},"NCT00774046","High-dose Cytarabine\u002FMitoxantrone Followed by Autotransplantation for t-MDS\u002Ft-AML",[88],"2011-03","2002-12",32,[2180,928],"Myelodysplastic Syndrome",[2182,2183,1374],"Ara-C","Mitoxantrone",{"nctId":601,"briefTitle":602,"status":332,"phases":2185,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":2186,"interventions":2187},[87,88],[609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680],[439,682,683,684,685,686,687],{"nctId":1363,"briefTitle":1364,"status":111,"phases":2189,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":1368,"conditions":2190,"interventions":2191},[88],[1370,1371,1305],[1373,1374,385],{"trials":2193,"activeCount":99},[],{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[],{"intervention":2199,"totalTrials":488,"cells":2200},"Enzalutamide",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2214,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2202,"activeCount":99},[],{"trials":2204,"activeCount":99},[2205],{"nctId":2206,"briefTitle":2207,"status":332,"phases":2208,"primaryCompletion":2209,"completion":2209,"start":2210,"enrollment":459,"conditions":2211,"interventions":2212},"NCT03674814","Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer",[87],"2024-06-10","2018-10-23",[18],[2199,2213],"Relacorilant",{"trials":2215,"activeCount":95,"soonestReadout":1366},[2216,2220],{"nctId":2129,"briefTitle":2130,"status":332,"phases":2217,"primaryCompletion":2132,"completion":2133,"start":2134,"enrollment":2135,"conditions":2218,"interventions":2219},[87,88],[2137,2138,2139],[2141,1188],{"nctId":2221,"briefTitle":2222,"status":111,"phases":2223,"primaryCompletion":1366,"completion":2224,"start":2225,"enrollment":1335,"conditions":2226,"interventions":2228},"NCT05726292","A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer",[88],"2028-04-01","2025-01-06",[18,2227],"Prostate Adenocarcinoma",[2213,2199],{"trials":2230,"activeCount":99},[],{"trials":2232,"activeCount":99},[],{"trials":2234,"activeCount":99},[],{"intervention":384,"totalTrials":488,"cells":2236},{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2245,"PHASE3":2255,"PHASE4":2257,"NA":2259},{"trials":2238,"activeCount":99},[],{"trials":2240,"activeCount":99},[2241],{"nctId":2115,"briefTitle":2116,"status":332,"phases":2242,"primaryCompletion":1175,"completion":1175,"start":1675,"enrollment":2118,"conditions":2243,"interventions":2244},[87],[1179,1180,2120,1184,1185,1186],[1188,384],{"trials":2246,"activeCount":95,"soonestReadout":54},[2247,2251],{"nctId":52,"briefTitle":53,"status":481,"phases":2248,"primaryCompletion":54,"completion":2144,"start":2145,"enrollment":2146,"conditions":2249,"interventions":2250},[88],[15],[55,2149],{"nctId":374,"briefTitle":375,"status":332,"phases":2252,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":2253,"interventions":2254},[88],[381,382],[384,385,386,387,388,389,299,390,391,392],{"trials":2256,"activeCount":99},[],{"trials":2258,"activeCount":99},[],{"trials":2260,"activeCount":99},[],{"intervention":1387,"totalTrials":488,"cells":2262},{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2277,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2264,"activeCount":99},[],{"trials":2266,"activeCount":99},[2267],{"nctId":2268,"briefTitle":2269,"status":363,"phases":2270,"primaryCompletion":2271,"completion":2271,"start":2272,"enrollment":19,"conditions":2273,"interventions":2274},"NCT01705106","Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies",[87],"2016-02-10","2012-08-29",[772],[2275,2276],"capecitabine","celecoxib",{"trials":2278,"activeCount":95,"soonestReadout":1379},[2279,2286],{"nctId":2280,"briefTitle":2281,"status":363,"phases":2282,"primaryCompletion":2283,"completion":2283,"start":1709,"enrollment":24,"conditions":2284,"interventions":2285},"NCT00347438","Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer",[88],"2013-03",[15],[1387],{"nctId":1376,"briefTitle":1377,"status":111,"phases":2287,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":1382,"conditions":2288,"interventions":2289},[88],[1384],[319,1386,60,385,1387],{"trials":2291,"activeCount":99},[],{"trials":2293,"activeCount":99},[],{"trials":2295,"activeCount":99},[],{"intervention":2297,"totalTrials":488,"cells":2298},"Tocilizumab",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2333,"PHASE4":2335,"NA":2337},{"trials":2300,"activeCount":99},[],{"trials":2302,"activeCount":99},[],{"trials":2304,"activeCount":95,"soonestReadout":2317},[2305,2313,2324],{"nctId":2306,"briefTitle":2307,"status":332,"phases":2308,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":2178,"conditions":2311,"interventions":2312},"NCT04331795","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",[88],"2020-06-05","2020-04-04",[117],[2297,2297],{"nctId":2314,"briefTitle":2315,"status":111,"phases":2316,"primaryCompletion":2317,"completion":2318,"start":2319,"enrollment":140,"conditions":2320,"interventions":2323},"NCT05640271","Tocilizumab for Acute Chest Syndrome",[88],"2026-07","2027-01","2023-04-10",[2321,2322],"Sickle Cell Disease","Acute Chest Syndrome",[2297],{"nctId":2325,"briefTitle":2326,"status":363,"phases":2327,"primaryCompletion":2328,"completion":2329,"start":2330,"enrollment":1382,"conditions":2331,"interventions":2332},"NCT04479358","Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19",[88],"2024-03-01","2025-02-10","2020-09-10",[117],[2297,2297],{"trials":2334,"activeCount":99},[],{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[],{"intervention":84,"totalTrials":367,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2363,"PHASE4":2365,"NA":2367},{"trials":2342,"activeCount":99},[],{"trials":2344,"activeCount":99},[],{"trials":2346,"activeCount":95,"soonestReadout":83},[2347,2354],{"nctId":81,"briefTitle":82,"status":481,"phases":2348,"primaryCompletion":83,"completion":83,"start":2349,"enrollment":1368,"conditions":2350,"interventions":2353},[88],"2023-06-22",[2351,2352],"Obsessive-Compulsive Disorder","OCD",[84],{"nctId":2355,"briefTitle":2356,"status":332,"phases":2357,"primaryCompletion":837,"completion":2358,"start":2359,"enrollment":782,"conditions":2360,"interventions":2362},"NCT00927563","Tolcapone Treatment of Pathological Gambling",[88],"2012-07","2009-06",[2361],"Pathological Gambling",[84],{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[],{"trials":2368,"activeCount":99},[],{"intervention":1261,"totalTrials":367,"cells":2370},{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":99},[],{"trials":2376,"activeCount":95,"soonestReadout":59},[2377,2381],{"nctId":1247,"briefTitle":1248,"status":981,"phases":2378,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":99,"conditions":2379,"interventions":2380},[88],[15,1254,1255],[392,1257,1258,1259,1260,1261,1262,385],{"nctId":57,"briefTitle":58,"status":481,"phases":2382,"primaryCompletion":59,"completion":1578,"start":1579,"enrollment":1580,"conditions":2383,"interventions":2384},[88],[15,1582,1583,1254,1255],[60,1585,1262,1259,1260,1261],{"trials":2386,"activeCount":99},[],{"trials":2388,"activeCount":99},[],{"trials":2390,"activeCount":99},[],{"intervention":1262,"totalTrials":367,"cells":2392},{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2397,"PHASE3":2407,"PHASE4":2409,"NA":2411},{"trials":2394,"activeCount":99},[],{"trials":2396,"activeCount":99},[],{"trials":2398,"activeCount":95,"soonestReadout":59},[2399,2403],{"nctId":1247,"briefTitle":1248,"status":981,"phases":2400,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":99,"conditions":2401,"interventions":2402},[88],[15,1254,1255],[392,1257,1258,1259,1260,1261,1262,385],{"nctId":57,"briefTitle":58,"status":481,"phases":2404,"primaryCompletion":59,"completion":1578,"start":1579,"enrollment":1580,"conditions":2405,"interventions":2406},[88],[15,1582,1583,1254,1255],[60,1585,1262,1259,1260,1261],{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":99},[],{"trials":2412,"activeCount":99},[],{"intervention":359,"totalTrials":367,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2419,"PHASE3":2429,"PHASE4":2431,"NA":2433},{"trials":2416,"activeCount":99},[],{"trials":2418,"activeCount":99},[],{"trials":2420,"activeCount":95,"soonestReadout":350},[2421,2425],{"nctId":347,"briefTitle":348,"status":111,"phases":2422,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":2423,"interventions":2424},[88],[354,355],[357,358,359,299],{"nctId":405,"briefTitle":406,"status":332,"phases":2426,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":2427,"interventions":2428},[87,88],[354],[359,358,343,413],{"trials":2430,"activeCount":99},[],{"trials":2432,"activeCount":99},[],{"trials":2434,"activeCount":99},[],{"intervention":2213,"totalTrials":367,"cells":2436},{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2445,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2438,"activeCount":99},[],{"trials":2440,"activeCount":99},[2441],{"nctId":2206,"briefTitle":2207,"status":332,"phases":2442,"primaryCompletion":2209,"completion":2209,"start":2210,"enrollment":459,"conditions":2443,"interventions":2444},[87],[18],[2199,2213],{"trials":2446,"activeCount":95,"soonestReadout":1366},[2447],{"nctId":2221,"briefTitle":2222,"status":111,"phases":2448,"primaryCompletion":1366,"completion":2224,"start":2225,"enrollment":1335,"conditions":2449,"interventions":2450},[88],[18,2227],[2213,2199],{"trials":2452,"activeCount":99},[],{"trials":2454,"activeCount":99},[],{"trials":2456,"activeCount":99},[],{"intervention":413,"totalTrials":367,"cells":2458},{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2473,"PHASE4":2475,"NA":2477},{"trials":2460,"activeCount":99},[],{"trials":2462,"activeCount":99},[],{"trials":2464,"activeCount":95,"soonestReadout":83},[2465,2469],{"nctId":405,"briefTitle":406,"status":332,"phases":2466,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":2467,"interventions":2468},[87,88],[354],[359,358,343,413],{"nctId":479,"briefTitle":480,"status":481,"phases":2470,"primaryCompletion":83,"completion":83,"start":483,"enrollment":484,"conditions":2471,"interventions":2472},[88],[486,354],[413,358,425,299],{"trials":2474,"activeCount":99},[],{"trials":2476,"activeCount":99},[],{"trials":2478,"activeCount":99},[],{"intervention":451,"totalTrials":367,"cells":2480},{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2485,"PHASE3":2495,"PHASE4":2497,"NA":2499},{"trials":2482,"activeCount":99},[],{"trials":2484,"activeCount":99},[],{"trials":2486,"activeCount":95,"soonestReadout":164},[2487,2491],{"nctId":441,"briefTitle":442,"status":111,"phases":2488,"primaryCompletion":164,"completion":164,"start":444,"enrollment":312,"conditions":2489,"interventions":2490},[87,88],[446,447,448],[450,451,322,299,325],{"nctId":466,"briefTitle":467,"status":468,"phases":2492,"primaryCompletion":470,"completion":470,"start":471,"enrollment":410,"conditions":2493,"interventions":2494},[88],[447,314,473],[475,476,299,325,322,451,477],{"trials":2496,"activeCount":99},[],{"trials":2498,"activeCount":99},[],{"trials":2500,"activeCount":99},[],{"intervention":1704,"totalTrials":95,"cells":2502},{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2513,"PHASE4":2515,"NA":2517},{"trials":2504,"activeCount":99},[],{"trials":2506,"activeCount":99},[],{"trials":2508,"activeCount":95,"soonestReadout":903},[2509],{"nctId":1696,"briefTitle":1697,"status":111,"phases":2510,"primaryCompletion":903,"completion":903,"start":1699,"enrollment":19,"conditions":2511,"interventions":2512},[88],[1701,1702],[387,1704],{"trials":2514,"activeCount":99},[],{"trials":2516,"activeCount":99},[],{"trials":2518,"activeCount":99},[],{"intervention":2520,"totalTrials":95,"cells":2521},"Androgen Deprivation Therapy",{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[],{"trials":2527,"activeCount":95,"soonestReadout":2532},[2528],{"nctId":2529,"briefTitle":2530,"status":111,"phases":2531,"primaryCompletion":2532,"completion":2532,"start":2533,"enrollment":2534,"conditions":2535,"interventions":2536},"NCT05790213","Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation",[88],"2028-12-18","2025-05-05",57,[18],[2520],{"trials":2538,"activeCount":99},[],{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[],{"intervention":1585,"totalTrials":95,"cells":2544},{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[],{"trials":2550,"activeCount":95,"soonestReadout":59},[2551],{"nctId":57,"briefTitle":58,"status":481,"phases":2552,"primaryCompletion":59,"completion":1578,"start":1579,"enrollment":1580,"conditions":2553,"interventions":2554},[88],[15,1582,1583,1254,1255],[60,1585,1262,1259,1260,1261],{"trials":2556,"activeCount":99},[],{"trials":2558,"activeCount":99},[],{"trials":2560,"activeCount":99},[],{"intervention":357,"totalTrials":95,"cells":2562},{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2573,"PHASE4":2575,"NA":2577},{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":95,"soonestReadout":350},[2569],{"nctId":347,"briefTitle":348,"status":111,"phases":2570,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":2571,"interventions":2572},[88],[354,355],[357,358,359,299],{"trials":2574,"activeCount":99},[],{"trials":2576,"activeCount":99},[],{"trials":2578,"activeCount":99},[],{"intervention":2580,"totalTrials":95,"cells":2581},"Olaparib",{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2586,"PHASE3":2597,"PHASE4":2599,"NA":2601},{"trials":2583,"activeCount":99},[],{"trials":2585,"activeCount":99},[],{"trials":2587,"activeCount":95,"soonestReadout":2592},[2588],{"nctId":2589,"briefTitle":2590,"status":111,"phases":2591,"primaryCompletion":2592,"completion":2592,"start":2593,"enrollment":770,"conditions":2594,"interventions":2596},"NCT04515836","Olaparib in Patients With HRD Malignant Mesothelioma",[88],"2028-04-15","2021-02-19",[1801,2595],"Homologous Recombination Deficiency",[2580],{"trials":2598,"activeCount":99},[],{"trials":2600,"activeCount":99},[],{"trials":2602,"activeCount":99},[],{"intervention":1297,"totalTrials":95,"cells":2604},{"EARLY_PHASE1":2605,"PHASE1":2607,"PHASE2":2609,"PHASE3":2615,"PHASE4":2617,"NA":2619},{"trials":2606,"activeCount":99},[],{"trials":2608,"activeCount":99},[],{"trials":2610,"activeCount":95,"soonestReadout":1291},[2611],{"nctId":1288,"briefTitle":1289,"status":111,"phases":2612,"primaryCompletion":1291,"completion":1292,"start":1293,"enrollment":1085,"conditions":2613,"interventions":2614},[88],[1295],[1297,385,392],{"trials":2616,"activeCount":99},[],{"trials":2618,"activeCount":99},[],{"trials":2620,"activeCount":99},[],{"intervention":1934,"totalTrials":95,"cells":2622},{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2633,"PHASE4":2635,"NA":2637},{"trials":2624,"activeCount":99},[],{"trials":2626,"activeCount":99},[],{"trials":2628,"activeCount":95,"soonestReadout":1928},[2629],{"nctId":1925,"briefTitle":1926,"status":111,"phases":2630,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":1930,"conditions":2631,"interventions":2632},[87,88],[1932,787],[1934,1897,324,1935,1936,1937],{"trials":2634,"activeCount":99},[],{"trials":2636,"activeCount":99},[],{"trials":2638,"activeCount":99},[],{"intervention":1935,"totalTrials":95,"cells":2640},{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2645,"PHASE3":2651,"PHASE4":2653,"NA":2655},{"trials":2642,"activeCount":99},[],{"trials":2644,"activeCount":99},[],{"trials":2646,"activeCount":95,"soonestReadout":1928},[2647],{"nctId":1925,"briefTitle":1926,"status":111,"phases":2648,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":1930,"conditions":2649,"interventions":2650},[87,88],[1932,787],[1934,1897,324,1935,1936,1937],{"trials":2652,"activeCount":99},[],{"trials":2654,"activeCount":99},[],{"trials":2656,"activeCount":99},[],{"intervention":1936,"totalTrials":95,"cells":2658},{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2669,"PHASE4":2671,"NA":2673},{"trials":2660,"activeCount":99},[],{"trials":2662,"activeCount":99},[],{"trials":2664,"activeCount":95,"soonestReadout":1928},[2665],{"nctId":1925,"briefTitle":1926,"status":111,"phases":2666,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":1930,"conditions":2667,"interventions":2668},[87,88],[1932,787],[1934,1897,324,1935,1936,1937],{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[],{"trials":2674,"activeCount":99},[],{"intervention":1937,"totalTrials":95,"cells":2676},{"EARLY_PHASE1":2677,"PHASE1":2679,"PHASE2":2681,"PHASE3":2687,"PHASE4":2689,"NA":2691},{"trials":2678,"activeCount":99},[],{"trials":2680,"activeCount":99},[],{"trials":2682,"activeCount":95,"soonestReadout":1928},[2683],{"nctId":1925,"briefTitle":1926,"status":111,"phases":2684,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":1930,"conditions":2685,"interventions":2686},[87,88],[1932,787],[1934,1897,324,1935,1936,1937],{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[],{"trials":2692,"activeCount":99},[],{"intervention":2694,"totalTrials":95,"cells":2695},"Trastuzumab Deruxtecan",{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2712,"PHASE4":2714,"NA":2716},{"trials":2697,"activeCount":99},[],{"trials":2699,"activeCount":99},[],{"trials":2701,"activeCount":95,"soonestReadout":2706},[2702],{"nctId":2703,"briefTitle":2704,"status":245,"phases":2705,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":2709,"interventions":2711},"NCT07126561","Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers",[88],"2028-11-01","2026-11-01",43,[2710],"HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2",[2694],{"trials":2713,"activeCount":99},[],{"trials":2715,"activeCount":99},[],{"trials":2717,"activeCount":99},[],{"intervention":1079,"totalTrials":95,"cells":2719},{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2724,"PHASE3":2730,"PHASE4":2732,"NA":2734},{"trials":2721,"activeCount":99},[],{"trials":2723,"activeCount":99},[],{"trials":2725,"activeCount":95,"soonestReadout":1071},[2726],{"nctId":1068,"briefTitle":1069,"status":481,"phases":2727,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":2728,"interventions":2729},[88],[1075,787,1076,996,1077],[46,1079],{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[],{"trials":2735,"activeCount":99},[],{"intervention":2737,"totalTrials":95,"cells":2738},"Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy",{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2754,"PHASE4":2756,"NA":2758},{"trials":2740,"activeCount":99},[],{"trials":2742,"activeCount":99},[],{"trials":2744,"activeCount":95,"soonestReadout":2749},[2745],{"nctId":2746,"briefTitle":2747,"status":111,"phases":2748,"primaryCompletion":2749,"completion":2749,"start":2750,"enrollment":1114,"conditions":2751,"interventions":2753},"NCT06305286","Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)",[87,88],"2029-03","2024-03-04",[2752],"Type 1 Diabetes Mellitus",[2737],{"trials":2755,"activeCount":99},[],{"trials":2757,"activeCount":99},[],{"trials":2759,"activeCount":99},[],{"intervention":1339,"totalTrials":95,"cells":2761},{"EARLY_PHASE1":2762,"PHASE1":2764,"PHASE2":2766,"PHASE3":2772,"PHASE4":2774,"NA":2776},{"trials":2763,"activeCount":99},[],{"trials":2765,"activeCount":99},[],{"trials":2767,"activeCount":95,"soonestReadout":1333},[2768],{"nctId":1330,"briefTitle":1331,"status":245,"phases":2769,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":2770,"interventions":2771},[88],[1241],[1338,1339,385,392],{"trials":2773,"activeCount":99},[],{"trials":2775,"activeCount":99},[],{"trials":2777,"activeCount":99},[],{"intervention":2779,"totalTrials":95,"cells":2780},"Aripiprazole",{"EARLY_PHASE1":2781,"PHASE1":2783,"PHASE2":2785,"PHASE3":2793,"PHASE4":2795,"NA":2797},{"trials":2782,"activeCount":99},[],{"trials":2784,"activeCount":99},[],{"trials":2786,"activeCount":95,"soonestReadout":746},[2787],{"nctId":2788,"briefTitle":2789,"status":245,"phases":2790,"primaryCompletion":746,"completion":746,"start":83,"enrollment":849,"conditions":2791,"interventions":2792},"NCT05545891","Aripiprazole in Body Focused Repetitive Behaviors",[88],[734,851],[2779],{"trials":2794,"activeCount":99},[],{"trials":2796,"activeCount":99},[],{"trials":2798,"activeCount":99},[],{"intervention":2044,"totalTrials":95,"cells":2800},{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2811,"PHASE4":2813,"NA":2815},{"trials":2802,"activeCount":99},[],{"trials":2804,"activeCount":99},[],{"trials":2806,"activeCount":95,"soonestReadout":2039},[2807],{"nctId":2036,"briefTitle":2037,"status":245,"phases":2808,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":782,"conditions":2809,"interventions":2810},[87,88],[518,2042],[1911,2044,2045,2046],{"trials":2812,"activeCount":99},[],{"trials":2814,"activeCount":99},[],{"trials":2816,"activeCount":99},[],{"intervention":2045,"totalTrials":95,"cells":2818},{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2829,"PHASE4":2831,"NA":2833},{"trials":2820,"activeCount":99},[],{"trials":2822,"activeCount":99},[],{"trials":2824,"activeCount":95,"soonestReadout":2039},[2825],{"nctId":2036,"briefTitle":2037,"status":245,"phases":2826,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":782,"conditions":2827,"interventions":2828},[87,88],[518,2042],[1911,2044,2045,2046],{"trials":2830,"activeCount":99},[],{"trials":2832,"activeCount":99},[],{"trials":2834,"activeCount":99},[],{"intervention":2046,"totalTrials":95,"cells":2836},{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2847,"PHASE4":2849,"NA":2851},{"trials":2838,"activeCount":99},[],{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":95,"soonestReadout":2039},[2843],{"nctId":2036,"briefTitle":2037,"status":245,"phases":2844,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":782,"conditions":2845,"interventions":2846},[87,88],[518,2042],[1911,2044,2045,2046],{"trials":2848,"activeCount":99},[],{"trials":2850,"activeCount":99},[],{"trials":2852,"activeCount":99},[],{"intervention":1350,"totalTrials":95,"cells":2854},{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2859,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2856,"activeCount":99},[],{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":95,"soonestReadout":1344},[2861],{"nctId":1341,"briefTitle":1342,"status":481,"phases":2862,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1106,"conditions":2863,"interventions":2864},[87,88],[1240,1347,1348,21],[1350,1351,385,392],{"trials":2866,"activeCount":99},[],{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[],{"intervention":1351,"totalTrials":95,"cells":2872},{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2877,"PHASE3":2883,"PHASE4":2885,"NA":2887},{"trials":2874,"activeCount":99},[],{"trials":2876,"activeCount":99},[],{"trials":2878,"activeCount":95,"soonestReadout":1344},[2879],{"nctId":1341,"briefTitle":1342,"status":481,"phases":2880,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1106,"conditions":2881,"interventions":2882},[87,88],[1240,1347,1348,21],[1350,1351,385,392],{"trials":2884,"activeCount":99},[],{"trials":2886,"activeCount":99},[],{"trials":2888,"activeCount":99},[],{"intervention":2890,"totalTrials":95,"cells":2891},"Investigator Choice Immunotherapy",{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2896,"PHASE3":2910,"PHASE4":2912,"NA":2914},{"trials":2893,"activeCount":99},[],{"trials":2895,"activeCount":99},[],{"trials":2897,"activeCount":95,"soonestReadout":2902},[2898],{"nctId":2899,"briefTitle":2900,"status":245,"phases":2901,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2904,"conditions":2905,"interventions":2908},"NCT07603856","A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer",[88],"2030-06-25","2026-12-12",39,[2906,2907],"Non-Small Cell Lung Cancer","Metastatic Lung Cancer",[2890,2909],"Investigator Choice Chemotherapy",{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"trials":2915,"activeCount":99},[],{"intervention":2909,"totalTrials":95,"cells":2917},{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2928,"PHASE4":2930,"NA":2932},{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":99},[],{"trials":2923,"activeCount":95,"soonestReadout":2902},[2924],{"nctId":2899,"briefTitle":2900,"status":245,"phases":2925,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2904,"conditions":2926,"interventions":2927},[88],[2906,2907],[2890,2909],{"trials":2929,"activeCount":99},[],{"trials":2931,"activeCount":99},[],{"trials":2933,"activeCount":99},[],{"intervention":2935,"totalTrials":95,"cells":2936},"Caffeine citrate 15mg\u002Fkg",{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2953,"PHASE4":2955,"NA":2957},{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[],{"trials":2942,"activeCount":95,"soonestReadout":2947},[2943],{"nctId":2944,"briefTitle":2945,"status":111,"phases":2946,"primaryCompletion":2947,"completion":138,"start":2948,"enrollment":849,"conditions":2949,"interventions":2951},"NCT06538584","Dex +\u002F- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population",[87,88],"2026-07-01","2024-09-09",[2950],"Enhanced Recovery After Surgery in a Pediatric Population",[2935,2952],"0.9% Sodium Citrate",{"trials":2954,"activeCount":99},[],{"trials":2956,"activeCount":99},[],{"trials":2958,"activeCount":99},[],{"intervention":2952,"totalTrials":95,"cells":2960},{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2971,"PHASE4":2973,"NA":2975},{"trials":2962,"activeCount":99},[],{"trials":2964,"activeCount":99},[],{"trials":2966,"activeCount":95,"soonestReadout":2947},[2967],{"nctId":2944,"briefTitle":2945,"status":111,"phases":2968,"primaryCompletion":2947,"completion":138,"start":2948,"enrollment":849,"conditions":2969,"interventions":2970},[87,88],[2950],[2935,2952],{"trials":2972,"activeCount":99},[],{"trials":2974,"activeCount":99},[],{"trials":2976,"activeCount":99},[],{"intervention":2016,"totalTrials":95,"cells":2978},{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2983,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2980,"activeCount":99},[],{"trials":2982,"activeCount":99},[],{"trials":2984,"activeCount":95,"soonestReadout":2012},[2985],{"nctId":2009,"briefTitle":2010,"status":245,"phases":2986,"primaryCompletion":2012,"completion":2012,"start":164,"enrollment":2013,"conditions":2987,"interventions":2988},[88],[21],[2016,1338],{"trials":2990,"activeCount":99},[],{"trials":2992,"activeCount":99},[],{"trials":2994,"activeCount":99},[],{"intervention":1600,"totalTrials":95,"cells":2996},{"EARLY_PHASE1":2997,"PHASE1":2999,"PHASE2":3001,"PHASE3":3007,"PHASE4":3009,"NA":3011},{"trials":2998,"activeCount":99},[],{"trials":3000,"activeCount":99},[],{"trials":3002,"activeCount":95,"soonestReadout":1594},[3003],{"nctId":1591,"briefTitle":1592,"status":111,"phases":3004,"primaryCompletion":1594,"completion":1595,"start":1381,"enrollment":1596,"conditions":3005,"interventions":3006},[88],[1598,1583,15],[1600,1601,60,1259,1260,1602],{"trials":3008,"activeCount":99},[],{"trials":3010,"activeCount":99},[],{"trials":3012,"activeCount":99},[],{"intervention":1601,"totalTrials":95,"cells":3014},{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3025,"PHASE4":3027,"NA":3029},{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":95,"soonestReadout":1594},[3021],{"nctId":1591,"briefTitle":1592,"status":111,"phases":3022,"primaryCompletion":1594,"completion":1595,"start":1381,"enrollment":1596,"conditions":3023,"interventions":3024},[88],[1598,1583,15],[1600,1601,60,1259,1260,1602],{"trials":3026,"activeCount":99},[],{"trials":3028,"activeCount":99},[],{"trials":3030,"activeCount":99},[],{"intervention":1602,"totalTrials":95,"cells":3032},{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3037,"PHASE3":3043,"PHASE4":3045,"NA":3047},{"trials":3034,"activeCount":99},[],{"trials":3036,"activeCount":99},[],{"trials":3038,"activeCount":95,"soonestReadout":1594},[3039],{"nctId":1591,"briefTitle":1592,"status":111,"phases":3040,"primaryCompletion":1594,"completion":1595,"start":1381,"enrollment":1596,"conditions":3041,"interventions":3042},[88],[1598,1583,15],[1600,1601,60,1259,1260,1602],{"trials":3044,"activeCount":99},[],{"trials":3046,"activeCount":99},[],{"trials":3048,"activeCount":99},[],{"intervention":1110,"totalTrials":95,"cells":3050},{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3055,"PHASE3":3061,"PHASE4":3063,"NA":3065},{"trials":3052,"activeCount":99},[],{"trials":3054,"activeCount":99},[],{"trials":3056,"activeCount":95,"soonestReadout":1104},[3057],{"nctId":1101,"briefTitle":1102,"status":111,"phases":3058,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":3059,"interventions":3060},[88],[951,1108],[46,1110],{"trials":3062,"activeCount":99},[],{"trials":3064,"activeCount":99},[],{"trials":3066,"activeCount":99},[],{"intervention":450,"totalTrials":95,"cells":3068},{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3073,"PHASE3":3079,"PHASE4":3081,"NA":3083},{"trials":3070,"activeCount":99},[],{"trials":3072,"activeCount":99},[],{"trials":3074,"activeCount":95,"soonestReadout":164},[3075],{"nctId":441,"briefTitle":442,"status":111,"phases":3076,"primaryCompletion":164,"completion":164,"start":444,"enrollment":312,"conditions":3077,"interventions":3078},[87,88],[446,447,448],[450,451,322,299,325],{"trials":3080,"activeCount":99},[],{"trials":3082,"activeCount":99},[],{"trials":3084,"activeCount":99},[],{"intervention":1361,"totalTrials":95,"cells":3086},{"EARLY_PHASE1":3087,"PHASE1":3089,"PHASE2":3091,"PHASE3":3097,"PHASE4":3099,"NA":3101},{"trials":3088,"activeCount":99},[],{"trials":3090,"activeCount":99},[],{"trials":3092,"activeCount":95,"soonestReadout":1356},[3093],{"nctId":1353,"briefTitle":1354,"status":111,"phases":3094,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":1358,"conditions":3095,"interventions":3096},[88],[21,1347],[1361,385,392],{"trials":3098,"activeCount":99},[],{"trials":3100,"activeCount":99},[],{"trials":3102,"activeCount":99},[],{"intervention":3104,"totalTrials":95,"cells":3105},"Tegoprubart",{"EARLY_PHASE1":3106,"PHASE1":3108,"PHASE2":3110,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3107,"activeCount":99},[],{"trials":3109,"activeCount":99},[],{"trials":3111,"activeCount":95,"soonestReadout":3116},[3112],{"nctId":3113,"briefTitle":3114,"status":111,"phases":3115,"primaryCompletion":3116,"completion":3116,"start":3117,"enrollment":732,"conditions":3118,"interventions":3121},"NCT07592000","Breakthrough - T1DM and Chronic Kidney Disease",[87,88],"2030-01-31","2026-04-29",[3119,3120],"Diabete Type 1","Chronic Kidney Disease",[3104,3122],"Islet Cell Transplant",{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[],{"trials":3128,"activeCount":99},[],{"intervention":3122,"totalTrials":95,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3135,"PHASE3":3141,"PHASE4":3143,"NA":3145},{"trials":3132,"activeCount":99},[],{"trials":3134,"activeCount":99},[],{"trials":3136,"activeCount":95,"soonestReadout":3116},[3137],{"nctId":3113,"briefTitle":3114,"status":111,"phases":3138,"primaryCompletion":3116,"completion":3116,"start":3117,"enrollment":732,"conditions":3139,"interventions":3140},[87,88],[3119,3120],[3104,3122],{"trials":3142,"activeCount":99},[],{"trials":3144,"activeCount":99},[],{"trials":3146,"activeCount":99},[],{"intervention":3148,"totalTrials":95,"cells":3149},"Lactulose",{"EARLY_PHASE1":3150,"PHASE1":3152,"PHASE2":3154,"PHASE3":3165,"PHASE4":3167,"NA":3169},{"trials":3151,"activeCount":99},[],{"trials":3153,"activeCount":99},[],{"trials":3155,"activeCount":95,"soonestReadout":3160},[3156],{"nctId":3157,"briefTitle":3158,"status":245,"phases":3159,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":607,"conditions":3162,"interventions":3164},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[87,88],"2029-04-13","2026-12-15",[3163],"Cancer",[3148],{"trials":3166,"activeCount":99},[],{"trials":3168,"activeCount":99},[],{"trials":3170,"activeCount":99},[],{"intervention":1373,"totalTrials":95,"cells":3172},{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3183,"PHASE4":3185,"NA":3187},{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[],{"trials":3178,"activeCount":95,"soonestReadout":1366},[3179],{"nctId":1363,"briefTitle":1364,"status":111,"phases":3180,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":1368,"conditions":3181,"interventions":3182},[88],[1370,1371,1305],[1373,1374,385],{"trials":3184,"activeCount":99},[],{"trials":3186,"activeCount":99},[],{"trials":3188,"activeCount":99},[],{"intervention":3190,"totalTrials":95,"cells":3191},"Valbenazine",{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3196,"PHASE3":3204,"PHASE4":3206,"NA":3208},{"trials":3193,"activeCount":99},[],{"trials":3195,"activeCount":99},[],{"trials":3197,"activeCount":95,"soonestReadout":746},[3198],{"nctId":3199,"briefTitle":3200,"status":245,"phases":3201,"primaryCompletion":746,"completion":746,"start":78,"enrollment":1085,"conditions":3202,"interventions":3203},"NCT07111988","Valbenazine in Obsessive Compulsive Disorder",[88],[2351],[3190],{"trials":3205,"activeCount":99},[],{"trials":3207,"activeCount":99},[],{"trials":3209,"activeCount":99},[],{"intervention":1386,"totalTrials":95,"cells":3211},{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3216,"PHASE3":3222,"PHASE4":3224,"NA":3226},{"trials":3213,"activeCount":99},[],{"trials":3215,"activeCount":99},[],{"trials":3217,"activeCount":95,"soonestReadout":1379},[3218],{"nctId":1376,"briefTitle":1377,"status":111,"phases":3219,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":1382,"conditions":3220,"interventions":3221},[88],[1384],[319,1386,60,385,1387],{"trials":3223,"activeCount":99},[],{"trials":3225,"activeCount":99},[],{"trials":3227,"activeCount":99},[],{"intervention":3229,"totalTrials":95,"cells":3230},"deuterated oxytocin",{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3247,"PHASE4":3249,"NA":3251},{"trials":3232,"activeCount":99},[],{"trials":3234,"activeCount":99},[],{"trials":3236,"activeCount":95,"soonestReadout":1578},[3237],{"nctId":3238,"briefTitle":3239,"status":111,"phases":3240,"primaryCompletion":1578,"completion":138,"start":3241,"enrollment":849,"conditions":3242,"interventions":3246},"NCT05488457","Oxytocin Pharmacokinetics and Pharmacodynamics",[88],"2025-01-01",[3243,3244,3245],"Post Partum Hemorrhage","Cesarean Section Complications","Blood Loss",[3229],{"trials":3248,"activeCount":99},[],{"trials":3250,"activeCount":99},[],{"trials":3252,"activeCount":99},[],{"intervention":530,"totalTrials":994,"cells":3254},{"EARLY_PHASE1":3255,"PHASE1":3257,"PHASE2":3259,"PHASE3":3271,"PHASE4":3273,"NA":3288},{"trials":3256,"activeCount":99},[],{"trials":3258,"activeCount":99},[],{"trials":3260,"activeCount":95,"soonestReadout":3265},[3261],{"nctId":3262,"briefTitle":3263,"status":111,"phases":3264,"primaryCompletion":3265,"completion":3265,"start":3266,"enrollment":3267,"conditions":3268,"interventions":3270},"NCT06635889","Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain",[88],"2029-10","2025-03-26",116,[3269],"Nephrolithiasis",[530],{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[3275,3279],{"nctId":521,"briefTitle":522,"status":363,"phases":3276,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":3277,"interventions":3278},[90],[528],[299,530],{"nctId":3280,"briefTitle":3281,"status":363,"phases":3282,"primaryCompletion":3283,"completion":3283,"start":432,"enrollment":367,"conditions":3284,"interventions":3286},"NCT01756560","Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair",[90],"2015-01",[3285],"Duration of Pain Relief",[3287,530],"dexamethsone",{"trials":3289,"activeCount":99},[3290,3301],{"nctId":3291,"briefTitle":3292,"status":332,"phases":3293,"primaryCompletion":3294,"completion":3294,"start":3295,"enrollment":3296,"conditions":3297,"interventions":3300},"NCT02121392","Epidural Catheter With or Without Adductor Canal Nerve Block for Postoperative Analgesia Following Total Knee Arthroplasty",[91],"2017-01","2014-10",165,[3298,3299],"Arthroplasty, Replacement, Knee","Nerve Block",[530],{"nctId":3302,"briefTitle":3303,"status":363,"phases":3304,"primaryCompletion":3283,"completion":3283,"start":432,"enrollment":994,"conditions":3305,"interventions":3306},"NCT01756573","Dexamethasone and Block Duration in Upper Extremity",[91],[3285],[3307,530],"Dexamthsone",{"intervention":958,"totalTrials":592,"cells":3309},{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3334,"PHASE3":3397,"PHASE4":3399,"NA":3401},{"trials":3311,"activeCount":99},[],{"trials":3313,"activeCount":367,"soonestReadout":83},[3314,3326,3330],{"nctId":3315,"briefTitle":3316,"status":981,"phases":3317,"primaryCompletion":365,"completion":365,"start":3318,"enrollment":99,"conditions":3319,"interventions":3322},"NCT02573220","Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer",[87],"2015-06",[3320,3321],"Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer",[958,3323,3324,3325],"Fluorouracil","Irinotecan Hydrochloride","Leucovorin Calcium",{"nctId":944,"briefTitle":945,"status":111,"phases":3327,"primaryCompletion":947,"completion":947,"start":948,"enrollment":400,"conditions":3328,"interventions":3329},[87],[950,951,952,953,954,955],[957,958,46],{"nctId":1201,"briefTitle":1202,"status":111,"phases":3331,"primaryCompletion":83,"completion":113,"start":1204,"enrollment":400,"conditions":3332,"interventions":3333},[87],[1206],[392,385,958,387,1208],{"trials":3335,"activeCount":99},[3336,3349,3353,3363],{"nctId":3337,"briefTitle":3338,"status":468,"phases":3339,"primaryCompletion":3340,"completion":3340,"start":1345,"enrollment":1580,"conditions":3341,"interventions":3347},"NCT05200442","A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer",[87,88],"2027-05-01",[3342,3343,3344,3345,3346],"Colorectal Cancer","Colorectal Adenocarcinoma","Colorectal Cancer Metastatic","Advanced Colorectal Carcinoma","Advanced Colorectal Adenocarcinoma",[3348,958],"VS-6766\u002Favutometinib",{"nctId":1723,"briefTitle":1724,"status":332,"phases":3350,"primaryCompletion":1726,"completion":1416,"start":1727,"enrollment":1728,"conditions":3351,"interventions":3352},[88],[21],[958,389,388,387],{"nctId":3354,"briefTitle":3355,"status":363,"phases":3356,"primaryCompletion":3357,"completion":3358,"start":3359,"enrollment":607,"conditions":3360,"interventions":3362},"NCT00203931","Trial Comparing Cetuximab With Pemetrexed\u002FCetuximab Therapy for Non-Small Cell Lung Cancer",[88],"2008-11","2009-11","2005-03",[3361],"Non-small Cell Lung Cancer",[958,1286],{"nctId":3364,"briefTitle":3365,"status":332,"phases":3366,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":35,"conditions":3370,"interventions":3394},"NCT01816984","PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",[87,88],"2018-04","2020-09","2013-05",[3371,3372,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,3373,3374,3375,3376,3377,1321,3378,3379,3380,3381,3382,3383,1322,3384,3385,3386,3387,3388,3389,3390,3391,3392,3393,1165],"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity",[3395,3396],"PI3K inhibitor BKM120","cetuximab",{"trials":3398,"activeCount":99},[],{"trials":3400,"activeCount":99},[],{"trials":3402,"activeCount":99},[],{"intervention":318,"totalTrials":367,"cells":3404},{"EARLY_PHASE1":3405,"PHASE1":3407,"PHASE2":3419,"PHASE3":3421,"PHASE4":3423,"NA":3425},{"trials":3406,"activeCount":99},[],{"trials":3408,"activeCount":367,"soonestReadout":78},[3409,3413],{"nctId":306,"briefTitle":307,"status":111,"phases":3410,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":3411,"interventions":3412},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"nctId":76,"briefTitle":77,"status":111,"phases":3414,"primaryCompletion":78,"completion":78,"start":3415,"enrollment":24,"conditions":3416,"interventions":3418},[87],"2024-09-19",[3417],"Myeloproliferative Neoplasms",[79,318],{"trials":3420,"activeCount":99},[],{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[],{"trials":3426,"activeCount":99},[],{"intervention":1169,"totalTrials":732,"cells":3428},{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3520,"PHASE3":3543,"PHASE4":3549,"NA":3563},{"trials":3430,"activeCount":99},[],{"trials":3432,"activeCount":95,"soonestReadout":3507},[3433,3437,3460,3503,3516],{"nctId":1148,"briefTitle":1149,"status":332,"phases":3434,"primaryCompletion":1151,"completion":1151,"start":1152,"enrollment":1153,"conditions":3435,"interventions":3436},[87],[1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165],[1167,1168,1169,1170],{"nctId":3438,"briefTitle":3439,"status":332,"phases":3440,"primaryCompletion":3441,"completion":3441,"start":524,"enrollment":1215,"conditions":3442,"interventions":3458},"NCT02333188","Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer",[87],"2017-12",[3443,3444,3445,1037,3446,3447,1555,3448,3449,3450,3451,3452,3453,3454,3455,3456,3457],"Adenocarcinoma of Unknown Primary","Adult Cholangiocarcinoma","Gallbladder Carcinoma","Malignant Gastrointestinal Neoplasm","Metastatic Pancreatic Adenocarcinoma","Stage III Ampulla of Vater Cancer","Stage III Pancreatic Cancer","Stage IIIA Gallbladder Cancer","Stage IIIA Gastric Cancer","Stage IIIB Gallbladder Cancer","Stage IIIB Gastric Cancer","Stage IV Ampulla of Vater Cancer","Stage IV Gallbladder Cancer","Stage IV Gastric Cancer","Stage IV Pancreatic Cancer",[3459,3325,3324,3323],"Paclitaxel Albumin-Stabilized Nanoparticle Formulation",{"nctId":3461,"briefTitle":3462,"status":332,"phases":3463,"primaryCompletion":3464,"completion":3465,"start":3466,"enrollment":3467,"conditions":3468,"interventions":3501},"NCT01643499","Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies",[87],"2016-08-28","2019-07","2012-03-26",79,[3469,3470,3443,3471,3472,3473,3474,3475,3476,3477,3478,3479,3480,3481,3482,3483,3484,3485,3486,3449,3487,3450,3451,3488,3489,3452,3453,3490,3491,3492,3493,3456,3457,3494,3495,3496,3497,3498,3499,3500],"Acinar Cell Adenocarcinoma of the Pancreas","Adenocarcinoma of the Gallbladder","Adult Primary Cholangiocellular Carcinoma","Advanced Adult Primary Liver Cancer","Cholangiocarcinoma of the Extrahepatic Bile Duct","Cholangiocarcinoma of the Gallbladder","Diffuse Adenocarcinoma of the Stomach","Duct Cell Adenocarcinoma of the Pancreas","Intestinal Adenocarcinoma of the Stomach","Localized Unresectable Adult Primary Liver Cancer","Metastatic Carcinoma of Unknown Primary","Metastatic Extrahepatic Bile Duct Cancer","Mixed Adenocarcinoma of the Stomach","Mucinous Adenocarcinoma of the Colon","Mucinous Adenocarcinoma of the Rectum","Newly Diagnosed Carcinoma of Unknown Primary","Signet Ring Adenocarcinoma of the Colon","Signet Ring Adenocarcinoma of the Rectum","Stage IIIA Colon Cancer","Stage IIIA Rectal Cancer","Stage IIIB Colon Cancer","Stage IIIB Rectal Cancer","Stage IIIC Colon Cancer","Stage IIIC Gastric Cancer","Stage IIIC Rectal Cancer","Stage IVA Colon Cancer","Stage IVA Gallbladder Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Gallbladder Cancer","Stage IVB Rectal Cancer","Unresectable Extrahepatic Bile Duct Cancer",[1488,1448,3502,1169],"leucovorin calcium",{"nctId":3504,"briefTitle":3505,"status":111,"phases":3506,"primaryCompletion":3507,"completion":3507,"start":3508,"enrollment":1085,"conditions":3509,"interventions":3513},"NCT05526924","Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer",[87],"2028-01-01","2023-03-07",[21,1087,3510,3511,3512],"Head and Neck Carcinoma","Head and Neck Cancer Stage IV","Head and Neck Cancers - Throat",[3514,388,3323,3515],"Pamiparib","Tislelizumab",{"nctId":3315,"briefTitle":3316,"status":981,"phases":3517,"primaryCompletion":365,"completion":365,"start":3318,"enrollment":99,"conditions":3518,"interventions":3519},[87],[3320,3321],[958,3323,3324,3325],{"trials":3521,"activeCount":99},[3522,3530,3539],{"nctId":3523,"briefTitle":3524,"status":332,"phases":3525,"primaryCompletion":538,"completion":1727,"start":3526,"enrollment":1580,"conditions":3527,"interventions":3529},"NCT00002951","Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer",[88],"1996-06",[3528,21],"Esophageal Cancer",[1169,1170],{"nctId":3531,"briefTitle":3532,"status":332,"phases":3533,"primaryCompletion":3534,"completion":1484,"start":3535,"enrollment":1106,"conditions":3536,"interventions":3537},"NCT00004127","Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach",[88],"2002-10","2000-02",[3528,1701],[3538,1169,3502,1488],"FOLFOX regimen",{"nctId":1313,"briefTitle":1314,"status":332,"phases":3540,"primaryCompletion":377,"completion":377,"start":1316,"enrollment":1317,"conditions":3541,"interventions":3542},[88],[1319,1320,1321,1322],[1168,1167,1307,1169,1170,1324],{"trials":3544,"activeCount":99},[3545],{"nctId":1610,"briefTitle":1611,"status":332,"phases":3546,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":1615,"conditions":3547,"interventions":3548},[89],[1617,1618,1619,1620,1621],[1574,1324,1170,1169],{"trials":3550,"activeCount":99},[3551],{"nctId":3552,"briefTitle":3553,"status":468,"phases":3554,"primaryCompletion":3555,"completion":3555,"start":3556,"enrollment":400,"conditions":3557,"interventions":3562},"NCT02366819","Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer",[90],"2026-06-08","2014-12-11",[1038,1037,3558,3559,3451,3560,3453,3561,3492],"Stage IIB Gastric Cancer","Stage IIIA Esophageal Adenocarcinoma","Stage IIIB Esophageal Adenocarcinoma","Stage IIIC Esophageal Adenocarcinoma",[1558,3325,3324,3323],{"trials":3564,"activeCount":99},[],{"intervention":1488,"totalTrials":592,"cells":3566},{"EARLY_PHASE1":3567,"PHASE1":3569,"PHASE2":3579,"PHASE3":3605,"PHASE4":3607,"NA":3613},{"trials":3568,"activeCount":99},[],{"trials":3570,"activeCount":95,"soonestReadout":83},[3571,3575],{"nctId":3461,"briefTitle":3462,"status":332,"phases":3572,"primaryCompletion":3464,"completion":3465,"start":3466,"enrollment":3467,"conditions":3573,"interventions":3574},[87],[3469,3470,3443,3471,3472,3473,3474,3475,3476,3477,3478,3479,3480,3481,3482,3483,3484,3485,3486,3449,3487,3450,3451,3488,3489,3452,3453,3490,3491,3492,3493,3456,3457,3494,3495,3496,3497,3498,3499,3500],[1488,1448,3502,1169],{"nctId":1548,"briefTitle":1549,"status":111,"phases":3576,"primaryCompletion":83,"completion":1551,"start":1552,"enrollment":1553,"conditions":3577,"interventions":3578},[87],[1555,1036,1556],[1558,60,1559,1560,1561],{"trials":3580,"activeCount":99},[3581,3585,3593,3597],{"nctId":1480,"briefTitle":1481,"status":332,"phases":3582,"primaryCompletion":1483,"completion":1484,"start":1485,"enrollment":1358,"conditions":3583,"interventions":3584},[88],[1305],[1488,1307],{"nctId":3586,"briefTitle":3587,"status":332,"phases":3588,"primaryCompletion":3589,"completion":1569,"start":3535,"enrollment":516,"conditions":3590,"interventions":3592},"NCT00004203","Oxaliplatin in Treating Patients With Metastatic Bladder Cancer",[88],"2002-02",[1434,3591],"Transitional Cell Cancer of the Renal Pelvis and Ureter",[1488],{"nctId":3531,"briefTitle":3532,"status":332,"phases":3594,"primaryCompletion":3534,"completion":1484,"start":3535,"enrollment":1106,"conditions":3595,"interventions":3596},[88],[3528,1701],[3538,1169,3502,1488],{"nctId":3598,"briefTitle":3599,"status":332,"phases":3600,"primaryCompletion":2177,"completion":3601,"start":1518,"enrollment":1779,"conditions":3602,"interventions":3603},"NCT00026299","Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer",[87,88],"2005-02",[3342],[3604,1488],"ZD1839",{"trials":3606,"activeCount":99},[],{"trials":3608,"activeCount":99},[3609],{"nctId":3552,"briefTitle":3553,"status":468,"phases":3610,"primaryCompletion":3555,"completion":3555,"start":3556,"enrollment":400,"conditions":3611,"interventions":3612},[90],[1038,1037,3558,3559,3451,3560,3453,3561,3492],[1558,3325,3324,3323],{"trials":3614,"activeCount":99},[],{"intervention":1170,"totalTrials":545,"cells":3616},{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3629,"PHASE3":3651,"PHASE4":3657,"NA":3659},{"trials":3618,"activeCount":99},[],{"trials":3620,"activeCount":95,"soonestReadout":3507},[3621,3625],{"nctId":1148,"briefTitle":1149,"status":332,"phases":3622,"primaryCompletion":1151,"completion":1151,"start":1152,"enrollment":1153,"conditions":3623,"interventions":3624},[87],[1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165],[1167,1168,1169,1170],{"nctId":3504,"briefTitle":3505,"status":111,"phases":3626,"primaryCompletion":3507,"completion":3507,"start":3508,"enrollment":1085,"conditions":3627,"interventions":3628},[87],[21,1087,3510,3511,3512],[3514,388,3323,3515],{"trials":3630,"activeCount":99},[3631,3635,3639,3643,3647],{"nctId":3523,"briefTitle":3524,"status":332,"phases":3632,"primaryCompletion":538,"completion":1727,"start":3526,"enrollment":1580,"conditions":3633,"interventions":3634},[88],[3528,21],[1169,1170],{"nctId":374,"briefTitle":375,"status":332,"phases":3636,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":3637,"interventions":3638},[88],[381,382],[384,385,386,387,388,389,299,390,391,392],{"nctId":1723,"briefTitle":1724,"status":332,"phases":3640,"primaryCompletion":1726,"completion":1416,"start":1727,"enrollment":1728,"conditions":3641,"interventions":3642},[88],[21],[958,389,388,387],{"nctId":1732,"briefTitle":1733,"status":332,"phases":3644,"primaryCompletion":1735,"completion":1736,"start":1737,"enrollment":1738,"conditions":3645,"interventions":3646},[88],[1740],[388,1742,387],{"nctId":1313,"briefTitle":1314,"status":332,"phases":3648,"primaryCompletion":377,"completion":377,"start":1316,"enrollment":1317,"conditions":3649,"interventions":3650},[88],[1319,1320,1321,1322],[1168,1167,1307,1169,1170,1324],{"trials":3652,"activeCount":99},[3653],{"nctId":1610,"briefTitle":1611,"status":332,"phases":3654,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":1615,"conditions":3655,"interventions":3656},[89],[1617,1618,1619,1620,1621],[1574,1324,1170,1169],{"trials":3658,"activeCount":99},[],{"trials":3660,"activeCount":99},[],{"intervention":386,"totalTrials":2118,"cells":3662},{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3696,"PHASE3":3732,"PHASE4":3734,"NA":3736},{"trials":3664,"activeCount":99},[],{"trials":3666,"activeCount":95,"soonestReadout":113},[3667,3671,3681,3692],{"nctId":1774,"briefTitle":1775,"status":363,"phases":3668,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1779,"conditions":3669,"interventions":3670},[87],[1781],[386,1117],{"nctId":3672,"briefTitle":3673,"status":363,"phases":3674,"primaryCompletion":3675,"completion":3676,"start":3677,"enrollment":488,"conditions":3678,"interventions":3680},"NCT02985554","Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies",[87],"2019-02-06","2020-06-22","2017-03-20",[3679],"Hematologic Malignancies",[386],{"nctId":3682,"briefTitle":3683,"status":332,"phases":3684,"primaryCompletion":3685,"completion":3686,"start":3687,"enrollment":802,"conditions":3688,"interventions":3689},"NCT03431948","Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer",[87],"2020-02-29","2022-04-11","2018-03-15",[3163],[386,3690,3691],"Cabiralizumab","Urelumab",{"nctId":1784,"briefTitle":1785,"status":481,"phases":3693,"primaryCompletion":113,"completion":746,"start":1787,"enrollment":1788,"conditions":3694,"interventions":3695},[87],[1790],[386,1117],{"trials":3697,"activeCount":99},[3698,3702,3716,3720,3724],{"nctId":1234,"briefTitle":1235,"status":332,"phases":3699,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1106,"conditions":3700,"interventions":3701},[88],[1240,1241,1064,381,382],[385,392,386,1243,1244,1245,387],{"nctId":3703,"briefTitle":3704,"status":332,"phases":3705,"primaryCompletion":3706,"completion":3707,"start":3708,"enrollment":249,"conditions":3709,"interventions":3710},"NCT02213289","PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression",[88],"2020-02-01","2020-08-20","2015-01-20",[1556],[3711,3712,3713,3714,386,3715],"Trastuzumab","ABT-806","Bemarituzumab","Ramucirumab","Standard cytotherapy",{"nctId":374,"briefTitle":375,"status":332,"phases":3717,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":3718,"interventions":3719},[88],[381,382],[384,385,386,387,388,389,299,390,391,392],{"nctId":1795,"briefTitle":1796,"status":332,"phases":3721,"primaryCompletion":1798,"completion":1798,"start":1799,"enrollment":367,"conditions":3722,"interventions":3723},[88],[1801,1802],[386,1117],{"nctId":3725,"briefTitle":3726,"status":363,"phases":3727,"primaryCompletion":3685,"completion":1214,"start":3728,"enrollment":35,"conditions":3729,"interventions":3730},"NCT03572478","Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer",[87,88],"2018-08-14",[18,1436],[3731,386],"Rucaparib",{"trials":3733,"activeCount":99},[],{"trials":3735,"activeCount":99},[],{"trials":3737,"activeCount":99},[],{"intervention":1244,"totalTrials":367,"cells":3739},{"EARLY_PHASE1":3740,"PHASE1":3742,"PHASE2":3748,"PHASE3":3754,"PHASE4":3756,"NA":3758},{"trials":3741,"activeCount":99},[],{"trials":3743,"activeCount":95,"soonestReadout":83},[3744],{"nctId":1548,"briefTitle":1549,"status":111,"phases":3745,"primaryCompletion":83,"completion":1551,"start":1552,"enrollment":1553,"conditions":3746,"interventions":3747},[87],[1555,1036,1556],[1558,60,1559,1560,1561],{"trials":3749,"activeCount":99},[3750],{"nctId":1234,"briefTitle":1235,"status":332,"phases":3751,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1106,"conditions":3752,"interventions":3753},[88],[1240,1241,1064,381,382],[385,392,386,1243,1244,1245,387],{"trials":3755,"activeCount":99},[],{"trials":3757,"activeCount":99},[],{"trials":3759,"activeCount":99},[],{"intervention":320,"totalTrials":488,"cells":3761},{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3809,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3763,"activeCount":99},[],{"trials":3765,"activeCount":95,"soonestReadout":309},[3766,3777,3805],{"nctId":3767,"briefTitle":3768,"status":332,"phases":3769,"primaryCompletion":3770,"completion":3771,"start":3772,"enrollment":410,"conditions":3773,"interventions":3774},"NCT02573363","Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia",[87],"2018-01-01","2019-05-03","2015-10-07",[928],[320,3775,3776],"Mitoxantrone Hydrochloride","Selinexor",{"nctId":3778,"briefTitle":3779,"status":332,"phases":3780,"primaryCompletion":3781,"completion":3781,"start":3782,"enrollment":1215,"conditions":3783,"interventions":3801},"NCT01839240","Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia",[87],"2019-08-16","2012-06-06",[3784,3785,3786,3787,3788,3789,3790,3791,3792,3793,3794,3795,3796,3797,3798,3799,3800],"Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Recurrent Adult Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia",[3802,3803,3804],"azacitidine","cytarabine","mitoxantrone hydrochloride",{"nctId":306,"briefTitle":307,"status":111,"phases":3806,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":3807,"interventions":3808},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"trials":3810,"activeCount":99},[],{"trials":3812,"activeCount":99},[],{"trials":3814,"activeCount":99},[],{"trials":3816,"activeCount":99},[],{"intervention":79,"totalTrials":367,"cells":3818},{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3842,"PHASE3":3844,"PHASE4":3846,"NA":3848},{"trials":3820,"activeCount":99},[],{"trials":3822,"activeCount":95,"soonestReadout":78},[3823,3838],{"nctId":3824,"briefTitle":3825,"status":981,"phases":3826,"primaryCompletion":3827,"completion":3827,"start":3828,"enrollment":99,"conditions":3829,"interventions":3835},"NCT04955938","A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms",[87],"2023-06-07","2021-10-29",[3830,3831,3832,3833,3834],"IDH Mutation","IDH1 Mutation","IDH2 Gene Mutation","Blood Cancer","Myeloproliferative Neoplasm",[79,3836,3837],"Enasidenib","Fedratinib",{"nctId":76,"briefTitle":77,"status":111,"phases":3839,"primaryCompletion":78,"completion":78,"start":3415,"enrollment":24,"conditions":3840,"interventions":3841},[87],[3417],[79,318],{"trials":3843,"activeCount":99},[],{"trials":3845,"activeCount":99},[],{"trials":3847,"activeCount":99},[],{"trials":3849,"activeCount":99},[],{"intervention":3851,"totalTrials":367,"cells":3852},"Azacitidine",{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3872,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3854,"activeCount":99},[],{"trials":3856,"activeCount":95,"soonestReadout":3861},[3857,3868],{"nctId":3858,"briefTitle":3859,"status":111,"phases":3860,"primaryCompletion":3861,"completion":3861,"start":3862,"enrollment":24,"conditions":3863,"interventions":3866},"NCT03326310","Selumetinib and Azacitidine in High Risk Chronic Blood Cancers",[87],"2027-09-04","2018-09-04",[3864,3865],"Chronic Myeloid Leukemia","Myelofibroses",[3851,3867],"Selumetinib",{"nctId":3778,"briefTitle":3779,"status":332,"phases":3869,"primaryCompletion":3781,"completion":3781,"start":3782,"enrollment":1215,"conditions":3870,"interventions":3871},[87],[3784,3785,3786,3787,3788,3789,3790,3791,3792,3793,3794,3795,3796,3797,3798,3799,3800],[3802,3803,3804],{"trials":3873,"activeCount":99},[],{"trials":3875,"activeCount":99},[],{"trials":3877,"activeCount":99},[],{"trials":3879,"activeCount":99},[],{"intervention":1559,"totalTrials":367,"cells":3881},{"EARLY_PHASE1":3882,"PHASE1":3884,"PHASE2":3894,"PHASE3":3896,"PHASE4":3898,"NA":3900},{"trials":3883,"activeCount":99},[],{"trials":3885,"activeCount":95,"soonestReadout":83},[3886,3890],{"nctId":1672,"briefTitle":1673,"status":363,"phases":3887,"primaryCompletion":1675,"completion":1675,"start":1280,"enrollment":367,"conditions":3888,"interventions":3889},[87],[1677,1678],[1680,326,387,1681,1682,1374,1683,1684,1559],{"nctId":1548,"briefTitle":1549,"status":111,"phases":3891,"primaryCompletion":83,"completion":1551,"start":1552,"enrollment":1553,"conditions":3892,"interventions":3893},[87],[1555,1036,1556],[1558,60,1559,1560,1561],{"trials":3895,"activeCount":99},[],{"trials":3897,"activeCount":99},[],{"trials":3899,"activeCount":99},[],{"trials":3901,"activeCount":99},[],{"intervention":1560,"totalTrials":367,"cells":3903},{"EARLY_PHASE1":3904,"PHASE1":3906,"PHASE2":3920,"PHASE3":3922,"PHASE4":3924,"NA":3926},{"trials":3905,"activeCount":99},[],{"trials":3907,"activeCount":95,"soonestReadout":83},[3908,3912],{"nctId":1548,"briefTitle":1549,"status":111,"phases":3909,"primaryCompletion":83,"completion":1551,"start":1552,"enrollment":1553,"conditions":3910,"interventions":3911},[87],[1555,1036,1556],[1558,60,1559,1560,1561],{"nctId":3913,"briefTitle":3914,"status":332,"phases":3915,"primaryCompletion":365,"completion":365,"start":3916,"enrollment":2013,"conditions":3917,"interventions":3919},"NCT00708773","Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors",[87],"2006-02",[3918],"Advanced Cancer",[1560],{"trials":3921,"activeCount":99},[],{"trials":3923,"activeCount":99},[],{"trials":3925,"activeCount":99},[],{"trials":3927,"activeCount":99},[],{"intervention":74,"totalTrials":95,"cells":3929},{"EARLY_PHASE1":3930,"PHASE1":3932,"PHASE2":3944,"PHASE3":3946,"PHASE4":3948,"NA":3950},{"trials":3931,"activeCount":99},[],{"trials":3933,"activeCount":95,"soonestReadout":73},[3934],{"nctId":71,"briefTitle":72,"status":111,"phases":3935,"primaryCompletion":73,"completion":73,"start":3936,"enrollment":3937,"conditions":3938,"interventions":3940},[87],"2020-06-25",264,[3939],"Metastatic Cancer",[74,3941,3942,3943],"Pembrolizumab Standard","Nivolumab Extended","Pembrolizumab Extended",{"trials":3945,"activeCount":99},[],{"trials":3947,"activeCount":99},[],{"trials":3949,"activeCount":99},[],{"trials":3951,"activeCount":99},[],{"intervention":3941,"totalTrials":95,"cells":3953},{"EARLY_PHASE1":3954,"PHASE1":3956,"PHASE2":3962,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3955,"activeCount":99},[],{"trials":3957,"activeCount":95,"soonestReadout":73},[3958],{"nctId":71,"briefTitle":72,"status":111,"phases":3959,"primaryCompletion":73,"completion":73,"start":3936,"enrollment":3937,"conditions":3960,"interventions":3961},[87],[3939],[74,3941,3942,3943],{"trials":3963,"activeCount":99},[],{"trials":3965,"activeCount":99},[],{"trials":3967,"activeCount":99},[],{"trials":3969,"activeCount":99},[],{"intervention":3942,"totalTrials":95,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3980,"PHASE3":3982,"PHASE4":3984,"NA":3986},{"trials":3973,"activeCount":99},[],{"trials":3975,"activeCount":95,"soonestReadout":73},[3976],{"nctId":71,"briefTitle":72,"status":111,"phases":3977,"primaryCompletion":73,"completion":73,"start":3936,"enrollment":3937,"conditions":3978,"interventions":3979},[87],[3939],[74,3941,3942,3943],{"trials":3981,"activeCount":99},[],{"trials":3983,"activeCount":99},[],{"trials":3985,"activeCount":99},[],{"trials":3987,"activeCount":99},[],{"intervention":3943,"totalTrials":95,"cells":3989},{"EARLY_PHASE1":3990,"PHASE1":3992,"PHASE2":3998,"PHASE3":4000,"PHASE4":4002,"NA":4004},{"trials":3991,"activeCount":99},[],{"trials":3993,"activeCount":95,"soonestReadout":73},[3994],{"nctId":71,"briefTitle":72,"status":111,"phases":3995,"primaryCompletion":73,"completion":73,"start":3936,"enrollment":3937,"conditions":3996,"interventions":3997},[87],[3939],[74,3941,3942,3943],{"trials":3999,"activeCount":99},[],{"trials":4001,"activeCount":99},[],{"trials":4003,"activeCount":99},[],{"trials":4005,"activeCount":99},[],{"intervention":3867,"totalTrials":95,"cells":4007},{"EARLY_PHASE1":4008,"PHASE1":4010,"PHASE2":4016,"PHASE3":4018,"PHASE4":4020,"NA":4022},{"trials":4009,"activeCount":99},[],{"trials":4011,"activeCount":95,"soonestReadout":3861},[4012],{"nctId":3858,"briefTitle":3859,"status":111,"phases":4013,"primaryCompletion":3861,"completion":3861,"start":3862,"enrollment":24,"conditions":4014,"interventions":4015},[87],[3864,3865],[3851,3867],{"trials":4017,"activeCount":99},[],{"trials":4019,"activeCount":99},[],{"trials":4021,"activeCount":99},[],{"trials":4023,"activeCount":99},[],{"intervention":4025,"totalTrials":95,"cells":4026},"Commensal Bacteria Strains",{"EARLY_PHASE1":4027,"PHASE1":4029,"PHASE2":4043,"PHASE3":4045,"PHASE4":4047,"NA":4049},{"trials":4028,"activeCount":99},[],{"trials":4030,"activeCount":95,"soonestReadout":4035},[4031],{"nctId":4032,"briefTitle":4033,"status":111,"phases":4034,"primaryCompletion":4035,"completion":4036,"start":4037,"enrollment":782,"conditions":4038,"interventions":4042},"NCT06871111","The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial",[87],"2027-08-04","2028-02-04","2025-08-04",[4039,4040,4041],"Liver Diseases","Liver Failure","Cirrhosis, Liver",[4025],{"trials":4044,"activeCount":99},[],{"trials":4046,"activeCount":99},[],{"trials":4048,"activeCount":99},[],{"trials":4050,"activeCount":99},[],{"intervention":65,"totalTrials":95,"cells":4052},{"EARLY_PHASE1":4053,"PHASE1":4055,"PHASE2":4065,"PHASE3":4067,"PHASE4":4069,"NA":4071},{"trials":4054,"activeCount":99},[],{"trials":4056,"activeCount":95,"soonestReadout":64},[4057],{"nctId":62,"briefTitle":63,"status":481,"phases":4058,"primaryCompletion":64,"completion":4059,"start":4060,"enrollment":732,"conditions":4061,"interventions":4063},[87],"2027-03","2018-10-03",[4062],"Malignant Glioma of Brain",[65,4064],"Temozolomide",{"trials":4066,"activeCount":99},[],{"trials":4068,"activeCount":99},[],{"trials":4070,"activeCount":99},[],{"trials":4072,"activeCount":99},[],{"intervention":4064,"totalTrials":95,"cells":4074},{"EARLY_PHASE1":4075,"PHASE1":4077,"PHASE2":4083,"PHASE3":4085,"PHASE4":4087,"NA":4089},{"trials":4076,"activeCount":99},[],{"trials":4078,"activeCount":95,"soonestReadout":64},[4079],{"nctId":62,"briefTitle":63,"status":481,"phases":4080,"primaryCompletion":64,"completion":4059,"start":4060,"enrollment":732,"conditions":4081,"interventions":4082},[87],[4062],[65,4064],{"trials":4084,"activeCount":99},[],{"trials":4086,"activeCount":99},[],{"trials":4088,"activeCount":99},[],{"trials":4090,"activeCount":99},[],{"intervention":4092,"totalTrials":95,"cells":4093},"Fulvestrant",{"EARLY_PHASE1":4094,"PHASE1":4096,"PHASE2":4107,"PHASE3":4109,"PHASE4":4111,"NA":4113},{"trials":4095,"activeCount":99},[],{"trials":4097,"activeCount":95,"soonestReadout":248},[4098],{"nctId":4099,"briefTitle":4100,"status":111,"phases":4101,"primaryCompletion":248,"completion":248,"start":4102,"enrollment":410,"conditions":4103,"interventions":4105},"NCT06663072","Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors",[87],"2024-12-13",[4104],"Metastatic Pancreatic Neuroendocrine Tumor",[4092,4106],"177Lu-DOTATATE",{"trials":4108,"activeCount":99},[],{"trials":4110,"activeCount":99},[],{"trials":4112,"activeCount":99},[],{"trials":4114,"activeCount":99},[],{"intervention":4106,"totalTrials":95,"cells":4116},{"EARLY_PHASE1":4117,"PHASE1":4119,"PHASE2":4125,"PHASE3":4127,"PHASE4":4129,"NA":4131},{"trials":4118,"activeCount":99},[],{"trials":4120,"activeCount":95,"soonestReadout":248},[4121],{"nctId":4099,"briefTitle":4100,"status":111,"phases":4122,"primaryCompletion":248,"completion":248,"start":4102,"enrollment":410,"conditions":4123,"interventions":4124},[87],[4104],[4092,4106],{"trials":4126,"activeCount":99},[],{"trials":4128,"activeCount":99},[],{"trials":4130,"activeCount":99},[],{"trials":4132,"activeCount":99},[],{"intervention":4134,"totalTrials":95,"cells":4135},"Bupivacain",{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4149,"PHASE3":4151,"PHASE4":4153,"NA":4155},{"trials":4137,"activeCount":99},[],{"trials":4139,"activeCount":95,"soonestReadout":309},[4140],{"nctId":4141,"briefTitle":4142,"status":111,"phases":4143,"primaryCompletion":309,"completion":4144,"start":4145,"enrollment":1358,"conditions":4146,"interventions":4148},"NCT06639503","Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau",[87],"2026-10-14","2024-11-01",[4147],"Tibial Plateau Fractures",[4134],{"trials":4150,"activeCount":99},[],{"trials":4152,"activeCount":99},[],{"trials":4154,"activeCount":99},[],{"trials":4156,"activeCount":99},[],{"intervention":3514,"totalTrials":95,"cells":4158},{"EARLY_PHASE1":4159,"PHASE1":4161,"PHASE2":4167,"PHASE3":4169,"PHASE4":4171,"NA":4173},{"trials":4160,"activeCount":99},[],{"trials":4162,"activeCount":95,"soonestReadout":3507},[4163],{"nctId":3504,"briefTitle":3505,"status":111,"phases":4164,"primaryCompletion":3507,"completion":3507,"start":3508,"enrollment":1085,"conditions":4165,"interventions":4166},[87],[21,1087,3510,3511,3512],[3514,388,3323,3515],{"trials":4168,"activeCount":99},[],{"trials":4170,"activeCount":99},[],{"trials":4172,"activeCount":99},[],{"trials":4174,"activeCount":99},[],{"intervention":3515,"totalTrials":95,"cells":4176},{"EARLY_PHASE1":4177,"PHASE1":4179,"PHASE2":4185,"PHASE3":4187,"PHASE4":4189,"NA":4191},{"trials":4178,"activeCount":99},[],{"trials":4180,"activeCount":95,"soonestReadout":3507},[4181],{"nctId":3504,"briefTitle":3505,"status":111,"phases":4182,"primaryCompletion":3507,"completion":3507,"start":3508,"enrollment":1085,"conditions":4183,"interventions":4184},[87],[21,1087,3510,3511,3512],[3514,388,3323,3515],{"trials":4186,"activeCount":99},[],{"trials":4188,"activeCount":99},[],{"trials":4190,"activeCount":99},[],{"trials":4192,"activeCount":99},[],{"intervention":957,"totalTrials":95,"cells":4194},{"EARLY_PHASE1":4195,"PHASE1":4197,"PHASE2":4203,"PHASE3":4205,"PHASE4":4207,"NA":4209},{"trials":4196,"activeCount":99},[],{"trials":4198,"activeCount":95,"soonestReadout":947},[4199],{"nctId":944,"briefTitle":945,"status":111,"phases":4200,"primaryCompletion":947,"completion":947,"start":948,"enrollment":400,"conditions":4201,"interventions":4202},[87],[950,951,952,953,954,955],[957,958,46],{"trials":4204,"activeCount":99},[],{"trials":4206,"activeCount":99},[],{"trials":4208,"activeCount":99},[],{"trials":4210,"activeCount":99},[],{"intervention":321,"totalTrials":95,"cells":4212},{"EARLY_PHASE1":4213,"PHASE1":4215,"PHASE2":4221,"PHASE3":4223,"PHASE4":4225,"NA":4227},{"trials":4214,"activeCount":99},[],{"trials":4216,"activeCount":95,"soonestReadout":309},[4217],{"nctId":306,"briefTitle":307,"status":111,"phases":4218,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":4219,"interventions":4220},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"trials":4222,"activeCount":99},[],{"trials":4224,"activeCount":99},[],{"trials":4226,"activeCount":99},[],{"trials":4228,"activeCount":99},[],{"intervention":323,"totalTrials":95,"cells":4230},{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4239,"PHASE3":4241,"PHASE4":4243,"NA":4245},{"trials":4232,"activeCount":99},[],{"trials":4234,"activeCount":95,"soonestReadout":309},[4235],{"nctId":306,"briefTitle":307,"status":111,"phases":4236,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":4237,"interventions":4238},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"trials":4240,"activeCount":99},[],{"trials":4242,"activeCount":99},[],{"trials":4244,"activeCount":99},[],{"trials":4246,"activeCount":99},[],{"intervention":327,"totalTrials":95,"cells":4248},{"EARLY_PHASE1":4249,"PHASE1":4251,"PHASE2":4257,"PHASE3":4259,"PHASE4":4261,"NA":4263},{"trials":4250,"activeCount":99},[],{"trials":4252,"activeCount":95,"soonestReadout":309},[4253],{"nctId":306,"briefTitle":307,"status":111,"phases":4254,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":4255,"interventions":4256},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"trials":4258,"activeCount":99},[],{"trials":4260,"activeCount":99},[],{"trials":4262,"activeCount":99},[],{"trials":4264,"activeCount":99},[],{"intervention":328,"totalTrials":95,"cells":4266},{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4275,"PHASE3":4277,"PHASE4":4279,"NA":4281},{"trials":4268,"activeCount":99},[],{"trials":4270,"activeCount":95,"soonestReadout":309},[4271],{"nctId":306,"briefTitle":307,"status":111,"phases":4272,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":4273,"interventions":4274},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"trials":4276,"activeCount":99},[],{"trials":4278,"activeCount":99},[],{"trials":4280,"activeCount":99},[],{"trials":4282,"activeCount":99},[],{"intervention":1208,"totalTrials":95,"cells":4284},{"EARLY_PHASE1":4285,"PHASE1":4287,"PHASE2":4293,"PHASE3":4295,"PHASE4":4297,"NA":4299},{"trials":4286,"activeCount":99},[],{"trials":4288,"activeCount":95,"soonestReadout":83},[4289],{"nctId":1201,"briefTitle":1202,"status":111,"phases":4290,"primaryCompletion":83,"completion":113,"start":1204,"enrollment":400,"conditions":4291,"interventions":4292},[87],[1206],[392,385,958,387,1208],{"trials":4294,"activeCount":99},[],{"trials":4296,"activeCount":99},[],{"trials":4298,"activeCount":99},[],{"trials":4300,"activeCount":99},[],{"intervention":975,"totalTrials":95,"cells":4302},{"EARLY_PHASE1":4303,"PHASE1":4305,"PHASE2":4311,"PHASE3":4313,"PHASE4":4315,"NA":4317},{"trials":4304,"activeCount":99},[],{"trials":4306,"activeCount":95,"soonestReadout":746},[4307],{"nctId":967,"briefTitle":968,"status":481,"phases":4308,"primaryCompletion":746,"completion":746,"start":970,"enrollment":516,"conditions":4309,"interventions":4310},[87],[972,973],[975,46],{"trials":4312,"activeCount":99},[],{"trials":4314,"activeCount":99},[],{"trials":4316,"activeCount":99},[],{"trials":4318,"activeCount":99},[],{"intervention":326,"totalTrials":488,"cells":4320},{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4333,"PHASE3":4335,"PHASE4":4337,"NA":4339},{"trials":4322,"activeCount":99},[],{"trials":4324,"activeCount":95,"soonestReadout":309},[4325,4329],{"nctId":306,"briefTitle":307,"status":111,"phases":4326,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":4327,"interventions":4328},[87],[314,315,316],[318,319,320,321,322,323,324,325,325,299,326,327,328],{"nctId":1672,"briefTitle":1673,"status":363,"phases":4330,"primaryCompletion":1675,"completion":1675,"start":1280,"enrollment":367,"conditions":4331,"interventions":4332},[87],[1677,1678],[1680,326,387,1681,1682,1374,1683,1684,1559],{"trials":4334,"activeCount":99},[],{"trials":4336,"activeCount":99},[],{"trials":4338,"activeCount":99},[],{"trials":4340,"activeCount":99},[4341],{"nctId":1533,"briefTitle":1534,"status":981,"phases":4342,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":99,"conditions":4343,"interventions":4344},[91],[15],[1540,392,326,319],{"intervention":4346,"totalTrials":367,"cells":4347},"LSD",{"EARLY_PHASE1":4348,"PHASE1":4366,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4349,"activeCount":367,"soonestReadout":903},[4350,4357],{"nctId":4351,"briefTitle":4352,"status":111,"phases":4353,"primaryCompletion":4354,"completion":4354,"start":64,"enrollment":1153,"conditions":4355,"interventions":4356},"NCT07061886","Drug Effects on Mood and Behavior - Expectancy",[86],"2026-06-05",[4346],[4346],{"nctId":4358,"briefTitle":4359,"status":111,"phases":4360,"primaryCompletion":903,"completion":903,"start":4361,"enrollment":1153,"conditions":4362,"interventions":4365},"NCT07017478","Mood Effects of Serotonin Agonists: Depression",[86],"2025-06-09",[4346,4363,4364],"Major Depressive Disorder","Depression",[4346],{"trials":4367,"activeCount":99},[],{"trials":4369,"activeCount":99},[],{"trials":4371,"activeCount":99},[],{"trials":4373,"activeCount":99},[],{"trials":4375,"activeCount":99},[],{"intervention":4377,"totalTrials":367,"cells":4378},"Ciprofloxacin",{"EARLY_PHASE1":4379,"PHASE1":4394,"PHASE2":4396,"PHASE3":4398,"PHASE4":4409,"NA":4411},{"trials":4380,"activeCount":95,"soonestReadout":138},[4381],{"nctId":4382,"briefTitle":4383,"status":481,"phases":4384,"primaryCompletion":138,"completion":3507,"start":4385,"enrollment":4386,"conditions":4387,"interventions":4390},"NCT05100654","Collaborative Urological Prosthetics Investigation Directive Research Group",[86],"2022-04-22",800,[4388,4389],"Erectile Dysfunction","Penile Prosthesis Infection",[4391,4377,4392,4393],"Doxycycline","Augmentin","Bactrim",{"trials":4395,"activeCount":99},[],{"trials":4397,"activeCount":99},[],{"trials":4399,"activeCount":99},[4400],{"nctId":4401,"briefTitle":4402,"status":363,"phases":4403,"primaryCompletion":4404,"completion":4404,"start":4405,"enrollment":1382,"conditions":4406,"interventions":4408},"NCT00840294","Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)",[89],"2011-05","2009-01",[4407],"Elevated Prostate Specific Antigen",[4377],{"trials":4410,"activeCount":99},[],{"trials":4412,"activeCount":99},[],{"intervention":4414,"totalTrials":95,"cells":4415},"Empagliflozin",{"EARLY_PHASE1":4416,"PHASE1":4427,"PHASE2":4429,"PHASE3":4431,"PHASE4":4433,"NA":4435},{"trials":4417,"activeCount":95,"soonestReadout":4422},[4418],{"nctId":4419,"briefTitle":4420,"status":111,"phases":4421,"primaryCompletion":4422,"completion":138,"start":4423,"enrollment":2178,"conditions":4424,"interventions":4426},"NCT07055282","SGLT2i in Kidney Stones",[86],"2027-11-01","2025-11-20",[4425],"Kidney Stones",[4414],{"trials":4428,"activeCount":99},[],{"trials":4430,"activeCount":99},[],{"trials":4432,"activeCount":99},[],{"trials":4434,"activeCount":99},[],{"trials":4436,"activeCount":99},[],{"intervention":4391,"totalTrials":95,"cells":4438},{"EARLY_PHASE1":4439,"PHASE1":4445,"PHASE2":4447,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4440,"activeCount":95,"soonestReadout":138},[4441],{"nctId":4382,"briefTitle":4383,"status":481,"phases":4442,"primaryCompletion":138,"completion":3507,"start":4385,"enrollment":4386,"conditions":4443,"interventions":4444},[86],[4388,4389],[4391,4377,4392,4393],{"trials":4446,"activeCount":99},[],{"trials":4448,"activeCount":99},[],{"trials":4450,"activeCount":99},[],{"trials":4452,"activeCount":99},[],{"trials":4454,"activeCount":99},[],{"intervention":4392,"totalTrials":95,"cells":4456},{"EARLY_PHASE1":4457,"PHASE1":4463,"PHASE2":4465,"PHASE3":4467,"PHASE4":4469,"NA":4471},{"trials":4458,"activeCount":95,"soonestReadout":138},[4459],{"nctId":4382,"briefTitle":4383,"status":481,"phases":4460,"primaryCompletion":138,"completion":3507,"start":4385,"enrollment":4386,"conditions":4461,"interventions":4462},[86],[4388,4389],[4391,4377,4392,4393],{"trials":4464,"activeCount":99},[],{"trials":4466,"activeCount":99},[],{"trials":4468,"activeCount":99},[],{"trials":4470,"activeCount":99},[],{"trials":4472,"activeCount":99},[],{"intervention":4393,"totalTrials":95,"cells":4474},{"EARLY_PHASE1":4475,"PHASE1":4481,"PHASE2":4483,"PHASE3":4485,"PHASE4":4487,"NA":4489},{"trials":4476,"activeCount":95,"soonestReadout":138},[4477],{"nctId":4382,"briefTitle":4383,"status":481,"phases":4478,"primaryCompletion":138,"completion":3507,"start":4385,"enrollment":4386,"conditions":4479,"interventions":4480},[86],[4388,4389],[4391,4377,4392,4393],{"trials":4482,"activeCount":99},[],{"trials":4484,"activeCount":99},[],{"trials":4486,"activeCount":99},[],{"trials":4488,"activeCount":99},[],{"trials":4490,"activeCount":99},[],{"intervention":4492,"totalTrials":95,"cells":4493},"1:1 Randomization to receive milrinone",{"EARLY_PHASE1":4494,"PHASE1":4505,"PHASE2":4507,"PHASE3":4509,"PHASE4":4511,"NA":4513},{"trials":4495,"activeCount":95,"soonestReadout":83},[4496],{"nctId":4497,"briefTitle":4498,"status":111,"phases":4499,"primaryCompletion":83,"completion":83,"start":4500,"enrollment":994,"conditions":4501,"interventions":4504},"NCT05700617","Cardiac Power Output in Cardiogenic Shock Patients",[86],"2023-07-06",[4502,4503],"Heart Failure","Cardiogenic Shock",[4492],{"trials":4506,"activeCount":99},[],{"trials":4508,"activeCount":99},[],{"trials":4510,"activeCount":99},[],{"trials":4512,"activeCount":99},[],{"trials":4514,"activeCount":99},[],{"intervention":4516,"totalTrials":95,"cells":4517},"CardiaMend in Combination with Amiodarone",{"EARLY_PHASE1":4518,"PHASE1":4530,"PHASE2":4532,"PHASE3":4534,"PHASE4":4536,"NA":4538},{"trials":4519,"activeCount":95,"soonestReadout":4524},[4520],{"nctId":4521,"briefTitle":4522,"status":111,"phases":4523,"primaryCompletion":4524,"completion":4524,"start":4525,"enrollment":4526,"conditions":4527,"interventions":4529},"NCT06063538","Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone",[86],"2027-06","2024-02-15",63,[751,4528],"Post-Op Complication",[4516],{"trials":4531,"activeCount":99},[],{"trials":4533,"activeCount":99},[],{"trials":4535,"activeCount":99},[],{"trials":4537,"activeCount":99},[],{"trials":4539,"activeCount":99},[],{"intervention":4541,"totalTrials":488,"cells":4542},"Ethanol",{"EARLY_PHASE1":4543,"PHASE1":4566,"PHASE2":4568,"PHASE3":4570,"PHASE4":4572,"NA":4574},{"trials":4544,"activeCount":99},[4545,4556],{"nctId":4546,"briefTitle":4547,"status":332,"phases":4548,"primaryCompletion":4549,"completion":4549,"start":311,"enrollment":1085,"conditions":4550,"interventions":4555},"NCT03964350","Behavior Brain Responses",[86],"2020-12-31",[4551,4552,4553,4554],"Alcohol Drinking","Drinking Behavior","Physiological Effects of Drugs","Central Nervous System Depression",[4541],{"nctId":4557,"briefTitle":4558,"status":332,"phases":4559,"primaryCompletion":4560,"completion":4560,"start":4561,"enrollment":249,"conditions":4562,"interventions":4565},"NCT03930446","Alcohol, Behavior, and Brain Imaging",[86],"2019-05-30","2016-01-01",[4551,4563,4552,23,4541,4553,4564],"Binge Drinking","Central Nervous System Depressants",[4541],{"trials":4567,"activeCount":99},[],{"trials":4569,"activeCount":99},[],{"trials":4571,"activeCount":99},[],{"trials":4573,"activeCount":99},[],{"trials":4575,"activeCount":95,"soonestReadout":4580},[4576],{"nctId":4577,"briefTitle":4578,"status":481,"phases":4579,"primaryCompletion":4580,"completion":4581,"start":4582,"enrollment":4386,"conditions":4583,"interventions":4585},"NCT00961792","Chicago Social Drinking Project",[91],"2026-09","2027-10","2004-03",[4584],"Alcoholism",[4541,391,4586],"Caffeine",{"intervention":4586,"totalTrials":488,"cells":4588},{"EARLY_PHASE1":4589,"PHASE1":4591,"PHASE2":4593,"PHASE3":4595,"PHASE4":4597,"NA":4616},{"trials":4590,"activeCount":99},[],{"trials":4592,"activeCount":99},[],{"trials":4594,"activeCount":99},[],{"trials":4596,"activeCount":99},[],{"trials":4598,"activeCount":99},[4599,4609],{"nctId":4600,"briefTitle":4601,"status":332,"phases":4602,"primaryCompletion":4603,"completion":4604,"start":4605,"enrollment":545,"conditions":4606,"interventions":4608},"NCT03360903","A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia",[90],"2018-12-31","2019-06-01","2018-01-02",[4607],"Anesthesia",[4586],{"nctId":4610,"briefTitle":4611,"status":332,"phases":4612,"primaryCompletion":4613,"completion":4613,"start":365,"enrollment":545,"conditions":4614,"interventions":4615},"NCT02567968","A Study to Determine if Caffeine Accelerates Emergence From Anesthesia",[90],"2017-05-01",[4607],[4586],{"trials":4617,"activeCount":95,"soonestReadout":4580},[4618],{"nctId":4577,"briefTitle":4578,"status":481,"phases":4619,"primaryCompletion":4580,"completion":4581,"start":4582,"enrollment":4386,"conditions":4620,"interventions":4621},[91],[4584],[4541,391,4586],{"intervention":391,"totalTrials":367,"cells":4623},{"EARLY_PHASE1":4624,"PHASE1":4626,"PHASE2":4628,"PHASE3":4634,"PHASE4":4636,"NA":4638},{"trials":4625,"activeCount":99},[],{"trials":4627,"activeCount":99},[],{"trials":4629,"activeCount":99},[4630],{"nctId":374,"briefTitle":375,"status":332,"phases":4631,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":4632,"interventions":4633},[88],[381,382],[384,385,386,387,388,389,299,390,391,392],{"trials":4635,"activeCount":99},[],{"trials":4637,"activeCount":99},[],{"trials":4639,"activeCount":95,"soonestReadout":4580},[4640],{"nctId":4577,"briefTitle":4578,"status":481,"phases":4641,"primaryCompletion":4580,"completion":4581,"start":4582,"enrollment":4386,"conditions":4642,"interventions":4643},[91],[4584],[4541,391,4586],{"intervention":4645,"totalTrials":367,"cells":4646},"bicalutamide",{"EARLY_PHASE1":4647,"PHASE1":4649,"PHASE2":4663,"PHASE3":4665,"PHASE4":4667,"NA":4669},{"trials":4648,"activeCount":99},[],{"trials":4650,"activeCount":99},[4651],{"nctId":4652,"briefTitle":4653,"status":332,"phases":4654,"primaryCompletion":4655,"completion":4656,"start":1303,"enrollment":488,"conditions":4657,"interventions":4658},"NCT00026377","SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",[87],"2002-03","2003-04",[18],[4645,4659,4660,4661,4662],"flutamide","goserelin acetate","leuprolide acetate","SU5416",{"trials":4664,"activeCount":99},[],{"trials":4666,"activeCount":99},[],{"trials":4668,"activeCount":99},[],{"trials":4670,"activeCount":95,"soonestReadout":40},[4671],{"nctId":38,"briefTitle":39,"status":481,"phases":4672,"primaryCompletion":40,"completion":1293,"start":4673,"enrollment":1596,"conditions":4674,"interventions":4675},[91],"2010-12-17",[18],[41,4676,4677],"Dutasteride","Finasteride",{"intervention":4679,"totalTrials":95,"cells":4680},"fenfluramine HCl",{"EARLY_PHASE1":4681,"PHASE1":4683,"PHASE2":4685,"PHASE3":4687,"PHASE4":4689,"NA":4691},{"trials":4682,"activeCount":99},[],{"trials":4684,"activeCount":99},[],{"trials":4686,"activeCount":99},[],{"trials":4688,"activeCount":99},[],{"trials":4690,"activeCount":99},[],{"trials":4692,"activeCount":95,"soonestReadout":746},[4693],{"nctId":4694,"briefTitle":4695,"status":4696,"phases":4697,"primaryCompletion":746,"completion":4698,"start":4699,"enrollment":516,"conditions":4700,"interventions":4702},"NCT07555171","EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment","ENROLLING_BY_INVITATION",[],"2028-04","2026-04",[4701],"Lennox Gastaut Syndrome (LGS)",[4679],{"intervention":4704,"totalTrials":95,"cells":4705},"Subjects with and without Long COVID",{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4710,"PHASE3":4712,"PHASE4":4714,"NA":4716},{"trials":4707,"activeCount":99},[],{"trials":4709,"activeCount":99},[],{"trials":4711,"activeCount":99},[],{"trials":4713,"activeCount":99},[],{"trials":4715,"activeCount":99},[],{"trials":4717,"activeCount":95,"soonestReadout":4722},[4718],{"nctId":4719,"briefTitle":4720,"status":111,"phases":4721,"primaryCompletion":4722,"completion":4722,"start":4723,"enrollment":4724,"conditions":4725,"interventions":4726},"NCT06825819","Dysbiosis & Long COVID",[],"2029-01","2025-01-21",400,[117],[4704],{"intervention":4676,"totalTrials":95,"cells":4728},{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4733,"PHASE3":4735,"PHASE4":4737,"NA":4739},{"trials":4730,"activeCount":99},[],{"trials":4732,"activeCount":99},[],{"trials":4734,"activeCount":99},[],{"trials":4736,"activeCount":99},[],{"trials":4738,"activeCount":99},[],{"trials":4740,"activeCount":95,"soonestReadout":40},[4741],{"nctId":38,"briefTitle":39,"status":481,"phases":4742,"primaryCompletion":40,"completion":1293,"start":4673,"enrollment":1596,"conditions":4743,"interventions":4744},[91],[18],[41,4676,4677],{"intervention":4677,"totalTrials":95,"cells":4746},{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4751,"PHASE3":4753,"PHASE4":4755,"NA":4757},{"trials":4748,"activeCount":99},[],{"trials":4750,"activeCount":99},[],{"trials":4752,"activeCount":99},[],{"trials":4754,"activeCount":99},[],{"trials":4756,"activeCount":99},[],{"trials":4758,"activeCount":95,"soonestReadout":40},[4759],{"nctId":38,"briefTitle":39,"status":481,"phases":4760,"primaryCompletion":40,"completion":1293,"start":4673,"enrollment":1596,"conditions":4761,"interventions":4762},[91],[18],[41,4676,4677],{"intervention":4764,"totalTrials":994,"cells":4765},"fluticasone furoate",{"EARLY_PHASE1":4766,"PHASE1":4768,"PHASE2":4770,"PHASE3":4772,"PHASE4":4774,"NA":4824},{"trials":4767,"activeCount":99},[],{"trials":4769,"activeCount":99},[],{"trials":4771,"activeCount":99},[],{"trials":4773,"activeCount":99},[],{"trials":4775,"activeCount":99},[4776,4786,4797,4807,4816],{"nctId":4777,"briefTitle":4778,"status":332,"phases":4779,"primaryCompletion":4780,"completion":4781,"start":4782,"enrollment":516,"conditions":4783,"interventions":4785},"NCT00473915","Intranasal Steroids and the Nasal Ocular Response",[90],"2007-12","2008-02","2007-04",[4784],"Seasonal Allergic Rhinitis",[4764],{"nctId":4787,"briefTitle":4788,"status":332,"phases":4789,"primaryCompletion":4790,"completion":4790,"start":1279,"enrollment":4791,"conditions":4792,"interventions":4794},"NCT00584987","Intranasal Steroids and Oxymetazoline in Allergic Rhinitis",[90],"2009-07",64,[4793],"Allergic Rhinitis",[4795,4796],"Fluticasone furoate","Oxymetazoline",{"nctId":4798,"briefTitle":4799,"status":332,"phases":4800,"primaryCompletion":4801,"completion":814,"start":3358,"enrollment":19,"conditions":4802,"interventions":4803},"NCT01007253","Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms",[90],"2010-04",[4784],[4804,4764,4805,4806],"PL nasal spray","PL eye drops","olopatadine",{"nctId":4808,"briefTitle":4809,"status":332,"phases":4810,"primaryCompletion":4405,"completion":4811,"start":4812,"enrollment":782,"conditions":4813,"interventions":4815},"NCT00603044","Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome",[90],"2009-08","2008-01",[4814],"Childhood Obstructive Sleep Apnea Syndrome (OSAS)",[4764],{"nctId":4817,"briefTitle":4818,"status":332,"phases":4819,"primaryCompletion":4820,"completion":4821,"start":3357,"enrollment":312,"conditions":4822,"interventions":4823},"NCT00791973","Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen",[90],"2009-04","2010-05",[4793],[4764],{"trials":4825,"activeCount":99},[],{"intervention":3325,"totalTrials":994,"cells":4827},{"EARLY_PHASE1":4828,"PHASE1":4830,"PHASE2":4844,"PHASE3":4850,"PHASE4":4852,"NA":4858},{"trials":4829,"activeCount":99},[],{"trials":4831,"activeCount":99},[4832,4836,4840],{"nctId":3438,"briefTitle":3439,"status":332,"phases":4833,"primaryCompletion":3441,"completion":3441,"start":524,"enrollment":1215,"conditions":4834,"interventions":4835},[87],[3443,3444,3445,1037,3446,3447,1555,3448,3449,3450,3451,3452,3453,3454,3455,3456,3457],[3459,3325,3324,3323],{"nctId":3461,"briefTitle":3462,"status":332,"phases":4837,"primaryCompletion":3464,"completion":3465,"start":3466,"enrollment":3467,"conditions":4838,"interventions":4839},[87],[3469,3470,3443,3471,3472,3473,3474,3475,3476,3477,3478,3479,3480,3481,3482,3483,3484,3485,3486,3449,3487,3450,3451,3488,3489,3452,3453,3490,3491,3492,3493,3456,3457,3494,3495,3496,3497,3498,3499,3500],[1488,1448,3502,1169],{"nctId":3315,"briefTitle":3316,"status":981,"phases":4841,"primaryCompletion":365,"completion":365,"start":3318,"enrollment":99,"conditions":4842,"interventions":4843},[87],[3320,3321],[958,3323,3324,3325],{"trials":4845,"activeCount":99},[4846],{"nctId":3531,"briefTitle":3532,"status":332,"phases":4847,"primaryCompletion":3534,"completion":1484,"start":3535,"enrollment":1106,"conditions":4848,"interventions":4849},[88],[3528,1701],[3538,1169,3502,1488],{"trials":4851,"activeCount":99},[],{"trials":4853,"activeCount":99},[4854],{"nctId":3552,"briefTitle":3553,"status":468,"phases":4855,"primaryCompletion":3555,"completion":3555,"start":3556,"enrollment":400,"conditions":4856,"interventions":4857},[90],[1038,1037,3558,3559,3451,3560,3453,3561,3492],[1558,3325,3324,3323],{"trials":4859,"activeCount":99},[],{"intervention":3324,"totalTrials":994,"cells":4861},{"EARLY_PHASE1":4862,"PHASE1":4864,"PHASE2":4882,"PHASE3":4884,"PHASE4":4886,"NA":4892},{"trials":4863,"activeCount":99},[],{"trials":4865,"activeCount":99},[4866,4870,4874,4878],{"nctId":3438,"briefTitle":3439,"status":332,"phases":4867,"primaryCompletion":3441,"completion":3441,"start":524,"enrollment":1215,"conditions":4868,"interventions":4869},[87],[3443,3444,3445,1037,3446,3447,1555,3448,3449,3450,3451,3452,3453,3454,3455,3456,3457],[3459,3325,3324,3323],{"nctId":3461,"briefTitle":3462,"status":332,"phases":4871,"primaryCompletion":3464,"completion":3465,"start":3466,"enrollment":3467,"conditions":4872,"interventions":4873},[87],[3469,3470,3443,3471,3472,3473,3474,3475,3476,3477,3478,3479,3480,3481,3482,3483,3484,3485,3486,3449,3487,3450,3451,3488,3489,3452,3453,3490,3491,3492,3493,3456,3457,3494,3495,3496,3497,3498,3499,3500],[1488,1448,3502,1169],{"nctId":3315,"briefTitle":3316,"status":981,"phases":4875,"primaryCompletion":365,"completion":365,"start":3318,"enrollment":99,"conditions":4876,"interventions":4877},[87],[3320,3321],[958,3323,3324,3325],{"nctId":1441,"briefTitle":1442,"status":332,"phases":4879,"primaryCompletion":1444,"completion":815,"start":1445,"enrollment":19,"conditions":4880,"interventions":4881},[87],[772],[1448,1307],{"trials":4883,"activeCount":99},[],{"trials":4885,"activeCount":99},[],{"trials":4887,"activeCount":99},[4888],{"nctId":3552,"briefTitle":3553,"status":468,"phases":4889,"primaryCompletion":3555,"completion":3555,"start":3556,"enrollment":400,"conditions":4890,"interventions":4891},[90],[1038,1037,3558,3559,3451,3560,3453,3561,3492],[1558,3325,3324,3323],{"trials":4893,"activeCount":99},[],{"intervention":4895,"totalTrials":488,"cells":4896},"Fluticasone propionate",{"EARLY_PHASE1":4897,"PHASE1":4899,"PHASE2":4901,"PHASE3":4903,"PHASE4":4905,"NA":4938},{"trials":4898,"activeCount":99},[],{"trials":4900,"activeCount":99},[],{"trials":4902,"activeCount":99},[],{"trials":4904,"activeCount":99},[],{"trials":4906,"activeCount":99},[4907,4917,4928],{"nctId":4908,"briefTitle":4909,"status":332,"phases":4910,"primaryCompletion":4911,"completion":4912,"start":4913,"enrollment":16,"conditions":4914,"interventions":4915},"NCT02402465","Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis",[90],"2018-03","2020-02","2015-02",[4793],[4895,4916],"Fluticasone\u002FAzelastine nasal spray",{"nctId":4918,"briefTitle":4919,"status":363,"phases":4920,"primaryCompletion":4921,"completion":4405,"start":4922,"enrollment":4923,"conditions":4924,"interventions":4926},"NCT00119015","The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis",[90],"2008-06","2005-07",102,[4925],"Rhinitis, Allergic, Perennial",[4927,4895],"Montelukast",{"nctId":4929,"briefTitle":4930,"status":332,"phases":4931,"primaryCompletion":4932,"completion":4932,"start":4933,"enrollment":1106,"conditions":4934,"interventions":4935},"NCT01103934","Vitamin D Plus Fluticasone Propionate",[90],"2011-07","2010-06",[4784],[4936,4937],"Vitamin D3","Fluticasone Propionate",{"trials":4939,"activeCount":99},[],{"intervention":4941,"totalTrials":367,"cells":4942},"SGLT2i",{"EARLY_PHASE1":4943,"PHASE1":4945,"PHASE2":4947,"PHASE3":4949,"PHASE4":4951,"NA":4971},{"trials":4944,"activeCount":99},[],{"trials":4946,"activeCount":99},[],{"trials":4948,"activeCount":99},[],{"trials":4950,"activeCount":99},[],{"trials":4952,"activeCount":99},[4953,4962],{"nctId":4954,"briefTitle":4955,"status":363,"phases":4956,"primaryCompletion":4957,"completion":4957,"start":4958,"enrollment":95,"conditions":4959,"interventions":4961},"NCT05346653","The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure",[90],"2023-05-23","2023-05-22",[4960],"Acute Decompensated Heart Failure",[4941],{"nctId":4963,"briefTitle":4964,"status":332,"phases":4965,"primaryCompletion":4966,"completion":4966,"start":4967,"enrollment":2178,"conditions":4968,"interventions":4970},"NCT05278962","HF Patients With LVADs Being Treated With SGLT2i",[90],"2025-08-31","2022-09-08",[4969],"Heart Failure With Reduced Ejection Fraction",[4941],{"trials":4972,"activeCount":99},[],{"intervention":4974,"totalTrials":367,"cells":4975},"Dexmedetomidine",{"EARLY_PHASE1":4976,"PHASE1":4978,"PHASE2":4980,"PHASE3":4982,"PHASE4":4984,"NA":5008},{"trials":4977,"activeCount":99},[],{"trials":4979,"activeCount":99},[],{"trials":4981,"activeCount":99},[],{"trials":4983,"activeCount":99},[],{"trials":4985,"activeCount":99},[4986,5000],{"nctId":4987,"briefTitle":4988,"status":363,"phases":4989,"primaryCompletion":4990,"completion":4990,"start":4991,"enrollment":4992,"conditions":4993,"interventions":4996},"NCT01059929","Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)",[90],"2015-09","2009-09",41,[4994,4995],"Mechanical Ventilation","Critical Illness",[4974,4997,4998,4999],"Propofol","Fentanyl","Midazolam",{"nctId":5001,"briefTitle":5002,"status":363,"phases":5003,"primaryCompletion":5004,"completion":5004,"start":5005,"enrollment":2118,"conditions":5006,"interventions":5007},"NCT04329091","Implications of Anesthetics on Sleep Consolidation",[90],"2021-12-20","2020-10-16",[29],[4974],{"trials":5009,"activeCount":99},[],{"intervention":5011,"totalTrials":367,"cells":5012},"ribavirin",{"EARLY_PHASE1":5013,"PHASE1":5015,"PHASE2":5017,"PHASE3":5031,"PHASE4":5033,"NA":5045},{"trials":5014,"activeCount":99},[],{"trials":5016,"activeCount":99},[],{"trials":5018,"activeCount":99},[5019],{"nctId":5020,"briefTitle":5021,"status":981,"phases":5022,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":99,"conditions":5025,"interventions":5028},"NCT00814606","A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C",[88],"2010-10","2010-02",[5026,5027],"Hepatitis C","Hepatitis C Virus",[5029,5030,5011],"Fluvastatin","Peginterferon alfa2a",{"trials":5032,"activeCount":99},[],{"trials":5034,"activeCount":99},[5035],{"nctId":5036,"briefTitle":5037,"status":363,"phases":5038,"primaryCompletion":5039,"completion":5039,"start":1226,"enrollment":488,"conditions":5040,"interventions":5041},"NCT01592006","Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients",[90],"2014-09",[5026],[5042,5043,5044],"Peginterferon alfa-2a","Ribavirin","telaprevir",{"trials":5046,"activeCount":99},[],{"intervention":4927,"totalTrials":367,"cells":5048},{"EARLY_PHASE1":5049,"PHASE1":5051,"PHASE2":5053,"PHASE3":5055,"PHASE4":5057,"NA":5071},{"trials":5050,"activeCount":99},[],{"trials":5052,"activeCount":99},[],{"trials":5054,"activeCount":99},[],{"trials":5056,"activeCount":99},[],{"trials":5058,"activeCount":99},[5059,5063],{"nctId":4918,"briefTitle":4919,"status":363,"phases":5060,"primaryCompletion":4921,"completion":4405,"start":4922,"enrollment":4923,"conditions":5061,"interventions":5062},[90],[4925],[4927,4895],{"nctId":5064,"briefTitle":5065,"status":363,"phases":5066,"primaryCompletion":5067,"completion":5067,"start":1280,"enrollment":4791,"conditions":5068,"interventions":5070},"NCT01027806","Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children",[90],"2014-08",[5069],"Obstructive Sleep Apnea",[4927],{"trials":5072,"activeCount":99},[],{"intervention":5074,"totalTrials":95,"cells":5075},"Cefdinir",{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5080,"PHASE3":5082,"PHASE4":5084,"NA":5096},{"trials":5077,"activeCount":99},[],{"trials":5079,"activeCount":99},[],{"trials":5081,"activeCount":99},[],{"trials":5083,"activeCount":99},[],{"trials":5085,"activeCount":99},[5086],{"nctId":5087,"briefTitle":5088,"status":332,"phases":5089,"primaryCompletion":5090,"completion":5091,"start":3601,"enrollment":849,"conditions":5092,"interventions":5094},"NCT00147914","Comparison Study Between Cefdinir & Amoxicilline\u002FClavulanate in Acute Sinusitis and Assessment of Quality of Life",[90],"2007-02","2017-02-18",[5093],"Acute Bacterial Sinusitis",[5074,5095],"amoxicillin\u002Fclavulanate",{"trials":5097,"activeCount":99},[],{"intervention":5095,"totalTrials":95,"cells":5099},{"EARLY_PHASE1":5100,"PHASE1":5102,"PHASE2":5104,"PHASE3":5106,"PHASE4":5108,"NA":5114},{"trials":5101,"activeCount":99},[],{"trials":5103,"activeCount":99},[],{"trials":5105,"activeCount":99},[],{"trials":5107,"activeCount":99},[],{"trials":5109,"activeCount":99},[5110],{"nctId":5087,"briefTitle":5088,"status":332,"phases":5111,"primaryCompletion":5090,"completion":5091,"start":3601,"enrollment":849,"conditions":5112,"interventions":5113},[90],[5093],[5074,5095],{"trials":5115,"activeCount":99},[],{"intervention":5117,"totalTrials":95,"cells":5118},"Alemtuzumab",{"EARLY_PHASE1":5119,"PHASE1":5121,"PHASE2":5123,"PHASE3":5125,"PHASE4":5127,"NA":5139},{"trials":5120,"activeCount":99},[],{"trials":5122,"activeCount":99},[],{"trials":5124,"activeCount":99},[],{"trials":5126,"activeCount":99},[],{"trials":5128,"activeCount":99},[5129],{"nctId":5130,"briefTitle":5131,"status":332,"phases":5132,"primaryCompletion":5133,"completion":5134,"start":5135,"enrollment":545,"conditions":5136,"interventions":5138},"NCT01395316","Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis",[90],"2015-10","2017-07","2011-06",[5137],"Multiple Sclerosis",[5117],{"trials":5140,"activeCount":99},[],{"intervention":4916,"totalTrials":95,"cells":5142},{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5147,"PHASE3":5149,"PHASE4":5151,"NA":5157},{"trials":5144,"activeCount":99},[],{"trials":5146,"activeCount":99},[],{"trials":5148,"activeCount":99},[],{"trials":5150,"activeCount":99},[],{"trials":5152,"activeCount":99},[5153],{"nctId":4908,"briefTitle":4909,"status":332,"phases":5154,"primaryCompletion":4911,"completion":4912,"start":4913,"enrollment":16,"conditions":5155,"interventions":5156},[90],[4793],[4895,4916],{"trials":5158,"activeCount":99},[],{"intervention":5160,"totalTrials":95,"cells":5161},"Ortho Tri-cyclen Lo",{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5166,"PHASE3":5168,"PHASE4":5170,"NA":5181},{"trials":5163,"activeCount":99},[],{"trials":5165,"activeCount":99},[],{"trials":5167,"activeCount":99},[],{"trials":5169,"activeCount":99},[],{"trials":5171,"activeCount":99},[5172],{"nctId":5173,"briefTitle":5174,"status":332,"phases":5175,"primaryCompletion":4405,"completion":4790,"start":5176,"enrollment":5177,"conditions":5178,"interventions":5180},"NCT00635570","Acceptability of the NuvaRing Among Students",[90],"2008-07",273,[5179],"Birth Control Compliance",[5160],{"trials":5182,"activeCount":99},[],{"intervention":5184,"totalTrials":95,"cells":5185},"Plasma",{"EARLY_PHASE1":5186,"PHASE1":5188,"PHASE2":5190,"PHASE3":5192,"PHASE4":5194,"NA":5205},{"trials":5187,"activeCount":99},[],{"trials":5189,"activeCount":99},[],{"trials":5191,"activeCount":99},[],{"trials":5193,"activeCount":99},[],{"trials":5195,"activeCount":99},[5196],{"nctId":5197,"briefTitle":5198,"status":981,"phases":5199,"primaryCompletion":5200,"completion":1044,"start":5201,"enrollment":99,"conditions":5202,"interventions":5204},"NCT02774317","Pilot Study to Compare Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months",[90],"2020-06","2017-10",[5203],"Blood Coagulation Disorders",[5184],{"trials":5206,"activeCount":99},[],{"intervention":5208,"totalTrials":95,"cells":5209},"Succinylcholine",{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5216,"PHASE4":5218,"NA":5231},{"trials":5211,"activeCount":99},[],{"trials":5213,"activeCount":99},[],{"trials":5215,"activeCount":99},[],{"trials":5217,"activeCount":99},[],{"trials":5219,"activeCount":99},[5220],{"nctId":5221,"briefTitle":5222,"status":332,"phases":5223,"primaryCompletion":5224,"completion":5224,"start":5225,"enrollment":849,"conditions":5226,"interventions":5229},"NCT02635542","Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery",[90],"2017-09-15","2016-03",[5227,5228],"Neuromuscular Blockade","Postoperative Complications",[5208,5230],"Cisatracurium",{"trials":5232,"activeCount":99},[],{"intervention":5230,"totalTrials":95,"cells":5234},{"EARLY_PHASE1":5235,"PHASE1":5237,"PHASE2":5239,"PHASE3":5241,"PHASE4":5243,"NA":5249},{"trials":5236,"activeCount":99},[],{"trials":5238,"activeCount":99},[],{"trials":5240,"activeCount":99},[],{"trials":5242,"activeCount":99},[],{"trials":5244,"activeCount":99},[5245],{"nctId":5221,"briefTitle":5222,"status":332,"phases":5246,"primaryCompletion":5224,"completion":5224,"start":5225,"enrollment":849,"conditions":5247,"interventions":5248},[90],[5227,5228],[5208,5230],{"trials":5250,"activeCount":99},[],{"intervention":5252,"totalTrials":95,"cells":5253},"Polyethylene Glycol 3350",{"EARLY_PHASE1":5254,"PHASE1":5256,"PHASE2":5258,"PHASE3":5260,"PHASE4":5262,"NA":5274},{"trials":5255,"activeCount":99},[],{"trials":5257,"activeCount":99},[],{"trials":5259,"activeCount":99},[],{"trials":5261,"activeCount":99},[],{"trials":5263,"activeCount":99},[5264],{"nctId":5265,"briefTitle":5266,"status":332,"phases":5267,"primaryCompletion":5268,"completion":4361,"start":5269,"enrollment":5270,"conditions":5271,"interventions":5273},"NCT04263896","Bowel Function After Minimally Invasive Hysterectomy",[90],"2024-06-30","2019-08-28",97,[5272],"Constipation",[5252],{"trials":5275,"activeCount":99},[],{"intervention":5277,"totalTrials":95,"cells":5278},"Mometasone",{"EARLY_PHASE1":5279,"PHASE1":5281,"PHASE2":5283,"PHASE3":5285,"PHASE4":5287,"NA":5297},{"trials":5280,"activeCount":99},[],{"trials":5282,"activeCount":99},[],{"trials":5284,"activeCount":99},[],{"trials":5286,"activeCount":99},[],{"trials":5288,"activeCount":99},[5289],{"nctId":5290,"briefTitle":5291,"status":363,"phases":5292,"primaryCompletion":5293,"completion":5293,"start":5294,"enrollment":27,"conditions":5295,"interventions":5296},"NCT00361439","Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis",[90],"2008-09","2006-08",[4784],[5277],{"trials":5298,"activeCount":99},[],{"intervention":5300,"totalTrials":95,"cells":5301},"Budesonide",{"EARLY_PHASE1":5302,"PHASE1":5304,"PHASE2":5306,"PHASE3":5308,"PHASE4":5310,"NA":5320},{"trials":5303,"activeCount":99},[],{"trials":5305,"activeCount":99},[],{"trials":5307,"activeCount":99},[],{"trials":5309,"activeCount":99},[],{"trials":5311,"activeCount":99},[5312],{"nctId":5313,"briefTitle":5314,"status":332,"phases":5315,"primaryCompletion":2358,"completion":1726,"start":5316,"enrollment":4992,"conditions":5317,"interventions":5319},"NCT01270256","NasoNeb Delivery of an Intranasal Steroid",[90],"2011-01",[5318],"Perennial Allergic Rhinitis",[5300],{"trials":5321,"activeCount":99},[],{"intervention":5323,"totalTrials":95,"cells":5324},"long acting oxycodone",{"EARLY_PHASE1":5325,"PHASE1":5327,"PHASE2":5329,"PHASE3":5331,"PHASE4":5333,"NA":5346},{"trials":5326,"activeCount":99},[],{"trials":5328,"activeCount":99},[],{"trials":5330,"activeCount":99},[],{"trials":5332,"activeCount":99},[],{"trials":5334,"activeCount":99},[5335],{"nctId":5336,"briefTitle":5337,"status":363,"phases":5338,"primaryCompletion":5339,"completion":5339,"start":5316,"enrollment":410,"conditions":5340,"interventions":5344},"NCT01264965","Non-cancer Pain and Cognitive Impairment: A Disabling Relationship",[90],"2014-02",[5341,5342,5343],"Arthritis","Pain","Cognitive Impairment",[5323,5345],"extra strength acetaminophen",{"trials":5347,"activeCount":99},[],{"intervention":5345,"totalTrials":95,"cells":5349},{"EARLY_PHASE1":5350,"PHASE1":5352,"PHASE2":5354,"PHASE3":5356,"PHASE4":5358,"NA":5364},{"trials":5351,"activeCount":99},[],{"trials":5353,"activeCount":99},[],{"trials":5355,"activeCount":99},[],{"trials":5357,"activeCount":99},[],{"trials":5359,"activeCount":99},[5360],{"nctId":5336,"briefTitle":5337,"status":363,"phases":5361,"primaryCompletion":5339,"completion":5339,"start":5316,"enrollment":410,"conditions":5362,"interventions":5363},[90],[5341,5342,5343],[5323,5345],{"trials":5365,"activeCount":99},[],{"intervention":4998,"totalTrials":95,"cells":5367},{"EARLY_PHASE1":5368,"PHASE1":5370,"PHASE2":5372,"PHASE3":5374,"PHASE4":5376,"NA":5382},{"trials":5369,"activeCount":99},[],{"trials":5371,"activeCount":99},[],{"trials":5373,"activeCount":99},[],{"trials":5375,"activeCount":99},[],{"trials":5377,"activeCount":99},[5378],{"nctId":4987,"briefTitle":4988,"status":363,"phases":5379,"primaryCompletion":4990,"completion":4990,"start":4991,"enrollment":4992,"conditions":5380,"interventions":5381},[90],[4994,4995],[4974,4997,4998,4999],{"trials":5383,"activeCount":99},[],{"intervention":4999,"totalTrials":95,"cells":5385},{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5390,"PHASE3":5392,"PHASE4":5394,"NA":5400},{"trials":5387,"activeCount":99},[],{"trials":5389,"activeCount":99},[],{"trials":5391,"activeCount":99},[],{"trials":5393,"activeCount":99},[],{"trials":5395,"activeCount":99},[5396],{"nctId":4987,"briefTitle":4988,"status":363,"phases":5397,"primaryCompletion":4990,"completion":4990,"start":4991,"enrollment":4992,"conditions":5398,"interventions":5399},[90],[4994,4995],[4974,4997,4998,4999],{"trials":5401,"activeCount":99},[],{"intervention":5403,"totalTrials":95,"cells":5404},"Inhaled Iloprost",{"EARLY_PHASE1":5405,"PHASE1":5407,"PHASE2":5409,"PHASE3":5411,"PHASE4":5413,"NA":5423},{"trials":5406,"activeCount":99},[],{"trials":5408,"activeCount":99},[],{"trials":5410,"activeCount":99},[],{"trials":5412,"activeCount":99},[],{"trials":5414,"activeCount":99},[5415],{"nctId":5416,"briefTitle":5417,"status":363,"phases":5418,"primaryCompletion":4780,"completion":4780,"start":5419,"enrollment":95,"conditions":5420,"interventions":5422},"NCT00409526","Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.",[90],"2006-12",[5421],"Pulmonary Hypertension",[5403],{"trials":5424,"activeCount":99},[],{"intervention":821,"totalTrials":95,"cells":5426},{"EARLY_PHASE1":5427,"PHASE1":5429,"PHASE2":5431,"PHASE3":5433,"PHASE4":5435,"NA":5441},{"trials":5428,"activeCount":99},[],{"trials":5430,"activeCount":99},[],{"trials":5432,"activeCount":99},[],{"trials":5434,"activeCount":99},[],{"trials":5436,"activeCount":99},[5437],{"nctId":811,"briefTitle":812,"status":332,"phases":5438,"primaryCompletion":814,"completion":814,"start":815,"enrollment":816,"conditions":5439,"interventions":5440},[90],[818,819],[821,758],{"trials":5442,"activeCount":99},[],{"intervention":5444,"totalTrials":95,"cells":5445},"Kaletra + Current Dual NRTI Backbone",{"EARLY_PHASE1":5446,"PHASE1":5448,"PHASE2":5450,"PHASE3":5452,"PHASE4":5454,"NA":5466},{"trials":5447,"activeCount":99},[],{"trials":5449,"activeCount":99},[],{"trials":5451,"activeCount":99},[],{"trials":5453,"activeCount":99},[],{"trials":5455,"activeCount":99},[5456],{"nctId":5457,"briefTitle":5458,"status":332,"phases":5459,"primaryCompletion":2359,"completion":5460,"start":5461,"enrollment":516,"conditions":5462,"interventions":5464},"NCT00145795","A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment",[90],"2009-12","2004-04",[5463],"HIV Infections",[5444,5465],"Current Regimen",{"trials":5467,"activeCount":99},[],{"intervention":5465,"totalTrials":95,"cells":5469},{"EARLY_PHASE1":5470,"PHASE1":5472,"PHASE2":5474,"PHASE3":5476,"PHASE4":5478,"NA":5484},{"trials":5471,"activeCount":99},[],{"trials":5473,"activeCount":99},[],{"trials":5475,"activeCount":99},[],{"trials":5477,"activeCount":99},[],{"trials":5479,"activeCount":99},[5480],{"nctId":5457,"briefTitle":5458,"status":332,"phases":5481,"primaryCompletion":2359,"completion":5460,"start":5461,"enrollment":516,"conditions":5482,"interventions":5483},[90],[5463],[5444,5465],{"trials":5485,"activeCount":99},[],{"intervention":5487,"totalTrials":95,"cells":5488},"QNASL",{"EARLY_PHASE1":5489,"PHASE1":5491,"PHASE2":5493,"PHASE3":5495,"PHASE4":5497,"NA":5506},{"trials":5490,"activeCount":99},[],{"trials":5492,"activeCount":99},[],{"trials":5494,"activeCount":99},[],{"trials":5496,"activeCount":99},[],{"trials":5498,"activeCount":99},[5499],{"nctId":5500,"briefTitle":5501,"status":332,"phases":5502,"primaryCompletion":1176,"completion":5503,"start":432,"enrollment":2904,"conditions":5504,"interventions":5505},"NCT01852513","Allergic Rhinitis Changes the Sinus Microbiome",[90],"2014-06",[4784],[5487],{"trials":5507,"activeCount":99},[],{"intervention":5509,"totalTrials":95,"cells":5510},"Claritin",{"EARLY_PHASE1":5511,"PHASE1":5513,"PHASE2":5515,"PHASE3":5517,"PHASE4":5519,"NA":5530},{"trials":5512,"activeCount":99},[],{"trials":5514,"activeCount":99},[],{"trials":5516,"activeCount":99},[],{"trials":5518,"activeCount":99},[],{"trials":5520,"activeCount":99},[5521],{"nctId":5522,"briefTitle":5523,"status":332,"phases":5524,"primaryCompletion":2358,"completion":5525,"start":5526,"enrollment":5527,"conditions":5528,"interventions":5529},"NCT01451996","The Efficacy of Claritin in Healthy Subjects",[90],"2012-12","2011-10",340,[32],[5509],{"trials":5531,"activeCount":99},[],{"intervention":5533,"totalTrials":95,"cells":5534},"lidocaine",{"EARLY_PHASE1":5535,"PHASE1":5537,"PHASE2":5539,"PHASE3":5541,"PHASE4":5543,"NA":5554},{"trials":5536,"activeCount":99},[],{"trials":5538,"activeCount":99},[],{"trials":5540,"activeCount":99},[],{"trials":5542,"activeCount":99},[],{"trials":5544,"activeCount":99},[5545],{"nctId":5546,"briefTitle":5547,"status":332,"phases":5548,"primaryCompletion":5549,"completion":5549,"start":5550,"enrollment":5551,"conditions":5552,"interventions":5553},"NCT01330134","Comparison of Two Lidocaine Administration Techniques",[90],"2015-04","2011-02",481,[5342],[5533,5533],{"trials":5555,"activeCount":99},[],{"intervention":5557,"totalTrials":95,"cells":5558},"Neupogen",{"EARLY_PHASE1":5559,"PHASE1":5561,"PHASE2":5563,"PHASE3":5565,"PHASE4":5567,"NA":5577},{"trials":5560,"activeCount":99},[],{"trials":5562,"activeCount":99},[],{"trials":5564,"activeCount":99},[],{"trials":5566,"activeCount":99},[],{"trials":5568,"activeCount":99},[5569],{"nctId":5570,"briefTitle":5571,"status":981,"phases":5572,"primaryCompletion":5573,"completion":5573,"start":5039,"enrollment":99,"conditions":5574,"interventions":5576},"NCT02408991","Use Art-assist and Neupogen to Treat Chronic Limb Ischemia",[90],"2015-07",[5575],"Lower Limb Ischemia",[5557],{"trials":5578,"activeCount":99},[],{"intervention":5580,"totalTrials":95,"cells":5581},"Intrathecal morphine",{"EARLY_PHASE1":5582,"PHASE1":5584,"PHASE2":5586,"PHASE3":5588,"PHASE4":5590,"NA":5600},{"trials":5583,"activeCount":99},[],{"trials":5585,"activeCount":99},[],{"trials":5587,"activeCount":99},[],{"trials":5589,"activeCount":99},[],{"trials":5591,"activeCount":99},[5592],{"nctId":5593,"briefTitle":5594,"status":332,"phases":5595,"primaryCompletion":5596,"completion":5596,"start":5597,"enrollment":3467,"conditions":5598,"interventions":5599},"NCT03241485","Trial Comparing Intrathecal Morphine With Placebo In Patients Undergoing Robotic Cardiac Surgery",[90],"2020-09-01","2018-06-19",[5342],[5580],{"trials":5601,"activeCount":99},[],{"intervention":5603,"totalTrials":95,"cells":5604},"Anti-IgE antibody omalizumab or placebo",{"EARLY_PHASE1":5605,"PHASE1":5607,"PHASE2":5609,"PHASE3":5611,"PHASE4":5613,"NA":5622},{"trials":5606,"activeCount":99},[],{"trials":5608,"activeCount":99},[],{"trials":5610,"activeCount":99},[],{"trials":5612,"activeCount":99},[],{"trials":5614,"activeCount":99},[5615],{"nctId":5616,"briefTitle":5617,"status":332,"phases":5618,"primaryCompletion":537,"completion":4405,"start":4922,"enrollment":1779,"conditions":5619,"interventions":5621},"NCT00117611","Xolair in Patients With Chronic Sinusitis",[90],[5620],"Sinusitis",[5603],{"trials":5623,"activeCount":99},[],{"intervention":5625,"totalTrials":95,"cells":5626},"Glutathione",{"EARLY_PHASE1":5627,"PHASE1":5629,"PHASE2":5631,"PHASE3":5633,"PHASE4":5635,"NA":5646},{"trials":5628,"activeCount":99},[],{"trials":5630,"activeCount":99},[],{"trials":5632,"activeCount":99},[],{"trials":5634,"activeCount":99},[],{"trials":5636,"activeCount":99},[5637],{"nctId":5638,"briefTitle":5639,"status":363,"phases":5640,"primaryCompletion":5641,"completion":5641,"start":5642,"enrollment":1571,"conditions":5643,"interventions":5645},"NCT05954052","A Study of Glutathione in Children With Autism Spectrum Disorder",[90],"2023-08-15","2019-07-01",[5644],"Autism Spectrum Disorder",[5625],{"trials":5647,"activeCount":99},[],{"intervention":4796,"totalTrials":95,"cells":5649},{"EARLY_PHASE1":5650,"PHASE1":5652,"PHASE2":5654,"PHASE3":5656,"PHASE4":5658,"NA":5664},{"trials":5651,"activeCount":99},[],{"trials":5653,"activeCount":99},[],{"trials":5655,"activeCount":99},[],{"trials":5657,"activeCount":99},[],{"trials":5659,"activeCount":99},[5660],{"nctId":4787,"briefTitle":4788,"status":332,"phases":5661,"primaryCompletion":4790,"completion":4790,"start":1279,"enrollment":4791,"conditions":5662,"interventions":5663},[90],[4793],[4795,4796],{"trials":5665,"activeCount":99},[],{"intervention":4804,"totalTrials":95,"cells":5667},{"EARLY_PHASE1":5668,"PHASE1":5670,"PHASE2":5672,"PHASE3":5674,"PHASE4":5676,"NA":5682},{"trials":5669,"activeCount":99},[],{"trials":5671,"activeCount":99},[],{"trials":5673,"activeCount":99},[],{"trials":5675,"activeCount":99},[],{"trials":5677,"activeCount":99},[5678],{"nctId":4798,"briefTitle":4799,"status":332,"phases":5679,"primaryCompletion":4801,"completion":814,"start":3358,"enrollment":19,"conditions":5680,"interventions":5681},[90],[4784],[4804,4764,4805,4806],{"trials":5683,"activeCount":99},[],{"intervention":4805,"totalTrials":95,"cells":5685},{"EARLY_PHASE1":5686,"PHASE1":5688,"PHASE2":5690,"PHASE3":5692,"PHASE4":5694,"NA":5700},{"trials":5687,"activeCount":99},[],{"trials":5689,"activeCount":99},[],{"trials":5691,"activeCount":99},[],{"trials":5693,"activeCount":99},[],{"trials":5695,"activeCount":99},[5696],{"nctId":4798,"briefTitle":4799,"status":332,"phases":5697,"primaryCompletion":4801,"completion":814,"start":3358,"enrollment":19,"conditions":5698,"interventions":5699},[90],[4784],[4804,4764,4805,4806],{"trials":5701,"activeCount":99},[],{"intervention":4806,"totalTrials":95,"cells":5703},{"EARLY_PHASE1":5704,"PHASE1":5706,"PHASE2":5708,"PHASE3":5710,"PHASE4":5712,"NA":5718},{"trials":5705,"activeCount":99},[],{"trials":5707,"activeCount":99},[],{"trials":5709,"activeCount":99},[],{"trials":5711,"activeCount":99},[],{"trials":5713,"activeCount":99},[5714],{"nctId":4798,"briefTitle":4799,"status":332,"phases":5715,"primaryCompletion":4801,"completion":814,"start":3358,"enrollment":19,"conditions":5716,"interventions":5717},[90],[4784],[4804,4764,4805,4806],{"trials":5719,"activeCount":99},[],{"intervention":5721,"totalTrials":95,"cells":5722},"Myfembree Oral Product",{"EARLY_PHASE1":5723,"PHASE1":5725,"PHASE2":5727,"PHASE3":5729,"PHASE4":5731,"NA":5745},{"trials":5724,"activeCount":99},[],{"trials":5726,"activeCount":99},[],{"trials":5728,"activeCount":99},[],{"trials":5730,"activeCount":99},[],{"trials":5732,"activeCount":99},[5733],{"nctId":5734,"briefTitle":5735,"status":981,"phases":5736,"primaryCompletion":5737,"completion":5737,"start":5738,"enrollment":99,"conditions":5739,"interventions":5744},"NCT05538689","Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)",[90],"2024-10-24","2022-11-20",[5740,5741,5742,5743],"Metrorrhagia","Pelvic Pain","Menorrhagia","Leiomyoma",[5721],{"trials":5746,"activeCount":99},[],{"intervention":5748,"totalTrials":95,"cells":5749},"ACTHar",{"EARLY_PHASE1":5750,"PHASE1":5752,"PHASE2":5754,"PHASE3":5756,"PHASE4":5758,"NA":5768},{"trials":5751,"activeCount":99},[],{"trials":5753,"activeCount":99},[],{"trials":5755,"activeCount":99},[],{"trials":5757,"activeCount":99},[],{"trials":5759,"activeCount":99},[5760],{"nctId":5761,"briefTitle":5762,"status":363,"phases":5763,"primaryCompletion":5764,"completion":5764,"start":5765,"enrollment":994,"conditions":5766,"interventions":5767},"NCT03021317","Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses",[90],"2020-10-07","2016-12-20",[5137],[5748],{"trials":5769,"activeCount":99},[],{"intervention":3287,"totalTrials":95,"cells":5771},{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5776,"PHASE3":5778,"PHASE4":5780,"NA":5786},{"trials":5773,"activeCount":99},[],{"trials":5775,"activeCount":99},[],{"trials":5777,"activeCount":99},[],{"trials":5779,"activeCount":99},[],{"trials":5781,"activeCount":99},[5782],{"nctId":3280,"briefTitle":3281,"status":363,"phases":5783,"primaryCompletion":3283,"completion":3283,"start":432,"enrollment":367,"conditions":5784,"interventions":5785},[90],[3285],[3287,530],{"trials":5787,"activeCount":99},[],{"intervention":5042,"totalTrials":95,"cells":5789},{"EARLY_PHASE1":5790,"PHASE1":5792,"PHASE2":5794,"PHASE3":5796,"PHASE4":5798,"NA":5804},{"trials":5791,"activeCount":99},[],{"trials":5793,"activeCount":99},[],{"trials":5795,"activeCount":99},[],{"trials":5797,"activeCount":99},[],{"trials":5799,"activeCount":99},[5800],{"nctId":5036,"briefTitle":5037,"status":363,"phases":5801,"primaryCompletion":5039,"completion":5039,"start":1226,"enrollment":488,"conditions":5802,"interventions":5803},[90],[5026],[5042,5043,5044],{"trials":5805,"activeCount":99},[],{"intervention":5044,"totalTrials":95,"cells":5807},{"EARLY_PHASE1":5808,"PHASE1":5810,"PHASE2":5812,"PHASE3":5814,"PHASE4":5816,"NA":5822},{"trials":5809,"activeCount":99},[],{"trials":5811,"activeCount":99},[],{"trials":5813,"activeCount":99},[],{"trials":5815,"activeCount":99},[],{"trials":5817,"activeCount":99},[5818],{"nctId":5036,"briefTitle":5037,"status":363,"phases":5819,"primaryCompletion":5039,"completion":5039,"start":1226,"enrollment":488,"conditions":5820,"interventions":5821},[90],[5026],[5042,5043,5044],{"trials":5823,"activeCount":99},[],{"intervention":5825,"totalTrials":95,"cells":5826},"Entresto",{"EARLY_PHASE1":5827,"PHASE1":5829,"PHASE2":5831,"PHASE3":5833,"PHASE4":5835,"NA":5844},{"trials":5828,"activeCount":99},[],{"trials":5830,"activeCount":99},[],{"trials":5832,"activeCount":99},[],{"trials":5834,"activeCount":99},[],{"trials":5836,"activeCount":99},[5837],{"nctId":5838,"briefTitle":5839,"status":332,"phases":5840,"primaryCompletion":1250,"completion":1250,"start":5841,"enrollment":539,"conditions":5842,"interventions":5843},"NCT02754518","Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis",[90],"2016-04",[4502],[5825],{"trials":5845,"activeCount":99},[],{"intervention":5847,"totalTrials":95,"cells":5848},"Eszopiclone",{"EARLY_PHASE1":5849,"PHASE1":5851,"PHASE2":5853,"PHASE3":5855,"PHASE4":5857,"NA":5869},{"trials":5850,"activeCount":99},[],{"trials":5852,"activeCount":99},[],{"trials":5854,"activeCount":99},[],{"trials":5856,"activeCount":99},[],{"trials":5858,"activeCount":99},[5859],{"nctId":5860,"briefTitle":5861,"status":332,"phases":5862,"primaryCompletion":5863,"completion":5863,"start":5864,"enrollment":516,"conditions":5865,"interventions":5868},"NCT00724282","Treatment of Insomnia and Glucose Metabolism",[90],"2012-03","2008-04",[29,5866,5867],"Insomnia","Insulin Resistance",[5847],{"trials":5870,"activeCount":99},[],{"intervention":5872,"totalTrials":95,"cells":5873},"Prednisolone and amoxicillin\u002Fclavulanate",{"EARLY_PHASE1":5874,"PHASE1":5876,"PHASE2":5878,"PHASE3":5880,"PHASE4":5882,"NA":5892},{"trials":5875,"activeCount":99},[],{"trials":5877,"activeCount":99},[],{"trials":5879,"activeCount":99},[],{"trials":5881,"activeCount":99},[],{"trials":5883,"activeCount":99},[5884],{"nctId":5885,"briefTitle":5886,"status":363,"phases":5887,"primaryCompletion":5888,"completion":5888,"start":1727,"enrollment":526,"conditions":5889,"interventions":5891},"NCT00456339","Systemic Steroids Plus Antibiotics in Sleep Apnea Syndrome in Children",[90],"2007-07",[5890],"Obstructive Sleep Apnea Syndrome",[5872],{"trials":5893,"activeCount":99},[],{"intervention":5895,"totalTrials":95,"cells":5896},"Nicotine",{"EARLY_PHASE1":5897,"PHASE1":5899,"PHASE2":5901,"PHASE3":5903,"PHASE4":5905,"NA":5917},{"trials":5898,"activeCount":99},[],{"trials":5900,"activeCount":99},[],{"trials":5902,"activeCount":99},[],{"trials":5904,"activeCount":99},[],{"trials":5906,"activeCount":99},[5907],{"nctId":5908,"briefTitle":5909,"status":981,"phases":5910,"primaryCompletion":5911,"completion":5911,"start":5912,"enrollment":99,"conditions":5913,"interventions":5916},"NCT06259630","Nicotine Virtual Reality Conditioned Place Preference",[90],"2018-06-22","2015-11-03",[5914,5915],"Nicotine Addiction","Nicotine Use Disorder",[5895],{"trials":5918,"activeCount":99},[],{"intervention":5920,"totalTrials":95,"cells":5921},"Ibuprofen, Hydrocodone\u002FAcetaminophen, Omeprazole",{"EARLY_PHASE1":5922,"PHASE1":5924,"PHASE2":5926,"PHASE3":5928,"PHASE4":5930,"NA":5940},{"trials":5923,"activeCount":99},[],{"trials":5925,"activeCount":99},[],{"trials":5927,"activeCount":99},[],{"trials":5929,"activeCount":99},[],{"trials":5931,"activeCount":99},[5932],{"nctId":5933,"briefTitle":5934,"status":981,"phases":5935,"primaryCompletion":1536,"completion":1536,"start":3283,"enrollment":99,"conditions":5936,"interventions":5938},"NCT02153177","The Effect of NSAIDs After a Rotator Cuff Repair Surgery.",[90],[5937],"Rotator Cuff Tear",[5920,5939],"Hydrocodone\u002FAcetaminophen",{"trials":5941,"activeCount":99},[],{"intervention":5939,"totalTrials":95,"cells":5943},{"EARLY_PHASE1":5944,"PHASE1":5946,"PHASE2":5948,"PHASE3":5950,"PHASE4":5952,"NA":5958},{"trials":5945,"activeCount":99},[],{"trials":5947,"activeCount":99},[],{"trials":5949,"activeCount":99},[],{"trials":5951,"activeCount":99},[],{"trials":5953,"activeCount":99},[5954],{"nctId":5933,"briefTitle":5934,"status":981,"phases":5955,"primaryCompletion":1536,"completion":1536,"start":3283,"enrollment":99,"conditions":5956,"interventions":5957},[90],[5937],[5920,5939],{"trials":5959,"activeCount":99},[],{"intervention":5961,"totalTrials":95,"cells":5962},"depot leuprolide plus estrogen\u002Fprogestin replacement",{"EARLY_PHASE1":5963,"PHASE1":5965,"PHASE2":5967,"PHASE3":5969,"PHASE4":5971,"NA":5981},{"trials":5964,"activeCount":99},[],{"trials":5966,"activeCount":99},[],{"trials":5968,"activeCount":99},[],{"trials":5970,"activeCount":99},[],{"trials":5972,"activeCount":99},[5973],{"nctId":5974,"briefTitle":5975,"status":363,"phases":5976,"primaryCompletion":4921,"completion":4921,"start":1735,"enrollment":1710,"conditions":5977,"interventions":5979},"NCT00203996","Polycystic Ovary Syndrome (PCOS) and Sleep Apnea",[90],[5978,5069],"Polycystic Ovary Syndrome",[5961,5980],"pioglitazone",{"trials":5982,"activeCount":99},[],{"intervention":5980,"totalTrials":95,"cells":5984},{"EARLY_PHASE1":5985,"PHASE1":5987,"PHASE2":5989,"PHASE3":5991,"PHASE4":5993,"NA":5999},{"trials":5986,"activeCount":99},[],{"trials":5988,"activeCount":99},[],{"trials":5990,"activeCount":99},[],{"trials":5992,"activeCount":99},[],{"trials":5994,"activeCount":99},[5995],{"nctId":5974,"briefTitle":5975,"status":363,"phases":5996,"primaryCompletion":4921,"completion":4921,"start":1735,"enrollment":1710,"conditions":5997,"interventions":5998},[90],[5978,5069],[5961,5980],{"trials":6000,"activeCount":99},[],{"intervention":6002,"totalTrials":95,"cells":6003},"Voriconazole",{"EARLY_PHASE1":6004,"PHASE1":6006,"PHASE2":6008,"PHASE3":6010,"PHASE4":6012,"NA":6021},{"trials":6005,"activeCount":99},[],{"trials":6007,"activeCount":99},[],{"trials":6009,"activeCount":99},[],{"trials":6011,"activeCount":99},[],{"trials":6013,"activeCount":99},[6014],{"nctId":6015,"briefTitle":6016,"status":363,"phases":6017,"primaryCompletion":4782,"completion":4782,"start":4782,"enrollment":516,"conditions":6018,"interventions":6020},"NCT00455364","Voriconazole as Prophylactic Therapy in Lung Transplant Recipients",[90],[6019],"Infection",[6002],{"trials":6022,"activeCount":99},[],{"intervention":6024,"totalTrials":95,"cells":6025},"Warfarin",{"EARLY_PHASE1":6026,"PHASE1":6028,"PHASE2":6030,"PHASE3":6032,"PHASE4":6034,"NA":6043},{"trials":6027,"activeCount":99},[],{"trials":6029,"activeCount":99},[],{"trials":6031,"activeCount":99},[],{"trials":6033,"activeCount":99},[],{"trials":6035,"activeCount":99},[6036],{"nctId":6037,"briefTitle":6038,"status":332,"phases":6039,"primaryCompletion":1726,"completion":781,"start":4811,"enrollment":6040,"conditions":6041,"interventions":6042},"NCT00964353","Clinical and Economic Implications of Genetic Testing for Warfarin Management",[90],359,[5203],[6024],{"trials":6044,"activeCount":99},[],{"intervention":6046,"totalTrials":95,"cells":6047},"Chantix",{"EARLY_PHASE1":6048,"PHASE1":6050,"PHASE2":6052,"PHASE3":6054,"PHASE4":6056,"NA":6070},{"trials":6049,"activeCount":99},[],{"trials":6051,"activeCount":99},[],{"trials":6053,"activeCount":99},[],{"trials":6055,"activeCount":99},[],{"trials":6057,"activeCount":99},[6058],{"nctId":6059,"briefTitle":6060,"status":332,"phases":6061,"primaryCompletion":6062,"completion":6063,"start":6064,"enrollment":6065,"conditions":6066,"interventions":6068},"NCT02859142","Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation",[90],"2020-09-30","2020-10-15","2018-03-29",122,[6067,4551],"Smoking Cessation",[6046,6069],"NicodermCQ",{"trials":6071,"activeCount":99},[],{"intervention":6069,"totalTrials":95,"cells":6073},{"EARLY_PHASE1":6074,"PHASE1":6076,"PHASE2":6078,"PHASE3":6080,"PHASE4":6082,"NA":6088},{"trials":6075,"activeCount":99},[],{"trials":6077,"activeCount":99},[],{"trials":6079,"activeCount":99},[],{"trials":6081,"activeCount":99},[],{"trials":6083,"activeCount":99},[6084],{"nctId":6059,"briefTitle":6060,"status":332,"phases":6085,"primaryCompletion":6062,"completion":6063,"start":6064,"enrollment":6065,"conditions":6086,"interventions":6087},[90],[6067,4551],[6046,6069],{"trials":6089,"activeCount":99},[],{"intervention":6091,"totalTrials":994,"cells":6092},"Dronabinol",{"EARLY_PHASE1":6093,"PHASE1":6126,"PHASE2":6128,"PHASE3":6137,"PHASE4":6148,"NA":6150},{"trials":6094,"activeCount":99},[6095,6104,6116],{"nctId":6096,"briefTitle":6097,"status":332,"phases":6098,"primaryCompletion":6099,"completion":6099,"start":6100,"enrollment":379,"conditions":6101,"interventions":6103},"NCT03804840","Developing a Mobile Method to Measure THC-induced Impairment",[86],"2018-12-01","2017-03-01",[6102],"Measuring THC-induced Cognitive Impairment Using a Mobile Application",[6091],{"nctId":6105,"briefTitle":6106,"status":332,"phases":6107,"primaryCompletion":6108,"completion":6108,"start":6109,"enrollment":782,"conditions":6110,"interventions":6114},"NCT04294966","Age-Related Effects of THC",[86],"2021-05-01","2020-03-10",[6111,6112,6113],"Tolerance","Adolescent Behavior","THC",[6115,6091,6091],"Dextrose",{"nctId":6117,"briefTitle":6118,"status":332,"phases":6119,"primaryCompletion":6120,"completion":6120,"start":6121,"enrollment":802,"conditions":6122,"interventions":6124},"NCT03809546","Individual Differences in Drug Response",[86],"2021-06-01","2018-11-06",[6123],"Differential Female Response to Δ9-tetrahydrocannabinol (THC)",[6091,6125],"dextrose",{"trials":6127,"activeCount":99},[],{"trials":6129,"activeCount":99},[6130],{"nctId":6131,"briefTitle":6132,"status":332,"phases":6133,"primaryCompletion":5316,"completion":5550,"start":4801,"enrollment":1779,"conditions":6134,"interventions":6136},"NCT01093976","Marinol in Trichotillomania or Obsessive Compulsive Disorder",[88],[735,6135],"Obsessive Compulsive Disorder",[6091],{"trials":6138,"activeCount":99},[6139],{"nctId":6140,"briefTitle":6141,"status":332,"phases":6142,"primaryCompletion":6143,"completion":6144,"start":6145,"enrollment":1215,"conditions":6146,"interventions":6147},"NCT03530800","Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors",[88,89],"2021-07-20","2021-11-01","2018-10-01",[735,862],[6091],{"trials":6149,"activeCount":99},[],{"trials":6151,"activeCount":99},[],{"intervention":6153,"totalTrials":488,"cells":6154},"Naltrexone",{"EARLY_PHASE1":6155,"PHASE1":6157,"PHASE2":6159,"PHASE3":6176,"PHASE4":6186,"NA":6188},{"trials":6156,"activeCount":99},[],{"trials":6158,"activeCount":99},[],{"trials":6160,"activeCount":99},[6161,6168],{"nctId":6162,"briefTitle":6163,"status":332,"phases":6164,"primaryCompletion":1416,"completion":5525,"start":6165,"enrollment":1073,"conditions":6166,"interventions":6167},"NCT00775229","Naltrexone in the Treatment of Trichotillomania",[88],"2008-08",[735],[6153],{"nctId":6169,"briefTitle":6170,"status":332,"phases":6171,"primaryCompletion":2359,"completion":1399,"start":1302,"enrollment":6172,"conditions":6173,"interventions":6175},"NCT00271024","Efficacy of Naltrexone in Women's Smoking Cessation",[88],333,[6174,6067],"Smoking",[6153],{"trials":6177,"activeCount":99},[6178],{"nctId":6179,"briefTitle":6180,"status":332,"phases":6181,"primaryCompletion":6182,"completion":6182,"start":2177,"enrollment":352,"conditions":6183,"interventions":6185},"NCT00053677","Drug Treatment for Pathologic Gambling Disorder",[89],"2005-11",[6184],"Gambling",[6153],{"trials":6187,"activeCount":99},[],{"trials":6189,"activeCount":99},[],{"intervention":6191,"totalTrials":367,"cells":6192},"Nebivolol",{"EARLY_PHASE1":6193,"PHASE1":6195,"PHASE2":6197,"PHASE3":6199,"PHASE4":6220,"NA":6222},{"trials":6194,"activeCount":99},[],{"trials":6196,"activeCount":99},[],{"trials":6198,"activeCount":99},[],{"trials":6200,"activeCount":99},[6201,6209],{"nctId":6202,"briefTitle":6203,"status":981,"phases":6204,"primaryCompletion":2283,"completion":2283,"start":6205,"enrollment":99,"conditions":6206,"interventions":6208},"NCT01939990","Safety Study of Nebivolol for COPD Patients",[88,89],"2012-01",[6207],"High Blood Pressure",[6191],{"nctId":6210,"briefTitle":6211,"status":332,"phases":6212,"primaryCompletion":1226,"completion":6213,"start":4405,"enrollment":1114,"conditions":6214,"interventions":6217},"NCT00829296","Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries",[88,89],"2013-04",[6215,6216],"Hypertension","Diabetes",[6218,6219],"nebivolol","Metoprolol",{"trials":6221,"activeCount":99},[],{"trials":6223,"activeCount":99},[],{"intervention":6225,"totalTrials":367,"cells":6226},"Simvastatin",{"EARLY_PHASE1":6227,"PHASE1":6229,"PHASE2":6231,"PHASE3":6242,"PHASE4":6252,"NA":6254},{"trials":6228,"activeCount":99},[],{"trials":6230,"activeCount":99},[],{"trials":6232,"activeCount":99},[6233],{"nctId":6234,"briefTitle":6235,"status":363,"phases":6236,"primaryCompletion":6237,"completion":6237,"start":4781,"enrollment":2013,"conditions":6238,"interventions":6240},"NCT00528580","Statins for the Early Treatment of Sepsis",[88],"2011-09",[6239],"Sepsis",[6225,6241],"Identical-appearing placebo",{"trials":6243,"activeCount":99},[6244],{"nctId":6245,"briefTitle":6246,"status":332,"phases":6247,"primaryCompletion":2176,"completion":1225,"start":1709,"enrollment":1580,"conditions":6248,"interventions":6250},"NCT00831129","A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs",[88,89],[6249],"Pre-diabetes",[6251,6225],"Rosiglitazone",{"trials":6253,"activeCount":99},[],{"trials":6255,"activeCount":99},[],{"intervention":6257,"totalTrials":367,"cells":6258},"Inhaled nitric oxide",{"EARLY_PHASE1":6259,"PHASE1":6261,"PHASE2":6263,"PHASE3":6265,"PHASE4":6290,"NA":6292},{"trials":6260,"activeCount":99},[],{"trials":6262,"activeCount":99},[],{"trials":6264,"activeCount":99},[],{"trials":6266,"activeCount":99},[6267,6276],{"nctId":6268,"briefTitle":6269,"status":332,"phases":6270,"primaryCompletion":1709,"completion":1709,"start":6271,"enrollment":6272,"conditions":6273,"interventions":6275},"NCT00152542","Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants",[89],"2005-05",160,[6274],"Prematurity, Respiratory Distress Syndrome,Hypoxemia",[6257],{"nctId":6277,"briefTitle":6278,"status":363,"phases":6279,"primaryCompletion":3827,"completion":6280,"start":6281,"enrollment":5177,"conditions":6282,"interventions":6287},"NCT00515281","Inhaled Nitric Oxide and Neuroprotection in Premature Infants",[88,89],"2023-11-28","2008-05",[6283,6284,6285,6286],"Prematurity","Bronchopulmonary Dysplasia","Intraventricular Hemorrhage","Periventricular Leukomalacia",[6288,6289],"inhaled nitric oxide","oxygen",{"trials":6291,"activeCount":99},[],{"trials":6293,"activeCount":99},[],{"intervention":6295,"totalTrials":95,"cells":6296},"Metoprolol Tartrate",{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6301,"PHASE3":6303,"PHASE4":6314,"NA":6316},{"trials":6298,"activeCount":99},[],{"trials":6300,"activeCount":99},[],{"trials":6302,"activeCount":99},[],{"trials":6304,"activeCount":99},[6305],{"nctId":6306,"briefTitle":6307,"status":332,"phases":6308,"primaryCompletion":6309,"completion":6310,"start":1613,"enrollment":379,"conditions":6311,"interventions":6313},"NCT03138603","Metoprolol to Reduce Perioperative Myocardial Injury",[89],"2023-04-18","2023-08-29",[6312],"Heart Diseases",[6295],{"trials":6315,"activeCount":99},[],{"trials":6317,"activeCount":99},[],{"intervention":6319,"totalTrials":95,"cells":6320},"Istradefylline",{"EARLY_PHASE1":6321,"PHASE1":6323,"PHASE2":6325,"PHASE3":6327,"PHASE4":6336,"NA":6338},{"trials":6322,"activeCount":99},[],{"trials":6324,"activeCount":99},[],{"trials":6326,"activeCount":99},[],{"trials":6328,"activeCount":99},[6329],{"nctId":6330,"briefTitle":6331,"status":332,"phases":6332,"primaryCompletion":5090,"completion":5090,"start":3359,"enrollment":732,"conditions":6333,"interventions":6335},"NCT00203957","Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa",[89],[6334],"Parkinson's Disease",[6319,6319],{"trials":6337,"activeCount":99},[],{"trials":6339,"activeCount":99},[],{"intervention":6219,"totalTrials":95,"cells":6341},{"EARLY_PHASE1":6342,"PHASE1":6344,"PHASE2":6346,"PHASE3":6348,"PHASE4":6354,"NA":6356},{"trials":6343,"activeCount":99},[],{"trials":6345,"activeCount":99},[],{"trials":6347,"activeCount":99},[],{"trials":6349,"activeCount":99},[6350],{"nctId":6210,"briefTitle":6211,"status":332,"phases":6351,"primaryCompletion":1226,"completion":6213,"start":4405,"enrollment":1114,"conditions":6352,"interventions":6353},[88,89],[6215,6216],[6218,6219],{"trials":6355,"activeCount":99},[],{"trials":6357,"activeCount":99},[],{"intervention":6359,"totalTrials":95,"cells":6360},"Tolcapone 200 MG",{"EARLY_PHASE1":6361,"PHASE1":6363,"PHASE2":6365,"PHASE3":6367,"PHASE4":6377,"NA":6379},{"trials":6362,"activeCount":99},[],{"trials":6364,"activeCount":99},[],{"trials":6366,"activeCount":99},[],{"trials":6368,"activeCount":99},[6369],{"nctId":6370,"briefTitle":6371,"status":332,"phases":6372,"primaryCompletion":6373,"completion":6373,"start":6374,"enrollment":516,"conditions":6375,"interventions":6376},"NCT03348930","Tolcapone in Obsessive Compulsive Disorder",[88,89],"2020-12-14","2018-03-20",[2351],[6359],{"trials":6378,"activeCount":99},[],{"trials":6380,"activeCount":99},[],{"intervention":6382,"totalTrials":95,"cells":6383},"ASP-1001 nasal spray",{"EARLY_PHASE1":6384,"PHASE1":6386,"PHASE2":6388,"PHASE3":6390,"PHASE4":6400,"NA":6402},{"trials":6385,"activeCount":99},[],{"trials":6387,"activeCount":99},[],{"trials":6389,"activeCount":99},[],{"trials":6391,"activeCount":99},[6392],{"nctId":6393,"briefTitle":6394,"status":332,"phases":6395,"primaryCompletion":6396,"completion":1649,"start":6397,"enrollment":516,"conditions":6398,"interventions":6399},"NCT00791102","Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)",[88,89],"2010-09","2010-01",[4793],[6382],{"trials":6401,"activeCount":99},[],{"trials":6403,"activeCount":99},[],{"intervention":6289,"totalTrials":95,"cells":6405},{"EARLY_PHASE1":6406,"PHASE1":6408,"PHASE2":6410,"PHASE3":6412,"PHASE4":6418,"NA":6420},{"trials":6407,"activeCount":99},[],{"trials":6409,"activeCount":99},[],{"trials":6411,"activeCount":99},[],{"trials":6413,"activeCount":99},[6414],{"nctId":6277,"briefTitle":6278,"status":363,"phases":6415,"primaryCompletion":3827,"completion":6280,"start":6281,"enrollment":5177,"conditions":6416,"interventions":6417},[88,89],[6283,6284,6285,6286],[6288,6289],{"trials":6419,"activeCount":99},[],{"trials":6421,"activeCount":99},[],{"intervention":6423,"totalTrials":95,"cells":6424},"Asacol",{"EARLY_PHASE1":6425,"PHASE1":6427,"PHASE2":6429,"PHASE3":6431,"PHASE4":6441,"NA":6443},{"trials":6426,"activeCount":99},[],{"trials":6428,"activeCount":99},[],{"trials":6430,"activeCount":99},[],{"trials":6432,"activeCount":99},[6433],{"nctId":6434,"briefTitle":6435,"status":332,"phases":6436,"primaryCompletion":6437,"completion":6437,"start":1709,"enrollment":1085,"conditions":6438,"interventions":6440},"NCT00343850","Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis",[89],"2007-03",[6439],"Ulcerative Colitis",[6423],{"trials":6442,"activeCount":99},[],{"trials":6444,"activeCount":99},[],{"intervention":6251,"totalTrials":95,"cells":6446},{"EARLY_PHASE1":6447,"PHASE1":6449,"PHASE2":6451,"PHASE3":6453,"PHASE4":6459,"NA":6461},{"trials":6448,"activeCount":99},[],{"trials":6450,"activeCount":99},[],{"trials":6452,"activeCount":99},[],{"trials":6454,"activeCount":99},[6455],{"nctId":6245,"briefTitle":6246,"status":332,"phases":6456,"primaryCompletion":2176,"completion":1225,"start":1709,"enrollment":1580,"conditions":6457,"interventions":6458},[88,89],[6249],[6251,6225],{"trials":6460,"activeCount":99},[],{"trials":6462,"activeCount":99},[],{"intervention":6464,"totalTrials":1571,"cells":6465},"Melphalan",{"EARLY_PHASE1":6466,"PHASE1":6468,"PHASE2":6506,"PHASE3":6544,"PHASE4":6546,"NA":6548},{"trials":6467,"activeCount":99},[],{"trials":6469,"activeCount":99},[6470,6480,6492],{"nctId":6471,"briefTitle":6472,"status":332,"phases":6473,"primaryCompletion":6474,"completion":6474,"start":6475,"enrollment":1085,"conditions":6476,"interventions":6477},"NCT01526096","Stem Cell Transplantation for Patients With Multiple Myeloma",[87],"2024-08-28","2011-07-12",[486],[1681,6478,6464,6479],"Plerixafor","Basiliximab",{"nctId":6481,"briefTitle":6482,"status":363,"phases":6483,"primaryCompletion":6237,"completion":6205,"start":6484,"enrollment":95,"conditions":6485,"interventions":6489},"NCT00943293","Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies",[87],"2003-05",[6486,6487,787,486,6488],"Preleukemia","Myeloproliferative Disorders","Graft Versus Host Disease",[6490,6464,6491],"Fludarabine","Campath",{"nctId":6493,"briefTitle":6494,"status":468,"phases":6495,"primaryCompletion":6496,"completion":6496,"start":6497,"enrollment":1085,"conditions":6498,"interventions":6502},"NCT02333162","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",[87],"2028-12-01","2014-12-05",[6499,6500,3798,6501],"Previously Treated Myelodysplastic Syndrome","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Hematologic Malignancy",[6503,6464,6504,6505],"Fludarabine Phosphate","Tacrolimus","Mycophenolate Mofetil",{"trials":6507,"activeCount":99},[6508,6518,6528],{"nctId":6509,"briefTitle":6510,"status":332,"phases":6511,"primaryCompletion":1225,"completion":1176,"start":6512,"enrollment":6513,"conditions":6514,"interventions":6516},"NCT00943592","Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies",[87,88],"2006-03",82,[6515,1932,6486],"Advanced Hematologic Malignancies",[6517,6464,6491],"Clofarabine",{"nctId":6519,"briefTitle":6520,"status":363,"phases":6521,"primaryCompletion":6237,"completion":838,"start":4801,"enrollment":95,"conditions":6522,"interventions":6524},"NCT01359254","Cord Blood Transplantation for Patients With Cancer",[88],[6523],"Hematological Disease",[6464,6490,6525,6526,6527],"Antithymocyte Globulin","Busulfan","Total Body Irradiation",{"nctId":6529,"briefTitle":6530,"status":332,"phases":6531,"primaryCompletion":524,"completion":524,"start":1303,"enrollment":6532,"conditions":6533,"interventions":6542},"NCT00683046","T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies",[88],204,[6534,6535,6536,6537,6538,6539,6540,6541,929],"Acute Myelogenous Leukemia","Lymphoid Leukemia","Chronic Myelogenous Leukemia","Malignant Lymphoma","Hodgkin's Disease","Chronic Lymphocytic Leukemia","Myeloproliferative Disorder","Anemia, Aplastic",[6490,6464,6543,6491],"Stem cells",{"trials":6545,"activeCount":99},[],{"trials":6547,"activeCount":99},[],{"trials":6549,"activeCount":99},[],{"intervention":6491,"totalTrials":526,"cells":6551},{"EARLY_PHASE1":6552,"PHASE1":6554,"PHASE2":6560,"PHASE3":6576,"PHASE4":6578,"NA":6580},{"trials":6553,"activeCount":99},[],{"trials":6555,"activeCount":99},[6556],{"nctId":6481,"briefTitle":6482,"status":363,"phases":6557,"primaryCompletion":6237,"completion":6205,"start":6484,"enrollment":95,"conditions":6558,"interventions":6559},[87],[6486,6487,787,486,6488],[6490,6464,6491],{"trials":6561,"activeCount":99},[6562,6566,6570],{"nctId":6509,"briefTitle":6510,"status":332,"phases":6563,"primaryCompletion":1225,"completion":1176,"start":6512,"enrollment":6513,"conditions":6564,"interventions":6565},[87,88],[6515,1932,6486],[6517,6464,6491],{"nctId":6529,"briefTitle":6530,"status":332,"phases":6567,"primaryCompletion":524,"completion":524,"start":1303,"enrollment":6532,"conditions":6568,"interventions":6569},[88],[6534,6535,6536,6537,6538,6539,6540,6541,929],[6490,6464,6543,6491],{"nctId":6571,"briefTitle":6572,"status":332,"phases":6573,"primaryCompletion":3441,"completion":1536,"start":5863,"enrollment":1215,"conditions":6574,"interventions":6575},"NCT00943319","Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies",[87,88],[1932,787,486],[6526,6490,6491],{"trials":6577,"activeCount":99},[],{"trials":6579,"activeCount":99},[],{"trials":6581,"activeCount":99},[],{"intervention":1245,"totalTrials":526,"cells":6583},{"EARLY_PHASE1":6584,"PHASE1":6586,"PHASE2":6592,"PHASE3":6606,"PHASE4":6608,"NA":6610},{"trials":6585,"activeCount":99},[],{"trials":6587,"activeCount":99},[6588],{"nctId":1412,"briefTitle":1413,"status":332,"phases":6589,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":860,"conditions":6590,"interventions":6591},[87],[15],[392,1420,1245],{"trials":6593,"activeCount":99},[6594,6598,6602],{"nctId":1234,"briefTitle":1235,"status":332,"phases":6595,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1106,"conditions":6596,"interventions":6597},[88],[1240,1241,1064,381,382],[385,392,386,1243,1244,1245,387],{"nctId":1264,"briefTitle":1265,"status":332,"phases":6599,"primaryCompletion":1267,"completion":1268,"start":1269,"enrollment":1228,"conditions":6600,"interventions":6601},[87,88],[518,1271],[1273,1274,1167,686],{"nctId":2070,"briefTitle":2071,"status":332,"phases":6603,"primaryCompletion":2073,"completion":1227,"start":2074,"enrollment":2075,"conditions":6604,"interventions":6605},[88],[2077,1005],[1273,2079,686,2080],{"trials":6607,"activeCount":99},[],{"trials":6609,"activeCount":99},[],{"trials":6611,"activeCount":99},[],{"intervention":6490,"totalTrials":526,"cells":6613},{"EARLY_PHASE1":6614,"PHASE1":6616,"PHASE2":6622,"PHASE3":6636,"PHASE4":6638,"NA":6640},{"trials":6615,"activeCount":99},[],{"trials":6617,"activeCount":99},[6618],{"nctId":6481,"briefTitle":6482,"status":363,"phases":6619,"primaryCompletion":6237,"completion":6205,"start":6484,"enrollment":95,"conditions":6620,"interventions":6621},[87],[6486,6487,787,486,6488],[6490,6464,6491],{"trials":6623,"activeCount":99},[6624,6628,6632],{"nctId":6519,"briefTitle":6520,"status":363,"phases":6625,"primaryCompletion":6237,"completion":838,"start":4801,"enrollment":95,"conditions":6626,"interventions":6627},[88],[6523],[6464,6490,6525,6526,6527],{"nctId":6529,"briefTitle":6530,"status":332,"phases":6629,"primaryCompletion":524,"completion":524,"start":1303,"enrollment":6532,"conditions":6630,"interventions":6631},[88],[6534,6535,6536,6537,6538,6539,6540,6541,929],[6490,6464,6543,6491],{"nctId":6571,"briefTitle":6572,"status":332,"phases":6633,"primaryCompletion":3441,"completion":1536,"start":5863,"enrollment":1215,"conditions":6634,"interventions":6635},[87,88],[1932,787,486],[6526,6490,6491],{"trials":6637,"activeCount":99},[],{"trials":6639,"activeCount":99},[],{"trials":6641,"activeCount":99},[],{"intervention":1232,"totalTrials":488,"cells":6643},{"EARLY_PHASE1":6644,"PHASE1":6646,"PHASE2":6657,"PHASE3":6667,"PHASE4":6669,"NA":6671},{"trials":6645,"activeCount":99},[],{"trials":6647,"activeCount":99},[6648],{"nctId":6649,"briefTitle":6650,"status":332,"phases":6651,"primaryCompletion":837,"completion":837,"start":5864,"enrollment":6652,"conditions":6653,"interventions":6654},"NCT00667485","Rapamycin Plus Bevacizumab in Advanced Cancers",[87],28,[3918,3939],[6655,6656,6655],"Rapamycin","Bevacizumab",{"trials":6658,"activeCount":99},[6659,6663],{"nctId":1222,"briefTitle":1223,"status":363,"phases":6660,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":6661,"interventions":6662},[88],[1230],[1167,1232],{"nctId":1299,"briefTitle":1300,"status":332,"phases":6664,"primaryCompletion":1302,"completion":1227,"start":1303,"enrollment":545,"conditions":6665,"interventions":6666},[88],[1305],[1232,1167,1307],{"trials":6668,"activeCount":99},[],{"trials":6670,"activeCount":99},[],{"trials":6672,"activeCount":99},[],{"intervention":1168,"totalTrials":488,"cells":6674},{"EARLY_PHASE1":6675,"PHASE1":6677,"PHASE2":6687,"PHASE3":6693,"PHASE4":6695,"NA":6697},{"trials":6676,"activeCount":99},[],{"trials":6678,"activeCount":99},[6679,6683],{"nctId":1148,"briefTitle":1149,"status":332,"phases":6680,"primaryCompletion":1151,"completion":1151,"start":1152,"enrollment":1153,"conditions":6681,"interventions":6682},[87],[1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165],[1167,1168,1169,1170],{"nctId":3438,"briefTitle":3439,"status":332,"phases":6684,"primaryCompletion":3441,"completion":3441,"start":524,"enrollment":1215,"conditions":6685,"interventions":6686},[87],[3443,3444,3445,1037,3446,3447,1555,3448,3449,3450,3451,3452,3453,3454,3455,3456,3457],[3459,3325,3324,3323],{"trials":6688,"activeCount":99},[6689],{"nctId":1313,"briefTitle":1314,"status":332,"phases":6690,"primaryCompletion":377,"completion":377,"start":1316,"enrollment":1317,"conditions":6691,"interventions":6692},[88],[1319,1320,1321,1322],[1168,1167,1307,1169,1170,1324],{"trials":6694,"activeCount":99},[],{"trials":6696,"activeCount":99},[],{"trials":6698,"activeCount":99},[],{"intervention":6700,"totalTrials":488,"cells":6701},"Nitrous oxide gas for inhalation",{"EARLY_PHASE1":6702,"PHASE1":6704,"PHASE2":6706,"PHASE3":6733,"PHASE4":6735,"NA":6737},{"trials":6703,"activeCount":99},[],{"trials":6705,"activeCount":99},[],{"trials":6707,"activeCount":99},[6708,6717,6724],{"nctId":6709,"briefTitle":6710,"status":981,"phases":6711,"primaryCompletion":6712,"completion":6712,"start":6712,"enrollment":99,"conditions":6713,"interventions":6716},"NCT05710887","N2O for Acute Suicidality and Depression in the ED",[88],"2026-02-27",[6714,4363,6715],"Suicidal Ideation","Treatment Resistant Depression",[6700],{"nctId":6718,"briefTitle":6719,"status":981,"phases":6720,"primaryCompletion":6712,"completion":6712,"start":6721,"enrollment":99,"conditions":6722,"interventions":6723},"NCT05357040","Antidepressant Effects of Nitrous Oxide",[88],"2021-06-30",[4363,6715],[6700],{"nctId":6725,"briefTitle":6726,"status":981,"phases":6727,"primaryCompletion":6712,"completion":6712,"start":6728,"enrollment":99,"conditions":6729,"interventions":6732},"NCT05357066","Nitrous Oxide as Treatment for Fibromyalgia",[88],"2021-11-12",[6730,6731],"Fibromyalgia","Central Neuropathic Pain",[6700],{"trials":6734,"activeCount":99},[],{"trials":6736,"activeCount":99},[],{"trials":6738,"activeCount":99},[],{"intervention":1189,"totalTrials":488,"cells":6740},{"EARLY_PHASE1":6741,"PHASE1":6743,"PHASE2":6749,"PHASE3":6759,"PHASE4":6761,"NA":6763},{"trials":6742,"activeCount":99},[],{"trials":6744,"activeCount":99},[6745],{"nctId":1172,"briefTitle":1173,"status":332,"phases":6746,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":6747,"interventions":6748},[87],[1179,1180,1181,1182,1183,1184,1185,1186],[1188,1167,1189],{"trials":6750,"activeCount":99},[6751,6755],{"nctId":1706,"briefTitle":1707,"status":332,"phases":6752,"primaryCompletion":1614,"completion":1709,"start":399,"enrollment":1710,"conditions":6753,"interventions":6754},[88],[1434,1712],[1274,1324,1189],{"nctId":1565,"briefTitle":1566,"status":332,"phases":6756,"primaryCompletion":1568,"completion":1569,"start":1570,"enrollment":1571,"conditions":6757,"interventions":6758},[88],[1434],[1324,1574,1189,1575],{"trials":6760,"activeCount":99},[],{"trials":6762,"activeCount":99},[],{"trials":6764,"activeCount":99},[],{"intervention":3604,"totalTrials":488,"cells":6766},{"EARLY_PHASE1":6767,"PHASE1":6769,"PHASE2":6771,"PHASE3":6793,"PHASE4":6795,"NA":6797},{"trials":6768,"activeCount":99},[],{"trials":6770,"activeCount":99},[],{"trials":6772,"activeCount":99},[6773,6782,6789],{"nctId":6774,"briefTitle":6775,"status":332,"phases":6776,"primaryCompletion":6777,"completion":6778,"start":6779,"enrollment":421,"conditions":6780,"interventions":6781},"NCT01185158","A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma",[88],"2004-08","2010-11","2002-05",[21],[3604],{"nctId":6783,"briefTitle":6784,"status":332,"phases":6785,"primaryCompletion":1518,"completion":4922,"start":6786,"enrollment":1073,"conditions":6787,"interventions":6788},"NCT00015964","ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck",[88],"2001-03",[21],[3604],{"nctId":3598,"briefTitle":3599,"status":332,"phases":6790,"primaryCompletion":2177,"completion":3601,"start":1518,"enrollment":1779,"conditions":6791,"interventions":6792},[87,88],[3342],[3604,1488],{"trials":6794,"activeCount":99},[],{"trials":6796,"activeCount":99},[],{"trials":6798,"activeCount":99},[],{"intervention":1066,"totalTrials":488,"cells":6800},{"EARLY_PHASE1":6801,"PHASE1":6803,"PHASE2":6805,"PHASE3":6819,"PHASE4":6821,"NA":6823},{"trials":6802,"activeCount":99},[],{"trials":6804,"activeCount":99},[],{"trials":6806,"activeCount":99},[6807,6811,6815],{"nctId":1041,"briefTitle":1042,"status":981,"phases":6808,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":99,"conditions":6809,"interventions":6810},[88],[21],[46,1048],{"nctId":1058,"briefTitle":1059,"status":981,"phases":6812,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":99,"conditions":6813,"interventions":6814},[88],[1064],[46,1066],{"nctId":1128,"briefTitle":1129,"status":363,"phases":6816,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":367,"conditions":6817,"interventions":6818},[88],[1087,21],[46,1066],{"trials":6820,"activeCount":99},[],{"trials":6822,"activeCount":99},[],{"trials":6824,"activeCount":99},[],{"intervention":6826,"totalTrials":488,"cells":6827},"Milk Thistle",{"EARLY_PHASE1":6828,"PHASE1":6830,"PHASE2":6832,"PHASE3":6859,"PHASE4":6861,"NA":6863},{"trials":6829,"activeCount":99},[],{"trials":6831,"activeCount":99},[],{"trials":6833,"activeCount":99},[6834,6842,6851],{"nctId":6835,"briefTitle":6836,"status":332,"phases":6837,"primaryCompletion":6838,"completion":6838,"start":3283,"enrollment":607,"conditions":6839,"interventions":6841},"NCT02337634","Milk Thistle in Pathological Gambling",[88],"2022-12",[2361,6840],"Gambling Disorder",[6826],{"nctId":6843,"briefTitle":6844,"status":981,"phases":6845,"primaryCompletion":6846,"completion":6846,"start":6847,"enrollment":99,"conditions":6848,"interventions":6850},"NCT02843451","Milk Thistle in Body Dysmorphic Disorder",[88],"2023-10","2016-10",[6849],"Body Dysmorphic Disorder",[6826],{"nctId":6852,"briefTitle":6853,"status":332,"phases":6854,"primaryCompletion":6855,"completion":3368,"start":6856,"enrollment":16,"conditions":6857,"interventions":6858},"NCT02473913","Milk Thistle in Trichotillomania in Children and Adults",[88],"2018-06","2015-03",[735,736],[6826],{"trials":6860,"activeCount":99},[],{"trials":6862,"activeCount":99},[],{"trials":6864,"activeCount":99},[],{"intervention":2080,"totalTrials":488,"cells":6866},{"EARLY_PHASE1":6867,"PHASE1":6869,"PHASE2":6875,"PHASE3":6885,"PHASE4":6887,"NA":6889},{"trials":6868,"activeCount":99},[],{"trials":6870,"activeCount":99},[6871],{"nctId":6493,"briefTitle":6494,"status":468,"phases":6872,"primaryCompletion":6496,"completion":6496,"start":6497,"enrollment":1085,"conditions":6873,"interventions":6874},[87],[6499,6500,3798,6501],[6503,6464,6504,6505],{"trials":6876,"activeCount":99},[6877,6881],{"nctId":2070,"briefTitle":2071,"status":332,"phases":6878,"primaryCompletion":2073,"completion":1227,"start":2074,"enrollment":2075,"conditions":6879,"interventions":6880},[88],[2077,1005],[1273,2079,686,2080],{"nctId":2086,"briefTitle":2087,"status":332,"phases":6882,"primaryCompletion":1501,"completion":814,"start":2089,"enrollment":30,"conditions":6883,"interventions":6884},[88],[1932,787,2091,929],[2093,686,2080],{"trials":6886,"activeCount":99},[],{"trials":6888,"activeCount":99},[],{"trials":6890,"activeCount":99},[],{"intervention":6517,"totalTrials":367,"cells":6892},{"EARLY_PHASE1":6893,"PHASE1":6895,"PHASE2":6897,"PHASE3":6910,"PHASE4":6912,"NA":6914},{"trials":6894,"activeCount":99},[],{"trials":6896,"activeCount":99},[],{"trials":6898,"activeCount":99},[6899,6903],{"nctId":6509,"briefTitle":6510,"status":332,"phases":6900,"primaryCompletion":1225,"completion":1176,"start":6512,"enrollment":6513,"conditions":6901,"interventions":6902},[87,88],[6515,1932,6486],[6517,6464,6491],{"nctId":6904,"briefTitle":6905,"status":332,"phases":6906,"primaryCompletion":6396,"completion":6907,"start":4780,"enrollment":2146,"conditions":6908,"interventions":6909},"NCT00724009","Clofarabine Bone Marrow Cytoreduction",[88],"2012-09",[1932],[6517],{"trials":6911,"activeCount":99},[],{"trials":6913,"activeCount":99},[],{"trials":6915,"activeCount":99},[],{"intervention":6917,"totalTrials":367,"cells":6918},"0% N2O",{"EARLY_PHASE1":6919,"PHASE1":6921,"PHASE2":6923,"PHASE3":6944,"PHASE4":6946,"NA":6948},{"trials":6920,"activeCount":99},[],{"trials":6922,"activeCount":99},[],{"trials":6924,"activeCount":99},[6925,6936],{"nctId":6926,"briefTitle":6927,"status":332,"phases":6928,"primaryCompletion":3526,"completion":3526,"start":6929,"enrollment":1228,"conditions":6930,"interventions":6931},"NCT00000252","Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4",[88],"1994-06",[26,23],[6917,6932,6933,6934,6935],"10% N2O","20% N2O","30% N2O","40% N2O",{"nctId":6937,"briefTitle":6938,"status":332,"phases":6939,"primaryCompletion":6940,"completion":6940,"start":6941,"enrollment":35,"conditions":6942,"interventions":6943},"NCT00000250","Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2",[88],"1995-05","1993-12",[26,23],[6917,6935],{"trials":6945,"activeCount":99},[],{"trials":6947,"activeCount":99},[],{"trials":6949,"activeCount":99},[],{"intervention":1274,"totalTrials":367,"cells":6951},{"EARLY_PHASE1":6952,"PHASE1":6954,"PHASE2":6956,"PHASE3":6966,"PHASE4":6968,"NA":6970},{"trials":6953,"activeCount":99},[],{"trials":6955,"activeCount":99},[],{"trials":6957,"activeCount":99},[6958,6962],{"nctId":1706,"briefTitle":1707,"status":332,"phases":6959,"primaryCompletion":1614,"completion":1709,"start":399,"enrollment":1710,"conditions":6960,"interventions":6961},[88],[1434,1712],[1274,1324,1189],{"nctId":1264,"briefTitle":1265,"status":332,"phases":6963,"primaryCompletion":1267,"completion":1268,"start":1269,"enrollment":1228,"conditions":6964,"interventions":6965},[87,88],[518,1271],[1273,1274,1167,686],{"trials":6967,"activeCount":99},[],{"trials":6969,"activeCount":99},[],{"trials":6971,"activeCount":99},[],{"intervention":6973,"totalTrials":367,"cells":6974},"N-Acetyl Cysteine",{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6979,"PHASE3":6997,"PHASE4":6999,"NA":7001},{"trials":6976,"activeCount":99},[],{"trials":6978,"activeCount":99},[],{"trials":6980,"activeCount":99},[6981,6987],{"nctId":6982,"briefTitle":6983,"status":332,"phases":6984,"primaryCompletion":5293,"completion":5293,"start":1727,"enrollment":1215,"conditions":6985,"interventions":6986},"NCT00354770","N-Acetyl Cysteine in Trichotillomania",[88],[735],[6973],{"nctId":6988,"briefTitle":6989,"status":332,"phases":6990,"primaryCompletion":5573,"completion":5573,"start":6907,"enrollment":6991,"conditions":6992,"interventions":6996},"NCT01063348","N-Acetyl Cysteine in Pathologic Skin Picking",[88],66,[6993,6994,6995,851],"Pathologic Skin Picking","Neurotic Excoriation","Psychogenic Excoriation",[6973],{"trials":6998,"activeCount":99},[],{"trials":7000,"activeCount":99},[],{"trials":7002,"activeCount":99},[],{"intervention":7004,"totalTrials":367,"cells":7005},"recombinant interleukin-12",{"EARLY_PHASE1":7006,"PHASE1":7008,"PHASE2":7010,"PHASE3":7031,"PHASE4":7033,"NA":7035},{"trials":7007,"activeCount":99},[],{"trials":7009,"activeCount":99},[],{"trials":7011,"activeCount":99},[7012,7021],{"nctId":7013,"briefTitle":7014,"status":332,"phases":7015,"primaryCompletion":1737,"completion":7016,"start":1303,"enrollment":7017,"conditions":7018,"interventions":7019},"NCT00015977","Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",[88],"2005-01",13,[18],[7020,7004],"PSA prostate cancer vaccine",{"nctId":7022,"briefTitle":7023,"status":332,"phases":7024,"primaryCompletion":1568,"completion":7025,"start":7026,"enrollment":516,"conditions":7027,"interventions":7028},"NCT00002952","Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma",[87,88],"2002-11","1997-01",[1005],[7029,7030,7004],"MART-1 antigen","recombinant MAGE-3.1 antigen",{"trials":7032,"activeCount":99},[],{"trials":7034,"activeCount":99},[],{"trials":7036,"activeCount":99},[],{"intervention":7038,"totalTrials":367,"cells":7039},"O6-benzylguanine",{"EARLY_PHASE1":7040,"PHASE1":7042,"PHASE2":7051,"PHASE3":7061,"PHASE4":7063,"NA":7065},{"trials":7041,"activeCount":99},[],{"trials":7043,"activeCount":99},[7044],{"nctId":7045,"briefTitle":7046,"status":332,"phases":7047,"primaryCompletion":1303,"completion":1303,"start":7048,"enrollment":410,"conditions":7049,"interventions":7050},"NCT00003766","O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery",[87],"1999-10",[772],[7038],{"trials":7052,"activeCount":99},[7053],{"nctId":7054,"briefTitle":7055,"status":332,"phases":7056,"primaryCompletion":1518,"completion":3534,"start":399,"enrollment":35,"conditions":7057,"interventions":7059},"NCT00005066","O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma",[88],[7058],"Sarcoma",[7038,7060],"carmustine",{"trials":7062,"activeCount":99},[],{"trials":7064,"activeCount":99},[],{"trials":7066,"activeCount":99},[],{"intervention":372,"totalTrials":367,"cells":7068},{"EARLY_PHASE1":7069,"PHASE1":7071,"PHASE2":7073,"PHASE3":7083,"PHASE4":7085,"NA":7087},{"trials":7070,"activeCount":99},[],{"trials":7072,"activeCount":99},[],{"trials":7074,"activeCount":99},[7075,7079],{"nctId":1915,"briefTitle":1916,"status":363,"phases":7076,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":367,"conditions":7077,"interventions":7078},[87,88],[1921],[1897,372,1923],{"nctId":361,"briefTitle":362,"status":363,"phases":7080,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":7081,"interventions":7082},[88],[369],[371,372,299],{"trials":7084,"activeCount":99},[],{"trials":7086,"activeCount":99},[],{"trials":7088,"activeCount":99},[],{"intervention":7090,"totalTrials":367,"cells":7091},"Atorvastatin",{"EARLY_PHASE1":7092,"PHASE1":7094,"PHASE2":7103,"PHASE3":7115,"PHASE4":7117,"NA":7119},{"trials":7093,"activeCount":99},[],{"trials":7095,"activeCount":99},[7096],{"nctId":7097,"briefTitle":7098,"status":332,"phases":7099,"primaryCompletion":1649,"completion":4932,"start":6271,"enrollment":516,"conditions":7100,"interventions":7102},"NCT00143741","Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers",[87],[7101],"End-Stage Kidney Disease",[7090],{"trials":7104,"activeCount":99},[7105],{"nctId":7106,"briefTitle":7107,"status":332,"phases":7108,"primaryCompletion":7109,"completion":7110,"start":7111,"enrollment":249,"conditions":7112,"interventions":7114},"NCT02603328","Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial",[87,88],"2024-07-31","2025-03-31","2018-07-17",[7113],"Cerebral Cavernous Malformation",[7090],{"trials":7116,"activeCount":99},[],{"trials":7118,"activeCount":99},[],{"trials":7120,"activeCount":99},[],{"intervention":7122,"totalTrials":367,"cells":7123},"RAD001",{"EARLY_PHASE1":7124,"PHASE1":7126,"PHASE2":7134,"PHASE3":7144,"PHASE4":7146,"NA":7148},{"trials":7125,"activeCount":99},[],{"trials":7127,"activeCount":99},[7128],{"nctId":7129,"briefTitle":7130,"status":363,"phases":7131,"primaryCompletion":5135,"completion":6205,"start":5024,"enrollment":488,"conditions":7132,"interventions":7133},"NCT01063478","Dose Escalation Study of RAD001 in Combination w\u002FChemotherapy & Radiation in Patients With NSCLC",[87],[2906],[7122],{"trials":7135,"activeCount":99},[7136],{"nctId":7137,"briefTitle":7138,"status":332,"phases":7139,"primaryCompletion":1280,"completion":1280,"start":7140,"enrollment":802,"conditions":7141,"interventions":7143},"NCT00529802","Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer",[88],"2007-09",[7142],"Carcinoma, Renal Cell",[7122],{"trials":7145,"activeCount":99},[],{"trials":7147,"activeCount":99},[],{"trials":7149,"activeCount":99},[],{"intervention":389,"totalTrials":367,"cells":7151},{"EARLY_PHASE1":7152,"PHASE1":7154,"PHASE2":7156,"PHASE3":7166,"PHASE4":7168,"NA":7170},{"trials":7153,"activeCount":99},[],{"trials":7155,"activeCount":99},[],{"trials":7157,"activeCount":99},[7158,7162],{"nctId":374,"briefTitle":375,"status":332,"phases":7159,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":7160,"interventions":7161},[88],[381,382],[384,385,386,387,388,389,299,390,391,392],{"nctId":1723,"briefTitle":1724,"status":332,"phases":7163,"primaryCompletion":1726,"completion":1416,"start":1727,"enrollment":1728,"conditions":7164,"interventions":7165},[88],[21],[958,389,388,387],{"trials":7167,"activeCount":99},[],{"trials":7169,"activeCount":99},[],{"trials":7171,"activeCount":99},[],{"intervention":7173,"totalTrials":367,"cells":7174},"0.2% isoflurane",{"EARLY_PHASE1":7175,"PHASE1":7177,"PHASE2":7179,"PHASE3":7200,"PHASE4":7202,"NA":7204},{"trials":7176,"activeCount":99},[],{"trials":7178,"activeCount":99},[],{"trials":7180,"activeCount":99},[7181,7190],{"nctId":7182,"briefTitle":7183,"status":332,"phases":7184,"primaryCompletion":7185,"completion":7185,"start":7186,"enrollment":732,"conditions":7187,"interventions":7188},"NCT00000251","Effects of Subanesthetic Concentrations of Isoflurane\u002FNitrous Oxide - 3",[88],"1996-01","1994-04",[26,23],[6934,7173,7189],"0.4% isoflurane",{"nctId":7191,"briefTitle":7192,"status":332,"phases":7193,"primaryCompletion":7194,"completion":7194,"start":7195,"enrollment":732,"conditions":7196,"interventions":7197},"NCT00000254","Isoflurane at Subanesthetic Concentrations - 6",[88],"1995-09","1995-01",[26,23],[7198,7173,7189,7199],"40% Nitrous oxide","0.6% isoflurane",{"trials":7201,"activeCount":99},[],{"trials":7203,"activeCount":99},[],{"trials":7205,"activeCount":99},[],{"intervention":7189,"totalTrials":367,"cells":7207},{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7212,"PHASE3":7222,"PHASE4":7224,"NA":7226},{"trials":7209,"activeCount":99},[],{"trials":7211,"activeCount":99},[],{"trials":7213,"activeCount":99},[7214,7218],{"nctId":7182,"briefTitle":7183,"status":332,"phases":7215,"primaryCompletion":7185,"completion":7185,"start":7186,"enrollment":732,"conditions":7216,"interventions":7217},[88],[26,23],[6934,7173,7189],{"nctId":7191,"briefTitle":7192,"status":332,"phases":7219,"primaryCompletion":7194,"completion":7194,"start":7195,"enrollment":732,"conditions":7220,"interventions":7221},[88],[26,23],[7198,7173,7189,7199],{"trials":7223,"activeCount":99},[],{"trials":7225,"activeCount":99},[],{"trials":7227,"activeCount":99},[],{"intervention":2079,"totalTrials":367,"cells":7229},{"EARLY_PHASE1":7230,"PHASE1":7232,"PHASE2":7234,"PHASE3":7298,"PHASE4":7300,"NA":7302},{"trials":7231,"activeCount":99},[],{"trials":7233,"activeCount":99},[],{"trials":7235,"activeCount":99},[7236,7294],{"nctId":7237,"briefTitle":7238,"status":332,"phases":7239,"primaryCompletion":7240,"completion":7240,"start":7241,"enrollment":7242,"conditions":7243,"interventions":7293},"NCT01839916","Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies",[88],"2018-08","2013-04-04",77,[7244,3790,3791,3792,7245,3793,3794,7246,7247,7248,7249,7250,7251,7252,7253,7254,7255,7256,621,7257,622,7258,623,624,7259,7260,7261,7262,6500,3798,7263,7264,7265,7266,7267,7268,7269,7270,7271,7272,7273,7274,7275,7276,7277,7278,7279,7280,7281,7282,7283,7284,7285,7286,7287,7288,7289,7290,7291,636,637,7292,678,680],"Accelerated Phase Chronic Myelogenous Leukemia","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Blastic Phase Chronic Myelogenous Leukemia","Childhood Burkitt Lymphoma","Childhood Chronic Myelogenous Leukemia","Childhood Diffuse Large Cell Lymphoma","Childhood Immunoblastic Large Cell Lymphoma","Childhood Myelodysplastic Syndromes","Childhood Nasal Type Extranodal NK\u002FT-cell Lymphoma","Chronic Phase Chronic Myelogenous Leukemia","de Novo Myelodysplastic Syndromes","Hepatosplenic T-cell Lymphoma","Noncutaneous Extranodal Lymphoma","Peripheral T-cell Lymphoma","Post-transplant Lymphoproliferative Disorder","Previously Treated Myelodysplastic Syndromes","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Anaplastic Large Cell Lymphoma","Recurrent Childhood Grade III Lymphomatoid Granulomatosis","Recurrent Childhood Large Cell Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Childhood Small Noncleaved Cell Lymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Recurrent Small Lymphocytic Lymphoma","Recurrent\u002FRefractory Childhood Hodgkin Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Hairy Cell Leukemia","Relapsing Chronic Myelogenous Leukemia","Secondary Myelodysplastic Syndromes","T-cell Large Granular Lymphocyte Leukemia",[2079],{"nctId":2070,"briefTitle":2071,"status":332,"phases":7295,"primaryCompletion":2073,"completion":1227,"start":2074,"enrollment":2075,"conditions":7296,"interventions":7297},[88],[2077,1005],[1273,2079,686,2080],{"trials":7299,"activeCount":99},[],{"trials":7301,"activeCount":99},[],{"trials":7303,"activeCount":99},[],{"intervention":6526,"totalTrials":367,"cells":7305},{"EARLY_PHASE1":7306,"PHASE1":7308,"PHASE2":7310,"PHASE3":7320,"PHASE4":7322,"NA":7324},{"trials":7307,"activeCount":99},[],{"trials":7309,"activeCount":99},[],{"trials":7311,"activeCount":99},[7312,7316],{"nctId":6519,"briefTitle":6520,"status":363,"phases":7313,"primaryCompletion":6237,"completion":838,"start":4801,"enrollment":95,"conditions":7314,"interventions":7315},[88],[6523],[6464,6490,6525,6526,6527],{"nctId":6571,"briefTitle":6572,"status":332,"phases":7317,"primaryCompletion":3441,"completion":1536,"start":5863,"enrollment":1215,"conditions":7318,"interventions":7319},[87,88],[1932,787,486],[6526,6490,6491],{"trials":7321,"activeCount":99},[],{"trials":7323,"activeCount":99},[],{"trials":7325,"activeCount":99},[],{"intervention":683,"totalTrials":367,"cells":7327},{"EARLY_PHASE1":7328,"PHASE1":7330,"PHASE2":7345,"PHASE3":7351,"PHASE4":7353,"NA":7355},{"trials":7329,"activeCount":99},[],{"trials":7331,"activeCount":99},[7332],{"nctId":7333,"briefTitle":7334,"status":363,"phases":7335,"primaryCompletion":7336,"completion":7336,"start":7337,"enrollment":1215,"conditions":7338,"interventions":7341},"NCT05276492","Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.",[87],"2024-11-16","2023-01-24",[18,2227,7339,7340],"Prostate Neoplasm","Prostate Cancer Metastatic",[7342,7343,7344],"Abiraterone Oral","Prednisone","Low-fat meal",{"trials":7346,"activeCount":99},[7347],{"nctId":601,"briefTitle":602,"status":332,"phases":7348,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":7349,"interventions":7350},[87,88],[609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680],[439,682,683,684,685,686,687],{"trials":7352,"activeCount":99},[],{"trials":7354,"activeCount":99},[],{"trials":7356,"activeCount":99},[],{"intervention":7358,"totalTrials":367,"cells":7359},"Everolimus",{"EARLY_PHASE1":7360,"PHASE1":7362,"PHASE2":7364,"PHASE3":7380,"PHASE4":7382,"NA":7384},{"trials":7361,"activeCount":99},[],{"trials":7363,"activeCount":99},[],{"trials":7365,"activeCount":99},[7366,7373],{"nctId":7367,"briefTitle":7368,"status":363,"phases":7369,"primaryCompletion":3367,"completion":7370,"start":4801,"enrollment":337,"conditions":7371,"interventions":7372},"NCT01111058","Everolimus Versus Placebo in Head and Neck Cancer",[88],"2018-10",[21],[7358],{"nctId":7374,"briefTitle":7375,"status":363,"phases":7376,"primaryCompletion":3283,"completion":3283,"start":7377,"enrollment":1215,"conditions":7378,"interventions":7379},"NCT01133678","Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck",[88],"2010-05-04",[21],[7358],{"trials":7381,"activeCount":99},[],{"trials":7383,"activeCount":99},[],{"trials":7385,"activeCount":99},[],{"intervention":7387,"totalTrials":95,"cells":7388},"modified CEA peptide",{"EARLY_PHASE1":7389,"PHASE1":7391,"PHASE2":7393,"PHASE3":7402,"PHASE4":7404,"NA":7406},{"trials":7390,"activeCount":99},[],{"trials":7392,"activeCount":99},[],{"trials":7394,"activeCount":99},[7395],{"nctId":7396,"briefTitle":7397,"status":332,"phases":7398,"primaryCompletion":2359,"completion":837,"start":4656,"enrollment":7399,"conditions":7400,"interventions":7401},"NCT00203892","Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma",[87,88],23,[1555],[7387,7387,7387],{"trials":7403,"activeCount":99},[],{"trials":7405,"activeCount":99},[],{"trials":7407,"activeCount":99},[],{"intervention":1243,"totalTrials":95,"cells":7409},{"EARLY_PHASE1":7410,"PHASE1":7412,"PHASE2":7414,"PHASE3":7420,"PHASE4":7422,"NA":7424},{"trials":7411,"activeCount":99},[],{"trials":7413,"activeCount":99},[],{"trials":7415,"activeCount":99},[7416],{"nctId":1234,"briefTitle":1235,"status":332,"phases":7417,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1106,"conditions":7418,"interventions":7419},[88],[1240,1241,1064,381,382],[385,392,386,1243,1244,1245,387],{"trials":7421,"activeCount":99},[],{"trials":7423,"activeCount":99},[],{"trials":7425,"activeCount":99},[],{"intervention":1257,"totalTrials":95,"cells":7427},{"EARLY_PHASE1":7428,"PHASE1":7430,"PHASE2":7432,"PHASE3":7438,"PHASE4":7440,"NA":7442},{"trials":7429,"activeCount":99},[],{"trials":7431,"activeCount":99},[],{"trials":7433,"activeCount":99},[7434],{"nctId":1247,"briefTitle":1248,"status":981,"phases":7435,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":99,"conditions":7436,"interventions":7437},[88],[15,1254,1255],[392,1257,1258,1259,1260,1261,1262,385],{"trials":7439,"activeCount":99},[],{"trials":7441,"activeCount":99},[],{"trials":7443,"activeCount":99},[],{"intervention":1258,"totalTrials":95,"cells":7445},{"EARLY_PHASE1":7446,"PHASE1":7448,"PHASE2":7450,"PHASE3":7456,"PHASE4":7458,"NA":7460},{"trials":7447,"activeCount":99},[],{"trials":7449,"activeCount":99},[],{"trials":7451,"activeCount":99},[7452],{"nctId":1247,"briefTitle":1248,"status":981,"phases":7453,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":99,"conditions":7454,"interventions":7455},[88],[15,1254,1255],[392,1257,1258,1259,1260,1261,1262,385],{"trials":7457,"activeCount":99},[],{"trials":7459,"activeCount":99},[],{"trials":7461,"activeCount":99},[],{"intervention":7463,"totalTrials":95,"cells":7464},"aminocamptothecin",{"EARLY_PHASE1":7465,"PHASE1":7467,"PHASE2":7469,"PHASE3":7478,"PHASE4":7480,"NA":7482},{"trials":7466,"activeCount":99},[],{"trials":7468,"activeCount":99},[],{"trials":7470,"activeCount":99},[7471],{"nctId":7472,"briefTitle":7473,"status":332,"phases":7474,"primaryCompletion":3589,"completion":1484,"start":7475,"enrollment":312,"conditions":7476,"interventions":7477},"NCT00003192","Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus",[88],"1998-03",[3528,1701],[7463],{"trials":7479,"activeCount":99},[],{"trials":7481,"activeCount":99},[],{"trials":7483,"activeCount":99},[],{"intervention":7485,"totalTrials":95,"cells":7486},"Haplo-Cord Transplant",{"EARLY_PHASE1":7487,"PHASE1":7489,"PHASE2":7491,"PHASE3":7503,"PHASE4":7505,"NA":7507},{"trials":7488,"activeCount":99},[],{"trials":7490,"activeCount":99},[],{"trials":7492,"activeCount":99},[7493],{"nctId":7494,"briefTitle":7495,"status":363,"phases":7496,"primaryCompletion":7497,"completion":7497,"start":7498,"enrollment":2118,"conditions":7499,"interventions":7502},"NCT02648932","The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients",[88],"2020-04","2016-02-04",[7500,7501],"Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)",[7485],{"trials":7504,"activeCount":99},[],{"trials":7506,"activeCount":99},[],{"trials":7508,"activeCount":99},[],{"intervention":7510,"totalTrials":95,"cells":7511},"erlotinib hydrochloride",{"EARLY_PHASE1":7512,"PHASE1":7514,"PHASE2":7516,"PHASE3":7526,"PHASE4":7528,"NA":7530},{"trials":7513,"activeCount":99},[],{"trials":7515,"activeCount":99},[],{"trials":7517,"activeCount":99},[7518],{"nctId":7519,"briefTitle":7520,"status":332,"phases":7521,"primaryCompletion":7522,"completion":7522,"start":838,"enrollment":367,"conditions":7523,"interventions":7525},"NCT01592383","Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma",[88],"2017-02",[7524],"Malignant Peritoneal Mesothelioma",[7510],{"trials":7527,"activeCount":99},[],{"trials":7529,"activeCount":99},[],{"trials":7531,"activeCount":99},[],{"intervention":1008,"totalTrials":95,"cells":7533},{"EARLY_PHASE1":7534,"PHASE1":7536,"PHASE2":7538,"PHASE3":7544,"PHASE4":7546,"NA":7548},{"trials":7535,"activeCount":99},[],{"trials":7537,"activeCount":99},[],{"trials":7539,"activeCount":99},[7540],{"nctId":999,"briefTitle":1000,"status":363,"phases":7541,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":545,"conditions":7542,"interventions":7543},[88],[1005,1006],[46,1008],{"trials":7545,"activeCount":99},[],{"trials":7547,"activeCount":99},[],{"trials":7549,"activeCount":99},[],{"intervention":7551,"totalTrials":95,"cells":7552},"Transdermal estradiol",{"EARLY_PHASE1":7553,"PHASE1":7555,"PHASE2":7557,"PHASE3":7571,"PHASE4":7573,"NA":7575},{"trials":7554,"activeCount":99},[],{"trials":7556,"activeCount":99},[],{"trials":7558,"activeCount":99},[7559],{"nctId":7560,"briefTitle":7561,"status":363,"phases":7562,"primaryCompletion":7563,"completion":7563,"start":7564,"enrollment":95,"conditions":7565,"interventions":7570},"NCT01928082","The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass",[88],"2014-08-01","2013-08-01",[7566,7567,7568,7569],"Hypercalciuria","Hypercalciuria, Familial Idiopathic","Osteopenia","Osteoporosis",[7551],{"trials":7572,"activeCount":99},[],{"trials":7574,"activeCount":99},[],{"trials":7576,"activeCount":99},[],{"intervention":7578,"totalTrials":95,"cells":7579},"Standard of Care Chemotherapy",{"EARLY_PHASE1":7580,"PHASE1":7582,"PHASE2":7584,"PHASE3":7599,"PHASE4":7601,"NA":7603},{"trials":7581,"activeCount":99},[],{"trials":7583,"activeCount":99},[],{"trials":7585,"activeCount":99},[7586],{"nctId":7587,"briefTitle":7588,"status":981,"phases":7589,"primaryCompletion":7590,"completion":4422,"start":7591,"enrollment":99,"conditions":7592,"interventions":7598},"NCT04931420","Study Comparing Standard of Care Chemotherapy With\u002F Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels",[88],"2026-05-01","2022-05-19",[3939,7593,1037,7594,7595,7596,7597,1305],"Foregut Carcinoid Tumor","Gallbladder Adenocarcinoma","Liver Cancer","GI Cancer","GI Carcinoma",[7578],{"trials":7600,"activeCount":99},[],{"trials":7602,"activeCount":99},[],{"trials":7604,"activeCount":99},[],{"intervention":7606,"totalTrials":95,"cells":7607},"G250 peptide",{"EARLY_PHASE1":7608,"PHASE1":7610,"PHASE2":7612,"PHASE3":7622,"PHASE4":7624,"NA":7626},{"trials":7609,"activeCount":99},[],{"trials":7611,"activeCount":99},[],{"trials":7613,"activeCount":99},[7614],{"nctId":7615,"briefTitle":7616,"status":363,"phases":7617,"primaryCompletion":6437,"completion":6437,"start":1641,"enrollment":539,"conditions":7618,"interventions":7620},"NCT00203866","Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced\u002FMetastatic Renal Cell Carcinoma",[88],[7619],"Metastatic Renal Cell Carcinoma",[7606,7621],"IL-2",{"trials":7623,"activeCount":99},[],{"trials":7625,"activeCount":99},[],{"trials":7627,"activeCount":99},[],{"intervention":7621,"totalTrials":95,"cells":7629},{"EARLY_PHASE1":7630,"PHASE1":7632,"PHASE2":7634,"PHASE3":7640,"PHASE4":7642,"NA":7644},{"trials":7631,"activeCount":99},[],{"trials":7633,"activeCount":99},[],{"trials":7635,"activeCount":99},[7636],{"nctId":7615,"briefTitle":7616,"status":363,"phases":7637,"primaryCompletion":6437,"completion":6437,"start":1641,"enrollment":539,"conditions":7638,"interventions":7639},[88],[7619],[7606,7621],{"trials":7641,"activeCount":99},[],{"trials":7643,"activeCount":99},[],{"trials":7645,"activeCount":99},[],{"intervention":1285,"totalTrials":95,"cells":7647},{"EARLY_PHASE1":7648,"PHASE1":7650,"PHASE2":7652,"PHASE3":7658,"PHASE4":7660,"NA":7662},{"trials":7649,"activeCount":99},[],{"trials":7651,"activeCount":99},[],{"trials":7653,"activeCount":99},[7654],{"nctId":1276,"briefTitle":1277,"status":332,"phases":7655,"primaryCompletion":1279,"completion":1280,"start":1281,"enrollment":1282,"conditions":7656,"interventions":7657},[88],[21],[1285,1286,385],{"trials":7659,"activeCount":99},[],{"trials":7661,"activeCount":99},[],{"trials":7663,"activeCount":99},[],{"intervention":7020,"totalTrials":95,"cells":7665},{"EARLY_PHASE1":7666,"PHASE1":7668,"PHASE2":7670,"PHASE3":7676,"PHASE4":7678,"NA":7680},{"trials":7667,"activeCount":99},[],{"trials":7669,"activeCount":99},[],{"trials":7671,"activeCount":99},[7672],{"nctId":7013,"briefTitle":7014,"status":332,"phases":7673,"primaryCompletion":1737,"completion":7016,"start":1303,"enrollment":7017,"conditions":7674,"interventions":7675},[88],[18],[7020,7004],{"trials":7677,"activeCount":99},[],{"trials":7679,"activeCount":99},[],{"trials":7681,"activeCount":99},[],{"intervention":7683,"totalTrials":95,"cells":7684},"Azithromycin",{"EARLY_PHASE1":7685,"PHASE1":7687,"PHASE2":7689,"PHASE3":7700,"PHASE4":7702,"NA":7704},{"trials":7686,"activeCount":99},[],{"trials":7688,"activeCount":99},[],{"trials":7690,"activeCount":99},[7691],{"nctId":7692,"briefTitle":7693,"status":363,"phases":7694,"primaryCompletion":7695,"completion":50,"start":7696,"enrollment":27,"conditions":7697,"interventions":7699},"NCT03736629","Azithromycin Treatment for the Airway Microbiome in Asthma",[88],"2021-03-01","2019-02-01",[7698],"Asthma Chronic",[7683],{"trials":7701,"activeCount":99},[],{"trials":7703,"activeCount":99},[],{"trials":7705,"activeCount":99},[],{"intervention":7707,"totalTrials":95,"cells":7708},"Fluoxetine",{"EARLY_PHASE1":7709,"PHASE1":7711,"PHASE2":7713,"PHASE3":7724,"PHASE4":7726,"NA":7728},{"trials":7710,"activeCount":99},[],{"trials":7712,"activeCount":99},[],{"trials":7714,"activeCount":99},[7715],{"nctId":7716,"briefTitle":7717,"status":332,"phases":7718,"primaryCompletion":7719,"completion":7719,"start":6484,"enrollment":1335,"conditions":7720,"interventions":7722},"NCT00078754","A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder",[88],"2008-10",[7721],"Intermittent Explosive Disorder",[7707,7723],"Divalproex",{"trials":7725,"activeCount":99},[],{"trials":7727,"activeCount":99},[],{"trials":7729,"activeCount":99},[],{"intervention":7723,"totalTrials":95,"cells":7731},{"EARLY_PHASE1":7732,"PHASE1":7734,"PHASE2":7736,"PHASE3":7742,"PHASE4":7744,"NA":7746},{"trials":7733,"activeCount":99},[],{"trials":7735,"activeCount":99},[],{"trials":7737,"activeCount":99},[7738],{"nctId":7716,"briefTitle":7717,"status":332,"phases":7739,"primaryCompletion":7719,"completion":7719,"start":6484,"enrollment":1335,"conditions":7740,"interventions":7741},[88],[7721],[7707,7723],{"trials":7743,"activeCount":99},[],{"trials":7745,"activeCount":99},[],{"trials":7747,"activeCount":99},[],{"intervention":7749,"totalTrials":95,"cells":7750},"Naltrexone plus N-Acetyl Cysteine",{"EARLY_PHASE1":7751,"PHASE1":7753,"PHASE2":7755,"PHASE3":7766,"PHASE4":7768,"NA":7770},{"trials":7752,"activeCount":99},[],{"trials":7754,"activeCount":99},[],{"trials":7756,"activeCount":99},[7757],{"nctId":7758,"briefTitle":7759,"status":332,"phases":7760,"primaryCompletion":5460,"completion":6397,"start":7761,"enrollment":7762,"conditions":7763,"interventions":7765},"NCT00332605","N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence",[88],"2006-06",45,[7764],"Methamphetamine Dependence",[7749],{"trials":7767,"activeCount":99},[],{"trials":7769,"activeCount":99},[],{"trials":7771,"activeCount":99},[],{"intervention":7060,"totalTrials":95,"cells":7773},{"EARLY_PHASE1":7774,"PHASE1":7776,"PHASE2":7778,"PHASE3":7784,"PHASE4":7786,"NA":7788},{"trials":7775,"activeCount":99},[],{"trials":7777,"activeCount":99},[],{"trials":7779,"activeCount":99},[7780],{"nctId":7054,"briefTitle":7055,"status":332,"phases":7781,"primaryCompletion":1518,"completion":3534,"start":399,"enrollment":35,"conditions":7782,"interventions":7783},[88],[7058],[7038,7060],{"trials":7785,"activeCount":99},[],{"trials":7787,"activeCount":99},[],{"trials":7789,"activeCount":99},[],{"intervention":7791,"totalTrials":95,"cells":7792},"BGJ398",{"EARLY_PHASE1":7793,"PHASE1":7795,"PHASE2":7797,"PHASE3":7816,"PHASE4":7818,"NA":7820},{"trials":7794,"activeCount":99},[],{"trials":7796,"activeCount":99},[],{"trials":7798,"activeCount":99},[7799],{"nctId":7800,"briefTitle":7801,"status":363,"phases":7802,"primaryCompletion":7803,"completion":7803,"start":7804,"enrollment":95,"conditions":7805,"interventions":7815},"NCT02706691","BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer",[88],"2019-02-11","2018-06-01",[7806,7807,7808,7809,7810,1087,7811,7812,7813,7814],"FGFR Gene Amplification","FGFR1 Gene Amplification","FGFR2 Gene Amplification","FGFR2 Gene Mutation","FGFR3 Gene Mutation","Human Papillomavirus Infection","Recurrent Head and Neck Carcinoma","Recurrent Nasopharynx Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma",[7791],{"trials":7817,"activeCount":99},[],{"trials":7819,"activeCount":99},[],{"trials":7821,"activeCount":99},[],{"intervention":1923,"totalTrials":95,"cells":7823},{"EARLY_PHASE1":7824,"PHASE1":7826,"PHASE2":7828,"PHASE3":7834,"PHASE4":7836,"NA":7838},{"trials":7825,"activeCount":99},[],{"trials":7827,"activeCount":99},[],{"trials":7829,"activeCount":99},[7830],{"nctId":1915,"briefTitle":1916,"status":363,"phases":7831,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":367,"conditions":7832,"interventions":7833},[87,88],[1921],[1897,372,1923],{"trials":7835,"activeCount":99},[],{"trials":7837,"activeCount":99},[],{"trials":7839,"activeCount":99},[],{"intervention":7841,"totalTrials":95,"cells":7842},"Polyphenon E",{"EARLY_PHASE1":7843,"PHASE1":7845,"PHASE2":7847,"PHASE3":7856,"PHASE4":7858,"NA":7860},{"trials":7844,"activeCount":99},[],{"trials":7846,"activeCount":99},[],{"trials":7848,"activeCount":99},[7849],{"nctId":7850,"briefTitle":7851,"status":363,"phases":7852,"primaryCompletion":4990,"completion":4990,"start":4821,"enrollment":516,"conditions":7853,"interventions":7855},"NCT01060345","A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ",[88],[7854],"Ductal Carcinoma in Situ",[7841],{"trials":7857,"activeCount":99},[],{"trials":7859,"activeCount":99},[],{"trials":7861,"activeCount":99},[],{"intervention":7863,"totalTrials":95,"cells":7864},"Belatacept",{"EARLY_PHASE1":7865,"PHASE1":7867,"PHASE2":7869,"PHASE3":7881,"PHASE4":7883,"NA":7885},{"trials":7866,"activeCount":99},[],{"trials":7868,"activeCount":99},[],{"trials":7870,"activeCount":99},[7871],{"nctId":7872,"briefTitle":7873,"status":332,"phases":7874,"primaryCompletion":7875,"completion":7875,"start":7876,"enrollment":994,"conditions":7877,"interventions":7880},"NCT05345717","Novel Desensitization Kidney Transplantation",[87,88],"2025-09-12","2022-05-01",[7878,7879],"Kidney Transplantation","End Stage Kidney Disease (ESRD)",[7863],{"trials":7882,"activeCount":99},[],{"trials":7884,"activeCount":99},[],{"trials":7886,"activeCount":99},[],{"intervention":7888,"totalTrials":95,"cells":7889},"arsenic trioxide",{"EARLY_PHASE1":7890,"PHASE1":7892,"PHASE2":7894,"PHASE3":7904,"PHASE4":7906,"NA":7908},{"trials":7891,"activeCount":99},[],{"trials":7893,"activeCount":99},[],{"trials":7895,"activeCount":99},[7896],{"nctId":7897,"briefTitle":7898,"status":332,"phases":7899,"primaryCompletion":7016,"completion":5888,"start":7900,"enrollment":7017,"conditions":7901,"interventions":7903},"NCT00053222","Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine",[88],"2003-02",[7902],"Pancreatic Cancer",[7888],{"trials":7905,"activeCount":99},[],{"trials":7907,"activeCount":99},[],{"trials":7909,"activeCount":99},[],{"intervention":7911,"totalTrials":95,"cells":7912},"Chlorhexidine Gluconate 2% Wipe",{"EARLY_PHASE1":7913,"PHASE1":7915,"PHASE2":7917,"PHASE3":7927,"PHASE4":7929,"NA":7931},{"trials":7914,"activeCount":99},[],{"trials":7916,"activeCount":99},[],{"trials":7918,"activeCount":99},[7919],{"nctId":7920,"briefTitle":7921,"status":332,"phases":7922,"primaryCompletion":7923,"completion":1251,"start":3294,"enrollment":1215,"conditions":7924,"interventions":7926},"NCT03030989","A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients",[88],"2019-01-02",[7925],"Stem Cell Transplant Complications",[7911],{"trials":7928,"activeCount":99},[],{"trials":7930,"activeCount":99},[],{"trials":7932,"activeCount":99},[],{"intervention":7934,"totalTrials":95,"cells":7935},"BMS-247550",{"EARLY_PHASE1":7936,"PHASE1":7938,"PHASE2":7940,"PHASE3":7949,"PHASE4":7951,"NA":7953},{"trials":7937,"activeCount":99},[],{"trials":7939,"activeCount":99},[],{"trials":7941,"activeCount":99},[7942],{"nctId":7943,"briefTitle":7944,"status":332,"phases":7945,"primaryCompletion":3534,"completion":7946,"start":1518,"enrollment":782,"conditions":7947,"interventions":7948},"NCT00022477","BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer",[88],"2004-12",[3342],[7934],{"trials":7950,"activeCount":99},[],{"trials":7952,"activeCount":99},[],{"trials":7954,"activeCount":99},[],{"intervention":3348,"totalTrials":95,"cells":7956},{"EARLY_PHASE1":7957,"PHASE1":7959,"PHASE2":7961,"PHASE3":7967,"PHASE4":7969,"NA":7971},{"trials":7958,"activeCount":99},[],{"trials":7960,"activeCount":99},[],{"trials":7962,"activeCount":99},[7963],{"nctId":3337,"briefTitle":3338,"status":468,"phases":7964,"primaryCompletion":3340,"completion":3340,"start":1345,"enrollment":1580,"conditions":7965,"interventions":7966},[87,88],[3342,3343,3344,3345,3346],[3348,958],{"trials":7968,"activeCount":99},[],{"trials":7970,"activeCount":99},[],{"trials":7972,"activeCount":99},[],{"intervention":3711,"totalTrials":95,"cells":7974},{"EARLY_PHASE1":7975,"PHASE1":7977,"PHASE2":7979,"PHASE3":7985,"PHASE4":7987,"NA":7989},{"trials":7976,"activeCount":99},[],{"trials":7978,"activeCount":99},[],{"trials":7980,"activeCount":99},[7981],{"nctId":3703,"briefTitle":3704,"status":332,"phases":7982,"primaryCompletion":3706,"completion":3707,"start":3708,"enrollment":249,"conditions":7983,"interventions":7984},[88],[1556],[3711,3712,3713,3714,386,3715],{"trials":7986,"activeCount":99},[],{"trials":7988,"activeCount":99},[],{"trials":7990,"activeCount":99},[],{"intervention":3712,"totalTrials":95,"cells":7992},{"EARLY_PHASE1":7993,"PHASE1":7995,"PHASE2":7997,"PHASE3":8003,"PHASE4":8005,"NA":8007},{"trials":7994,"activeCount":99},[],{"trials":7996,"activeCount":99},[],{"trials":7998,"activeCount":99},[7999],{"nctId":3703,"briefTitle":3704,"status":332,"phases":8000,"primaryCompletion":3706,"completion":3707,"start":3708,"enrollment":249,"conditions":8001,"interventions":8002},[88],[1556],[3711,3712,3713,3714,386,3715],{"trials":8004,"activeCount":99},[],{"trials":8006,"activeCount":99},[],{"trials":8008,"activeCount":99},[],{"intervention":3713,"totalTrials":95,"cells":8010},{"EARLY_PHASE1":8011,"PHASE1":8013,"PHASE2":8015,"PHASE3":8021,"PHASE4":8023,"NA":8025},{"trials":8012,"activeCount":99},[],{"trials":8014,"activeCount":99},[],{"trials":8016,"activeCount":99},[8017],{"nctId":3703,"briefTitle":3704,"status":332,"phases":8018,"primaryCompletion":3706,"completion":3707,"start":3708,"enrollment":249,"conditions":8019,"interventions":8020},[88],[1556],[3711,3712,3713,3714,386,3715],{"trials":8022,"activeCount":99},[],{"trials":8024,"activeCount":99},[],{"trials":8026,"activeCount":99},[],{"intervention":3714,"totalTrials":95,"cells":8028},{"EARLY_PHASE1":8029,"PHASE1":8031,"PHASE2":8033,"PHASE3":8039,"PHASE4":8041,"NA":8043},{"trials":8030,"activeCount":99},[],{"trials":8032,"activeCount":99},[],{"trials":8034,"activeCount":99},[8035],{"nctId":3703,"briefTitle":3704,"status":332,"phases":8036,"primaryCompletion":3706,"completion":3707,"start":3708,"enrollment":249,"conditions":8037,"interventions":8038},[88],[1556],[3711,3712,3713,3714,386,3715],{"trials":8040,"activeCount":99},[],{"trials":8042,"activeCount":99},[],{"trials":8044,"activeCount":99},[],{"intervention":3715,"totalTrials":95,"cells":8046},{"EARLY_PHASE1":8047,"PHASE1":8049,"PHASE2":8051,"PHASE3":8057,"PHASE4":8059,"NA":8061},{"trials":8048,"activeCount":99},[],{"trials":8050,"activeCount":99},[],{"trials":8052,"activeCount":99},[8053],{"nctId":3703,"briefTitle":3704,"status":332,"phases":8054,"primaryCompletion":3706,"completion":3707,"start":3708,"enrollment":249,"conditions":8055,"interventions":8056},[88],[1556],[3711,3712,3713,3714,386,3715],{"trials":8058,"activeCount":99},[],{"trials":8060,"activeCount":99},[],{"trials":8062,"activeCount":99},[],{"intervention":8064,"totalTrials":95,"cells":8065},"abiraterone acetate",{"EARLY_PHASE1":8066,"PHASE1":8068,"PHASE2":8070,"PHASE3":8080,"PHASE4":8082,"NA":8084},{"trials":8067,"activeCount":99},[],{"trials":8069,"activeCount":99},[],{"trials":8071,"activeCount":99},[8072],{"nctId":8073,"briefTitle":8074,"status":332,"phases":8075,"primaryCompletion":8076,"completion":3441,"start":6205,"enrollment":379,"conditions":8077,"interventions":8079},"NCT01543776","Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer",[88],"2017-09",[8078,2139],"Castration-resistant Prostate Cancer",[8064],{"trials":8081,"activeCount":99},[],{"trials":8083,"activeCount":99},[],{"trials":8085,"activeCount":99},[],{"intervention":371,"totalTrials":95,"cells":8087},{"EARLY_PHASE1":8088,"PHASE1":8090,"PHASE2":8092,"PHASE3":8098,"PHASE4":8100,"NA":8102},{"trials":8089,"activeCount":99},[],{"trials":8091,"activeCount":99},[],{"trials":8093,"activeCount":99},[8094],{"nctId":361,"briefTitle":362,"status":363,"phases":8095,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":8096,"interventions":8097},[88],[369],[371,372,299],{"trials":8099,"activeCount":99},[],{"trials":8101,"activeCount":99},[],{"trials":8103,"activeCount":99},[],{"intervention":8105,"totalTrials":95,"cells":8106},"Docetaxel and cisplatin",{"EARLY_PHASE1":8107,"PHASE1":8109,"PHASE2":8111,"PHASE3":8119,"PHASE4":8121,"NA":8123},{"trials":8108,"activeCount":99},[],{"trials":8110,"activeCount":99},[],{"trials":8112,"activeCount":99},[8113],{"nctId":8114,"briefTitle":8115,"status":363,"phases":8116,"primaryCompletion":2176,"completion":5135,"start":4820,"enrollment":1228,"conditions":8117,"interventions":8118},"NCT00887315","The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)",[88],[3361],[8105],{"trials":8120,"activeCount":99},[],{"trials":8122,"activeCount":99},[],{"trials":8124,"activeCount":99},[],{"intervention":390,"totalTrials":95,"cells":8126},{"EARLY_PHASE1":8127,"PHASE1":8129,"PHASE2":8131,"PHASE3":8137,"PHASE4":8139,"NA":8141},{"trials":8128,"activeCount":99},[],{"trials":8130,"activeCount":99},[],{"trials":8132,"activeCount":99},[8133],{"nctId":374,"briefTitle":375,"status":332,"phases":8134,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":8135,"interventions":8136},[88],[381,382],[384,385,386,387,388,389,299,390,391,392],{"trials":8138,"activeCount":99},[],{"trials":8140,"activeCount":99},[],{"trials":8142,"activeCount":99},[],{"intervention":8144,"totalTrials":95,"cells":8145},"AndroGel",{"EARLY_PHASE1":8146,"PHASE1":8148,"PHASE2":8150,"PHASE3":8158,"PHASE4":8160,"NA":8162},{"trials":8147,"activeCount":99},[],{"trials":8149,"activeCount":99},[],{"trials":8151,"activeCount":99},[8152],{"nctId":8153,"briefTitle":8154,"status":363,"phases":8155,"primaryCompletion":6778,"completion":1726,"start":5888,"enrollment":1571,"conditions":8156,"interventions":8157},"NCT00515112","Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer",[88],[18],[8144],{"trials":8159,"activeCount":99},[],{"trials":8161,"activeCount":99},[],{"trials":8163,"activeCount":99},[],{"intervention":8165,"totalTrials":95,"cells":8166},"Abatacept",{"EARLY_PHASE1":8167,"PHASE1":8169,"PHASE2":8171,"PHASE3":8181,"PHASE4":8183,"NA":8185},{"trials":8168,"activeCount":99},[],{"trials":8170,"activeCount":99},[],{"trials":8172,"activeCount":99},[8173],{"nctId":8174,"briefTitle":8175,"status":363,"phases":8176,"primaryCompletion":8177,"completion":8177,"start":6165,"enrollment":95,"conditions":8178,"interventions":8180},"NCT00739960","Safety Study of Abatacept to Treat Refractory Sarcoidosis",[88],"2008-12",[8179],"Sarcoidosis",[8165],{"trials":8182,"activeCount":99},[],{"trials":8184,"activeCount":99},[],{"trials":8186,"activeCount":99},[],{"intervention":6241,"totalTrials":95,"cells":8188},{"EARLY_PHASE1":8189,"PHASE1":8191,"PHASE2":8193,"PHASE3":8199,"PHASE4":8201,"NA":8203},{"trials":8190,"activeCount":99},[],{"trials":8192,"activeCount":99},[],{"trials":8194,"activeCount":99},[8195],{"nctId":6234,"briefTitle":6235,"status":363,"phases":8196,"primaryCompletion":6237,"completion":6237,"start":4781,"enrollment":2013,"conditions":8197,"interventions":8198},[88],[6239],[6225,6241],{"trials":8200,"activeCount":99},[],{"trials":8202,"activeCount":99},[],{"trials":8204,"activeCount":99},[],{"intervention":8206,"totalTrials":95,"cells":8207},"Caplyta",{"EARLY_PHASE1":8208,"PHASE1":8210,"PHASE2":8212,"PHASE3":8223,"PHASE4":8225,"NA":8227},{"trials":8209,"activeCount":99},[],{"trials":8211,"activeCount":99},[],{"trials":8213,"activeCount":99},[8214],{"nctId":8215,"briefTitle":8216,"status":332,"phases":8217,"primaryCompletion":8218,"completion":8218,"start":8219,"enrollment":802,"conditions":8220,"interventions":8222},"NCT05356013","Caplyta in Borderline Personality Disorder",[88],"2025-12-31","2023-05-10",[8221],"Borderline Personality Disorder",[8206],{"trials":8224,"activeCount":99},[],{"trials":8226,"activeCount":99},[],{"trials":8228,"activeCount":99},[],{"intervention":2182,"totalTrials":95,"cells":8230},{"EARLY_PHASE1":8231,"PHASE1":8233,"PHASE2":8235,"PHASE3":8241,"PHASE4":8243,"NA":8245},{"trials":8232,"activeCount":99},[],{"trials":8234,"activeCount":99},[],{"trials":8236,"activeCount":99},[8237],{"nctId":2173,"briefTitle":2174,"status":332,"phases":8238,"primaryCompletion":2176,"completion":2176,"start":2177,"enrollment":2178,"conditions":8239,"interventions":8240},[88],[2180,928],[2182,2183,1374],{"trials":8242,"activeCount":99},[],{"trials":8244,"activeCount":99},[],{"trials":8246,"activeCount":99},[],{"intervention":2183,"totalTrials":95,"cells":8248},{"EARLY_PHASE1":8249,"PHASE1":8251,"PHASE2":8253,"PHASE3":8259,"PHASE4":8261,"NA":8263},{"trials":8250,"activeCount":99},[],{"trials":8252,"activeCount":99},[],{"trials":8254,"activeCount":99},[8255],{"nctId":2173,"briefTitle":2174,"status":332,"phases":8256,"primaryCompletion":2176,"completion":2176,"start":2177,"enrollment":2178,"conditions":8257,"interventions":8258},[88],[2180,928],[2182,2183,1374],{"trials":8260,"activeCount":99},[],{"trials":8262,"activeCount":99},[],{"trials":8264,"activeCount":99},[],{"intervention":3538,"totalTrials":95,"cells":8266},{"EARLY_PHASE1":8267,"PHASE1":8269,"PHASE2":8271,"PHASE3":8277,"PHASE4":8279,"NA":8281},{"trials":8268,"activeCount":99},[],{"trials":8270,"activeCount":99},[],{"trials":8272,"activeCount":99},[8273],{"nctId":3531,"briefTitle":3532,"status":332,"phases":8274,"primaryCompletion":3534,"completion":1484,"start":3535,"enrollment":1106,"conditions":8275,"interventions":8276},[88],[3528,1701],[3538,1169,3502,1488],{"trials":8278,"activeCount":99},[],{"trials":8280,"activeCount":99},[],{"trials":8282,"activeCount":99},[],{"intervention":8284,"totalTrials":95,"cells":8285},"Prebiotic",{"EARLY_PHASE1":8286,"PHASE1":8288,"PHASE2":8290,"PHASE3":8301,"PHASE4":8303,"NA":8305},{"trials":8287,"activeCount":99},[],{"trials":8289,"activeCount":99},[],{"trials":8291,"activeCount":99},[8292],{"nctId":8293,"briefTitle":8294,"status":332,"phases":8295,"primaryCompletion":8296,"completion":8296,"start":8297,"enrollment":516,"conditions":8298,"interventions":8300},"NCT05138757","Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy",[87,88],"2025-03-12","2021-11-30",[8299],"Peanut Allergy",[8284],{"trials":8302,"activeCount":99},[],{"trials":8304,"activeCount":99},[],{"trials":8306,"activeCount":99},[],{"intervention":403,"totalTrials":95,"cells":8308},{"EARLY_PHASE1":8309,"PHASE1":8311,"PHASE2":8313,"PHASE3":8319,"PHASE4":8321,"NA":8323},{"trials":8310,"activeCount":99},[],{"trials":8312,"activeCount":99},[],{"trials":8314,"activeCount":99},[8315],{"nctId":394,"briefTitle":395,"status":332,"phases":8316,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":8317,"interventions":8318},[88],[18],[343,403],{"trials":8320,"activeCount":99},[],{"trials":8322,"activeCount":99},[],{"trials":8324,"activeCount":99},[],{"intervention":8326,"totalTrials":95,"cells":8327},"nesiritide, continuous",{"EARLY_PHASE1":8328,"PHASE1":8330,"PHASE2":8332,"PHASE3":8340,"PHASE4":8342,"NA":8344},{"trials":8329,"activeCount":99},[],{"trials":8331,"activeCount":99},[],{"trials":8333,"activeCount":99},[8334],{"nctId":8335,"briefTitle":8336,"status":363,"phases":8337,"primaryCompletion":1709,"completion":1709,"start":1484,"enrollment":516,"conditions":8338,"interventions":8339},"NCT00145873","Nesiritide in Chronic Heart Failure",[88],[4502],[8326],{"trials":8341,"activeCount":99},[],{"trials":8343,"activeCount":99},[],{"trials":8345,"activeCount":99},[],{"intervention":5029,"totalTrials":95,"cells":8347},{"EARLY_PHASE1":8348,"PHASE1":8350,"PHASE2":8352,"PHASE3":8358,"PHASE4":8360,"NA":8362},{"trials":8349,"activeCount":99},[],{"trials":8351,"activeCount":99},[],{"trials":8353,"activeCount":99},[8354],{"nctId":5020,"briefTitle":5021,"status":981,"phases":8355,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":99,"conditions":8356,"interventions":8357},[88],[5026,5027],[5029,5030,5011],{"trials":8359,"activeCount":99},[],{"trials":8361,"activeCount":99},[],{"trials":8363,"activeCount":99},[],{"intervention":5030,"totalTrials":95,"cells":8365},{"EARLY_PHASE1":8366,"PHASE1":8368,"PHASE2":8370,"PHASE3":8376,"PHASE4":8378,"NA":8380},{"trials":8367,"activeCount":99},[],{"trials":8369,"activeCount":99},[],{"trials":8371,"activeCount":99},[8372],{"nctId":5020,"briefTitle":5021,"status":981,"phases":8373,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":99,"conditions":8374,"interventions":8375},[88],[5026,5027],[5029,5030,5011],{"trials":8377,"activeCount":99},[],{"trials":8379,"activeCount":99},[],{"trials":8381,"activeCount":99},[],{"intervention":1742,"totalTrials":95,"cells":8383},{"EARLY_PHASE1":8384,"PHASE1":8386,"PHASE2":8388,"PHASE3":8394,"PHASE4":8396,"NA":8398},{"trials":8385,"activeCount":99},[],{"trials":8387,"activeCount":99},[],{"trials":8389,"activeCount":99},[8390],{"nctId":1732,"briefTitle":1733,"status":332,"phases":8391,"primaryCompletion":1735,"completion":1736,"start":1737,"enrollment":1738,"conditions":8392,"interventions":8393},[88],[1740],[388,1742,387],{"trials":8395,"activeCount":99},[],{"trials":8397,"activeCount":99},[],{"trials":8399,"activeCount":99},[],{"intervention":8401,"totalTrials":95,"cells":8402},"cyclosporine",{"EARLY_PHASE1":8403,"PHASE1":8405,"PHASE2":8407,"PHASE3":8418,"PHASE4":8420,"NA":8422},{"trials":8404,"activeCount":99},[],{"trials":8406,"activeCount":99},[],{"trials":8408,"activeCount":99},[8409],{"nctId":8410,"briefTitle":8411,"status":332,"phases":8412,"primaryCompletion":8413,"completion":7016,"start":8414,"enrollment":30,"conditions":8415,"interventions":8416},"NCT00003950","Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer",[88],"2001-12","2000-01",[3342],[8401,8417],"CPT-11",{"trials":8419,"activeCount":99},[],{"trials":8421,"activeCount":99},[],{"trials":8423,"activeCount":99},[],{"intervention":8417,"totalTrials":95,"cells":8425},{"EARLY_PHASE1":8426,"PHASE1":8428,"PHASE2":8430,"PHASE3":8436,"PHASE4":8438,"NA":8440},{"trials":8427,"activeCount":99},[],{"trials":8429,"activeCount":99},[],{"trials":8431,"activeCount":99},[8432],{"nctId":8410,"briefTitle":8411,"status":332,"phases":8433,"primaryCompletion":8413,"completion":7016,"start":8414,"enrollment":30,"conditions":8434,"interventions":8435},[88],[3342],[8401,8417],{"trials":8437,"activeCount":99},[],{"trials":8439,"activeCount":99},[],{"trials":8441,"activeCount":99},[],{"intervention":8443,"totalTrials":95,"cells":8444},"Duloxetine",{"EARLY_PHASE1":8445,"PHASE1":8447,"PHASE2":8449,"PHASE3":8461,"PHASE4":8463,"NA":8465},{"trials":8446,"activeCount":99},[],{"trials":8448,"activeCount":99},[],{"trials":8450,"activeCount":99},[8451],{"nctId":8452,"briefTitle":8453,"status":981,"phases":8454,"primaryCompletion":8455,"completion":8455,"start":8456,"enrollment":99,"conditions":8457,"interventions":8458},"NCT02857244","A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients",[88],"2017-11","2016-11",[6334],[8443,8459,8460],"Donepezil","Modafinil",{"trials":8462,"activeCount":99},[],{"trials":8464,"activeCount":99},[],{"trials":8466,"activeCount":99},[],{"intervention":8459,"totalTrials":95,"cells":8468},{"EARLY_PHASE1":8469,"PHASE1":8471,"PHASE2":8473,"PHASE3":8479,"PHASE4":8481,"NA":8483},{"trials":8470,"activeCount":99},[],{"trials":8472,"activeCount":99},[],{"trials":8474,"activeCount":99},[8475],{"nctId":8452,"briefTitle":8453,"status":981,"phases":8476,"primaryCompletion":8455,"completion":8455,"start":8456,"enrollment":99,"conditions":8477,"interventions":8478},[88],[6334],[8443,8459,8460],{"trials":8480,"activeCount":99},[],{"trials":8482,"activeCount":99},[],{"trials":8484,"activeCount":99},[],{"intervention":8460,"totalTrials":95,"cells":8486},{"EARLY_PHASE1":8487,"PHASE1":8489,"PHASE2":8491,"PHASE3":8497,"PHASE4":8499,"NA":8501},{"trials":8488,"activeCount":99},[],{"trials":8490,"activeCount":99},[],{"trials":8492,"activeCount":99},[8493],{"nctId":8452,"briefTitle":8453,"status":981,"phases":8494,"primaryCompletion":8455,"completion":8455,"start":8456,"enrollment":99,"conditions":8495,"interventions":8496},[88],[6334],[8443,8459,8460],{"trials":8498,"activeCount":99},[],{"trials":8500,"activeCount":99},[],{"trials":8502,"activeCount":99},[],{"intervention":1755,"totalTrials":95,"cells":8504},{"EARLY_PHASE1":8505,"PHASE1":8507,"PHASE2":8509,"PHASE3":8515,"PHASE4":8517,"NA":8519},{"trials":8506,"activeCount":99},[],{"trials":8508,"activeCount":99},[],{"trials":8510,"activeCount":99},[8511],{"nctId":1748,"briefTitle":1749,"status":332,"phases":8512,"primaryCompletion":515,"completion":1751,"start":1752,"enrollment":421,"conditions":8513,"interventions":8514},[88],[1005],[387,1755,1756],{"trials":8516,"activeCount":99},[],{"trials":8518,"activeCount":99},[],{"trials":8520,"activeCount":99},[],{"intervention":1756,"totalTrials":95,"cells":8522},{"EARLY_PHASE1":8523,"PHASE1":8525,"PHASE2":8527,"PHASE3":8533,"PHASE4":8535,"NA":8537},{"trials":8524,"activeCount":99},[],{"trials":8526,"activeCount":99},[],{"trials":8528,"activeCount":99},[8529],{"nctId":1748,"briefTitle":1749,"status":332,"phases":8530,"primaryCompletion":515,"completion":1751,"start":1752,"enrollment":421,"conditions":8531,"interventions":8532},[88],[1005],[387,1755,1756],{"trials":8534,"activeCount":99},[],{"trials":8536,"activeCount":99},[],{"trials":8538,"activeCount":99},[],{"intervention":1505,"totalTrials":95,"cells":8540},{"EARLY_PHASE1":8541,"PHASE1":8543,"PHASE2":8545,"PHASE3":8551,"PHASE4":8553,"NA":8555},{"trials":8542,"activeCount":99},[],{"trials":8544,"activeCount":99},[],{"trials":8546,"activeCount":99},[8547],{"nctId":1498,"briefTitle":1499,"status":332,"phases":8548,"primaryCompletion":397,"completion":1501,"start":1502,"enrollment":312,"conditions":8549,"interventions":8550},[88],[1305],[1505,1307],{"trials":8552,"activeCount":99},[],{"trials":8554,"activeCount":99},[],{"trials":8556,"activeCount":99},[],{"intervention":8558,"totalTrials":95,"cells":8559},"Escitalopram",{"EARLY_PHASE1":8560,"PHASE1":8562,"PHASE2":8564,"PHASE3":8573,"PHASE4":8575,"NA":8577},{"trials":8561,"activeCount":99},[],{"trials":8563,"activeCount":99},[],{"trials":8565,"activeCount":99},[8566],{"nctId":8567,"briefTitle":8568,"status":363,"phases":8569,"primaryCompletion":8570,"completion":8570,"start":6396,"enrollment":1114,"conditions":8571,"interventions":8572},"NCT01103180","Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder",[88],"2014-11",[8221],[8558],{"trials":8574,"activeCount":99},[],{"trials":8576,"activeCount":99},[],{"trials":8578,"activeCount":99},[],{"intervention":6525,"totalTrials":95,"cells":8580},{"EARLY_PHASE1":8581,"PHASE1":8583,"PHASE2":8585,"PHASE3":8591,"PHASE4":8593,"NA":8595},{"trials":8582,"activeCount":99},[],{"trials":8584,"activeCount":99},[],{"trials":8586,"activeCount":99},[8587],{"nctId":6519,"briefTitle":6520,"status":363,"phases":8588,"primaryCompletion":6237,"completion":838,"start":4801,"enrollment":95,"conditions":8589,"interventions":8590},[88],[6523],[6464,6490,6525,6526,6527],{"trials":8592,"activeCount":99},[],{"trials":8594,"activeCount":99},[],{"trials":8596,"activeCount":99},[],{"intervention":6527,"totalTrials":95,"cells":8598},{"EARLY_PHASE1":8599,"PHASE1":8601,"PHASE2":8603,"PHASE3":8609,"PHASE4":8611,"NA":8613},{"trials":8600,"activeCount":99},[],{"trials":8602,"activeCount":99},[],{"trials":8604,"activeCount":99},[8605],{"nctId":6519,"briefTitle":6520,"status":363,"phases":8606,"primaryCompletion":6237,"completion":838,"start":4801,"enrollment":95,"conditions":8607,"interventions":8608},[88],[6523],[6464,6490,6525,6526,6527],{"trials":8610,"activeCount":99},[],{"trials":8612,"activeCount":99},[],{"trials":8614,"activeCount":99},[],{"intervention":684,"totalTrials":95,"cells":8616},{"EARLY_PHASE1":8617,"PHASE1":8619,"PHASE2":8621,"PHASE3":8627,"PHASE4":8629,"NA":8631},{"trials":8618,"activeCount":99},[],{"trials":8620,"activeCount":99},[],{"trials":8622,"activeCount":99},[8623],{"nctId":601,"briefTitle":602,"status":332,"phases":8624,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":8625,"interventions":8626},[87,88],[609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680],[439,682,683,684,685,686,687],{"trials":8628,"activeCount":99},[],{"trials":8630,"activeCount":99},[],{"trials":8632,"activeCount":99},[],{"intervention":685,"totalTrials":95,"cells":8634},{"EARLY_PHASE1":8635,"PHASE1":8637,"PHASE2":8639,"PHASE3":8645,"PHASE4":8647,"NA":8649},{"trials":8636,"activeCount":99},[],{"trials":8638,"activeCount":99},[],{"trials":8640,"activeCount":99},[8641],{"nctId":601,"briefTitle":602,"status":332,"phases":8642,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":8643,"interventions":8644},[87,88],[609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680],[439,682,683,684,685,686,687],{"trials":8646,"activeCount":99},[],{"trials":8648,"activeCount":99},[],{"trials":8650,"activeCount":99},[],{"intervention":8652,"totalTrials":95,"cells":8653},"topotecan hydrochloride",{"EARLY_PHASE1":8654,"PHASE1":8656,"PHASE2":8658,"PHASE3":8671,"PHASE4":8673,"NA":8675},{"trials":8655,"activeCount":99},[],{"trials":8657,"activeCount":99},[],{"trials":8659,"activeCount":99},[8660],{"nctId":8661,"briefTitle":8662,"status":363,"phases":8663,"primaryCompletion":5225,"completion":8664,"start":8665,"enrollment":2146,"conditions":8666,"interventions":8669},"NCT01803269","Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer",[88],"2016-03-30","2013-01-16",[8667,8668],"Extensive Stage Small Cell Lung Cancer","Recurrent Small Cell Lung Cancer",[8652,8670],"cyclodextrin-based polymer-camptothecin CRLX101",{"trials":8672,"activeCount":99},[],{"trials":8674,"activeCount":99},[],{"trials":8676,"activeCount":99},[],{"intervention":8670,"totalTrials":95,"cells":8678},{"EARLY_PHASE1":8679,"PHASE1":8681,"PHASE2":8683,"PHASE3":8689,"PHASE4":8691,"NA":8693},{"trials":8680,"activeCount":99},[],{"trials":8682,"activeCount":99},[],{"trials":8684,"activeCount":99},[8685],{"nctId":8661,"briefTitle":8662,"status":363,"phases":8686,"primaryCompletion":5225,"completion":8664,"start":8665,"enrollment":2146,"conditions":8687,"interventions":8688},[88],[8667,8668],[8652,8670],{"trials":8690,"activeCount":99},[],{"trials":8692,"activeCount":99},[],{"trials":8694,"activeCount":99},[],{"intervention":8696,"totalTrials":95,"cells":8697},"irofulven",{"EARLY_PHASE1":8698,"PHASE1":8700,"PHASE2":8702,"PHASE3":8711,"PHASE4":8713,"NA":8715},{"trials":8699,"activeCount":99},[],{"trials":8701,"activeCount":99},[],{"trials":8703,"activeCount":99},[8704],{"nctId":8705,"briefTitle":8706,"status":981,"phases":8707,"primaryCompletion":1429,"completion":1429,"start":8708,"enrollment":99,"conditions":8709,"interventions":8710},"NCT00003786","Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer",[88],"1999-04",[3342],[8696],{"trials":8712,"activeCount":99},[],{"trials":8714,"activeCount":99},[],{"trials":8716,"activeCount":99},[],{"intervention":8718,"totalTrials":95,"cells":8719},"metformin hydrochloride",{"EARLY_PHASE1":8720,"PHASE1":8722,"PHASE2":8724,"PHASE3":8762,"PHASE4":8764,"NA":8766},{"trials":8721,"activeCount":99},[],{"trials":8723,"activeCount":99},[],{"trials":8725,"activeCount":99},[8726],{"nctId":8727,"briefTitle":8728,"status":332,"phases":8729,"primaryCompletion":8730,"completion":8731,"start":8732,"enrollment":8733,"conditions":8734,"interventions":8760},"NCT02122185","Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[88],"2022-10-27","2024-10-08","2015-02-25",111,[8735,8736,8737,8738,8739,8740,8741,8742,1181,1182,8743,1183,8744,8745,8746,8747,8748,8749,8750,8751,8752,8753,8754,8755,8756,8757,8758,8759],"Brenner Tumor","Malignant Ascites","Malignant Pleural Effusion","Ovarian Clear Cell Cystadenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Mixed Epithelial Carcinoma","Ovarian Serous Cystadenocarcinoma","Ovarian Undifferentiated Adenocarcinoma","Recurrent Ovarian Germ Cell Tumor","Stage IIIA Fallopian Tube Cancer","Stage IIIA Ovarian Epithelial Cancer","Stage IIIA Ovarian Germ Cell Tumor","Stage IIIA Primary Peritoneal Cavity Cancer","Stage IIIB Fallopian Tube Cancer","Stage IIIB Ovarian Epithelial Cancer","Stage IIIB Ovarian Germ Cell Tumor","Stage IIIB Primary Peritoneal Cavity Cancer","Stage IIIC Fallopian Tube Cancer","Stage IIIC Ovarian Epithelial Cancer","Stage IIIC Ovarian Germ Cell Tumor","Stage IIIC Primary Peritoneal Cavity Cancer","Stage IV Fallopian Tube Cancer","Stage IV Ovarian Epithelial Cancer","Stage IV Ovarian Germ Cell Tumor","Stage IV Primary Peritoneal Cavity Cancer",[8718,8761],"Chemotherapy",{"trials":8763,"activeCount":99},[],{"trials":8765,"activeCount":99},[],{"trials":8767,"activeCount":99},[],{"intervention":8761,"totalTrials":95,"cells":8769},{"EARLY_PHASE1":8770,"PHASE1":8772,"PHASE2":8774,"PHASE3":8780,"PHASE4":8782,"NA":8784},{"trials":8771,"activeCount":99},[],{"trials":8773,"activeCount":99},[],{"trials":8775,"activeCount":99},[8776],{"nctId":8727,"briefTitle":8728,"status":332,"phases":8777,"primaryCompletion":8730,"completion":8731,"start":8732,"enrollment":8733,"conditions":8778,"interventions":8779},[88],[8735,8736,8737,8738,8739,8740,8741,8742,1181,1182,8743,1183,8744,8745,8746,8747,8748,8749,8750,8751,8752,8753,8754,8755,8756,8757,8758,8759],[8718,8761],{"trials":8781,"activeCount":99},[],{"trials":8783,"activeCount":99},[],{"trials":8785,"activeCount":99},[],{"intervention":8787,"totalTrials":95,"cells":8788},"Fluticasone",{"EARLY_PHASE1":8789,"PHASE1":8791,"PHASE2":8793,"PHASE3":8802,"PHASE4":8804,"NA":8806},{"trials":8790,"activeCount":99},[],{"trials":8792,"activeCount":99},[],{"trials":8794,"activeCount":99},[8795],{"nctId":8796,"briefTitle":8797,"status":981,"phases":8798,"primaryCompletion":6237,"completion":6237,"start":6281,"enrollment":99,"conditions":8799,"interventions":8801},"NCT00695604","Repeated High-dose Inhaled Corticosteroids for Asthma",[88],[8800],"Asthma",[8787],{"trials":8803,"activeCount":99},[],{"trials":8805,"activeCount":99},[],{"trials":8807,"activeCount":99},[],{"intervention":8809,"totalTrials":95,"cells":8810},"Cetuximab and Lenalidomide",{"EARLY_PHASE1":8811,"PHASE1":8813,"PHASE2":8815,"PHASE3":8823,"PHASE4":8825,"NA":8827},{"trials":8812,"activeCount":99},[],{"trials":8814,"activeCount":99},[],{"trials":8816,"activeCount":99},[8817],{"nctId":8818,"briefTitle":8819,"status":332,"phases":8820,"primaryCompletion":814,"completion":1726,"start":5024,"enrollment":459,"conditions":8821,"interventions":8822},"NCT01133665","Cetuximab and Lenalidomide in Head and Neck",[88],[1241],[8809],{"trials":8824,"activeCount":99},[],{"trials":8826,"activeCount":99},[],{"trials":8828,"activeCount":99},[],{"intervention":8830,"totalTrials":95,"cells":8831},"Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy",{"EARLY_PHASE1":8832,"PHASE1":8834,"PHASE2":8836,"PHASE3":8847,"PHASE4":8849,"NA":8851},{"trials":8833,"activeCount":99},[],{"trials":8835,"activeCount":99},[],{"trials":8837,"activeCount":99},[8838],{"nctId":8839,"briefTitle":8840,"status":981,"phases":8841,"primaryCompletion":8842,"completion":8842,"start":3508,"enrollment":99,"conditions":8843,"interventions":8846},"NCT05610826","Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver",[87,88],"2024-09-11",[8844,8845],"Pancreatic Neuroendocrine Tumor","Pancreas Cancer",[8830],{"trials":8848,"activeCount":99},[],{"trials":8850,"activeCount":99},[],{"trials":8852,"activeCount":99},[],{"intervention":8854,"totalTrials":95,"cells":8855},"Vilazodone",{"EARLY_PHASE1":8856,"PHASE1":8858,"PHASE2":8860,"PHASE3":8869,"PHASE4":8871,"NA":8873},{"trials":8857,"activeCount":99},[],{"trials":8859,"activeCount":99},[],{"trials":8861,"activeCount":99},[8862],{"nctId":8863,"briefTitle":8864,"status":332,"phases":8865,"primaryCompletion":5225,"completion":5225,"start":3369,"enrollment":3467,"conditions":8866,"interventions":8867},"NCT01742832","Double-Blind Treatment of Major Depressive Disorder With Vilazodone",[88],[4363],[8854,8868],"Citalopram",{"trials":8870,"activeCount":99},[],{"trials":8872,"activeCount":99},[],{"trials":8874,"activeCount":99},[],{"intervention":8868,"totalTrials":95,"cells":8876},{"EARLY_PHASE1":8877,"PHASE1":8879,"PHASE2":8881,"PHASE3":8887,"PHASE4":8889,"NA":8891},{"trials":8878,"activeCount":99},[],{"trials":8880,"activeCount":99},[],{"trials":8882,"activeCount":99},[8883],{"nctId":8863,"briefTitle":8864,"status":332,"phases":8884,"primaryCompletion":5225,"completion":5225,"start":3369,"enrollment":3467,"conditions":8885,"interventions":8886},[88],[4363],[8854,8868],{"trials":8888,"activeCount":99},[],{"trials":8890,"activeCount":99},[],{"trials":8892,"activeCount":99},[],{"intervention":8894,"totalTrials":95,"cells":8895},"sildenafil",{"EARLY_PHASE1":8896,"PHASE1":8898,"PHASE2":8900,"PHASE3":8908,"PHASE4":8910,"NA":8912},{"trials":8897,"activeCount":99},[],{"trials":8899,"activeCount":99},[],{"trials":8901,"activeCount":99},[8902],{"nctId":8903,"briefTitle":8904,"status":363,"phases":8905,"primaryCompletion":1709,"completion":1709,"start":1735,"enrollment":732,"conditions":8906,"interventions":8907},"NCT00145938","Sildenafil and Pulmonary Artery Pressure",[88],[5421],[8894],{"trials":8909,"activeCount":99},[],{"trials":8911,"activeCount":99},[],{"trials":8913,"activeCount":99},[],{"intervention":8915,"totalTrials":95,"cells":8916},"N Acetyl Cysteine",{"EARLY_PHASE1":8917,"PHASE1":8919,"PHASE2":8921,"PHASE3":8930,"PHASE4":8932,"NA":8934},{"trials":8918,"activeCount":99},[],{"trials":8920,"activeCount":99},[],{"trials":8922,"activeCount":99},[8923],{"nctId":8924,"briefTitle":8925,"status":332,"phases":8926,"primaryCompletion":6907,"completion":5067,"start":4991,"enrollment":6652,"conditions":8927,"interventions":8929},"NCT00967005","N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers",[88],[6184,8928],"Tobacco Use Disorder",[8915],{"trials":8931,"activeCount":99},[],{"trials":8933,"activeCount":99},[],{"trials":8935,"activeCount":99},[],{"intervention":8937,"totalTrials":95,"cells":8938},"5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab",{"EARLY_PHASE1":8939,"PHASE1":8941,"PHASE2":8943,"PHASE3":8954,"PHASE4":8956,"NA":8958},{"trials":8940,"activeCount":99},[],{"trials":8942,"activeCount":99},[],{"trials":8944,"activeCount":99},[8945],{"nctId":8946,"briefTitle":8947,"status":332,"phases":8948,"primaryCompletion":8949,"completion":3357,"start":8950,"enrollment":7399,"conditions":8951,"interventions":8952},"NCT00203905","A Study of Chemoradiotherapy for Intermediate Stage\u002FSelected Stage IV Cancers of the Head and Neck",[88],"2007-11","2004-01",[21],[8937,8953],"5-Fluorouracil, Hydroxyurea-[FHX]",{"trials":8955,"activeCount":99},[],{"trials":8957,"activeCount":99},[],{"trials":8959,"activeCount":99},[],{"intervention":8953,"totalTrials":95,"cells":8961},{"EARLY_PHASE1":8962,"PHASE1":8964,"PHASE2":8966,"PHASE3":8972,"PHASE4":8974,"NA":8976},{"trials":8963,"activeCount":99},[],{"trials":8965,"activeCount":99},[],{"trials":8967,"activeCount":99},[8968],{"nctId":8946,"briefTitle":8947,"status":332,"phases":8969,"primaryCompletion":8949,"completion":3357,"start":8950,"enrollment":7399,"conditions":8970,"interventions":8971},[88],[21],[8937,8953],{"trials":8973,"activeCount":99},[],{"trials":8975,"activeCount":99},[],{"trials":8977,"activeCount":99},[],{"intervention":8979,"totalTrials":95,"cells":8980},"depsipeptide",{"EARLY_PHASE1":8981,"PHASE1":8983,"PHASE2":8985,"PHASE3":8994,"PHASE4":8996,"NA":8998},{"trials":8982,"activeCount":99},[],{"trials":8984,"activeCount":99},[],{"trials":8986,"activeCount":99},[8987],{"nctId":8988,"briefTitle":8989,"status":981,"phases":8990,"primaryCompletion":8991,"completion":8991,"start":6271,"enrollment":99,"conditions":8992,"interventions":8993},"NCT00085527","FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer",[88],"2005-09",[518],[8979],{"trials":8995,"activeCount":99},[],{"trials":8997,"activeCount":99},[],{"trials":8999,"activeCount":99},[],{"intervention":9001,"totalTrials":95,"cells":9002},"Rexulti",{"EARLY_PHASE1":9003,"PHASE1":9005,"PHASE2":9007,"PHASE3":9018,"PHASE4":9020,"NA":9022},{"trials":9004,"activeCount":99},[],{"trials":9006,"activeCount":99},[],{"trials":9008,"activeCount":99},[9009],{"nctId":9010,"briefTitle":9011,"status":332,"phases":9012,"primaryCompletion":9013,"completion":9014,"start":9015,"enrollment":249,"conditions":9016,"interventions":9017},"NCT03418675","Brexpiprazole in Borderline Personality Disorder",[88],"2020-12-30","2021-04-14","2018-11-26",[8221],[9001],{"trials":9019,"activeCount":99},[],{"trials":9021,"activeCount":99},[],{"trials":9023,"activeCount":99},[],{"intervention":7198,"totalTrials":95,"cells":9025},{"EARLY_PHASE1":9026,"PHASE1":9028,"PHASE2":9030,"PHASE3":9036,"PHASE4":9038,"NA":9040},{"trials":9027,"activeCount":99},[],{"trials":9029,"activeCount":99},[],{"trials":9031,"activeCount":99},[9032],{"nctId":7191,"briefTitle":7192,"status":332,"phases":9033,"primaryCompletion":7194,"completion":7194,"start":7195,"enrollment":732,"conditions":9034,"interventions":9035},[88],[26,23],[7198,7173,7189,7199],{"trials":9037,"activeCount":99},[],{"trials":9039,"activeCount":99},[],{"trials":9041,"activeCount":99},[],{"intervention":7199,"totalTrials":95,"cells":9043},{"EARLY_PHASE1":9044,"PHASE1":9046,"PHASE2":9048,"PHASE3":9054,"PHASE4":9056,"NA":9058},{"trials":9045,"activeCount":99},[],{"trials":9047,"activeCount":99},[],{"trials":9049,"activeCount":99},[9050],{"nctId":7191,"briefTitle":7192,"status":332,"phases":9051,"primaryCompletion":7194,"completion":7194,"start":7195,"enrollment":732,"conditions":9052,"interventions":9053},[88],[26,23],[7198,7173,7189,7199],{"trials":9055,"activeCount":99},[],{"trials":9057,"activeCount":99},[],{"trials":9059,"activeCount":99},[],{"intervention":9061,"totalTrials":95,"cells":9062},"MAGE-3\u002FMelan-A\u002Fgp100\u002FNA PBMC, rhIL-12",{"EARLY_PHASE1":9063,"PHASE1":9065,"PHASE2":9067,"PHASE3":9078,"PHASE4":9080,"NA":9082},{"trials":9064,"activeCount":99},[],{"trials":9066,"activeCount":99},[],{"trials":9068,"activeCount":99},[9069],{"nctId":9070,"briefTitle":9071,"status":332,"phases":9072,"primaryCompletion":9073,"completion":537,"start":3589,"enrollment":2075,"conditions":9074,"interventions":9076},"NCT00203879","Study of MAGE-3\u002FMelan-A\u002Fgp 100\u002FNA17 and rhIL-12 With\u002FOut Low Dose IL-2 in Metastatic Melanoma",[88],"2006-05",[9075],"Metastatic Melanoma",[9061,9077],"MAGE-3\u002FMelan-A\u002Fgp100\u002FNA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2",{"trials":9079,"activeCount":99},[],{"trials":9081,"activeCount":99},[],{"trials":9083,"activeCount":99},[],{"intervention":9077,"totalTrials":95,"cells":9085},{"EARLY_PHASE1":9086,"PHASE1":9088,"PHASE2":9090,"PHASE3":9096,"PHASE4":9098,"NA":9100},{"trials":9087,"activeCount":99},[],{"trials":9089,"activeCount":99},[],{"trials":9091,"activeCount":99},[9092],{"nctId":9070,"briefTitle":9071,"status":332,"phases":9093,"primaryCompletion":9073,"completion":537,"start":3589,"enrollment":2075,"conditions":9094,"interventions":9095},[88],[9075],[9061,9077],{"trials":9097,"activeCount":99},[],{"trials":9099,"activeCount":99},[],{"trials":9101,"activeCount":99},[],{"intervention":424,"totalTrials":95,"cells":9103},{"EARLY_PHASE1":9104,"PHASE1":9106,"PHASE2":9108,"PHASE3":9114,"PHASE4":9116,"NA":9118},{"trials":9105,"activeCount":99},[],{"trials":9107,"activeCount":99},[],{"trials":9109,"activeCount":99},[9110],{"nctId":415,"briefTitle":416,"status":332,"phases":9111,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":9112,"interventions":9113},[88],[354],[424,358,425,299],{"trials":9115,"activeCount":99},[],{"trials":9117,"activeCount":99},[],{"trials":9119,"activeCount":99},[],{"intervention":6543,"totalTrials":95,"cells":9121},{"EARLY_PHASE1":9122,"PHASE1":9124,"PHASE2":9126,"PHASE3":9132,"PHASE4":9134,"NA":9136},{"trials":9123,"activeCount":99},[],{"trials":9125,"activeCount":99},[],{"trials":9127,"activeCount":99},[9128],{"nctId":6529,"briefTitle":6530,"status":332,"phases":9129,"primaryCompletion":524,"completion":524,"start":1303,"enrollment":6532,"conditions":9130,"interventions":9131},[88],[6534,6535,6536,6537,6538,6539,6540,6541,929],[6490,6464,6543,6491],{"trials":9133,"activeCount":99},[],{"trials":9135,"activeCount":99},[],{"trials":9137,"activeCount":99},[],{"intervention":9139,"totalTrials":95,"cells":9140},"vandetanib",{"EARLY_PHASE1":9141,"PHASE1":9143,"PHASE2":9145,"PHASE3":9157,"PHASE4":9159,"NA":9161},{"trials":9142,"activeCount":99},[],{"trials":9144,"activeCount":99},[],{"trials":9146,"activeCount":99},[9147],{"nctId":9148,"briefTitle":9149,"status":332,"phases":9150,"primaryCompletion":9151,"completion":4604,"start":6205,"enrollment":516,"conditions":9152,"interventions":9156},"NCT01414426","Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions",[88],"2019-01-01",[9153,9154,9155],"Lip and Oral Cavity Squamous Cell Carcinoma","Oral Cavity Verrucous Carcinoma","Precancerous Condition",[9139],{"trials":9158,"activeCount":99},[],{"trials":9160,"activeCount":99},[],{"trials":9162,"activeCount":99},[],{"intervention":9164,"totalTrials":95,"cells":9165},"Telotristat Ethyl Oral",{"EARLY_PHASE1":9166,"PHASE1":9168,"PHASE2":9170,"PHASE3":9182,"PHASE4":9184,"NA":9186},{"trials":9167,"activeCount":99},[],{"trials":9169,"activeCount":99},[],{"trials":9171,"activeCount":99},[9172],{"nctId":9173,"briefTitle":9174,"status":981,"phases":9175,"primaryCompletion":9176,"completion":9177,"start":9178,"enrollment":99,"conditions":9179,"interventions":9181},"NCT04672876","Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors",[88],"2022-10-01","2023-10-01","2022-01",[9180],"Neuroendocrine Tumors",[9164],{"trials":9183,"activeCount":99},[],{"trials":9185,"activeCount":99},[],{"trials":9187,"activeCount":99},[],{"intervention":9189,"totalTrials":95,"cells":9190},"afatinib dimaleate",{"EARLY_PHASE1":9191,"PHASE1":9193,"PHASE2":9195,"PHASE3":9214,"PHASE4":9216,"NA":9218},{"trials":9192,"activeCount":99},[],{"trials":9194,"activeCount":99},[],{"trials":9196,"activeCount":99},[9197],{"nctId":9198,"briefTitle":9199,"status":363,"phases":9200,"primaryCompletion":9201,"completion":9201,"start":9202,"enrollment":2178,"conditions":9203,"interventions":9213},"NCT02122172","Afatinib in Advanced Refractory Urothelial Cancer",[88],"2024-04-04","2017-09-13",[9204,9205,9206,9207,9208,9209,9210,9211,9212],"Distal Urethral Cancer","Proximal Urethral Cancer","Recurrent Bladder Cancer","Recurrent Urethral Cancer","Stage III Bladder Cancer","Stage III Urethral Cancer","Stage IV Bladder Cancer","Stage IV Urethral Cancer","Ureter Cancer",[9189],{"trials":9215,"activeCount":99},[],{"trials":9217,"activeCount":99},[],{"trials":9219,"activeCount":99},[],{"intervention":1521,"totalTrials":95,"cells":9221},{"EARLY_PHASE1":9222,"PHASE1":9224,"PHASE2":9226,"PHASE3":9232,"PHASE4":9234,"NA":9236},{"trials":9223,"activeCount":99},[],{"trials":9225,"activeCount":99},[],{"trials":9227,"activeCount":99},[9228],{"nctId":1515,"briefTitle":1516,"status":332,"phases":9229,"primaryCompletion":1483,"completion":1518,"start":1502,"enrollment":35,"conditions":9230,"interventions":9231},[87,88],[1305],[1521,1307],{"trials":9233,"activeCount":99},[],{"trials":9235,"activeCount":99},[],{"trials":9237,"activeCount":99},[],{"intervention":9239,"totalTrials":95,"cells":9240},"Inositol",{"EARLY_PHASE1":9241,"PHASE1":9243,"PHASE2":9245,"PHASE3":9253,"PHASE4":9255,"NA":9257},{"trials":9242,"activeCount":99},[],{"trials":9244,"activeCount":99},[],{"trials":9246,"activeCount":99},[9247],{"nctId":9248,"briefTitle":9249,"status":332,"phases":9250,"primaryCompletion":1537,"completion":1537,"start":3369,"enrollment":1358,"conditions":9251,"interventions":9252},"NCT01875445","Inositol in Trichotillomania",[88],[735,737],[9239],{"trials":9254,"activeCount":99},[],{"trials":9256,"activeCount":99},[],{"trials":9258,"activeCount":99},[],{"intervention":9260,"totalTrials":95,"cells":9261},"4-peptide melanoma vaccine",{"EARLY_PHASE1":9262,"PHASE1":9264,"PHASE2":9266,"PHASE3":9276,"PHASE4":9278,"NA":9280},{"trials":9263,"activeCount":99},[],{"trials":9265,"activeCount":99},[],{"trials":9267,"activeCount":99},[9268],{"nctId":9269,"briefTitle":9270,"status":363,"phases":9271,"primaryCompletion":5225,"completion":5225,"start":9272,"enrollment":27,"conditions":9273,"interventions":9274},"NCT00515528","Vaccination Plus Ontak in Patients With Metastatic Melanoma",[88],"2007-04-23",[1006],[9260,9275],"Ontak",{"trials":9277,"activeCount":99},[],{"trials":9279,"activeCount":99},[],{"trials":9281,"activeCount":99},[],{"intervention":9275,"totalTrials":95,"cells":9283},{"EARLY_PHASE1":9284,"PHASE1":9286,"PHASE2":9288,"PHASE3":9294,"PHASE4":9296,"NA":9298},{"trials":9285,"activeCount":99},[],{"trials":9287,"activeCount":99},[],{"trials":9289,"activeCount":99},[9290],{"nctId":9269,"briefTitle":9270,"status":363,"phases":9291,"primaryCompletion":5225,"completion":5225,"start":9272,"enrollment":27,"conditions":9292,"interventions":9293},[88],[1006],[9260,9275],{"trials":9295,"activeCount":99},[],{"trials":9297,"activeCount":99},[],{"trials":9299,"activeCount":99},[],{"intervention":7029,"totalTrials":95,"cells":9301},{"EARLY_PHASE1":9302,"PHASE1":9304,"PHASE2":9306,"PHASE3":9312,"PHASE4":9314,"NA":9316},{"trials":9303,"activeCount":99},[],{"trials":9305,"activeCount":99},[],{"trials":9307,"activeCount":99},[9308],{"nctId":7022,"briefTitle":7023,"status":332,"phases":9309,"primaryCompletion":1568,"completion":7025,"start":7026,"enrollment":516,"conditions":9310,"interventions":9311},[87,88],[1005],[7029,7030,7004],{"trials":9313,"activeCount":99},[],{"trials":9315,"activeCount":99},[],{"trials":9317,"activeCount":99},[],{"intervention":7030,"totalTrials":95,"cells":9319},{"EARLY_PHASE1":9320,"PHASE1":9322,"PHASE2":9324,"PHASE3":9330,"PHASE4":9332,"NA":9334},{"trials":9321,"activeCount":99},[],{"trials":9323,"activeCount":99},[],{"trials":9325,"activeCount":99},[9326],{"nctId":7022,"briefTitle":7023,"status":332,"phases":9327,"primaryCompletion":1568,"completion":7025,"start":7026,"enrollment":516,"conditions":9328,"interventions":9329},[87,88],[1005],[7029,7030,7004],{"trials":9331,"activeCount":99},[],{"trials":9333,"activeCount":99},[],{"trials":9335,"activeCount":99},[],{"intervention":9337,"totalTrials":95,"cells":9338},"Gabapentin",{"EARLY_PHASE1":9339,"PHASE1":9341,"PHASE2":9343,"PHASE3":9352,"PHASE4":9354,"NA":9356},{"trials":9340,"activeCount":99},[],{"trials":9342,"activeCount":99},[],{"trials":9344,"activeCount":99},[9345],{"nctId":9346,"briefTitle":9347,"status":981,"phases":9348,"primaryCompletion":9349,"completion":9349,"start":1062,"enrollment":99,"conditions":9350,"interventions":9351},"NCT03423264","PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing",[88],"2022-11-08",[1295,381],[9337],{"trials":9353,"activeCount":99},[],{"trials":9355,"activeCount":99},[],{"trials":9357,"activeCount":99},[],{"intervention":9359,"totalTrials":95,"cells":9360},"Psilocybin",{"EARLY_PHASE1":9361,"PHASE1":9363,"PHASE2":9365,"PHASE3":9373,"PHASE4":9375,"NA":9377},{"trials":9362,"activeCount":99},[],{"trials":9364,"activeCount":99},[],{"trials":9366,"activeCount":99},[9367],{"nctId":9368,"briefTitle":9369,"status":332,"phases":9370,"primaryCompletion":419,"completion":419,"start":1237,"enrollment":2118,"conditions":9371,"interventions":9372},"NCT05399498","Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder",[88],[8221,4363],[9359],{"trials":9374,"activeCount":99},[],{"trials":9376,"activeCount":99},[],{"trials":9378,"activeCount":99},[],{"intervention":9380,"totalTrials":95,"cells":9381},"Cipro, metronidazole, neomycin combo",{"EARLY_PHASE1":9382,"PHASE1":9384,"PHASE2":9386,"PHASE3":9398,"PHASE4":9400,"NA":9402},{"trials":9383,"activeCount":99},[],{"trials":9385,"activeCount":99},[],{"trials":9387,"activeCount":99},[9388],{"nctId":9389,"briefTitle":9390,"status":981,"phases":9391,"primaryCompletion":9392,"completion":9392,"start":9392,"enrollment":99,"conditions":9393,"interventions":9396},"NCT02682485","Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing",[88],"2017-03-03",[9394,9395],"Anastomotic Leak","Rectal Cancer",[9380,9397],"Saline",{"trials":9399,"activeCount":99},[],{"trials":9401,"activeCount":99},[],{"trials":9403,"activeCount":99},[],{"intervention":9397,"totalTrials":95,"cells":9405},{"EARLY_PHASE1":9406,"PHASE1":9408,"PHASE2":9410,"PHASE3":9416,"PHASE4":9418,"NA":9420},{"trials":9407,"activeCount":99},[],{"trials":9409,"activeCount":99},[],{"trials":9411,"activeCount":99},[9412],{"nctId":9389,"briefTitle":9390,"status":981,"phases":9413,"primaryCompletion":9392,"completion":9392,"start":9392,"enrollment":99,"conditions":9414,"interventions":9415},[88],[9394,9395],[9380,9397],{"trials":9417,"activeCount":99},[],{"trials":9419,"activeCount":99},[],{"trials":9421,"activeCount":99},[],{"intervention":9423,"totalTrials":95,"cells":9424},"combination of gemcitabine, capecitabine, and bevacizumab",{"EARLY_PHASE1":9425,"PHASE1":9427,"PHASE2":9429,"PHASE3":9437,"PHASE4":9439,"NA":9441},{"trials":9426,"activeCount":99},[],{"trials":9428,"activeCount":99},[],{"trials":9430,"activeCount":99},[9431],{"nctId":9432,"briefTitle":9433,"status":363,"phases":9434,"primaryCompletion":1225,"completion":1225,"start":3359,"enrollment":1085,"conditions":9435,"interventions":9436},"NCT00523640","A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma",[88],[7142],[9423],{"trials":9438,"activeCount":99},[],{"trials":9440,"activeCount":99},[],{"trials":9442,"activeCount":99},[],{"intervention":3395,"totalTrials":95,"cells":9444},{"EARLY_PHASE1":9445,"PHASE1":9447,"PHASE2":9449,"PHASE3":9455,"PHASE4":9457,"NA":9459},{"trials":9446,"activeCount":99},[],{"trials":9448,"activeCount":99},[],{"trials":9450,"activeCount":99},[9451],{"nctId":3364,"briefTitle":3365,"status":332,"phases":9452,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":35,"conditions":9453,"interventions":9454},[87,88],[3371,3372,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,3373,3374,3375,3376,3377,1321,3378,3379,3380,3381,3382,3383,1322,3384,3385,3386,3387,3388,3389,3390,3391,3392,3393,1165],[3395,3396],{"trials":9456,"activeCount":99},[],{"trials":9458,"activeCount":99},[],{"trials":9460,"activeCount":99},[],{"intervention":9462,"totalTrials":95,"cells":9463},"PS-341",{"EARLY_PHASE1":9464,"PHASE1":9466,"PHASE2":9468,"PHASE3":9476,"PHASE4":9478,"NA":9480},{"trials":9465,"activeCount":99},[],{"trials":9467,"activeCount":99},[],{"trials":9469,"activeCount":99},[9470],{"nctId":9471,"briefTitle":9472,"status":332,"phases":9473,"primaryCompletion":397,"completion":6512,"start":1268,"enrollment":7399,"conditions":9474,"interventions":9475},"NCT00025376","PS-341 in Treating Patients With Metastatic Kidney Cancer",[88],[2077],[9462],{"trials":9477,"activeCount":99},[],{"trials":9479,"activeCount":99},[],{"trials":9481,"activeCount":99},[],{"intervention":464,"totalTrials":95,"cells":9483},{"EARLY_PHASE1":9484,"PHASE1":9486,"PHASE2":9488,"PHASE3":9494,"PHASE4":9496,"NA":9498},{"trials":9485,"activeCount":99},[],{"trials":9487,"activeCount":99},[],{"trials":9489,"activeCount":99},[9490],{"nctId":453,"briefTitle":454,"status":332,"phases":9491,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":9492,"interventions":9493},[88],[461,462],[464,425,299],{"trials":9495,"activeCount":99},[],{"trials":9497,"activeCount":99},[],{"trials":9499,"activeCount":99},[],{"intervention":2093,"totalTrials":95,"cells":9501},{"EARLY_PHASE1":9502,"PHASE1":9504,"PHASE2":9506,"PHASE3":9512,"PHASE4":9514,"NA":9516},{"trials":9503,"activeCount":99},[],{"trials":9505,"activeCount":99},[],{"trials":9507,"activeCount":99},[9508],{"nctId":2086,"briefTitle":2087,"status":332,"phases":9509,"primaryCompletion":1501,"completion":814,"start":2089,"enrollment":30,"conditions":9510,"interventions":9511},[88],[1932,787,2091,929],[2093,686,2080],{"trials":9513,"activeCount":99},[],{"trials":9515,"activeCount":99},[],{"trials":9517,"activeCount":99},[],{"intervention":9519,"totalTrials":95,"cells":9520},"dolastatin 10",{"EARLY_PHASE1":9521,"PHASE1":9523,"PHASE2":9525,"PHASE3":9536,"PHASE4":9538,"NA":9540},{"trials":9522,"activeCount":99},[],{"trials":9524,"activeCount":99},[],{"trials":9526,"activeCount":99},[9527],{"nctId":9528,"briefTitle":9529,"status":332,"phases":9530,"primaryCompletion":399,"completion":1484,"start":9531,"enrollment":30,"conditions":9532,"interventions":9535},"NCT00003557","Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer",[88],"1999-01",[9533,9534,7595],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer",[9519],{"trials":9537,"activeCount":99},[],{"trials":9539,"activeCount":99},[],{"trials":9541,"activeCount":99},[],{"intervention":475,"totalTrials":95,"cells":9543},{"EARLY_PHASE1":9544,"PHASE1":9546,"PHASE2":9548,"PHASE3":9554,"PHASE4":9556,"NA":9558},{"trials":9545,"activeCount":99},[],{"trials":9547,"activeCount":99},[],{"trials":9549,"activeCount":99},[9550],{"nctId":466,"briefTitle":467,"status":468,"phases":9551,"primaryCompletion":470,"completion":470,"start":471,"enrollment":410,"conditions":9552,"interventions":9553},[88],[447,314,473],[475,476,299,325,322,451,477],{"trials":9555,"activeCount":99},[],{"trials":9557,"activeCount":99},[],{"trials":9559,"activeCount":99},[],{"intervention":476,"totalTrials":95,"cells":9561},{"EARLY_PHASE1":9562,"PHASE1":9564,"PHASE2":9566,"PHASE3":9572,"PHASE4":9574,"NA":9576},{"trials":9563,"activeCount":99},[],{"trials":9565,"activeCount":99},[],{"trials":9567,"activeCount":99},[9568],{"nctId":466,"briefTitle":467,"status":468,"phases":9569,"primaryCompletion":470,"completion":470,"start":471,"enrollment":410,"conditions":9570,"interventions":9571},[88],[447,314,473],[475,476,299,325,322,451,477],{"trials":9573,"activeCount":99},[],{"trials":9575,"activeCount":99},[],{"trials":9577,"activeCount":99},[],{"intervention":477,"totalTrials":95,"cells":9579},{"EARLY_PHASE1":9580,"PHASE1":9582,"PHASE2":9584,"PHASE3":9590,"PHASE4":9592,"NA":9594},{"trials":9581,"activeCount":99},[],{"trials":9583,"activeCount":99},[],{"trials":9585,"activeCount":99},[9586],{"nctId":466,"briefTitle":467,"status":468,"phases":9587,"primaryCompletion":470,"completion":470,"start":471,"enrollment":410,"conditions":9588,"interventions":9589},[88],[447,314,473],[475,476,299,325,322,451,477],{"trials":9591,"activeCount":99},[],{"trials":9593,"activeCount":99},[],{"trials":9595,"activeCount":99},[],{"intervention":9597,"totalTrials":95,"cells":9598},"ZD 1839 500mg",{"EARLY_PHASE1":9599,"PHASE1":9601,"PHASE2":9603,"PHASE3":9612,"PHASE4":9614,"NA":9616},{"trials":9600,"activeCount":99},[],{"trials":9602,"activeCount":99},[],{"trials":9604,"activeCount":99},[9605],{"nctId":9606,"briefTitle":9607,"status":332,"phases":9608,"primaryCompletion":780,"completion":7240,"start":9609,"enrollment":1114,"conditions":9610,"interventions":9611},"NCT01185171","Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy\u002FRadiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer",[88],"2003-01-27",[21],[9597],{"trials":9613,"activeCount":99},[],{"trials":9615,"activeCount":99},[],{"trials":9617,"activeCount":99},[],{"intervention":9619,"totalTrials":95,"cells":9620},"Bevacizumab and Temozolomide",{"EARLY_PHASE1":9621,"PHASE1":9623,"PHASE2":9625,"PHASE3":9634,"PHASE4":9636,"NA":9638},{"trials":9622,"activeCount":99},[],{"trials":9624,"activeCount":99},[],{"trials":9626,"activeCount":99},[9627],{"nctId":9628,"briefTitle":9629,"status":332,"phases":9630,"primaryCompletion":5039,"completion":5039,"start":5090,"enrollment":1317,"conditions":9631,"interventions":9633},"NCT00590681","Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme",[88],[9632],"Glioblastoma Multiforme",[9619],{"trials":9635,"activeCount":99},[],{"trials":9637,"activeCount":99},[],{"trials":9639,"activeCount":99},[],{"intervention":9641,"totalTrials":95,"cells":9642},"Omega 3 fatty acids",{"EARLY_PHASE1":9643,"PHASE1":9645,"PHASE2":9647,"PHASE3":9658,"PHASE4":9660,"NA":9662},{"trials":9644,"activeCount":99},[],{"trials":9646,"activeCount":99},[],{"trials":9648,"activeCount":99},[9649],{"nctId":9650,"briefTitle":9651,"status":363,"phases":9652,"primaryCompletion":9653,"completion":9653,"start":9654,"enrollment":1106,"conditions":9655,"interventions":9657},"NCT03784963","Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD",[87,88],"2020-07-15","2019-01-23",[4502,9656],"Gastrointestinal Bleeding",[9641],{"trials":9659,"activeCount":99},[],{"trials":9661,"activeCount":99},[],{"trials":9663,"activeCount":99},[],{"intervention":3731,"totalTrials":95,"cells":9665},{"EARLY_PHASE1":9666,"PHASE1":9668,"PHASE2":9670,"PHASE3":9676,"PHASE4":9678,"NA":9680},{"trials":9667,"activeCount":99},[],{"trials":9669,"activeCount":99},[],{"trials":9671,"activeCount":99},[9672],{"nctId":3725,"briefTitle":3726,"status":363,"phases":9673,"primaryCompletion":3685,"completion":1214,"start":3728,"enrollment":35,"conditions":9674,"interventions":9675},[87,88],[18,1436],[3731,386],{"trials":9677,"activeCount":99},[],{"trials":9679,"activeCount":99},[],{"trials":9681,"activeCount":99},[],{"intervention":9683,"totalTrials":95,"cells":9684},"Pregnenolone 175mg",{"EARLY_PHASE1":9685,"PHASE1":9687,"PHASE2":9689,"PHASE3":9700,"PHASE4":9702,"NA":9704},{"trials":9686,"activeCount":99},[],{"trials":9688,"activeCount":99},[],{"trials":9690,"activeCount":99},[9691],{"nctId":9692,"briefTitle":9693,"status":363,"phases":9694,"primaryCompletion":9695,"completion":54,"start":4613,"enrollment":1282,"conditions":9696,"interventions":9698},"NCT02826577","Effects of Pregnenolone on Perceived Social Isolation",[88],"2021-12-21",[9697],"Perceived Social Isolation",[9683,9699],"Pregnenolone 400mg",{"trials":9701,"activeCount":99},[],{"trials":9703,"activeCount":99},[],{"trials":9705,"activeCount":99},[],{"intervention":9699,"totalTrials":95,"cells":9707},{"EARLY_PHASE1":9708,"PHASE1":9710,"PHASE2":9712,"PHASE3":9718,"PHASE4":9720,"NA":9722},{"trials":9709,"activeCount":99},[],{"trials":9711,"activeCount":99},[],{"trials":9713,"activeCount":99},[9714],{"nctId":9692,"briefTitle":9693,"status":363,"phases":9715,"primaryCompletion":9695,"completion":54,"start":4613,"enrollment":1282,"conditions":9716,"interventions":9717},[88],[9697],[9683,9699],{"trials":9719,"activeCount":99},[],{"trials":9721,"activeCount":99},[],{"trials":9723,"activeCount":99},[],{"intervention":9725,"totalTrials":95,"cells":9726},"Oxytocin",{"EARLY_PHASE1":9727,"PHASE1":9729,"PHASE2":9731,"PHASE3":9743,"PHASE4":9745,"NA":9747},{"trials":9728,"activeCount":99},[],{"trials":9730,"activeCount":99},[],{"trials":9732,"activeCount":99},[9733],{"nctId":9734,"briefTitle":9735,"status":981,"phases":9736,"primaryCompletion":9737,"completion":113,"start":9738,"enrollment":99,"conditions":9739,"interventions":9742},"NCT06550089","High Or Low Dose pOstpartUm Oxytocin at the Time of Cesarean Birth",[88],"2026-10","2024-10",[9740,9741,3244],"Postpartum Hemorrhage","Pregnancy Complications",[9725],{"trials":9744,"activeCount":99},[],{"trials":9746,"activeCount":99},[],{"trials":9748,"activeCount":99},[],{"intervention":9750,"totalTrials":95,"cells":9751},"Adalimumab",{"EARLY_PHASE1":9752,"PHASE1":9754,"PHASE2":9756,"PHASE3":9764,"PHASE4":9766,"NA":9768},{"trials":9753,"activeCount":99},[],{"trials":9755,"activeCount":99},[],{"trials":9757,"activeCount":99},[9758],{"nctId":9759,"briefTitle":9760,"status":363,"phases":9761,"primaryCompletion":6281,"completion":5293,"start":1751,"enrollment":1228,"conditions":9762,"interventions":9763},"NCT00311246","Trial of Adalimumab in Progressive Sarcoidosis",[88],[8179],[9750],{"trials":9765,"activeCount":99},[],{"trials":9767,"activeCount":99},[],{"trials":9769,"activeCount":99},[],{"intervention":9771,"totalTrials":95,"cells":9772},"Lamictal",{"EARLY_PHASE1":9773,"PHASE1":9775,"PHASE2":9777,"PHASE3":9785,"PHASE4":9787,"NA":9789},{"trials":9774,"activeCount":99},[],{"trials":9776,"activeCount":99},[],{"trials":9778,"activeCount":99},[9779],{"nctId":9780,"briefTitle":9781,"status":332,"phases":9782,"primaryCompletion":4811,"completion":4991,"start":1227,"enrollment":1106,"conditions":9783,"interventions":9784},"NCT00513019","Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation",[88],[6994,6993,6995,851],[9771],{"trials":9786,"activeCount":99},[],{"trials":9788,"activeCount":99},[],{"trials":9790,"activeCount":99},[],{"intervention":9792,"totalTrials":95,"cells":9793},"Vortioxetine",{"EARLY_PHASE1":9794,"PHASE1":9796,"PHASE2":9798,"PHASE3":9808,"PHASE4":9810,"NA":9812},{"trials":9795,"activeCount":99},[],{"trials":9797,"activeCount":99},[],{"trials":9799,"activeCount":99},[9800],{"nctId":9801,"briefTitle":9802,"status":332,"phases":9803,"primaryCompletion":1252,"completion":9804,"start":1398,"enrollment":249,"conditions":9805,"interventions":9807},"NCT02528409","Vortioxetine for Binge Eating Disorder",[88],"2018-11-01",[9806],"Binge Eating Disorder",[9792],{"trials":9809,"activeCount":99},[],{"trials":9811,"activeCount":99},[],{"trials":9813,"activeCount":99},[],{"intervention":9815,"totalTrials":95,"cells":9816},"Lovastatin",{"EARLY_PHASE1":9817,"PHASE1":9819,"PHASE2":9821,"PHASE3":9830,"PHASE4":9832,"NA":9834},{"trials":9818,"activeCount":99},[],{"trials":9820,"activeCount":99},[],{"trials":9822,"activeCount":99},[9823],{"nctId":9824,"briefTitle":9825,"status":981,"phases":9826,"enrollment":99,"conditions":9827,"interventions":9829},"NCT00689806","Evaluation of Lovastatin in Severe Persistent Asthma",[87,88],[9828],"Severe Persistent Asthma",[9815],{"trials":9831,"activeCount":99},[],{"trials":9833,"activeCount":99},[],{"trials":9835,"activeCount":99},[],{"intervention":9837,"totalTrials":95,"cells":9838},"cabozantinib",{"EARLY_PHASE1":9839,"PHASE1":9841,"PHASE2":9843,"PHASE3":9853,"PHASE4":9855,"NA":9857},{"trials":9840,"activeCount":99},[],{"trials":9842,"activeCount":99},[],{"trials":9844,"activeCount":99},[9845],{"nctId":9846,"briefTitle":9847,"status":332,"phases":9848,"primaryCompletion":3441,"completion":1536,"start":837,"enrollment":2075,"conditions":9849,"interventions":9852},"NCT01599793","Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer",[88],[9850,9851,2138,2139],"Bone Metastases","Castrate-resistant Prostate Cancer",[9837],{"trials":9854,"activeCount":99},[],{"trials":9856,"activeCount":99},[],{"trials":9858,"activeCount":99},[],{"intervention":9860,"totalTrials":95,"cells":9861},"Gefitinib",{"EARLY_PHASE1":9862,"PHASE1":9864,"PHASE2":9866,"PHASE3":9874,"PHASE4":9876,"NA":9878},{"trials":9863,"activeCount":99},[],{"trials":9865,"activeCount":99},[],{"trials":9867,"activeCount":99},[9868],{"nctId":9869,"briefTitle":9870,"status":332,"phases":9871,"primaryCompletion":6281,"completion":3369,"start":3359,"enrollment":1738,"conditions":9872,"interventions":9873},"NCT00519077","Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck",[88],[950],[9860],{"trials":9875,"activeCount":99},[],{"trials":9877,"activeCount":99},[],{"trials":9879,"activeCount":99},[],{"intervention":6655,"totalTrials":1571,"cells":9881},{"EARLY_PHASE1":9882,"PHASE1":9894,"PHASE2":9930,"PHASE3":9932,"PHASE4":9934,"NA":9936},{"trials":9883,"activeCount":99},[9884],{"nctId":9885,"briefTitle":9886,"status":332,"phases":9887,"primaryCompletion":5864,"completion":5864,"start":9888,"enrollment":7399,"conditions":9889,"interventions":9891},"NCT00583063","Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers",[86],"2007-10",[9890],"Solid Tumors",[9892,9893],"sunitinib","rapamycin",{"trials":9895,"activeCount":99},[9896,9902,9906,9914,9923],{"nctId":9897,"briefTitle":9898,"status":332,"phases":9899,"primaryCompletion":5293,"completion":8177,"start":1281,"enrollment":539,"conditions":9900,"interventions":9901},"NCT00707135","Rapamycin in Advanced Cancers",[87],[3918],[6655],{"nctId":6649,"briefTitle":6650,"status":332,"phases":9903,"primaryCompletion":837,"completion":837,"start":5864,"enrollment":6652,"conditions":9904,"interventions":9905},[87],[3918,3939],[6655,6656,6655],{"nctId":9907,"briefTitle":9908,"status":332,"phases":9909,"primaryCompletion":9910,"completion":837,"start":1709,"enrollment":4992,"conditions":9911,"interventions":9913},"NCT00375245","Rapamycin With Grapefruit Juice for Advanced Malignancies",[87],"2009-05",[9912,953],"Tumors",[6655],{"nctId":9915,"briefTitle":9916,"status":332,"phases":9917,"primaryCompletion":2359,"completion":4991,"start":9918,"enrollment":1282,"conditions":9919,"interventions":9921},"NCT00449280","Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies",[87],"2006-11",[9920],"Advanced Solid Tumor",[9922,6655,6655],"Sorafenib",{"nctId":9924,"briefTitle":9925,"status":332,"phases":9926,"primaryCompletion":8177,"completion":8177,"start":2073,"enrollment":2534,"conditions":9927,"interventions":9928},"NCT00708591","Study of Rapamycin Plus Ketoconazole in Advanced Cancers",[87],[3918],[6655,9929],"Ketoconazole",{"trials":9931,"activeCount":99},[],{"trials":9933,"activeCount":99},[],{"trials":9935,"activeCount":99},[],{"trials":9937,"activeCount":99},[],{"intervention":3776,"totalTrials":488,"cells":9939},{"EARLY_PHASE1":9940,"PHASE1":9942,"PHASE2":9963,"PHASE3":9965,"PHASE4":9967,"NA":9969},{"trials":9941,"activeCount":99},[],{"trials":9943,"activeCount":99},[9944,9948,9959],{"nctId":3767,"briefTitle":3768,"status":332,"phases":9945,"primaryCompletion":3770,"completion":3771,"start":3772,"enrollment":410,"conditions":9946,"interventions":9947},[87],[928],[320,3775,3776],{"nctId":9949,"briefTitle":9950,"status":332,"phases":9951,"primaryCompletion":9952,"completion":9953,"start":9954,"enrollment":35,"conditions":9955,"interventions":9958},"NCT02485535","Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant",[87],"2018-02-28","2020-07","2015-09-04",[928,9956,2180,3799,9957],"de Novo Myelodysplastic Syndrome","Secondary Myelodysplastic Syndrome",[3776],{"nctId":330,"briefTitle":331,"status":332,"phases":9960,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":9961,"interventions":9962},[87],[339],[341,342,343],{"trials":9964,"activeCount":99},[],{"trials":9966,"activeCount":99},[],{"trials":9968,"activeCount":99},[],{"trials":9970,"activeCount":99},[],{"intervention":3775,"totalTrials":367,"cells":9972},{"EARLY_PHASE1":9973,"PHASE1":9975,"PHASE2":9985,"PHASE3":9987,"PHASE4":9989,"NA":9991},{"trials":9974,"activeCount":99},[],{"trials":9976,"activeCount":99},[9977,9981],{"nctId":3767,"briefTitle":3768,"status":332,"phases":9978,"primaryCompletion":3770,"completion":3771,"start":3772,"enrollment":410,"conditions":9979,"interventions":9980},[87],[928],[320,3775,3776],{"nctId":3778,"briefTitle":3779,"status":332,"phases":9982,"primaryCompletion":3781,"completion":3781,"start":3782,"enrollment":1215,"conditions":9983,"interventions":9984},[87],[3784,3785,3786,3787,3788,3789,3790,3791,3792,3793,3794,3795,3796,3797,3798,3799,3800],[3802,3803,3804],{"trials":9986,"activeCount":99},[],{"trials":9988,"activeCount":99},[],{"trials":9990,"activeCount":99},[],{"trials":9992,"activeCount":99},[],{"intervention":9994,"totalTrials":367,"cells":9995},"basiliximab",{"EARLY_PHASE1":9996,"PHASE1":9998,"PHASE2":10015,"PHASE3":10017,"PHASE4":10019,"NA":10021},{"trials":9997,"activeCount":99},[],{"trials":9999,"activeCount":99},[10000,10011],{"nctId":10001,"briefTitle":10002,"status":332,"phases":10003,"primaryCompletion":10004,"completion":4911,"start":10005,"enrollment":592,"conditions":10006,"interventions":10007},"NCT01842139","Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission",[87],"2015-02-02","2011-12-05",[3789,3790,3791,3792,7245,3793,3794],[9994,10008,10009,10010],"WT1 126-134 peptide vaccine","Montanide ISA 51 VG","poly ICLC",{"nctId":6471,"briefTitle":6472,"status":332,"phases":10012,"primaryCompletion":6474,"completion":6474,"start":6475,"enrollment":1085,"conditions":10013,"interventions":10014},[87],[486],[1681,6478,6464,6479],{"trials":10016,"activeCount":99},[],{"trials":10018,"activeCount":99},[],{"trials":10020,"activeCount":99},[],{"trials":10022,"activeCount":99},[],{"intervention":1681,"totalTrials":367,"cells":10024},{"EARLY_PHASE1":10025,"PHASE1":10027,"PHASE2":10037,"PHASE3":10039,"PHASE4":10041,"NA":10043},{"trials":10026,"activeCount":99},[],{"trials":10028,"activeCount":99},[10029,10033],{"nctId":6471,"briefTitle":6472,"status":332,"phases":10030,"primaryCompletion":6474,"completion":6474,"start":6475,"enrollment":1085,"conditions":10031,"interventions":10032},[87],[486],[1681,6478,6464,6479],{"nctId":1672,"briefTitle":1673,"status":363,"phases":10034,"primaryCompletion":1675,"completion":1675,"start":1280,"enrollment":367,"conditions":10035,"interventions":10036},[87],[1677,1678],[1680,326,387,1681,1682,1374,1683,1684,1559],{"trials":10038,"activeCount":99},[],{"trials":10040,"activeCount":99},[],{"trials":10042,"activeCount":99},[],{"trials":10044,"activeCount":99},[],{"intervention":10046,"totalTrials":95,"cells":10047},"Relugolix Pill",{"EARLY_PHASE1":10048,"PHASE1":10050,"PHASE2":10062,"PHASE3":10064,"PHASE4":10066,"NA":10068},{"trials":10049,"activeCount":99},[],{"trials":10051,"activeCount":99},[10052],{"nctId":10053,"briefTitle":10054,"status":363,"phases":10055,"primaryCompletion":10056,"completion":10056,"start":10057,"enrollment":802,"conditions":10058,"interventions":10059},"NCT05679388","A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients",[87],"2024-08-05","2023-02-13",[18,7340,2227],[10046,10060,10061],"Ritonavir","Itraconazole",{"trials":10063,"activeCount":99},[],{"trials":10065,"activeCount":99},[],{"trials":10067,"activeCount":99},[],{"trials":10069,"activeCount":99},[],{"intervention":10060,"totalTrials":95,"cells":10071},{"EARLY_PHASE1":10072,"PHASE1":10074,"PHASE2":10080,"PHASE3":10082,"PHASE4":10084,"NA":10086},{"trials":10073,"activeCount":99},[],{"trials":10075,"activeCount":99},[10076],{"nctId":10053,"briefTitle":10054,"status":363,"phases":10077,"primaryCompletion":10056,"completion":10056,"start":10057,"enrollment":802,"conditions":10078,"interventions":10079},[87],[18,7340,2227],[10046,10060,10061],{"trials":10081,"activeCount":99},[],{"trials":10083,"activeCount":99},[],{"trials":10085,"activeCount":99},[],{"trials":10087,"activeCount":99},[],{"intervention":10061,"totalTrials":95,"cells":10089},{"EARLY_PHASE1":10090,"PHASE1":10092,"PHASE2":10098,"PHASE3":10100,"PHASE4":10102,"NA":10104},{"trials":10091,"activeCount":99},[],{"trials":10093,"activeCount":99},[10094],{"nctId":10053,"briefTitle":10054,"status":363,"phases":10095,"primaryCompletion":10056,"completion":10056,"start":10057,"enrollment":802,"conditions":10096,"interventions":10097},[87],[18,7340,2227],[10046,10060,10061],{"trials":10099,"activeCount":99},[],{"trials":10101,"activeCount":99},[],{"trials":10103,"activeCount":99},[],{"trials":10105,"activeCount":99},[],{"intervention":10107,"totalTrials":95,"cells":10108},"Ranolazine",{"EARLY_PHASE1":10109,"PHASE1":10111,"PHASE2":10120,"PHASE3":10122,"PHASE4":10124,"NA":10126},{"trials":10110,"activeCount":99},[],{"trials":10112,"activeCount":99},[10113],{"nctId":10114,"briefTitle":10115,"status":332,"phases":10116,"primaryCompletion":3283,"completion":3283,"start":814,"enrollment":35,"conditions":10117,"interventions":10119},"NCT01757808","A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension",[87],[10118],"Pulmonary Arterial Hypertension",[10107],{"trials":10121,"activeCount":99},[],{"trials":10123,"activeCount":99},[],{"trials":10125,"activeCount":99},[],{"trials":10127,"activeCount":99},[],{"intervention":3836,"totalTrials":95,"cells":10129},{"EARLY_PHASE1":10130,"PHASE1":10132,"PHASE2":10138,"PHASE3":10140,"PHASE4":10142,"NA":10144},{"trials":10131,"activeCount":99},[],{"trials":10133,"activeCount":99},[10134],{"nctId":3824,"briefTitle":3825,"status":981,"phases":10135,"primaryCompletion":3827,"completion":3827,"start":3828,"enrollment":99,"conditions":10136,"interventions":10137},[87],[3830,3831,3832,3833,3834],[79,3836,3837],{"trials":10139,"activeCount":99},[],{"trials":10141,"activeCount":99},[],{"trials":10143,"activeCount":99},[],{"trials":10145,"activeCount":99},[],{"intervention":3837,"totalTrials":95,"cells":10147},{"EARLY_PHASE1":10148,"PHASE1":10150,"PHASE2":10156,"PHASE3":10158,"PHASE4":10160,"NA":10162},{"trials":10149,"activeCount":99},[],{"trials":10151,"activeCount":99},[10152],{"nctId":3824,"briefTitle":3825,"status":981,"phases":10153,"primaryCompletion":3827,"completion":3827,"start":3828,"enrollment":99,"conditions":10154,"interventions":10155},[87],[3830,3831,3832,3833,3834],[79,3836,3837],{"trials":10157,"activeCount":99},[],{"trials":10159,"activeCount":99},[],{"trials":10161,"activeCount":99},[],{"trials":10163,"activeCount":99},[],{"intervention":10165,"totalTrials":95,"cells":10166},"FOLFIRINOX",{"EARLY_PHASE1":10167,"PHASE1":10169,"PHASE2":10178,"PHASE3":10180,"PHASE4":10182,"NA":10184},{"trials":10168,"activeCount":99},[],{"trials":10170,"activeCount":99},[10171],{"nctId":10172,"briefTitle":10173,"status":363,"phases":10174,"primaryCompletion":6064,"completion":6064,"start":1113,"enrollment":95,"conditions":10175,"interventions":10177},"NCT02782182","Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study",[87],[10176],"Pancreatic Ductal Adenocarcinoma (PDAC)",[10165],{"trials":10179,"activeCount":99},[],{"trials":10181,"activeCount":99},[],{"trials":10183,"activeCount":99},[],{"trials":10185,"activeCount":99},[],{"intervention":10187,"totalTrials":95,"cells":10188},"fecal microbiota transplantation",{"EARLY_PHASE1":10189,"PHASE1":10191,"PHASE2":10200,"PHASE3":10202,"PHASE4":10204,"NA":10206},{"trials":10190,"activeCount":99},[],{"trials":10192,"activeCount":99},[10193],{"nctId":10194,"briefTitle":10195,"status":363,"phases":10196,"primaryCompletion":1398,"completion":1398,"start":10197,"enrollment":95,"conditions":10198,"interventions":10199},"NCT02058524","A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis",[87],"2013-06",[6439],[10187],{"trials":10201,"activeCount":99},[],{"trials":10203,"activeCount":99},[],{"trials":10205,"activeCount":99},[],{"trials":10207,"activeCount":99},[],{"intervention":1420,"totalTrials":95,"cells":10209},{"EARLY_PHASE1":10210,"PHASE1":10212,"PHASE2":10218,"PHASE3":10220,"PHASE4":10222,"NA":10224},{"trials":10211,"activeCount":99},[],{"trials":10213,"activeCount":99},[10214],{"nctId":1412,"briefTitle":1413,"status":332,"phases":10215,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":860,"conditions":10216,"interventions":10217},[87],[15],[392,1420,1245],{"trials":10219,"activeCount":99},[],{"trials":10221,"activeCount":99},[],{"trials":10223,"activeCount":99},[],{"trials":10225,"activeCount":99},[],{"intervention":10227,"totalTrials":95,"cells":10228},"GLP-1",{"EARLY_PHASE1":10229,"PHASE1":10231,"PHASE2":10243,"PHASE3":10245,"PHASE4":10247,"NA":10249},{"trials":10230,"activeCount":99},[],{"trials":10232,"activeCount":99},[10233],{"nctId":10234,"briefTitle":10235,"status":332,"phases":10236,"primaryCompletion":10237,"completion":10237,"start":10238,"enrollment":732,"conditions":10239,"interventions":10241},"NCT01795144","Incretin Regulation of Insulin Secretion in Monogenic Diabetes",[87],"2017-03","2014-01",[10240],"Monogenic Diabetes",[10227,10242],"Exendin 9-39",{"trials":10244,"activeCount":99},[],{"trials":10246,"activeCount":99},[],{"trials":10248,"activeCount":99},[],{"trials":10250,"activeCount":99},[],{"intervention":10242,"totalTrials":95,"cells":10252},{"EARLY_PHASE1":10253,"PHASE1":10255,"PHASE2":10261,"PHASE3":10263,"PHASE4":10265,"NA":10267},{"trials":10254,"activeCount":99},[],{"trials":10256,"activeCount":99},[10257],{"nctId":10234,"briefTitle":10235,"status":332,"phases":10258,"primaryCompletion":10237,"completion":10237,"start":10238,"enrollment":732,"conditions":10259,"interventions":10260},[87],[10240],[10227,10242],{"trials":10262,"activeCount":99},[],{"trials":10264,"activeCount":99},[],{"trials":10266,"activeCount":99},[],{"trials":10268,"activeCount":99},[],{"intervention":10008,"totalTrials":95,"cells":10270},{"EARLY_PHASE1":10271,"PHASE1":10273,"PHASE2":10279,"PHASE3":10281,"PHASE4":10283,"NA":10285},{"trials":10272,"activeCount":99},[],{"trials":10274,"activeCount":99},[10275],{"nctId":10001,"briefTitle":10002,"status":332,"phases":10276,"primaryCompletion":10004,"completion":4911,"start":10005,"enrollment":592,"conditions":10277,"interventions":10278},[87],[3789,3790,3791,3792,7245,3793,3794],[9994,10008,10009,10010],{"trials":10280,"activeCount":99},[],{"trials":10282,"activeCount":99},[],{"trials":10284,"activeCount":99},[],{"trials":10286,"activeCount":99},[],{"intervention":10009,"totalTrials":95,"cells":10288},{"EARLY_PHASE1":10289,"PHASE1":10291,"PHASE2":10297,"PHASE3":10299,"PHASE4":10301,"NA":10303},{"trials":10290,"activeCount":99},[],{"trials":10292,"activeCount":99},[10293],{"nctId":10001,"briefTitle":10002,"status":332,"phases":10294,"primaryCompletion":10004,"completion":4911,"start":10005,"enrollment":592,"conditions":10295,"interventions":10296},[87],[3789,3790,3791,3792,7245,3793,3794],[9994,10008,10009,10010],{"trials":10298,"activeCount":99},[],{"trials":10300,"activeCount":99},[],{"trials":10302,"activeCount":99},[],{"trials":10304,"activeCount":99},[],{"intervention":10010,"totalTrials":95,"cells":10306},{"EARLY_PHASE1":10307,"PHASE1":10309,"PHASE2":10315,"PHASE3":10317,"PHASE4":10319,"NA":10321},{"trials":10308,"activeCount":99},[],{"trials":10310,"activeCount":99},[10311],{"nctId":10001,"briefTitle":10002,"status":332,"phases":10312,"primaryCompletion":10004,"completion":4911,"start":10005,"enrollment":592,"conditions":10313,"interventions":10314},[87],[3789,3790,3791,3792,7245,3793,3794],[9994,10008,10009,10010],{"trials":10316,"activeCount":99},[],{"trials":10318,"activeCount":99},[],{"trials":10320,"activeCount":99},[],{"trials":10322,"activeCount":99},[],{"intervention":10324,"totalTrials":95,"cells":10325},"Serotonin agonist - 13ug",{"EARLY_PHASE1":10326,"PHASE1":10328,"PHASE2":10339,"PHASE3":10341,"PHASE4":10343,"NA":10345},{"trials":10327,"activeCount":99},[],{"trials":10329,"activeCount":99},[10330],{"nctId":10331,"briefTitle":10332,"status":332,"phases":10333,"primaryCompletion":10334,"completion":10334,"start":10335,"enrollment":770,"conditions":10336,"interventions":10337},"NCT03934710","Mood Effects of Serotonin Agonists Extended",[87],"2021-06-07","2019-04-20",[32],[10324,10338],"Serotonin agonist - 26ug",{"trials":10340,"activeCount":99},[],{"trials":10342,"activeCount":99},[],{"trials":10344,"activeCount":99},[],{"trials":10346,"activeCount":99},[],{"intervention":10338,"totalTrials":95,"cells":10348},{"EARLY_PHASE1":10349,"PHASE1":10351,"PHASE2":10357,"PHASE3":10359,"PHASE4":10361,"NA":10363},{"trials":10350,"activeCount":99},[],{"trials":10352,"activeCount":99},[10353],{"nctId":10331,"briefTitle":10332,"status":332,"phases":10354,"primaryCompletion":10334,"completion":10334,"start":10335,"enrollment":770,"conditions":10355,"interventions":10356},[87],[32],[10324,10338],{"trials":10358,"activeCount":99},[],{"trials":10360,"activeCount":99},[],{"trials":10362,"activeCount":99},[],{"trials":10364,"activeCount":99},[],{"intervention":10366,"totalTrials":95,"cells":10367},"Leflunomide",{"EARLY_PHASE1":10368,"PHASE1":10370,"PHASE2":10380,"PHASE3":10382,"PHASE4":10384,"NA":10386},{"trials":10369,"activeCount":99},[],{"trials":10371,"activeCount":99},[10372],{"nctId":10373,"briefTitle":10374,"status":363,"phases":10375,"primaryCompletion":10376,"completion":10376,"start":10377,"enrollment":1228,"conditions":10378,"interventions":10379},"NCT04361214","Leflunomide in Mild COVID-19 Patients",[87],"2022-01-31","2020-05-05",[117],[10366],{"trials":10381,"activeCount":99},[],{"trials":10383,"activeCount":99},[],{"trials":10385,"activeCount":99},[],{"trials":10387,"activeCount":99},[],{"intervention":790,"totalTrials":95,"cells":10389},{"EARLY_PHASE1":10390,"PHASE1":10392,"PHASE2":10398,"PHASE3":10400,"PHASE4":10402,"NA":10404},{"trials":10391,"activeCount":99},[],{"trials":10393,"activeCount":99},[10394],{"nctId":776,"briefTitle":777,"status":332,"phases":10395,"primaryCompletion":779,"completion":780,"start":781,"enrollment":782,"conditions":10396,"interventions":10397},[87],[784,785,786,787,788],[790,791,792],{"trials":10399,"activeCount":99},[],{"trials":10401,"activeCount":99},[],{"trials":10403,"activeCount":99},[],{"trials":10405,"activeCount":99},[],{"intervention":791,"totalTrials":95,"cells":10407},{"EARLY_PHASE1":10408,"PHASE1":10410,"PHASE2":10416,"PHASE3":10418,"PHASE4":10420,"NA":10422},{"trials":10409,"activeCount":99},[],{"trials":10411,"activeCount":99},[10412],{"nctId":776,"briefTitle":777,"status":332,"phases":10413,"primaryCompletion":779,"completion":780,"start":781,"enrollment":782,"conditions":10414,"interventions":10415},[87],[784,785,786,787,788],[790,791,792],{"trials":10417,"activeCount":99},[],{"trials":10419,"activeCount":99},[],{"trials":10421,"activeCount":99},[],{"trials":10423,"activeCount":99},[],{"intervention":10425,"totalTrials":95,"cells":10426},"3,4-Methylenedioxymethamphetamine",{"EARLY_PHASE1":10427,"PHASE1":10429,"PHASE2":10441,"PHASE3":10443,"PHASE4":10445,"NA":10447},{"trials":10428,"activeCount":99},[],{"trials":10430,"activeCount":99},[10431],{"nctId":10432,"briefTitle":10433,"status":332,"phases":10434,"primaryCompletion":10435,"completion":10435,"start":10436,"enrollment":400,"conditions":10437,"interventions":10439},"NCT03790618","Effect of Stimulant Drugs on Social Perception",[87],"2018-08-01","2016-06-01",[32,10438],"MDMA ('Ecstasy')",[10425,10440],"methamphetamine",{"trials":10442,"activeCount":99},[],{"trials":10444,"activeCount":99},[],{"trials":10446,"activeCount":99},[],{"trials":10448,"activeCount":99},[],{"intervention":942,"totalTrials":95,"cells":10450},{"EARLY_PHASE1":10451,"PHASE1":10453,"PHASE2":10459,"PHASE3":10461,"PHASE4":10463,"NA":10465},{"trials":10452,"activeCount":99},[],{"trials":10454,"activeCount":99},[10455],{"nctId":934,"briefTitle":935,"status":363,"phases":10456,"primaryCompletion":937,"completion":937,"start":938,"enrollment":592,"conditions":10457,"interventions":10458},[87],[940],[46,942],{"trials":10460,"activeCount":99},[],{"trials":10462,"activeCount":99},[],{"trials":10464,"activeCount":99},[],{"trials":10466,"activeCount":99},[],{"intervention":10468,"totalTrials":95,"cells":10469},"fluticasone and salmeterol",{"EARLY_PHASE1":10470,"PHASE1":10472,"PHASE2":10482,"PHASE3":10484,"PHASE4":10486,"NA":10488},{"trials":10471,"activeCount":99},[],{"trials":10473,"activeCount":99},[10474],{"nctId":10475,"briefTitle":10476,"status":332,"phases":10477,"primaryCompletion":4991,"completion":10478,"start":7016,"enrollment":312,"conditions":10479,"interventions":10481},"NCT00116402","A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations",[87],"2009-10",[10480],"Pulmonary Disease, Chronic Obstructive",[10468],{"trials":10483,"activeCount":99},[],{"trials":10485,"activeCount":99},[],{"trials":10487,"activeCount":99},[],{"trials":10489,"activeCount":99},[],{"intervention":10491,"totalTrials":95,"cells":10492},"Topotecan",{"EARLY_PHASE1":10493,"PHASE1":10495,"PHASE2":10505,"PHASE3":10507,"PHASE4":10509,"NA":10511},{"trials":10494,"activeCount":99},[],{"trials":10496,"activeCount":99},[10497],{"nctId":10498,"briefTitle":10499,"status":332,"phases":10500,"primaryCompletion":4991,"completion":1649,"start":1227,"enrollment":312,"conditions":10501,"interventions":10503},"NCT00523432","A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies",[87],[10502],"Genital Neoplasms, Female",[10491,10504],"CCI-779",{"trials":10506,"activeCount":99},[],{"trials":10508,"activeCount":99},[],{"trials":10510,"activeCount":99},[],{"trials":10512,"activeCount":99},[],{"intervention":10504,"totalTrials":95,"cells":10514},{"EARLY_PHASE1":10515,"PHASE1":10517,"PHASE2":10523,"PHASE3":10525,"PHASE4":10527,"NA":10529},{"trials":10516,"activeCount":99},[],{"trials":10518,"activeCount":99},[10519],{"nctId":10498,"briefTitle":10499,"status":332,"phases":10520,"primaryCompletion":4991,"completion":1649,"start":1227,"enrollment":312,"conditions":10521,"interventions":10522},[87],[10502],[10491,10504],{"trials":10524,"activeCount":99},[],{"trials":10526,"activeCount":99},[],{"trials":10528,"activeCount":99},[],{"trials":10530,"activeCount":99},[],{"intervention":6478,"totalTrials":95,"cells":10532},{"EARLY_PHASE1":10533,"PHASE1":10535,"PHASE2":10541,"PHASE3":10543,"PHASE4":10545,"NA":10547},{"trials":10534,"activeCount":99},[],{"trials":10536,"activeCount":99},[10537],{"nctId":6471,"briefTitle":6472,"status":332,"phases":10538,"primaryCompletion":6474,"completion":6474,"start":6475,"enrollment":1085,"conditions":10539,"interventions":10540},[87],[486],[1681,6478,6464,6479],{"trials":10542,"activeCount":99},[],{"trials":10544,"activeCount":99},[],{"trials":10546,"activeCount":99},[],{"trials":10548,"activeCount":99},[],{"intervention":10550,"totalTrials":95,"cells":10551},"Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch",{"EARLY_PHASE1":10552,"PHASE1":10554,"PHASE2":10563,"PHASE3":10565,"PHASE4":10567,"NA":10569},{"trials":10553,"activeCount":99},[],{"trials":10555,"activeCount":99},[10556],{"nctId":10557,"briefTitle":10558,"status":363,"phases":10559,"primaryCompletion":2176,"completion":2176,"start":4820,"enrollment":95,"conditions":10560,"interventions":10562},"NCT00870220","Initiating Transdermal Estradiol Therapy in Turner's Syndrome",[87],[10561],"Turner's Syndrome",[10550],{"trials":10564,"activeCount":99},[],{"trials":10566,"activeCount":99},[],{"trials":10568,"activeCount":99},[],{"trials":10570,"activeCount":99},[],{"intervention":2276,"totalTrials":95,"cells":10572},{"EARLY_PHASE1":10573,"PHASE1":10575,"PHASE2":10581,"PHASE3":10583,"PHASE4":10585,"NA":10587},{"trials":10574,"activeCount":99},[],{"trials":10576,"activeCount":99},[10577],{"nctId":2268,"briefTitle":2269,"status":363,"phases":10578,"primaryCompletion":2271,"completion":2271,"start":2272,"enrollment":19,"conditions":10579,"interventions":10580},[87],[772],[2275,2276],{"trials":10582,"activeCount":99},[],{"trials":10584,"activeCount":99},[],{"trials":10586,"activeCount":99},[],{"trials":10588,"activeCount":99},[],{"intervention":10590,"totalTrials":95,"cells":10591},"Atipamezole & Caffeine",{"EARLY_PHASE1":10592,"PHASE1":10594,"PHASE2":10605,"PHASE3":10607,"PHASE4":10609,"NA":10611},{"trials":10593,"activeCount":99},[],{"trials":10595,"activeCount":99},[10596],{"nctId":10597,"briefTitle":10598,"status":981,"phases":10599,"primaryCompletion":4699,"completion":78,"start":10600,"enrollment":99,"conditions":10601,"interventions":10603},"NCT04942340","Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed",[87],"2023-05",[10602],"Emergence From Anesthesia",[10590,10604],"Dexmedetomidine Hydrochloride & Saline",{"trials":10606,"activeCount":99},[],{"trials":10608,"activeCount":99},[],{"trials":10610,"activeCount":99},[],{"trials":10612,"activeCount":99},[],{"intervention":10604,"totalTrials":95,"cells":10614},{"EARLY_PHASE1":10615,"PHASE1":10617,"PHASE2":10623,"PHASE3":10625,"PHASE4":10627,"NA":10629},{"trials":10616,"activeCount":99},[],{"trials":10618,"activeCount":99},[10619],{"nctId":10597,"briefTitle":10598,"status":981,"phases":10620,"primaryCompletion":4699,"completion":78,"start":10600,"enrollment":99,"conditions":10621,"interventions":10622},[87],[10602],[10590,10604],{"trials":10624,"activeCount":99},[],{"trials":10626,"activeCount":99},[],{"trials":10628,"activeCount":99},[],{"trials":10630,"activeCount":99},[],{"intervention":10632,"totalTrials":95,"cells":10633},"Lysergic Acid Diethylamide",{"EARLY_PHASE1":10634,"PHASE1":10636,"PHASE2":10646,"PHASE3":10648,"PHASE4":10650,"NA":10652},{"trials":10635,"activeCount":99},[],{"trials":10637,"activeCount":99},[10638],{"nctId":10639,"briefTitle":10640,"status":332,"phases":10641,"primaryCompletion":10642,"completion":10642,"start":10643,"enrollment":249,"conditions":10644,"interventions":10645},"NCT03790358","Mood Effects of Serotonin Agonists",[87],"2023-01-27","2018-05-01",[32],[10632],{"trials":10647,"activeCount":99},[],{"trials":10649,"activeCount":99},[],{"trials":10651,"activeCount":99},[],{"trials":10653,"activeCount":99},[],{"intervention":1199,"totalTrials":95,"cells":10655},{"EARLY_PHASE1":10656,"PHASE1":10658,"PHASE2":10664,"PHASE3":10666,"PHASE4":10668,"NA":10670},{"trials":10657,"activeCount":99},[],{"trials":10659,"activeCount":99},[10660],{"nctId":1191,"briefTitle":1192,"status":363,"phases":10661,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":459,"conditions":10662,"interventions":10663},[87],[21,950,1197],[1199,385,392],{"trials":10665,"activeCount":99},[],{"trials":10667,"activeCount":99},[],{"trials":10669,"activeCount":99},[],{"trials":10671,"activeCount":99},[],{"intervention":10673,"totalTrials":95,"cells":10674},"18F-AV-1451",{"EARLY_PHASE1":10675,"PHASE1":10677,"PHASE2":10688,"PHASE3":10690,"PHASE4":10692,"NA":10694},{"trials":10676,"activeCount":99},[],{"trials":10678,"activeCount":99},[10679],{"nctId":10680,"briefTitle":10681,"status":332,"phases":10682,"primaryCompletion":10683,"completion":10683,"start":10684,"enrollment":1114,"conditions":10685,"interventions":10687},"NCT03283449","Tau PET Imaging in Atypical Dementias",[87],"2025-02-28","2016-02",[10686],"Primary Progressive Aphasia With Suspected Alzheimer's Disease",[10673],{"trials":10689,"activeCount":99},[],{"trials":10691,"activeCount":99},[],{"trials":10693,"activeCount":99},[],{"trials":10695,"activeCount":99},[],{"intervention":1439,"totalTrials":95,"cells":10697},{"EARLY_PHASE1":10698,"PHASE1":10700,"PHASE2":10706,"PHASE3":10708,"PHASE4":10710,"NA":10712},{"trials":10699,"activeCount":99},[],{"trials":10701,"activeCount":99},[10702],{"nctId":1426,"briefTitle":1427,"status":332,"phases":10703,"primaryCompletion":1429,"completion":1430,"start":1431,"enrollment":1432,"conditions":10704,"interventions":10705},[87],[1434,1435,1436,1437],[1307,1439],{"trials":10707,"activeCount":99},[],{"trials":10709,"activeCount":99},[],{"trials":10711,"activeCount":99},[],{"trials":10713,"activeCount":99},[],{"intervention":10715,"totalTrials":95,"cells":10716},"Multipeptide vaccine S-588210",{"EARLY_PHASE1":10717,"PHASE1":10719,"PHASE2":10730,"PHASE3":10732,"PHASE4":10734,"NA":10736},{"trials":10718,"activeCount":99},[],{"trials":10720,"activeCount":99},[10721],{"nctId":10722,"briefTitle":10723,"status":981,"phases":10724,"primaryCompletion":10725,"completion":10725,"start":10726,"enrollment":99,"conditions":10727,"interventions":10729},"NCT02661659","A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy",[87],"2017-10-03","2016-06-12",[10728],"Malignant Pleural Mesothelioma (MPM)",[10715],{"trials":10731,"activeCount":99},[],{"trials":10733,"activeCount":99},[],{"trials":10735,"activeCount":99},[],{"trials":10737,"activeCount":99},[],{"intervention":10739,"totalTrials":95,"cells":10740},"rhPTH",{"EARLY_PHASE1":10741,"PHASE1":10743,"PHASE2":10752,"PHASE3":10754,"PHASE4":10756,"NA":10758},{"trials":10742,"activeCount":99},[],{"trials":10744,"activeCount":99},[10745],{"nctId":10746,"briefTitle":10747,"status":363,"phases":10748,"primaryCompletion":6237,"completion":6237,"start":7900,"enrollment":367,"conditions":10749,"interventions":10751},"NCT00145886","rhPTH Therapy for Low Turnover Bone Fragility",[87],[10750],"Osteopetrosis",[10739],{"trials":10753,"activeCount":99},[],{"trials":10755,"activeCount":99},[],{"trials":10757,"activeCount":99},[],{"trials":10759,"activeCount":99},[],{"intervention":3690,"totalTrials":95,"cells":10761},{"EARLY_PHASE1":10762,"PHASE1":10764,"PHASE2":10770,"PHASE3":10772,"PHASE4":10774,"NA":10776},{"trials":10763,"activeCount":99},[],{"trials":10765,"activeCount":99},[10766],{"nctId":3682,"briefTitle":3683,"status":332,"phases":10767,"primaryCompletion":3685,"completion":3686,"start":3687,"enrollment":802,"conditions":10768,"interventions":10769},[87],[3163],[386,3690,3691],{"trials":10771,"activeCount":99},[],{"trials":10773,"activeCount":99},[],{"trials":10775,"activeCount":99},[],{"trials":10777,"activeCount":99},[],{"intervention":3691,"totalTrials":95,"cells":10779},{"EARLY_PHASE1":10780,"PHASE1":10782,"PHASE2":10788,"PHASE3":10790,"PHASE4":10792,"NA":10794},{"trials":10781,"activeCount":99},[],{"trials":10783,"activeCount":99},[10784],{"nctId":3682,"briefTitle":3683,"status":332,"phases":10785,"primaryCompletion":3685,"completion":3686,"start":3687,"enrollment":802,"conditions":10786,"interventions":10787},[87],[3163],[386,3690,3691],{"trials":10789,"activeCount":99},[],{"trials":10791,"activeCount":99},[],{"trials":10793,"activeCount":99},[],{"trials":10795,"activeCount":99},[],{"intervention":10797,"totalTrials":95,"cells":10798},"d-amphetamine 10 mg oral",{"EARLY_PHASE1":10799,"PHASE1":10801,"PHASE2":10814,"PHASE3":10816,"PHASE4":10818,"NA":10820},{"trials":10800,"activeCount":99},[],{"trials":10802,"activeCount":99},[10803],{"nctId":10804,"briefTitle":10805,"status":332,"phases":10806,"primaryCompletion":10807,"completion":10807,"start":10808,"enrollment":10809,"conditions":10810,"interventions":10812},"NCT03810703","Differential Responses to Drugs and Sweet Tastes",[87],"2018-08-09","2017-02-09",93,[10811],"Bipolar II Disorder",[10797,10813],"d-amphetamine 20 mg oral",{"trials":10815,"activeCount":99},[],{"trials":10817,"activeCount":99},[],{"trials":10819,"activeCount":99},[],{"trials":10821,"activeCount":99},[],{"intervention":10813,"totalTrials":95,"cells":10823},{"EARLY_PHASE1":10824,"PHASE1":10826,"PHASE2":10832,"PHASE3":10834,"PHASE4":10836,"NA":10838},{"trials":10825,"activeCount":99},[],{"trials":10827,"activeCount":99},[10828],{"nctId":10804,"briefTitle":10805,"status":332,"phases":10829,"primaryCompletion":10807,"completion":10807,"start":10808,"enrollment":10809,"conditions":10830,"interventions":10831},[87],[10811],[10797,10813],{"trials":10833,"activeCount":99},[],{"trials":10835,"activeCount":99},[],{"trials":10837,"activeCount":99},[],{"trials":10839,"activeCount":99},[],{"intervention":10841,"totalTrials":95,"cells":10842},"Hydroxychloroquine",{"EARLY_PHASE1":10843,"PHASE1":10845,"PHASE2":10855,"PHASE3":10857,"PHASE4":10859,"NA":10861},{"trials":10844,"activeCount":99},[],{"trials":10846,"activeCount":99},[10847],{"nctId":10848,"briefTitle":10849,"status":332,"phases":10850,"primaryCompletion":10851,"completion":10851,"start":10852,"enrollment":35,"conditions":10853,"interventions":10854},"NCT04351620","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19",[87],"2020-06-10","2020-04-20",[117],[10841],{"trials":10856,"activeCount":99},[],{"trials":10858,"activeCount":99},[],{"trials":10860,"activeCount":99},[],{"trials":10862,"activeCount":99},[],{"intervention":10864,"totalTrials":95,"cells":10865},"Androderm® 2.5mg",{"EARLY_PHASE1":10866,"PHASE1":10868,"PHASE2":10879,"PHASE3":10881,"PHASE4":10883,"NA":10885},{"trials":10867,"activeCount":99},[],{"trials":10869,"activeCount":99},[10870],{"nctId":10871,"briefTitle":10872,"status":332,"phases":10873,"primaryCompletion":4781,"completion":10874,"start":538,"enrollment":312,"conditions":10875,"interventions":10876},"NCT01187485","A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer",[87],"2009-02",[18],[10864,10877,10878],"Androderm® 5.0mg","Androderm® 7.5mg",{"trials":10880,"activeCount":99},[],{"trials":10882,"activeCount":99},[],{"trials":10884,"activeCount":99},[],{"trials":10886,"activeCount":99},[],{"intervention":10877,"totalTrials":95,"cells":10888},{"EARLY_PHASE1":10889,"PHASE1":10891,"PHASE2":10897,"PHASE3":10899,"PHASE4":10901,"NA":10903},{"trials":10890,"activeCount":99},[],{"trials":10892,"activeCount":99},[10893],{"nctId":10871,"briefTitle":10872,"status":332,"phases":10894,"primaryCompletion":4781,"completion":10874,"start":538,"enrollment":312,"conditions":10895,"interventions":10896},[87],[18],[10864,10877,10878],{"trials":10898,"activeCount":99},[],{"trials":10900,"activeCount":99},[],{"trials":10902,"activeCount":99},[],{"trials":10904,"activeCount":99},[],{"intervention":10878,"totalTrials":95,"cells":10906},{"EARLY_PHASE1":10907,"PHASE1":10909,"PHASE2":10915,"PHASE3":10917,"PHASE4":10919,"NA":10921},{"trials":10908,"activeCount":99},[],{"trials":10910,"activeCount":99},[10911],{"nctId":10871,"briefTitle":10872,"status":332,"phases":10912,"primaryCompletion":4781,"completion":10874,"start":538,"enrollment":312,"conditions":10913,"interventions":10914},[87],[18],[10864,10877,10878],{"trials":10916,"activeCount":99},[],{"trials":10918,"activeCount":99},[],{"trials":10920,"activeCount":99},[],{"trials":10922,"activeCount":99},[],{"intervention":7342,"totalTrials":95,"cells":10924},{"EARLY_PHASE1":10925,"PHASE1":10927,"PHASE2":10933,"PHASE3":10935,"PHASE4":10937,"NA":10939},{"trials":10926,"activeCount":99},[],{"trials":10928,"activeCount":99},[10929],{"nctId":7333,"briefTitle":7334,"status":363,"phases":10930,"primaryCompletion":7336,"completion":7336,"start":7337,"enrollment":1215,"conditions":10931,"interventions":10932},[87],[18,2227,7339,7340],[7342,7343,7344],{"trials":10934,"activeCount":99},[],{"trials":10936,"activeCount":99},[],{"trials":10938,"activeCount":99},[],{"trials":10940,"activeCount":99},[],{"intervention":7344,"totalTrials":95,"cells":10942},{"EARLY_PHASE1":10943,"PHASE1":10945,"PHASE2":10951,"PHASE3":10953,"PHASE4":10955,"NA":10957},{"trials":10944,"activeCount":99},[],{"trials":10946,"activeCount":99},[10947],{"nctId":7333,"briefTitle":7334,"status":363,"phases":10948,"primaryCompletion":7336,"completion":7336,"start":7337,"enrollment":1215,"conditions":10949,"interventions":10950},[87],[18,2227,7339,7340],[7342,7343,7344],{"trials":10952,"activeCount":99},[],{"trials":10954,"activeCount":99},[],{"trials":10956,"activeCount":99},[],{"trials":10958,"activeCount":99},[],{"intervention":1680,"totalTrials":95,"cells":10960},{"EARLY_PHASE1":10961,"PHASE1":10963,"PHASE2":10969,"PHASE3":10971,"PHASE4":10973,"NA":10975},{"trials":10962,"activeCount":99},[],{"trials":10964,"activeCount":99},[10965],{"nctId":1672,"briefTitle":1673,"status":363,"phases":10966,"primaryCompletion":1675,"completion":1675,"start":1280,"enrollment":367,"conditions":10967,"interventions":10968},[87],[1677,1678],[1680,326,387,1681,1682,1374,1683,1684,1559],{"trials":10970,"activeCount":99},[],{"trials":10972,"activeCount":99},[],{"trials":10974,"activeCount":99},[],{"trials":10976,"activeCount":99},[],{"intervention":1682,"totalTrials":95,"cells":10978},{"EARLY_PHASE1":10979,"PHASE1":10981,"PHASE2":10987,"PHASE3":10989,"PHASE4":10991,"NA":10993},{"trials":10980,"activeCount":99},[],{"trials":10982,"activeCount":99},[10983],{"nctId":1672,"briefTitle":1673,"status":363,"phases":10984,"primaryCompletion":1675,"completion":1675,"start":1280,"enrollment":367,"conditions":10985,"interventions":10986},[87],[1677,1678],[1680,326,387,1681,1682,1374,1683,1684,1559],{"trials":10988,"activeCount":99},[],{"trials":10990,"activeCount":99},[],{"trials":10992,"activeCount":99},[],{"trials":10994,"activeCount":99},[],{"intervention":1683,"totalTrials":95,"cells":10996},{"EARLY_PHASE1":10997,"PHASE1":10999,"PHASE2":11005,"PHASE3":11007,"PHASE4":11009,"NA":11011},{"trials":10998,"activeCount":99},[],{"trials":11000,"activeCount":99},[11001],{"nctId":1672,"briefTitle":1673,"status":363,"phases":11002,"primaryCompletion":1675,"completion":1675,"start":1280,"enrollment":367,"conditions":11003,"interventions":11004},[87],[1677,1678],[1680,326,387,1681,1682,1374,1683,1684,1559],{"trials":11006,"activeCount":99},[],{"trials":11008,"activeCount":99},[],{"trials":11010,"activeCount":99},[],{"trials":11012,"activeCount":99},[],{"intervention":1684,"totalTrials":95,"cells":11014},{"EARLY_PHASE1":11015,"PHASE1":11017,"PHASE2":11023,"PHASE3":11025,"PHASE4":11027,"NA":11029},{"trials":11016,"activeCount":99},[],{"trials":11018,"activeCount":99},[11019],{"nctId":1672,"briefTitle":1673,"status":363,"phases":11020,"primaryCompletion":1675,"completion":1675,"start":1280,"enrollment":367,"conditions":11021,"interventions":11022},[87],[1677,1678],[1680,326,387,1681,1682,1374,1683,1684,1559],{"trials":11024,"activeCount":99},[],{"trials":11026,"activeCount":99},[],{"trials":11028,"activeCount":99},[],{"trials":11030,"activeCount":99},[],{"intervention":6504,"totalTrials":95,"cells":11032},{"EARLY_PHASE1":11033,"PHASE1":11035,"PHASE2":11041,"PHASE3":11043,"PHASE4":11045,"NA":11047},{"trials":11034,"activeCount":99},[],{"trials":11036,"activeCount":99},[11037],{"nctId":6493,"briefTitle":6494,"status":468,"phases":11038,"primaryCompletion":6496,"completion":6496,"start":6497,"enrollment":1085,"conditions":11039,"interventions":11040},[87],[6499,6500,3798,6501],[6503,6464,6504,6505],{"trials":11042,"activeCount":99},[],{"trials":11044,"activeCount":99},[],{"trials":11046,"activeCount":99},[],{"trials":11048,"activeCount":99},[],{"intervention":6505,"totalTrials":95,"cells":11050},{"EARLY_PHASE1":11051,"PHASE1":11053,"PHASE2":11059,"PHASE3":11061,"PHASE4":11063,"NA":11065},{"trials":11052,"activeCount":99},[],{"trials":11054,"activeCount":99},[11055],{"nctId":6493,"briefTitle":6494,"status":468,"phases":11056,"primaryCompletion":6496,"completion":6496,"start":6497,"enrollment":1085,"conditions":11057,"interventions":11058},[87],[6499,6500,3798,6501],[6503,6464,6504,6505],{"trials":11060,"activeCount":99},[],{"trials":11062,"activeCount":99},[],{"trials":11064,"activeCount":99},[],{"trials":11066,"activeCount":99},[],{"intervention":11068,"totalTrials":95,"cells":11069},"FOLFIRI, Avastin, Irinotecan",{"EARLY_PHASE1":11070,"PHASE1":11072,"PHASE2":11083,"PHASE3":11085,"PHASE4":11087,"NA":11089},{"trials":11071,"activeCount":99},[],{"trials":11073,"activeCount":99},[11074],{"nctId":11075,"briefTitle":11076,"status":332,"phases":11077,"primaryCompletion":11078,"completion":11078,"start":11079,"enrollment":27,"conditions":11080,"interventions":11082},"NCT01183494","A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil\u002FLeucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients",[87],"2017-06-02","2009-12-12",[11081],"Metastatic Colorectal Cancer",[11068],{"trials":11084,"activeCount":99},[],{"trials":11086,"activeCount":99},[],{"trials":11088,"activeCount":99},[],{"trials":11090,"activeCount":99},[],{"intervention":4659,"totalTrials":95,"cells":11092},{"EARLY_PHASE1":11093,"PHASE1":11095,"PHASE2":11101,"PHASE3":11103,"PHASE4":11105,"NA":11107},{"trials":11094,"activeCount":99},[],{"trials":11096,"activeCount":99},[11097],{"nctId":4652,"briefTitle":4653,"status":332,"phases":11098,"primaryCompletion":4655,"completion":4656,"start":1303,"enrollment":488,"conditions":11099,"interventions":11100},[87],[18],[4645,4659,4660,4661,4662],{"trials":11102,"activeCount":99},[],{"trials":11104,"activeCount":99},[],{"trials":11106,"activeCount":99},[],{"trials":11108,"activeCount":99},[],{"intervention":4660,"totalTrials":95,"cells":11110},{"EARLY_PHASE1":11111,"PHASE1":11113,"PHASE2":11119,"PHASE3":11121,"PHASE4":11123,"NA":11125},{"trials":11112,"activeCount":99},[],{"trials":11114,"activeCount":99},[11115],{"nctId":4652,"briefTitle":4653,"status":332,"phases":11116,"primaryCompletion":4655,"completion":4656,"start":1303,"enrollment":488,"conditions":11117,"interventions":11118},[87],[18],[4645,4659,4660,4661,4662],{"trials":11120,"activeCount":99},[],{"trials":11122,"activeCount":99},[],{"trials":11124,"activeCount":99},[],{"trials":11126,"activeCount":99},[],{"intervention":4661,"totalTrials":95,"cells":11128},{"EARLY_PHASE1":11129,"PHASE1":11131,"PHASE2":11137,"PHASE3":11139,"PHASE4":11141,"NA":11143},{"trials":11130,"activeCount":99},[],{"trials":11132,"activeCount":99},[11133],{"nctId":4652,"briefTitle":4653,"status":332,"phases":11134,"primaryCompletion":4655,"completion":4656,"start":1303,"enrollment":488,"conditions":11135,"interventions":11136},[87],[18],[4645,4659,4660,4661,4662],{"trials":11138,"activeCount":99},[],{"trials":11140,"activeCount":99},[],{"trials":11142,"activeCount":99},[],{"trials":11144,"activeCount":99},[],{"intervention":4662,"totalTrials":95,"cells":11146},{"EARLY_PHASE1":11147,"PHASE1":11149,"PHASE2":11155,"PHASE3":11157,"PHASE4":11159,"NA":11161},{"trials":11148,"activeCount":99},[],{"trials":11150,"activeCount":99},[11151],{"nctId":4652,"briefTitle":4653,"status":332,"phases":11152,"primaryCompletion":4655,"completion":4656,"start":1303,"enrollment":488,"conditions":11153,"interventions":11154},[87],[18],[4645,4659,4660,4661,4662],{"trials":11156,"activeCount":99},[],{"trials":11158,"activeCount":99},[],{"trials":11160,"activeCount":99},[],{"trials":11162,"activeCount":99},[],{"intervention":9929,"totalTrials":95,"cells":11164},{"EARLY_PHASE1":11165,"PHASE1":11167,"PHASE2":11173,"PHASE3":11175,"PHASE4":11177,"NA":11179},{"trials":11166,"activeCount":99},[],{"trials":11168,"activeCount":99},[11169],{"nctId":9924,"briefTitle":9925,"status":332,"phases":11170,"primaryCompletion":8177,"completion":8177,"start":2073,"enrollment":2534,"conditions":11171,"interventions":11172},[87],[3918],[6655,9929],{"trials":11174,"activeCount":99},[],{"trials":11176,"activeCount":99},[],{"trials":11178,"activeCount":99},[],{"trials":11180,"activeCount":99},[],{"intervention":11182,"totalTrials":95,"cells":11183},"Ilorasertib",{"EARLY_PHASE1":11184,"PHASE1":11186,"PHASE2":11199,"PHASE3":11201,"PHASE4":11203,"NA":11205},{"trials":11185,"activeCount":99},[],{"trials":11187,"activeCount":99},[11188],{"nctId":11189,"briefTitle":11190,"status":332,"phases":11191,"primaryCompletion":11192,"completion":11192,"start":11193,"enrollment":35,"conditions":11194,"interventions":11198},"NCT02540876","Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery",[87],"2019-02-08","2015-09-08",[11195,11196,11197],"Metastatic Malignant Neoplasm","Solid Neoplasm","Unresectable Malignant Neoplasm",[11182],{"trials":11200,"activeCount":99},[],{"trials":11202,"activeCount":99},[],{"trials":11204,"activeCount":99},[],{"trials":11206,"activeCount":99},[],{"intervention":11208,"totalTrials":95,"cells":11209},"Alcohol",{"EARLY_PHASE1":11210,"PHASE1":11220,"PHASE2":11222,"PHASE3":11224,"PHASE4":11226,"NA":11228},{"trials":11211,"activeCount":99},[11212],{"nctId":11213,"briefTitle":11214,"status":332,"phases":11215,"primaryCompletion":11216,"completion":11216,"start":11217,"enrollment":1710,"conditions":11218,"interventions":11219},"NCT05826951","Social Effects of Alcohol",[86],"2023-10-03","2023-02-20",[4551],[11208],{"trials":11221,"activeCount":99},[],{"trials":11223,"activeCount":99},[],{"trials":11225,"activeCount":99},[],{"trials":11227,"activeCount":99},[],{"trials":11229,"activeCount":99},[],{"intervention":11231,"totalTrials":95,"cells":11232},"Liraglutide Pen Injector [Saxenda]",{"EARLY_PHASE1":11233,"PHASE1":11247,"PHASE2":11249,"PHASE3":11251,"PHASE4":11253,"NA":11255},{"trials":11234,"activeCount":99},[11235],{"nctId":11236,"briefTitle":11237,"status":468,"phases":11238,"primaryCompletion":11239,"completion":1366,"start":11240,"enrollment":1085,"conditions":11241,"interventions":11246},"NCT06171152","Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues",[86],"2027-06-01","2024-01-26",[5137,806,11242,11243,34,11244,11245],"Long Covid19","Obese","Obesity, Morbid","Acute Leukemia in Remission",[11231],{"trials":11248,"activeCount":99},[],{"trials":11250,"activeCount":99},[],{"trials":11252,"activeCount":99},[],{"trials":11254,"activeCount":99},[],{"trials":11256,"activeCount":99},[],{"intervention":11258,"totalTrials":95,"cells":11259},"Abbreviated MRI protocol: initial experience with Dotarem®",{"EARLY_PHASE1":11260,"PHASE1":11272,"PHASE2":11274,"PHASE3":11276,"PHASE4":11278,"NA":11280},{"trials":11261,"activeCount":99},[11262],{"nctId":11263,"briefTitle":11264,"status":332,"phases":11265,"primaryCompletion":11266,"completion":11266,"start":11267,"enrollment":1215,"conditions":11268,"interventions":11271},"NCT04341129","Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)",[86],"2023-06-30","2020-07-13",[784,11269,11270,15],"Breast Diseases","Breast Fibroadenoma",[11258],{"trials":11273,"activeCount":99},[],{"trials":11275,"activeCount":99},[],{"trials":11277,"activeCount":99},[],{"trials":11279,"activeCount":99},[],{"trials":11281,"activeCount":99},[],{"intervention":11283,"totalTrials":95,"cells":11284},"99mTc-EC-DG",{"EARLY_PHASE1":11285,"PHASE1":11295,"PHASE2":11297,"PHASE3":11299,"PHASE4":11301,"NA":11303},{"trials":11286,"activeCount":99},[11287],{"nctId":11288,"briefTitle":11289,"status":332,"phases":11290,"primaryCompletion":11291,"completion":11291,"start":11292,"enrollment":35,"conditions":11293,"interventions":11294},"NCT01359267","Feasibility of Imaging in the Treatment of Patients With Advanced Head and Neck Cancer",[86],"2015-09-15","2011-04-19",[21],[11283],{"trials":11296,"activeCount":99},[],{"trials":11298,"activeCount":99},[],{"trials":11300,"activeCount":99},[],{"trials":11302,"activeCount":99},[],{"trials":11304,"activeCount":99},[],{"intervention":9892,"totalTrials":95,"cells":11306},{"EARLY_PHASE1":11307,"PHASE1":11313,"PHASE2":11315,"PHASE3":11317,"PHASE4":11319,"NA":11321},{"trials":11308,"activeCount":99},[11309],{"nctId":9885,"briefTitle":9886,"status":332,"phases":11310,"primaryCompletion":5864,"completion":5864,"start":9888,"enrollment":7399,"conditions":11311,"interventions":11312},[86],[9890],[9892,9893],{"trials":11314,"activeCount":99},[],{"trials":11316,"activeCount":99},[],{"trials":11318,"activeCount":99},[],{"trials":11320,"activeCount":99},[],{"trials":11322,"activeCount":99},[],{"intervention":11324,"totalTrials":95,"cells":11325},"delta-9-tetrahydrocannabinol",{"EARLY_PHASE1":11326,"PHASE1":11338,"PHASE2":11340,"PHASE3":11342,"PHASE4":11344,"NA":11346},{"trials":11327,"activeCount":99},[11328],{"nctId":11329,"briefTitle":11330,"status":332,"phases":11331,"primaryCompletion":11332,"completion":11332,"start":11333,"enrollment":400,"conditions":11334,"interventions":11337},"NCT06471647","Effects of Drugs on Stress Memories",[86],"2025-03-25","2024-07-01",[11335,11336],"Delta-9-tetrahydrocannabinol (THC)","Stress",[11324,11324],{"trials":11339,"activeCount":99},[],{"trials":11341,"activeCount":99},[],{"trials":11343,"activeCount":99},[],{"trials":11345,"activeCount":99},[],{"trials":11347,"activeCount":99},[],{"intervention":11349,"totalTrials":95,"cells":11350},"Buprenorphine 0.2 MG Sublingual",{"EARLY_PHASE1":11351,"PHASE1":11362,"PHASE2":11364,"PHASE3":11366,"PHASE4":11368,"NA":11370},{"trials":11352,"activeCount":99},[11353],{"nctId":11354,"briefTitle":11355,"status":332,"phases":11356,"primaryCompletion":3294,"completion":3294,"start":11357,"enrollment":1153,"conditions":11358,"interventions":11360},"NCT01860287","The Effects of Buprenorphine on Responses to Verbal Tasks",[86],"2013-09",[11359],"Basic Science",[11349,11361],"Buprenorphine 0.4 MG Sublingual",{"trials":11363,"activeCount":99},[],{"trials":11365,"activeCount":99},[],{"trials":11367,"activeCount":99},[],{"trials":11369,"activeCount":99},[],{"trials":11371,"activeCount":99},[],{"intervention":11361,"totalTrials":95,"cells":11373},{"EARLY_PHASE1":11374,"PHASE1":11380,"PHASE2":11382,"PHASE3":11384,"PHASE4":11386,"NA":11388},{"trials":11375,"activeCount":99},[11376],{"nctId":11354,"briefTitle":11355,"status":332,"phases":11377,"primaryCompletion":3294,"completion":3294,"start":11357,"enrollment":1153,"conditions":11378,"interventions":11379},[86],[11359],[11349,11361],{"trials":11381,"activeCount":99},[],{"trials":11383,"activeCount":99},[],{"trials":11385,"activeCount":99},[],{"trials":11387,"activeCount":99},[],{"trials":11389,"activeCount":99},[],{"intervention":11391,"totalTrials":95,"cells":11392},"anti-SARS-CoV-2 convalescent plasma",{"EARLY_PHASE1":11393,"PHASE1":11404,"PHASE2":11406,"PHASE3":11408,"PHASE4":11410,"NA":11412},{"trials":11394,"activeCount":99},[11395],{"nctId":11396,"briefTitle":11397,"status":332,"phases":11398,"primaryCompletion":11399,"completion":11399,"start":11400,"enrollment":732,"conditions":11401,"interventions":11403},"NCT04340050","COVID-19 Convalescent Plasma",[86],"2020-12-23","2020-04-10",[11402],"Coronavirus",[11391],{"trials":11405,"activeCount":99},[],{"trials":11407,"activeCount":99},[],{"trials":11409,"activeCount":99},[],{"trials":11411,"activeCount":99},[],{"trials":11413,"activeCount":99},[],{"intervention":11415,"totalTrials":994,"cells":11416},"30% Nitrous oxide",{"EARLY_PHASE1":11417,"PHASE1":11419,"PHASE2":11421,"PHASE3":11435,"PHASE4":11437,"NA":11439},{"trials":11418,"activeCount":99},[],{"trials":11420,"activeCount":99},[],{"trials":11422,"activeCount":99},[11423],{"nctId":11424,"briefTitle":11425,"status":332,"phases":11426,"primaryCompletion":11427,"completion":11427,"start":11428,"enrollment":1779,"conditions":11429,"interventions":11431},"NCT00000261","Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13",[88],"1998-10","1997-11",[11430,26,23],"Alcohol-Related Disorders",[11415,11432,11433,11434],"0.2% sevoflurane","0.4% sevoflurane","0.6% sevoflurane",{"trials":11436,"activeCount":99},[],{"trials":11438,"activeCount":99},[],{"trials":11440,"activeCount":99},[11441,11448,11454,11461],{"nctId":11442,"briefTitle":11443,"status":332,"phases":11444,"primaryCompletion":2074,"completion":2074,"start":1445,"enrollment":516,"conditions":11445,"interventions":11446},"NCT00000262","Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14",[91],[26,23],[11415,11447,11432],"0.4% Sevoflurane",{"nctId":11449,"briefTitle":11450,"status":332,"phases":11451,"primaryCompletion":11427,"completion":11427,"start":7026,"enrollment":1228,"conditions":11452,"interventions":11453},"NCT00000263","Effects of Combined Alcohol and Nitrous Oxide Intake - 15",[91],[26,23],[11415],{"nctId":11455,"briefTitle":11456,"status":332,"phases":11457,"primaryCompletion":7048,"completion":7048,"start":11458,"enrollment":545,"conditions":11459,"interventions":11460},"NCT00000264","Subjective\u002FPsychomotor\u002F Effects of Combined Alcohol & Nitrous Oxide - 16",[91],"1997-09",[26,23],[11415],{"nctId":11462,"briefTitle":11463,"status":332,"phases":11464,"primaryCompletion":11428,"completion":11428,"start":11465,"enrollment":35,"conditions":11466,"interventions":11467},"NCT00000259","Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11",[91],"1996-08",[26,23],[11468,11469,11415,11470],"15 % Nitrous oxide","0.3 % Sevoflurane","0.6% Sevoflurane",{"intervention":6935,"totalTrials":994,"cells":11472},{"EARLY_PHASE1":11473,"PHASE1":11475,"PHASE2":11477,"PHASE3":11495,"PHASE4":11497,"NA":11499},{"trials":11474,"activeCount":99},[],{"trials":11476,"activeCount":99},[],{"trials":11478,"activeCount":99},[11479,11483,11487],{"nctId":6926,"briefTitle":6927,"status":332,"phases":11480,"primaryCompletion":3526,"completion":3526,"start":6929,"enrollment":1228,"conditions":11481,"interventions":11482},[88],[26,23],[6917,6932,6933,6934,6935],{"nctId":6937,"briefTitle":6938,"status":332,"phases":11484,"primaryCompletion":6940,"completion":6940,"start":6941,"enrollment":35,"conditions":11485,"interventions":11486},[88],[26,23],[6917,6935],{"nctId":11488,"briefTitle":11489,"status":332,"phases":11490,"primaryCompletion":11491,"completion":11491,"start":11492,"enrollment":732,"conditions":11493,"interventions":11494},"NCT00000249","Effects of Subanesthetic Concentrations of Nitrous Oxide - 1",[88],"1995-06","1993-09",[26,23],[6933,6934,6935],{"trials":11496,"activeCount":99},[],{"trials":11498,"activeCount":99},[],{"trials":11500,"activeCount":99},[11501,11510],{"nctId":11502,"briefTitle":11503,"status":332,"phases":11504,"primaryCompletion":1445,"completion":1445,"start":11505,"enrollment":1228,"conditions":11506,"interventions":11507},"NCT00000256","Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8",[91],"1995-08",[26,23],[6933,6935,11508,11509],"60% N2O","80% N2O",{"nctId":11511,"briefTitle":11512,"status":332,"phases":11513,"primaryCompletion":11514,"completion":11514,"start":11515,"enrollment":30,"conditions":11516,"interventions":11517},"NCT00000253","Effects of Nitrous Oxide: A Dose-Response Analysis - 5",[91],"1996-03","1994-11",[26,23],[6932,6933,6934,6935],{"intervention":11519,"totalTrials":994,"cells":11520},"Methamphetamine",{"EARLY_PHASE1":11521,"PHASE1":11553,"PHASE2":11559,"PHASE3":11561,"PHASE4":11563,"NA":11565},{"trials":11522,"activeCount":99},[11523,11536,11544],{"nctId":11524,"briefTitle":11525,"status":332,"phases":11526,"primaryCompletion":11527,"completion":11528,"start":11529,"enrollment":2708,"conditions":11530,"interventions":11534},"NCT05379959","Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function",[86],"2022-10-24","2023-10-24","2022-05-11",[11531,10438,11532,11533],"Stimulant Use","Social Behavior","Motivation",[11535,11519],"MDMA",{"nctId":11537,"briefTitle":11538,"status":332,"phases":11539,"primaryCompletion":9177,"completion":11540,"start":923,"enrollment":11541,"conditions":11542,"interventions":11543},"NCT04642820","Drugs Brain and Behavior (DDP)",[86],"2024-06-01",138,[11531],[11519],{"nctId":11545,"briefTitle":11546,"status":332,"phases":11547,"primaryCompletion":11548,"completion":11548,"start":11549,"enrollment":539,"conditions":11550,"interventions":11552},"NCT05003076","Brain Function and EEG",[86],"2023-04-01","2021-07-01",[32,11551],"Mood",[11519],{"trials":11554,"activeCount":99},[11555],{"nctId":10432,"briefTitle":10433,"status":332,"phases":11556,"primaryCompletion":10435,"completion":10435,"start":10436,"enrollment":400,"conditions":11557,"interventions":11558},[87],[32,10438],[10425,10440],{"trials":11560,"activeCount":99},[],{"trials":11562,"activeCount":99},[],{"trials":11564,"activeCount":99},[],{"trials":11566,"activeCount":99},[11567],{"nctId":11568,"briefTitle":11569,"status":332,"phases":11570,"primaryCompletion":8570,"completion":524,"start":11571,"enrollment":1335,"conditions":11572,"interventions":11574},"NCT02323048","Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans",[91],"2014-07",[11573],"Substance Abuse",[10440],{"intervention":11535,"totalTrials":994,"cells":11576},{"EARLY_PHASE1":11577,"PHASE1":11608,"PHASE2":11610,"PHASE3":11612,"PHASE4":11614,"NA":11616},{"trials":11578,"activeCount":99},[11579,11587,11591,11599],{"nctId":11580,"briefTitle":11581,"status":332,"phases":11582,"primaryCompletion":11583,"completion":11583,"start":11584,"enrollment":16,"conditions":11585,"interventions":11586},"NCT04053036","Effects of Drugs on Responses to Brain and Emotional Processes",[86],"2021-04-12","2019-08-08",[5644,32],[11535],{"nctId":11524,"briefTitle":11525,"status":332,"phases":11588,"primaryCompletion":11527,"completion":11528,"start":11529,"enrollment":2708,"conditions":11589,"interventions":11590},[86],[11531,10438,11532,11533],[11535,11519],{"nctId":11592,"briefTitle":11593,"status":332,"phases":11594,"primaryCompletion":7876,"completion":7876,"start":11595,"enrollment":1085,"conditions":11596,"interventions":11598},"NCT05123716","Drug Effects on Interpersonal Interaction",[86],"2021-08-01",[11597],"Interaction, Social",[11535],{"nctId":11600,"briefTitle":11601,"status":332,"phases":11602,"primaryCompletion":11603,"completion":11603,"start":11604,"enrollment":1432,"conditions":11605,"interventions":11607},"NCT05948683","Prosocial Effects of MDMA",[86],"2024-07-15","2023-07-21",[10438,11606],"Social Interaction",[11535],{"trials":11609,"activeCount":99},[],{"trials":11611,"activeCount":99},[],{"trials":11613,"activeCount":99},[],{"trials":11615,"activeCount":99},[],{"trials":11617,"activeCount":99},[11618],{"nctId":11619,"briefTitle":11620,"status":332,"phases":11621,"primaryCompletion":11622,"completion":11622,"start":524,"enrollment":11623,"conditions":11624,"interventions":11625},"NCT03050541","Effects of MDMA on Emotional and Social Memories",[91],"2016-09",84,[32],[11535],{"intervention":6933,"totalTrials":526,"cells":11627},{"EARLY_PHASE1":11628,"PHASE1":11630,"PHASE2":11632,"PHASE3":11642,"PHASE4":11644,"NA":11646},{"trials":11629,"activeCount":99},[],{"trials":11631,"activeCount":99},[],{"trials":11633,"activeCount":99},[11634,11638],{"nctId":6926,"briefTitle":6927,"status":332,"phases":11635,"primaryCompletion":3526,"completion":3526,"start":6929,"enrollment":1228,"conditions":11636,"interventions":11637},[88],[26,23],[6917,6932,6933,6934,6935],{"nctId":11488,"briefTitle":11489,"status":332,"phases":11639,"primaryCompletion":11491,"completion":11491,"start":11492,"enrollment":732,"conditions":11640,"interventions":11641},[88],[26,23],[6933,6934,6935],{"trials":11643,"activeCount":99},[],{"trials":11645,"activeCount":99},[],{"trials":11647,"activeCount":99},[11648,11652],{"nctId":11502,"briefTitle":11503,"status":332,"phases":11649,"primaryCompletion":1445,"completion":1445,"start":11505,"enrollment":1228,"conditions":11650,"interventions":11651},[91],[26,23],[6933,6935,11508,11509],{"nctId":11511,"briefTitle":11512,"status":332,"phases":11653,"primaryCompletion":11514,"completion":11514,"start":11515,"enrollment":30,"conditions":11654,"interventions":11655},[91],[26,23],[6932,6933,6934,6935],{"intervention":6934,"totalTrials":526,"cells":11657},{"EARLY_PHASE1":11658,"PHASE1":11660,"PHASE2":11662,"PHASE3":11676,"PHASE4":11678,"NA":11680},{"trials":11659,"activeCount":99},[],{"trials":11661,"activeCount":99},[],{"trials":11663,"activeCount":99},[11664,11668,11672],{"nctId":6926,"briefTitle":6927,"status":332,"phases":11665,"primaryCompletion":3526,"completion":3526,"start":6929,"enrollment":1228,"conditions":11666,"interventions":11667},[88],[26,23],[6917,6932,6933,6934,6935],{"nctId":7182,"briefTitle":7183,"status":332,"phases":11669,"primaryCompletion":7185,"completion":7185,"start":7186,"enrollment":732,"conditions":11670,"interventions":11671},[88],[26,23],[6934,7173,7189],{"nctId":11488,"briefTitle":11489,"status":332,"phases":11673,"primaryCompletion":11491,"completion":11491,"start":11492,"enrollment":732,"conditions":11674,"interventions":11675},[88],[26,23],[6933,6934,6935],{"trials":11677,"activeCount":99},[],{"trials":11679,"activeCount":99},[],{"trials":11681,"activeCount":99},[11682],{"nctId":11511,"briefTitle":11512,"status":332,"phases":11683,"primaryCompletion":11514,"completion":11514,"start":11515,"enrollment":30,"conditions":11684,"interventions":11685},[91],[26,23],[6932,6933,6934,6935],{"intervention":9922,"totalTrials":526,"cells":11687},{"EARLY_PHASE1":11688,"PHASE1":11690,"PHASE2":11702,"PHASE3":11704,"PHASE4":11714,"NA":11716},{"trials":11689,"activeCount":99},[],{"trials":11691,"activeCount":99},[11692,11698],{"nctId":11693,"briefTitle":11694,"status":332,"phases":11695,"primaryCompletion":837,"completion":837,"start":6437,"enrollment":35,"conditions":11696,"interventions":11697},"NCT00452218","Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)",[87],[10118],[9922],{"nctId":9915,"briefTitle":9916,"status":332,"phases":11699,"primaryCompletion":2359,"completion":4991,"start":9918,"enrollment":1282,"conditions":11700,"interventions":11701},[87],[9920],[9922,6655,6655],{"trials":11703,"activeCount":99},[],{"trials":11705,"activeCount":99},[11706],{"nctId":11707,"briefTitle":11708,"status":332,"phases":11709,"primaryCompletion":11710,"completion":4921,"start":11711,"enrollment":2534,"conditions":11712,"interventions":11713},"NCT00606866","MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma",[89],"2007-01","2004-07",[7619],[9922,9922],{"trials":11715,"activeCount":99},[],{"trials":11717,"activeCount":99},[11718],{"nctId":11719,"briefTitle":11720,"status":363,"phases":11721,"primaryCompletion":4991,"completion":4991,"start":7761,"enrollment":488,"conditions":11722,"interventions":11723},"NCT00619242","The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer",[91],[3528],[11724],"sorafenib",{"intervention":11726,"totalTrials":488,"cells":11727},"regadenoson",{"EARLY_PHASE1":11728,"PHASE1":11730,"PHASE2":11732,"PHASE3":11734,"PHASE4":11736,"NA":11746},{"trials":11729,"activeCount":99},[],{"trials":11731,"activeCount":99},[],{"trials":11733,"activeCount":99},[],{"trials":11735,"activeCount":99},[],{"trials":11737,"activeCount":99},[11738],{"nctId":11739,"briefTitle":11740,"status":332,"phases":11741,"primaryCompletion":11742,"completion":11742,"start":4820,"enrollment":516,"conditions":11743,"interventions":11745},"NCT00871260","Stress Testing and Cardiac Magnetic Resonance",[90],"2014-06-04",[11744],"Coronary Disease",[11726],{"trials":11747,"activeCount":99},[11748,11757],{"nctId":11749,"briefTitle":11750,"status":332,"phases":11751,"primaryCompletion":6855,"completion":6855,"start":5503,"enrollment":11752,"conditions":11753,"interventions":11755},"NCT01969916","Stress CT Perfusion in Patients With Chest Pain",[91],150,[11754],"Coronary Artery Disease",[11756],"Regadenoson",{"nctId":11758,"briefTitle":11759,"status":332,"phases":11760,"primaryCompletion":432,"completion":432,"start":839,"enrollment":11761,"conditions":11762,"interventions":11763},"NCT00857792","Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging",[91],120,[11744],[11726],{"intervention":1286,"totalTrials":488,"cells":11765},{"EARLY_PHASE1":11766,"PHASE1":11768,"PHASE2":11770,"PHASE3":11780,"PHASE4":11782,"NA":11784},{"trials":11767,"activeCount":99},[],{"trials":11769,"activeCount":99},[],{"trials":11771,"activeCount":99},[11772,11776],{"nctId":1276,"briefTitle":1277,"status":332,"phases":11773,"primaryCompletion":1279,"completion":1280,"start":1281,"enrollment":1282,"conditions":11774,"interventions":11775},[88],[21],[1285,1286,385],{"nctId":3354,"briefTitle":3355,"status":363,"phases":11777,"primaryCompletion":3357,"completion":3358,"start":3359,"enrollment":607,"conditions":11778,"interventions":11779},[88],[3361],[958,1286],{"trials":11781,"activeCount":99},[],{"trials":11783,"activeCount":99},[],{"trials":11785,"activeCount":99},[11786],{"nctId":1395,"briefTitle":1396,"status":332,"phases":11787,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":516,"conditions":11788,"interventions":11789},[91],[1401],[1286,385,1403,1404],{"intervention":6125,"totalTrials":488,"cells":11791},{"EARLY_PHASE1":11792,"PHASE1":11802,"PHASE2":11804,"PHASE3":11806,"PHASE4":11808,"NA":11810},{"trials":11793,"activeCount":99},[11794,11798],{"nctId":6105,"briefTitle":6106,"status":332,"phases":11795,"primaryCompletion":6108,"completion":6108,"start":6109,"enrollment":782,"conditions":11796,"interventions":11797},[86],[6111,6112,6113],[6115,6091,6091],{"nctId":6117,"briefTitle":6118,"status":332,"phases":11799,"primaryCompletion":6120,"completion":6120,"start":6121,"enrollment":802,"conditions":11800,"interventions":11801},[86],[6123],[6091,6125],{"trials":11803,"activeCount":99},[],{"trials":11805,"activeCount":99},[],{"trials":11807,"activeCount":99},[],{"trials":11809,"activeCount":99},[],{"trials":11811,"activeCount":99},[11812],{"nctId":11813,"briefTitle":11814,"status":332,"phases":11815,"primaryCompletion":11816,"completion":11622,"start":3283,"enrollment":1215,"conditions":11817,"interventions":11818},"NCT02205983","The Effects of Hydromorphone on Responses to Verbal Tasks",[91],"2016-07",[32],[11819,11820,11821,6125],"2 mg hydromorphone","1000 mg Acetaminophen","4 mg hydromorphone",{"intervention":11432,"totalTrials":367,"cells":11823},{"EARLY_PHASE1":11824,"PHASE1":11826,"PHASE2":11828,"PHASE3":11834,"PHASE4":11836,"NA":11838},{"trials":11825,"activeCount":99},[],{"trials":11827,"activeCount":99},[],{"trials":11829,"activeCount":99},[11830],{"nctId":11424,"briefTitle":11425,"status":332,"phases":11831,"primaryCompletion":11427,"completion":11427,"start":11428,"enrollment":1779,"conditions":11832,"interventions":11833},[88],[11430,26,23],[11415,11432,11433,11434],{"trials":11835,"activeCount":99},[],{"trials":11837,"activeCount":99},[],{"trials":11839,"activeCount":99},[11840],{"nctId":11442,"briefTitle":11443,"status":332,"phases":11841,"primaryCompletion":2074,"completion":2074,"start":1445,"enrollment":516,"conditions":11842,"interventions":11843},[91],[26,23],[11415,11447,11432],{"intervention":11433,"totalTrials":367,"cells":11845},{"EARLY_PHASE1":11846,"PHASE1":11848,"PHASE2":11850,"PHASE3":11856,"PHASE4":11858,"NA":11860},{"trials":11847,"activeCount":99},[],{"trials":11849,"activeCount":99},[],{"trials":11851,"activeCount":99},[11852],{"nctId":11424,"briefTitle":11425,"status":332,"phases":11853,"primaryCompletion":11427,"completion":11427,"start":11428,"enrollment":1779,"conditions":11854,"interventions":11855},[88],[11430,26,23],[11415,11432,11433,11434],{"trials":11857,"activeCount":99},[],{"trials":11859,"activeCount":99},[],{"trials":11861,"activeCount":99},[11862],{"nctId":11442,"briefTitle":11443,"status":332,"phases":11863,"primaryCompletion":2074,"completion":2074,"start":1445,"enrollment":516,"conditions":11864,"interventions":11865},[91],[26,23],[11415,11447,11432],{"intervention":11434,"totalTrials":367,"cells":11867},{"EARLY_PHASE1":11868,"PHASE1":11870,"PHASE2":11872,"PHASE3":11878,"PHASE4":11880,"NA":11882},{"trials":11869,"activeCount":99},[],{"trials":11871,"activeCount":99},[],{"trials":11873,"activeCount":99},[11874],{"nctId":11424,"briefTitle":11425,"status":332,"phases":11875,"primaryCompletion":11427,"completion":11427,"start":11428,"enrollment":1779,"conditions":11876,"interventions":11877},[88],[11430,26,23],[11415,11432,11433,11434],{"trials":11879,"activeCount":99},[],{"trials":11881,"activeCount":99},[],{"trials":11883,"activeCount":99},[11884],{"nctId":11462,"briefTitle":11463,"status":332,"phases":11885,"primaryCompletion":11428,"completion":11428,"start":11465,"enrollment":35,"conditions":11886,"interventions":11887},[91],[26,23],[11468,11469,11415,11470],{"intervention":11889,"totalTrials":367,"cells":11890},"leuprolide",{"EARLY_PHASE1":11891,"PHASE1":11893,"PHASE2":11895,"PHASE3":11897,"PHASE4":11899,"NA":11901},{"trials":11892,"activeCount":99},[],{"trials":11894,"activeCount":99},[],{"trials":11896,"activeCount":99},[],{"trials":11898,"activeCount":99},[],{"trials":11900,"activeCount":99},[],{"trials":11902,"activeCount":99},[11903,11913],{"nctId":11904,"briefTitle":11905,"status":332,"phases":11906,"completion":11907,"start":11908,"enrollment":1335,"conditions":11909,"interventions":11911},"NCT00004426","Leuprolide in Determining the Cause of Gonadotropin Deficiency",[91],"1998-09","1994-08",[11910],"Hypogonadism",[11912,11889],"gonadotropin releasing hormone",{"nctId":11914,"briefTitle":11915,"status":332,"phases":11916,"completion":397,"start":11458,"enrollment":7762,"conditions":11917,"interventions":11918},"NCT00004438","Leuprolide in Treating Adults With Hypogonadotropism",[91],[11910],[11889],{"intervention":6932,"totalTrials":367,"cells":11920},{"EARLY_PHASE1":11921,"PHASE1":11923,"PHASE2":11925,"PHASE3":11931,"PHASE4":11933,"NA":11935},{"trials":11922,"activeCount":99},[],{"trials":11924,"activeCount":99},[],{"trials":11926,"activeCount":99},[11927],{"nctId":6926,"briefTitle":6927,"status":332,"phases":11928,"primaryCompletion":3526,"completion":3526,"start":6929,"enrollment":1228,"conditions":11929,"interventions":11930},[88],[26,23],[6917,6932,6933,6934,6935],{"trials":11932,"activeCount":99},[],{"trials":11934,"activeCount":99},[],{"trials":11936,"activeCount":99},[11937],{"nctId":11511,"briefTitle":11512,"status":332,"phases":11938,"primaryCompletion":11514,"completion":11514,"start":11515,"enrollment":30,"conditions":11939,"interventions":11940},[91],[26,23],[6932,6933,6934,6935],{"intervention":11942,"totalTrials":367,"cells":11943},"Cannabidiol",{"EARLY_PHASE1":11944,"PHASE1":11946,"PHASE2":11948,"PHASE3":11960,"PHASE4":11962,"NA":11964},{"trials":11945,"activeCount":99},[],{"trials":11947,"activeCount":99},[],{"trials":11949,"activeCount":99},[11950],{"nctId":11951,"briefTitle":11952,"status":332,"phases":11953,"primaryCompletion":11954,"completion":11954,"start":11955,"enrollment":526,"conditions":11956,"interventions":11959},"NCT04978428","Epidiolex in Obsessive Compulsive Disorder and Related Disorders",[88],"2025-11-01","2022-04-14",[2351,734,11957,11958],"Tourette Syndrome","Hoarding Disorder",[11942],{"trials":11961,"activeCount":99},[],{"trials":11963,"activeCount":99},[],{"trials":11965,"activeCount":99},[11966],{"nctId":11967,"briefTitle":11968,"status":332,"phases":11969,"primaryCompletion":10237,"completion":10237,"start":525,"enrollment":1358,"conditions":11970,"interventions":11972},"NCT02902081","Cannabidiol and Emotional Stimuli",[91],[11971],"Drug Addiction",[11942],{"intervention":11974,"totalTrials":367,"cells":11975},"propofol",{"EARLY_PHASE1":11976,"PHASE1":11978,"PHASE2":11980,"PHASE3":11982,"PHASE4":11984,"NA":11990},{"trials":11977,"activeCount":99},[],{"trials":11979,"activeCount":99},[],{"trials":11981,"activeCount":99},[],{"trials":11983,"activeCount":99},[],{"trials":11985,"activeCount":99},[11986],{"nctId":4987,"briefTitle":4988,"status":363,"phases":11987,"primaryCompletion":4990,"completion":4990,"start":4991,"enrollment":4992,"conditions":11988,"interventions":11989},[90],[4994,4995],[4974,4997,4998,4999],{"trials":11991,"activeCount":99},[11992],{"nctId":11993,"briefTitle":11994,"status":332,"phases":11995,"primaryCompletion":5863,"completion":838,"start":3358,"enrollment":1432,"conditions":11996,"interventions":11997},"NCT01014728","Intraoperative Bleeding During Endoscopic Sinus Surgery",[91],[3245],[11974,11998],"sevoflurane",{"intervention":6113,"totalTrials":367,"cells":12000},{"EARLY_PHASE1":12001,"PHASE1":12011,"PHASE2":12013,"PHASE3":12015,"PHASE4":12017,"NA":12019},{"trials":12002,"activeCount":99},[12003],{"nctId":12004,"briefTitle":12005,"status":332,"phases":12006,"primaryCompletion":12007,"completion":12007,"start":12008,"enrollment":782,"conditions":12009,"interventions":12010},"NCT03471585","Effects of THC on Emotional Memory Retrieval",[86],"2017-10-04","2017-02-15",[32],[6113],{"trials":12012,"activeCount":99},[],{"trials":12014,"activeCount":99},[],{"trials":12016,"activeCount":99},[],{"trials":12018,"activeCount":99},[],{"trials":12020,"activeCount":99},[12021],{"nctId":12022,"briefTitle":12023,"status":332,"phases":12024,"primaryCompletion":12025,"completion":12025,"start":12026,"enrollment":6652,"conditions":12027,"interventions":12028},"NCT02485158","Individual Differences in the Response to Drugs",[91],"2013-12","2013-07",[32],[6113,12029,12030],"AMP","ALC",{"intervention":12032,"totalTrials":367,"cells":12033},"Exenatide",{"EARLY_PHASE1":12034,"PHASE1":12036,"PHASE2":12038,"PHASE3":12040,"PHASE4":12042,"NA":12044},{"trials":12035,"activeCount":99},[],{"trials":12037,"activeCount":99},[],{"trials":12039,"activeCount":99},[],{"trials":12041,"activeCount":99},[],{"trials":12043,"activeCount":99},[],{"trials":12045,"activeCount":99},[12046,12055],{"nctId":12047,"briefTitle":12048,"status":332,"phases":12049,"primaryCompletion":12050,"completion":12050,"start":12051,"enrollment":545,"conditions":12052,"interventions":12054},"NCT01416649","Impact of Exenatide on Sleep Duration",[],"2021-04-21","2011-02-01",[12053],"Type 2 Diabetes",[12032],{"nctId":12056,"briefTitle":12057,"status":332,"phases":12058,"primaryCompletion":12059,"completion":12059,"start":12060,"enrollment":24,"conditions":12061,"interventions":12063},"NCT01136798","Impact of Exenatide on Sleep in Type 2 Diabetes",[91],"2016-09-01","2010-06-01",[12053,12062],"Sleep Disordered Breathing",[12032],{"intervention":4936,"totalTrials":367,"cells":12065},{"EARLY_PHASE1":12066,"PHASE1":12068,"PHASE2":12070,"PHASE3":12072,"PHASE4":12074,"NA":12080},{"trials":12067,"activeCount":99},[],{"trials":12069,"activeCount":99},[],{"trials":12071,"activeCount":99},[],{"trials":12073,"activeCount":99},[],{"trials":12075,"activeCount":99},[12076],{"nctId":4929,"briefTitle":4930,"status":332,"phases":12077,"primaryCompletion":4932,"completion":4932,"start":4933,"enrollment":1106,"conditions":12078,"interventions":12079},[90],[4784],[4936,4937],{"trials":12081,"activeCount":99},[12082],{"nctId":12083,"briefTitle":12084,"status":981,"phases":12085,"primaryCompletion":5503,"completion":524,"start":2358,"enrollment":99,"conditions":12086,"interventions":12088},"NCT01640496","Vitamin D Treatment in Ulcerative Colitis",[91],[6439,12087],"Inflammatory Bowel Disease",[4936],{"intervention":12090,"totalTrials":367,"cells":12091},"Nitrous oxide",{"EARLY_PHASE1":12092,"PHASE1":12094,"PHASE2":12096,"PHASE3":12106,"PHASE4":12108,"NA":12110},{"trials":12093,"activeCount":99},[],{"trials":12095,"activeCount":99},[],{"trials":12097,"activeCount":99},[12098],{"nctId":12099,"briefTitle":12100,"status":332,"phases":12101,"primaryCompletion":12102,"completion":12102,"start":12103,"enrollment":732,"conditions":12104,"interventions":12105},"NCT00000255","Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7",[88],"1996-05","1995-04",[26,23],[12090],{"trials":12107,"activeCount":99},[],{"trials":12109,"activeCount":99},[],{"trials":12111,"activeCount":99},[12112],{"nctId":12113,"briefTitle":12114,"status":332,"phases":12115,"primaryCompletion":12116,"completion":12116,"start":12117,"enrollment":24,"conditions":12118,"interventions":12119},"NCT00000260","Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12",[91],"1998-01","1997-06",[26,23],[12090],{"intervention":12121,"totalTrials":95,"cells":12122},"5-ALA with Blu-U Light",{"EARLY_PHASE1":12123,"PHASE1":12125,"PHASE2":12127,"PHASE3":12129,"PHASE4":12131,"NA":12133},{"trials":12124,"activeCount":99},[],{"trials":12126,"activeCount":99},[],{"trials":12128,"activeCount":99},[],{"trials":12130,"activeCount":99},[],{"trials":12132,"activeCount":99},[],{"trials":12134,"activeCount":99},[12135],{"nctId":12136,"briefTitle":12137,"status":981,"phases":12138,"primaryCompletion":525,"completion":5339,"start":10874,"enrollment":99,"conditions":12139,"interventions":12141},"NCT00814918","Topical 5-ALA-PDT With Blu-U Therapy Versus Topical 5-ALA With Pulse Dye Laser In Treating Recalcitrant Acne Vulgaris",[91],[12140],"Acne Vulgaris",[12121,12142],"5-ALA with Candela V-beam Pulse Dye Laser",{"intervention":12142,"totalTrials":95,"cells":12144},{"EARLY_PHASE1":12145,"PHASE1":12147,"PHASE2":12149,"PHASE3":12151,"PHASE4":12153,"NA":12155},{"trials":12146,"activeCount":99},[],{"trials":12148,"activeCount":99},[],{"trials":12150,"activeCount":99},[],{"trials":12152,"activeCount":99},[],{"trials":12154,"activeCount":99},[],{"trials":12156,"activeCount":99},[12157],{"nctId":12136,"briefTitle":12137,"status":981,"phases":12158,"primaryCompletion":525,"completion":5339,"start":10874,"enrollment":99,"conditions":12159,"interventions":12160},[91],[12140],[12121,12142],{"intervention":12162,"totalTrials":95,"cells":12163},"mupirocin ointment",{"EARLY_PHASE1":12164,"PHASE1":12166,"PHASE2":12168,"PHASE3":12170,"PHASE4":12172,"NA":12174},{"trials":12165,"activeCount":99},[],{"trials":12167,"activeCount":99},[],{"trials":12169,"activeCount":99},[],{"trials":12171,"activeCount":99},[],{"trials":12173,"activeCount":99},[],{"trials":12175,"activeCount":99},[12176],{"nctId":12177,"briefTitle":12178,"status":332,"phases":12179,"primaryCompletion":9918,"completion":9918,"start":1415,"enrollment":1710,"conditions":12180,"interventions":12184},"NCT00406913","Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery",[91],[12181,12182,12183],"Endophthalmitis","Cataract Surgery","Prophylaxis",[12162],{"intervention":11912,"totalTrials":95,"cells":12186},{"EARLY_PHASE1":12187,"PHASE1":12189,"PHASE2":12191,"PHASE3":12193,"PHASE4":12195,"NA":12197},{"trials":12188,"activeCount":99},[],{"trials":12190,"activeCount":99},[],{"trials":12192,"activeCount":99},[],{"trials":12194,"activeCount":99},[],{"trials":12196,"activeCount":99},[],{"trials":12198,"activeCount":99},[12199],{"nctId":11904,"briefTitle":11905,"status":332,"phases":12200,"completion":11907,"start":11908,"enrollment":1335,"conditions":12201,"interventions":12202},[91],[11910],[11912,11889],{"intervention":12204,"totalTrials":95,"cells":12205},"tolvaptan",{"EARLY_PHASE1":12206,"PHASE1":12208,"PHASE2":12210,"PHASE3":12212,"PHASE4":12214,"NA":12216},{"trials":12207,"activeCount":99},[],{"trials":12209,"activeCount":99},[],{"trials":12211,"activeCount":99},[],{"trials":12213,"activeCount":99},[],{"trials":12215,"activeCount":99},[],{"trials":12217,"activeCount":99},[12218],{"nctId":12219,"briefTitle":12220,"status":332,"phases":12221,"primaryCompletion":7876,"completion":7876,"start":12222,"enrollment":6652,"conditions":12223,"interventions":12226},"NCT05408104","Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients",[],"2019-03-28",[4502,12224,12225],"Heart Assist Device","Hyponatremic",[12204],{"intervention":12228,"totalTrials":95,"cells":12229},"Tysabri",{"EARLY_PHASE1":12230,"PHASE1":12232,"PHASE2":12234,"PHASE3":12236,"PHASE4":12238,"NA":12240},{"trials":12231,"activeCount":99},[],{"trials":12233,"activeCount":99},[],{"trials":12235,"activeCount":99},[],{"trials":12237,"activeCount":99},[],{"trials":12239,"activeCount":99},[],{"trials":12241,"activeCount":99},[12242],{"nctId":12243,"briefTitle":12244,"status":332,"phases":12245,"primaryCompletion":12246,"completion":12246,"start":4801,"enrollment":516,"conditions":12247,"interventions":12248},"NCT01071512","Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis",[91],"2016-01",[5137],[12228],{"intervention":12250,"totalTrials":95,"cells":12251},"Ampicillin",{"EARLY_PHASE1":12252,"PHASE1":12254,"PHASE2":12256,"PHASE3":12258,"PHASE4":12260,"NA":12262},{"trials":12253,"activeCount":99},[],{"trials":12255,"activeCount":99},[],{"trials":12257,"activeCount":99},[],{"trials":12259,"activeCount":99},[],{"trials":12261,"activeCount":99},[],{"trials":12263,"activeCount":99},[12264],{"nctId":12265,"briefTitle":12266,"status":332,"phases":12267,"primaryCompletion":1251,"completion":1251,"start":5573,"enrollment":9,"conditions":12268,"interventions":12271},"NCT02477423","A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome",[91],[12269,12270],"Premature Birth of Newborn","Enterocolitis, Necrotizing",[12250,12272],"Gentamicins",{"intervention":12272,"totalTrials":95,"cells":12274},{"EARLY_PHASE1":12275,"PHASE1":12277,"PHASE2":12279,"PHASE3":12281,"PHASE4":12283,"NA":12285},{"trials":12276,"activeCount":99},[],{"trials":12278,"activeCount":99},[],{"trials":12280,"activeCount":99},[],{"trials":12282,"activeCount":99},[],{"trials":12284,"activeCount":99},[],{"trials":12286,"activeCount":99},[12287],{"nctId":12265,"briefTitle":12266,"status":332,"phases":12288,"primaryCompletion":1251,"completion":1251,"start":5573,"enrollment":9,"conditions":12289,"interventions":12290},[91],[12269,12270],[12250,12272],{"intervention":12292,"totalTrials":95,"cells":12293},"Sinofresh",{"EARLY_PHASE1":12294,"PHASE1":12296,"PHASE2":12298,"PHASE3":12300,"PHASE4":12302,"NA":12304},{"trials":12295,"activeCount":99},[],{"trials":12297,"activeCount":99},[],{"trials":12299,"activeCount":99},[],{"trials":12301,"activeCount":99},[],{"trials":12303,"activeCount":99},[],{"trials":12305,"activeCount":99},[12306],{"nctId":12307,"briefTitle":12308,"status":981,"phases":12309,"primaryCompletion":4933,"completion":10197,"start":1279,"enrollment":99,"conditions":12310,"interventions":12312},"NCT00790972","The Efficacy of SinoFresh Nasal and Sinus Care Nasal Spray in Eliminating MRSA From the Nasal Cavity",[91],[12311],"MRSA Infection",[12292],{"intervention":11998,"totalTrials":95,"cells":12314},{"EARLY_PHASE1":12315,"PHASE1":12317,"PHASE2":12319,"PHASE3":12321,"PHASE4":12323,"NA":12325},{"trials":12316,"activeCount":99},[],{"trials":12318,"activeCount":99},[],{"trials":12320,"activeCount":99},[],{"trials":12322,"activeCount":99},[],{"trials":12324,"activeCount":99},[],{"trials":12326,"activeCount":99},[12327],{"nctId":11993,"briefTitle":11994,"status":332,"phases":12328,"primaryCompletion":5863,"completion":838,"start":3358,"enrollment":1432,"conditions":12329,"interventions":12330},[91],[3245],[11974,11998],{"intervention":11508,"totalTrials":95,"cells":12332},{"EARLY_PHASE1":12333,"PHASE1":12335,"PHASE2":12337,"PHASE3":12339,"PHASE4":12341,"NA":12343},{"trials":12334,"activeCount":99},[],{"trials":12336,"activeCount":99},[],{"trials":12338,"activeCount":99},[],{"trials":12340,"activeCount":99},[],{"trials":12342,"activeCount":99},[],{"trials":12344,"activeCount":99},[12345],{"nctId":11502,"briefTitle":11503,"status":332,"phases":12346,"primaryCompletion":1445,"completion":1445,"start":11505,"enrollment":1228,"conditions":12347,"interventions":12348},[91],[26,23],[6933,6935,11508,11509],{"intervention":11509,"totalTrials":95,"cells":12350},{"EARLY_PHASE1":12351,"PHASE1":12353,"PHASE2":12355,"PHASE3":12357,"PHASE4":12359,"NA":12361},{"trials":12352,"activeCount":99},[],{"trials":12354,"activeCount":99},[],{"trials":12356,"activeCount":99},[],{"trials":12358,"activeCount":99},[],{"trials":12360,"activeCount":99},[],{"trials":12362,"activeCount":99},[12363],{"nctId":11502,"briefTitle":11503,"status":332,"phases":12364,"primaryCompletion":1445,"completion":1445,"start":11505,"enrollment":1228,"conditions":12365,"interventions":12366},[91],[26,23],[6933,6935,11508,11509],{"intervention":12368,"totalTrials":95,"cells":12369},"5-ALA plus Blu-Light",{"EARLY_PHASE1":12370,"PHASE1":12372,"PHASE2":12374,"PHASE3":12376,"PHASE4":12378,"NA":12380},{"trials":12371,"activeCount":99},[],{"trials":12373,"activeCount":99},[],{"trials":12375,"activeCount":99},[],{"trials":12377,"activeCount":99},[],{"trials":12379,"activeCount":99},[],{"trials":12381,"activeCount":99},[12382],{"nctId":12383,"briefTitle":12384,"status":981,"phases":12385,"primaryCompletion":4991,"completion":4991,"start":8949,"enrollment":99,"conditions":12386,"interventions":12388},"NCT00814528","Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses",[91],[12387],"Actinic Keratosis",[12368,12389],"5-FU, Imiquimod or treatment with cryotherapy",{"intervention":12389,"totalTrials":95,"cells":12391},{"EARLY_PHASE1":12392,"PHASE1":12394,"PHASE2":12396,"PHASE3":12398,"PHASE4":12400,"NA":12402},{"trials":12393,"activeCount":99},[],{"trials":12395,"activeCount":99},[],{"trials":12397,"activeCount":99},[],{"trials":12399,"activeCount":99},[],{"trials":12401,"activeCount":99},[],{"trials":12403,"activeCount":99},[12404],{"nctId":12383,"briefTitle":12384,"status":981,"phases":12405,"primaryCompletion":4991,"completion":4991,"start":8949,"enrollment":99,"conditions":12406,"interventions":12407},[91],[12387],[12368,12389],{"intervention":12409,"totalTrials":95,"cells":12410},"Florbetaben F18",{"EARLY_PHASE1":12411,"PHASE1":12413,"PHASE2":12415,"PHASE3":12417,"PHASE4":12419,"NA":12421},{"trials":12412,"activeCount":99},[],{"trials":12414,"activeCount":99},[],{"trials":12416,"activeCount":99},[],{"trials":12418,"activeCount":99},[],{"trials":12420,"activeCount":99},[],{"trials":12422,"activeCount":99},[12423],{"nctId":12424,"briefTitle":12425,"status":332,"phases":12426,"primaryCompletion":12427,"completion":12428,"start":12429,"enrollment":95,"conditions":12430,"interventions":12433},"NCT04720001","Florbetaben PET Imaging in PPA",[],"2021-01-21","2021-02-26","2018-08-23",[12431,12432],"Primary Progressive Aphasia","Alzheimer Disease",[12409],{"intervention":12029,"totalTrials":95,"cells":12435},{"EARLY_PHASE1":12436,"PHASE1":12438,"PHASE2":12440,"PHASE3":12442,"PHASE4":12444,"NA":12446},{"trials":12437,"activeCount":99},[],{"trials":12439,"activeCount":99},[],{"trials":12441,"activeCount":99},[],{"trials":12443,"activeCount":99},[],{"trials":12445,"activeCount":99},[],{"trials":12447,"activeCount":99},[12448],{"nctId":12022,"briefTitle":12023,"status":332,"phases":12449,"primaryCompletion":12025,"completion":12025,"start":12026,"enrollment":6652,"conditions":12450,"interventions":12451},[91],[32],[6113,12029,12030],{"intervention":12030,"totalTrials":95,"cells":12453},{"EARLY_PHASE1":12454,"PHASE1":12456,"PHASE2":12458,"PHASE3":12460,"PHASE4":12462,"NA":12464},{"trials":12455,"activeCount":99},[],{"trials":12457,"activeCount":99},[],{"trials":12459,"activeCount":99},[],{"trials":12461,"activeCount":99},[],{"trials":12463,"activeCount":99},[],{"trials":12465,"activeCount":99},[12466],{"nctId":12022,"briefTitle":12023,"status":332,"phases":12467,"primaryCompletion":12025,"completion":12025,"start":12026,"enrollment":6652,"conditions":12468,"interventions":12469},[91],[32],[6113,12029,12030],{"intervention":12471,"totalTrials":95,"cells":12472},"Azelastine nasal spray",{"EARLY_PHASE1":12473,"PHASE1":12475,"PHASE2":12477,"PHASE3":12479,"PHASE4":12481,"NA":12483},{"trials":12474,"activeCount":99},[],{"trials":12476,"activeCount":99},[],{"trials":12478,"activeCount":99},[],{"trials":12480,"activeCount":99},[],{"trials":12482,"activeCount":99},[],{"trials":12484,"activeCount":99},[12485],{"nctId":12486,"briefTitle":12487,"status":332,"phases":12488,"primaryCompletion":9073,"completion":12489,"start":3359,"enrollment":516,"conditions":12490,"interventions":12492},"NCT00117832","Nasal Ocular Reflexes Contribute to Eye Symptoms",[91],"2006-10",[12491],"Rhinitis, Allergic, Seasonal",[12471],{"intervention":12494,"totalTrials":95,"cells":12495},"Gamimune N or Gamunex 10%",{"EARLY_PHASE1":12496,"PHASE1":12498,"PHASE2":12500,"PHASE3":12502,"PHASE4":12504,"NA":12506},{"trials":12497,"activeCount":99},[],{"trials":12499,"activeCount":99},[],{"trials":12501,"activeCount":99},[],{"trials":12503,"activeCount":99},[],{"trials":12505,"activeCount":99},[],{"trials":12507,"activeCount":99},[12508],{"nctId":12509,"briefTitle":12510,"status":332,"phases":12511,"primaryCompletion":839,"completion":6397,"start":1485,"enrollment":6513,"conditions":12512,"interventions":12515},"NCT00606905","Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage",[91],[12513,12514],"Miscarriage, Recurrent","Abortion, Habitual",[12494],{"intervention":12517,"totalTrials":95,"cells":12518},"ocrelizumab",{"EARLY_PHASE1":12519,"PHASE1":12521,"PHASE2":12523,"PHASE3":12525,"PHASE4":12527,"NA":12529},{"trials":12520,"activeCount":99},[],{"trials":12522,"activeCount":99},[],{"trials":12524,"activeCount":99},[],{"trials":12526,"activeCount":99},[],{"trials":12528,"activeCount":99},[],{"trials":12530,"activeCount":99},[12531],{"nctId":12532,"briefTitle":12533,"status":332,"phases":12534,"primaryCompletion":12535,"completion":12535,"start":12536,"enrollment":1085,"conditions":12537,"interventions":12539},"NCT03344094","Mechanism of Action of Ocrelizumab in Multiple Sclerosis",[],"2019-04-10","2018-02-23",[5137,12538],"Immune System Diseases",[12517],{"intervention":12541,"totalTrials":95,"cells":12542},"Linezolid",{"EARLY_PHASE1":12543,"PHASE1":12545,"PHASE2":12547,"PHASE3":12549,"PHASE4":12551,"NA":12553},{"trials":12544,"activeCount":99},[],{"trials":12546,"activeCount":99},[],{"trials":12548,"activeCount":99},[],{"trials":12550,"activeCount":99},[],{"trials":12552,"activeCount":99},[],{"trials":12554,"activeCount":99},[12555],{"nctId":12556,"briefTitle":12557,"status":363,"phases":12558,"primaryCompletion":1613,"completion":1613,"start":6205,"enrollment":410,"conditions":12559,"interventions":12562},"NCT01619410","Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections",[91],[12560,12561],"Skin Diseases, Bacterial","Abscess",[12541,12563],"Clindamycin",{"intervention":12563,"totalTrials":95,"cells":12565},{"EARLY_PHASE1":12566,"PHASE1":12568,"PHASE2":12570,"PHASE3":12572,"PHASE4":12574,"NA":12576},{"trials":12567,"activeCount":99},[],{"trials":12569,"activeCount":99},[],{"trials":12571,"activeCount":99},[],{"trials":12573,"activeCount":99},[],{"trials":12575,"activeCount":99},[],{"trials":12577,"activeCount":99},[12578],{"nctId":12556,"briefTitle":12557,"status":363,"phases":12579,"primaryCompletion":1613,"completion":1613,"start":6205,"enrollment":410,"conditions":12580,"interventions":12581},[91],[12560,12561],[12541,12563],{"intervention":12583,"totalTrials":95,"cells":12584},"Azilsartan medoximil",{"EARLY_PHASE1":12585,"PHASE1":12587,"PHASE2":12589,"PHASE3":12591,"PHASE4":12593,"NA":12595},{"trials":12586,"activeCount":99},[],{"trials":12588,"activeCount":99},[],{"trials":12590,"activeCount":99},[],{"trials":12592,"activeCount":99},[],{"trials":12594,"activeCount":99},[],{"trials":12596,"activeCount":99},[12597],{"nctId":12598,"briefTitle":12599,"status":332,"phases":12600,"primaryCompletion":366,"completion":12246,"start":432,"enrollment":19,"conditions":12601,"interventions":12602},"NCT01774591","Effect of Azilsartan on Aldosterone in Postmenopausal Females",[91],[6215],[12583],{"intervention":1403,"totalTrials":95,"cells":12604},{"EARLY_PHASE1":12605,"PHASE1":12607,"PHASE2":12609,"PHASE3":12611,"PHASE4":12613,"NA":12615},{"trials":12606,"activeCount":99},[],{"trials":12608,"activeCount":99},[],{"trials":12610,"activeCount":99},[],{"trials":12612,"activeCount":99},[],{"trials":12614,"activeCount":99},[],{"trials":12616,"activeCount":99},[12617],{"nctId":1395,"briefTitle":1396,"status":332,"phases":12618,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":516,"conditions":12619,"interventions":12620},[91],[1401],[1286,385,1403,1404],{"intervention":1404,"totalTrials":95,"cells":12622},{"EARLY_PHASE1":12623,"PHASE1":12625,"PHASE2":12627,"PHASE3":12629,"PHASE4":12631,"NA":12633},{"trials":12624,"activeCount":99},[],{"trials":12626,"activeCount":99},[],{"trials":12628,"activeCount":99},[],{"trials":12630,"activeCount":99},[],{"trials":12632,"activeCount":99},[],{"trials":12634,"activeCount":99},[12635],{"nctId":1395,"briefTitle":1396,"status":332,"phases":12636,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":516,"conditions":12637,"interventions":12638},[91],[1401],[1286,385,1403,1404],{"intervention":12640,"totalTrials":95,"cells":12641},"Gardasil",{"EARLY_PHASE1":12642,"PHASE1":12644,"PHASE2":12646,"PHASE3":12648,"PHASE4":12650,"NA":12652},{"trials":12643,"activeCount":99},[],{"trials":12645,"activeCount":99},[],{"trials":12647,"activeCount":99},[],{"trials":12649,"activeCount":99},[],{"trials":12651,"activeCount":99},[],{"trials":12653,"activeCount":99},[12654],{"nctId":12655,"briefTitle":12656,"status":332,"phases":12657,"primaryCompletion":12658,"completion":12659,"start":3357,"enrollment":9,"conditions":12660,"interventions":12662},"NCT00786409","Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women",[91],"2010-08","2011-12",[12661],"Systemic Lupus Erythematosus",[12640],{"intervention":12664,"totalTrials":95,"cells":12665},"Fludarabine-Melphalan & Rabbit antithymocyte globulin",{"EARLY_PHASE1":12666,"PHASE1":12668,"PHASE2":12670,"PHASE3":12672,"PHASE4":12674,"NA":12676},{"trials":12667,"activeCount":99},[],{"trials":12669,"activeCount":99},[],{"trials":12671,"activeCount":99},[],{"trials":12673,"activeCount":99},[],{"trials":12675,"activeCount":99},[],{"trials":12677,"activeCount":99},[12678],{"nctId":12679,"briefTitle":12680,"status":332,"phases":12681,"primaryCompletion":1045,"completion":1045,"start":12682,"enrollment":12683,"conditions":12684,"interventions":12685},"NCT00943800","Combined Haploidentical-Cord Blood Transplantation for Adults and Children",[91],"2006-10-09",87,[1932,2180,354,787],[12664,12686,12687],"Fludarabine, Thiotepa, Antithymocyte globulin","Fludarabine, Busulfan, and ATG",{"intervention":12686,"totalTrials":95,"cells":12689},{"EARLY_PHASE1":12690,"PHASE1":12692,"PHASE2":12694,"PHASE3":12696,"PHASE4":12698,"NA":12700},{"trials":12691,"activeCount":99},[],{"trials":12693,"activeCount":99},[],{"trials":12695,"activeCount":99},[],{"trials":12697,"activeCount":99},[],{"trials":12699,"activeCount":99},[],{"trials":12701,"activeCount":99},[12702],{"nctId":12679,"briefTitle":12680,"status":332,"phases":12703,"primaryCompletion":1045,"completion":1045,"start":12682,"enrollment":12683,"conditions":12704,"interventions":12705},[91],[1932,2180,354,787],[12664,12686,12687],{"intervention":12687,"totalTrials":95,"cells":12707},{"EARLY_PHASE1":12708,"PHASE1":12710,"PHASE2":12712,"PHASE3":12714,"PHASE4":12716,"NA":12718},{"trials":12709,"activeCount":99},[],{"trials":12711,"activeCount":99},[],{"trials":12713,"activeCount":99},[],{"trials":12715,"activeCount":99},[],{"trials":12717,"activeCount":99},[],{"trials":12719,"activeCount":99},[12720],{"nctId":12679,"briefTitle":12680,"status":332,"phases":12721,"primaryCompletion":1045,"completion":1045,"start":12682,"enrollment":12683,"conditions":12722,"interventions":12723},[91],[1932,2180,354,787],[12664,12686,12687],{"intervention":12725,"totalTrials":95,"cells":12726},"Florbetapir F 18",{"EARLY_PHASE1":12727,"PHASE1":12729,"PHASE2":12731,"PHASE3":12733,"PHASE4":12735,"NA":12737},{"trials":12728,"activeCount":99},[],{"trials":12730,"activeCount":99},[],{"trials":12732,"activeCount":99},[],{"trials":12734,"activeCount":99},[],{"trials":12736,"activeCount":99},[],{"trials":12738,"activeCount":99},[12739],{"nctId":12740,"briefTitle":12741,"status":332,"phases":12742,"primaryCompletion":12743,"completion":12744,"start":12745,"enrollment":1153,"conditions":12746,"interventions":12748},"NCT04726527","Clinical Evaluation of Florbetapir in Primary Progressive Aphasia",[],"2015-09-02","2017-02-28","2012-03-15",[12431,12432,12747],"Dementia",[12725],{"intervention":543,"totalTrials":95,"cells":12750},{"EARLY_PHASE1":12751,"PHASE1":12753,"PHASE2":12755,"PHASE3":12757,"PHASE4":12759,"NA":12761},{"trials":12752,"activeCount":99},[],{"trials":12754,"activeCount":99},[],{"trials":12756,"activeCount":99},[],{"trials":12758,"activeCount":99},[],{"trials":12760,"activeCount":99},[],{"trials":12762,"activeCount":99},[12763],{"nctId":534,"briefTitle":535,"status":363,"phases":12764,"completion":537,"start":538,"enrollment":539,"conditions":12765,"interventions":12766},[91],[541],[299,543],{"intervention":12768,"totalTrials":95,"cells":12769},"pazopanib hydrochloride",{"EARLY_PHASE1":12770,"PHASE1":12772,"PHASE2":12774,"PHASE3":12776,"PHASE4":12778,"NA":12780},{"trials":12771,"activeCount":99},[],{"trials":12773,"activeCount":99},[],{"trials":12775,"activeCount":99},[],{"trials":12777,"activeCount":99},[],{"trials":12779,"activeCount":99},[],{"trials":12781,"activeCount":99},[12782],{"nctId":12783,"briefTitle":12784,"status":363,"phases":12785,"primaryCompletion":961,"completion":961,"start":838,"enrollment":516,"conditions":12786,"interventions":12790},"NCT01599832","Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer",[91],[12787,12788,12789],"Clear Cell Renal Cell Carcinoma","Recurrent Renal Cell Cancer","Stage IV Renal Cell Cancer",[12768],{"intervention":12792,"totalTrials":95,"cells":12793},"0% N2O and 10% N2O",{"EARLY_PHASE1":12794,"PHASE1":12796,"PHASE2":12798,"PHASE3":12800,"PHASE4":12802,"NA":12804},{"trials":12795,"activeCount":99},[],{"trials":12797,"activeCount":99},[],{"trials":12799,"activeCount":99},[],{"trials":12801,"activeCount":99},[],{"trials":12803,"activeCount":99},[],{"trials":12805,"activeCount":99},[12806],{"nctId":12807,"briefTitle":12808,"status":332,"phases":12809,"primaryCompletion":12810,"completion":12810,"start":7194,"enrollment":2075,"conditions":12811,"interventions":12812},"NCT00000257","Effects of Alcohol History on Effects of Nitrous Oxide - 9",[91],"1997-04",[11430,26,23],[12792,12813,12814,12815],"0% N2O and 20% N2O","0% N2O and 30% N2O","0% N2O and 40% N2O",{"intervention":12813,"totalTrials":95,"cells":12817},{"EARLY_PHASE1":12818,"PHASE1":12820,"PHASE2":12822,"PHASE3":12824,"PHASE4":12826,"NA":12828},{"trials":12819,"activeCount":99},[],{"trials":12821,"activeCount":99},[],{"trials":12823,"activeCount":99},[],{"trials":12825,"activeCount":99},[],{"trials":12827,"activeCount":99},[],{"trials":12829,"activeCount":99},[12830],{"nctId":12807,"briefTitle":12808,"status":332,"phases":12831,"primaryCompletion":12810,"completion":12810,"start":7194,"enrollment":2075,"conditions":12832,"interventions":12833},[91],[11430,26,23],[12792,12813,12814,12815],{"intervention":12814,"totalTrials":95,"cells":12835},{"EARLY_PHASE1":12836,"PHASE1":12838,"PHASE2":12840,"PHASE3":12842,"PHASE4":12844,"NA":12846},{"trials":12837,"activeCount":99},[],{"trials":12839,"activeCount":99},[],{"trials":12841,"activeCount":99},[],{"trials":12843,"activeCount":99},[],{"trials":12845,"activeCount":99},[],{"trials":12847,"activeCount":99},[12848],{"nctId":12807,"briefTitle":12808,"status":332,"phases":12849,"primaryCompletion":12810,"completion":12810,"start":7194,"enrollment":2075,"conditions":12850,"interventions":12851},[91],[11430,26,23],[12792,12813,12814,12815],{"intervention":12815,"totalTrials":95,"cells":12853},{"EARLY_PHASE1":12854,"PHASE1":12856,"PHASE2":12858,"PHASE3":12860,"PHASE4":12862,"NA":12864},{"trials":12855,"activeCount":99},[],{"trials":12857,"activeCount":99},[],{"trials":12859,"activeCount":99},[],{"trials":12861,"activeCount":99},[],{"trials":12863,"activeCount":99},[],{"trials":12865,"activeCount":99},[12866],{"nctId":12807,"briefTitle":12808,"status":332,"phases":12867,"primaryCompletion":12810,"completion":12810,"start":7194,"enrollment":2075,"conditions":12868,"interventions":12869},[91],[11430,26,23],[12792,12813,12814,12815],{"intervention":12871,"totalTrials":95,"cells":12872},"Nitrous oxide 10% & placebo",{"EARLY_PHASE1":12873,"PHASE1":12875,"PHASE2":12877,"PHASE3":12879,"PHASE4":12881,"NA":12883},{"trials":12874,"activeCount":99},[],{"trials":12876,"activeCount":99},[],{"trials":12878,"activeCount":99},[],{"trials":12880,"activeCount":99},[],{"trials":12882,"activeCount":99},[],{"trials":12884,"activeCount":99},[12885],{"nctId":12886,"briefTitle":12887,"status":332,"phases":12888,"primaryCompletion":11428,"completion":11428,"start":12889,"enrollment":16,"conditions":12890,"interventions":12891},"NCT00000258","Role of Instructions in Nitrous Oxide Effects and Choice - 10",[91],"1996-04",[26,23],[12871,12892,12893,12894],"Nitrous oxide 20% & placebo","Nitrous oxide 30% & placebo","Nitrous oxide 40% and placebo",{"intervention":12892,"totalTrials":95,"cells":12896},{"EARLY_PHASE1":12897,"PHASE1":12899,"PHASE2":12901,"PHASE3":12903,"PHASE4":12905,"NA":12907},{"trials":12898,"activeCount":99},[],{"trials":12900,"activeCount":99},[],{"trials":12902,"activeCount":99},[],{"trials":12904,"activeCount":99},[],{"trials":12906,"activeCount":99},[],{"trials":12908,"activeCount":99},[12909],{"nctId":12886,"briefTitle":12887,"status":332,"phases":12910,"primaryCompletion":11428,"completion":11428,"start":12889,"enrollment":16,"conditions":12911,"interventions":12912},[91],[26,23],[12871,12892,12893,12894],{"intervention":12893,"totalTrials":95,"cells":12914},{"EARLY_PHASE1":12915,"PHASE1":12917,"PHASE2":12919,"PHASE3":12921,"PHASE4":12923,"NA":12925},{"trials":12916,"activeCount":99},[],{"trials":12918,"activeCount":99},[],{"trials":12920,"activeCount":99},[],{"trials":12922,"activeCount":99},[],{"trials":12924,"activeCount":99},[],{"trials":12926,"activeCount":99},[12927],{"nctId":12886,"briefTitle":12887,"status":332,"phases":12928,"primaryCompletion":11428,"completion":11428,"start":12889,"enrollment":16,"conditions":12929,"interventions":12930},[91],[26,23],[12871,12892,12893,12894],{"intervention":12894,"totalTrials":95,"cells":12932},{"EARLY_PHASE1":12933,"PHASE1":12935,"PHASE2":12937,"PHASE3":12939,"PHASE4":12941,"NA":12943},{"trials":12934,"activeCount":99},[],{"trials":12936,"activeCount":99},[],{"trials":12938,"activeCount":99},[],{"trials":12940,"activeCount":99},[],{"trials":12942,"activeCount":99},[],{"trials":12944,"activeCount":99},[12945],{"nctId":12886,"briefTitle":12887,"status":332,"phases":12946,"primaryCompletion":11428,"completion":11428,"start":12889,"enrollment":16,"conditions":12947,"interventions":12948},[91],[26,23],[12871,12892,12893,12894],{"intervention":11819,"totalTrials":95,"cells":12950},{"EARLY_PHASE1":12951,"PHASE1":12953,"PHASE2":12955,"PHASE3":12957,"PHASE4":12959,"NA":12961},{"trials":12952,"activeCount":99},[],{"trials":12954,"activeCount":99},[],{"trials":12956,"activeCount":99},[],{"trials":12958,"activeCount":99},[],{"trials":12960,"activeCount":99},[],{"trials":12962,"activeCount":99},[12963],{"nctId":11813,"briefTitle":11814,"status":332,"phases":12964,"primaryCompletion":11816,"completion":11622,"start":3283,"enrollment":1215,"conditions":12965,"interventions":12966},[91],[32],[11819,11820,11821,6125],{"intervention":11820,"totalTrials":95,"cells":12968},{"EARLY_PHASE1":12969,"PHASE1":12971,"PHASE2":12973,"PHASE3":12975,"PHASE4":12977,"NA":12979},{"trials":12970,"activeCount":99},[],{"trials":12972,"activeCount":99},[],{"trials":12974,"activeCount":99},[],{"trials":12976,"activeCount":99},[],{"trials":12978,"activeCount":99},[],{"trials":12980,"activeCount":99},[12981],{"nctId":11813,"briefTitle":11814,"status":332,"phases":12982,"primaryCompletion":11816,"completion":11622,"start":3283,"enrollment":1215,"conditions":12983,"interventions":12984},[91],[32],[11819,11820,11821,6125],{"intervention":11821,"totalTrials":95,"cells":12986},{"EARLY_PHASE1":12987,"PHASE1":12989,"PHASE2":12991,"PHASE3":12993,"PHASE4":12995,"NA":12997},{"trials":12988,"activeCount":99},[],{"trials":12990,"activeCount":99},[],{"trials":12992,"activeCount":99},[],{"trials":12994,"activeCount":99},[],{"trials":12996,"activeCount":99},[],{"trials":12998,"activeCount":99},[12999],{"nctId":11813,"briefTitle":11814,"status":332,"phases":13000,"primaryCompletion":11816,"completion":11622,"start":3283,"enrollment":1215,"conditions":13001,"interventions":13002},[91],[32],[11819,11820,11821,6125],{"intervention":13004,"totalTrials":95,"cells":13005},"Within-subjects",{"EARLY_PHASE1":13006,"PHASE1":13008,"PHASE2":13010,"PHASE3":13012,"PHASE4":13014,"NA":13016},{"trials":13007,"activeCount":99},[],{"trials":13009,"activeCount":99},[],{"trials":13011,"activeCount":99},[],{"trials":13013,"activeCount":99},[],{"trials":13015,"activeCount":99},[],{"trials":13017,"activeCount":99},[13018],{"nctId":13019,"briefTitle":13020,"status":332,"phases":13021,"primaryCompletion":2283,"completion":2283,"start":1280,"enrollment":1016,"conditions":13022,"interventions":13023},"NCT01849419","Effects of MDMA on Social and Emotional Processing",[91],[11971],[13004,13004,13004],{"intervention":13025,"totalTrials":95,"cells":13026},"Furosemide",{"EARLY_PHASE1":13027,"PHASE1":13029,"PHASE2":13031,"PHASE3":13033,"PHASE4":13035,"NA":13037},{"trials":13028,"activeCount":99},[],{"trials":13030,"activeCount":99},[],{"trials":13032,"activeCount":99},[],{"trials":13034,"activeCount":99},[],{"trials":13036,"activeCount":99},[],{"trials":13038,"activeCount":99},[13039],{"nctId":13040,"briefTitle":13041,"status":332,"phases":13042,"primaryCompletion":13043,"completion":13043,"start":1649,"enrollment":13044,"conditions":13045,"interventions":13047},"NCT01275729","The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury",[91],"2022-06",96,[13046],"Acute Kidney Failure",[13025],{"intervention":13049,"totalTrials":95,"cells":13050},"0.2mg Buprenorphine",{"EARLY_PHASE1":13051,"PHASE1":13053,"PHASE2":13055,"PHASE3":13057,"PHASE4":13059,"NA":13061},{"trials":13052,"activeCount":99},[],{"trials":13054,"activeCount":99},[],{"trials":13056,"activeCount":99},[],{"trials":13058,"activeCount":99},[],{"trials":13060,"activeCount":99},[],{"trials":13062,"activeCount":99},[13063],{"nctId":13064,"briefTitle":13065,"status":332,"phases":13066,"primaryCompletion":13067,"completion":13067,"start":1398,"enrollment":1358,"conditions":13068,"interventions":13069},"NCT02659787","Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology",[91],"2017-04",[4364],[13049],{"intervention":13071,"totalTrials":95,"cells":13072},"0.9% saline",{"EARLY_PHASE1":13073,"PHASE1":13075,"PHASE2":13077,"PHASE3":13079,"PHASE4":13081,"NA":13083},{"trials":13074,"activeCount":99},[],{"trials":13076,"activeCount":99},[],{"trials":13078,"activeCount":99},[],{"trials":13080,"activeCount":99},[],{"trials":13082,"activeCount":99},[],{"trials":13084,"activeCount":99},[13085],{"nctId":13086,"briefTitle":13087,"status":332,"phases":13088,"primaryCompletion":13089,"completion":13090,"start":11571,"enrollment":400,"conditions":13091,"interventions":13097},"NCT02205801","Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy",[91],"2017-02-10","2017-02-17",[13092,13093,13094,13095,13096],"Thyroid Neoplasms","Goiter, Nodular","Thyroid Nodule","Graves' Disease","Hyperparathyroidism",[13071,13098],"Marcaine",{"intervention":13098,"totalTrials":95,"cells":13100},{"EARLY_PHASE1":13101,"PHASE1":13103,"PHASE2":13105,"PHASE3":13107,"PHASE4":13109,"NA":13111},{"trials":13102,"activeCount":99},[],{"trials":13104,"activeCount":99},[],{"trials":13106,"activeCount":99},[],{"trials":13108,"activeCount":99},[],{"trials":13110,"activeCount":99},[],{"trials":13112,"activeCount":99},[13113],{"nctId":13086,"briefTitle":13087,"status":332,"phases":13114,"primaryCompletion":13089,"completion":13090,"start":11571,"enrollment":400,"conditions":13115,"interventions":13116},[91],[13092,13093,13094,13095,13096],[13071,13098],{"intervention":3307,"totalTrials":95,"cells":13118},{"EARLY_PHASE1":13119,"PHASE1":13121,"PHASE2":13123,"PHASE3":13125,"PHASE4":13127,"NA":13129},{"trials":13120,"activeCount":99},[],{"trials":13122,"activeCount":99},[],{"trials":13124,"activeCount":99},[],{"trials":13126,"activeCount":99},[],{"trials":13128,"activeCount":99},[],{"trials":13130,"activeCount":99},[13131],{"nctId":3302,"briefTitle":3303,"status":363,"phases":13132,"primaryCompletion":3283,"completion":3283,"start":432,"enrollment":994,"conditions":13133,"interventions":13134},[91],[3285],[3307,530],{"intervention":1540,"totalTrials":95,"cells":13136},{"EARLY_PHASE1":13137,"PHASE1":13139,"PHASE2":13141,"PHASE3":13143,"PHASE4":13145,"NA":13147},{"trials":13138,"activeCount":99},[],{"trials":13140,"activeCount":99},[],{"trials":13142,"activeCount":99},[],{"trials":13144,"activeCount":99},[],{"trials":13146,"activeCount":99},[],{"trials":13148,"activeCount":99},[13149],{"nctId":1533,"briefTitle":1534,"status":981,"phases":13150,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":99,"conditions":13151,"interventions":13152},[91],[15],[1540,392,326,319],{"intervention":13154,"totalTrials":95,"cells":13155},"mometasone furoate nasal spray",{"EARLY_PHASE1":13156,"PHASE1":13158,"PHASE2":13160,"PHASE3":13162,"PHASE4":13164,"NA":13166},{"trials":13157,"activeCount":99},[],{"trials":13159,"activeCount":99},[],{"trials":13161,"activeCount":99},[],{"trials":13163,"activeCount":99},[],{"trials":13165,"activeCount":99},[],{"trials":13167,"activeCount":99},[13168],{"nctId":13169,"briefTitle":13170,"status":332,"phases":13171,"primaryCompletion":5176,"completion":1280,"start":5864,"enrollment":539,"conditions":13172,"interventions":13173},"NCT00618332","Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?",[91],[4784],[13154],{"intervention":13175,"totalTrials":95,"cells":13176},"Nasaleze Spray",{"EARLY_PHASE1":13177,"PHASE1":13179,"PHASE2":13181,"PHASE3":13183,"PHASE4":13185,"NA":13187},{"trials":13178,"activeCount":99},[],{"trials":13180,"activeCount":99},[],{"trials":13182,"activeCount":99},[],{"trials":13184,"activeCount":99},[],{"trials":13186,"activeCount":99},[],{"trials":13188,"activeCount":99},[13189],{"nctId":13190,"briefTitle":13191,"status":363,"phases":13192,"primaryCompletion":11571,"completion":11571,"start":1416,"enrollment":1779,"conditions":13193,"interventions":13194},"NCT01723397","Effect of Nasaleze on Nasal Challenge With Allergen",[91],[4793],[13175,13195],"Allergen",{"intervention":13195,"totalTrials":95,"cells":13197},{"EARLY_PHASE1":13198,"PHASE1":13200,"PHASE2":13202,"PHASE3":13204,"PHASE4":13206,"NA":13208},{"trials":13199,"activeCount":99},[],{"trials":13201,"activeCount":99},[],{"trials":13203,"activeCount":99},[],{"trials":13205,"activeCount":99},[],{"trials":13207,"activeCount":99},[],{"trials":13209,"activeCount":99},[13210],{"nctId":13190,"briefTitle":13191,"status":363,"phases":13211,"primaryCompletion":11571,"completion":11571,"start":1416,"enrollment":1779,"conditions":13212,"interventions":13213},[91],[4793],[13175,13195],{"intervention":13215,"totalTrials":95,"cells":13216},"Alendronate",{"EARLY_PHASE1":13217,"PHASE1":13219,"PHASE2":13221,"PHASE3":13223,"PHASE4":13225,"NA":13227},{"trials":13218,"activeCount":99},[],{"trials":13220,"activeCount":99},[],{"trials":13222,"activeCount":99},[],{"trials":13224,"activeCount":99},[],{"trials":13226,"activeCount":99},[],{"trials":13228,"activeCount":99},[13229],{"nctId":13230,"briefTitle":13231,"status":332,"phases":13232,"primaryCompletion":5460,"completion":5460,"start":13233,"enrollment":400,"conditions":13234,"interventions":13235},"NCT00145977","Texture Analysis for Postmenopausal Osteoporosis",[91],"2001-07",[7569,7568],[13215],{"intervention":13237,"totalTrials":95,"cells":13238},"Minoxidil",{"EARLY_PHASE1":13239,"PHASE1":13241,"PHASE2":13243,"PHASE3":13245,"PHASE4":13247,"NA":13249},{"trials":13240,"activeCount":99},[],{"trials":13242,"activeCount":99},[],{"trials":13244,"activeCount":99},[],{"trials":13246,"activeCount":99},[],{"trials":13248,"activeCount":99},[],{"trials":13250,"activeCount":99},[13251],{"nctId":13252,"briefTitle":13253,"status":363,"phases":13254,"primaryCompletion":4405,"completion":4405,"start":4812,"enrollment":367,"conditions":13255,"interventions":13257},"NCT00607477","Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension",[91],[13256],"Treatment Induced Hypertension",[13237,13258],"Hydralazine",{"intervention":13258,"totalTrials":95,"cells":13260},{"EARLY_PHASE1":13261,"PHASE1":13263,"PHASE2":13265,"PHASE3":13267,"PHASE4":13269,"NA":13271},{"trials":13262,"activeCount":99},[],{"trials":13264,"activeCount":99},[],{"trials":13266,"activeCount":99},[],{"trials":13268,"activeCount":99},[],{"trials":13270,"activeCount":99},[],{"trials":13272,"activeCount":99},[13273],{"nctId":13252,"briefTitle":13253,"status":363,"phases":13274,"primaryCompletion":4405,"completion":4405,"start":4812,"enrollment":367,"conditions":13275,"interventions":13276},[91],[13256],[13237,13258],{"intervention":13278,"totalTrials":95,"cells":13279},"Depot Lupron followed by estrogen plus placebo",{"EARLY_PHASE1":13280,"PHASE1":13282,"PHASE2":13284,"PHASE3":13286,"PHASE4":13288,"NA":13290},{"trials":13281,"activeCount":99},[],{"trials":13283,"activeCount":99},[],{"trials":13285,"activeCount":99},[],{"trials":13287,"activeCount":99},[],{"trials":13289,"activeCount":99},[],{"trials":13291,"activeCount":99},[13292],{"nctId":13293,"briefTitle":13294,"status":332,"phases":13295,"primaryCompletion":13296,"completion":13296,"start":4780,"enrollment":24,"conditions":13297,"interventions":13298},"NCT00696111","Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea",[91],"2022-06-30",[5978,5069],[13278],{"intervention":13300,"totalTrials":95,"cells":13301},"Emtricitabine \u002F Tenofovir Disoproxil Oral",{"EARLY_PHASE1":13302,"PHASE1":13304,"PHASE2":13306,"PHASE3":13308,"PHASE4":13310,"NA":13312},{"trials":13303,"activeCount":99},[],{"trials":13305,"activeCount":99},[],{"trials":13307,"activeCount":99},[],{"trials":13309,"activeCount":99},[],{"trials":13311,"activeCount":99},[],{"trials":13313,"activeCount":99},[13314],{"nctId":13315,"briefTitle":13316,"status":981,"phases":13317,"primaryCompletion":13318,"completion":13318,"start":13319,"enrollment":99,"conditions":13320,"interventions":13322},"NCT04329442","Accelerated PrEP Access for Black MSM and TW",[91],"2021-07-31","2020-04-01",[13321],"HIV\u002FAIDS",[13300],{"intervention":13324,"totalTrials":95,"cells":13325},"Flibanserin",{"EARLY_PHASE1":13326,"PHASE1":13328,"PHASE2":13330,"PHASE3":13332,"PHASE4":13334,"NA":13336},{"trials":13327,"activeCount":99},[],{"trials":13329,"activeCount":99},[],{"trials":13331,"activeCount":99},[],{"trials":13333,"activeCount":99},[],{"trials":13335,"activeCount":99},[],{"trials":13337,"activeCount":99},[13338],{"nctId":13339,"briefTitle":13340,"status":363,"phases":13341,"primaryCompletion":9695,"completion":9695,"start":6847,"enrollment":2534,"conditions":13342,"interventions":13344},"NCT02770768","Effects of Flibanserin on the Pre- and Post-menopausal Female Brain",[91],[13343],"Hypoactive Sexual Desire Disorder",[13324],{"intervention":11468,"totalTrials":95,"cells":13346},{"EARLY_PHASE1":13347,"PHASE1":13349,"PHASE2":13351,"PHASE3":13353,"PHASE4":13355,"NA":13357},{"trials":13348,"activeCount":99},[],{"trials":13350,"activeCount":99},[],{"trials":13352,"activeCount":99},[],{"trials":13354,"activeCount":99},[],{"trials":13356,"activeCount":99},[],{"trials":13358,"activeCount":99},[13359],{"nctId":11462,"briefTitle":11463,"status":332,"phases":13360,"primaryCompletion":11428,"completion":11428,"start":11465,"enrollment":35,"conditions":13361,"interventions":13362},[91],[26,23],[11468,11469,11415,11470],{"intervention":11469,"totalTrials":95,"cells":13364},{"EARLY_PHASE1":13365,"PHASE1":13367,"PHASE2":13369,"PHASE3":13371,"PHASE4":13373,"NA":13375},{"trials":13366,"activeCount":99},[],{"trials":13368,"activeCount":99},[],{"trials":13370,"activeCount":99},[],{"trials":13372,"activeCount":99},[],{"trials":13374,"activeCount":99},[],{"trials":13376,"activeCount":99},[13377],{"nctId":11462,"briefTitle":11463,"status":332,"phases":13378,"primaryCompletion":11428,"completion":11428,"start":11465,"enrollment":35,"conditions":13379,"interventions":13380},[91],[26,23],[11468,11469,11415,11470],{"intervention":13382,"totalTrials":95,"cells":13383},"reverse transcriptase-polymerase chain reaction",{"EARLY_PHASE1":13384,"PHASE1":13386,"PHASE2":13388,"PHASE3":13390,"PHASE4":13392,"NA":13394},{"trials":13385,"activeCount":99},[],{"trials":13387,"activeCount":99},[],{"trials":13389,"activeCount":99},[],{"trials":13391,"activeCount":99},[],{"trials":13393,"activeCount":99},[],{"trials":13395,"activeCount":99},[13396],{"nctId":13397,"briefTitle":13398,"status":332,"phases":13399,"primaryCompletion":4582,"completion":7016,"start":13400,"enrollment":13401,"conditions":13402,"interventions":13403},"NCT00004153","Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma",[91],"1998-06",106,[1005],[13382]]